# TABLE OF CONTENTS

## 2014 CROI PROGRAM COMMITTEE

### General Information
- Overview .......................................................... 4
- Americans with Disabilities Act .......................... 4
- CROI Foundation ................................................ 4
- IAS–USA ............................................................ 4
- Continuing Medical Education (CME) .................. 4
  - Objectives ...................................................... 4
  - Statement of Need ......................................... 4
  - Accreditation Statement ................................ 4
  - Faculty Financial Disclosure .......................... 4
  - Drug and Product Disclaimer ......................... 5
- Welcome Reception ............................................ 5
- Meals ............................................................... 5
- Overflow Accommodations for Session Rooms .... 5
- Webcasts and Podcasts .................................... 5
- WiFi Access at the Conference ....................... 5
- Badges ............................................................. 6
- Child Care ........................................................ 6
- Conference Etiquette ....................................... 6
- Conference Services ......................................... 6
- Hotel Information ............................................ 7
- Commercial Support ......................................... 8

### Program and Agenda
- Oral Sessions .................................................. 9
- Poster Abstracts ................................................. 37
- Conference Schedule Overview ....................... Inside Back Cover
- Convention Center Meeting Room Layout ........... Outside Back Cover
2014 CROI PROGRAM COMMITTEE

Scientific Program Committee

Kevin M. De Cock, MD, Chair
Centers for Disease Control and Prevention
Nairobi, Kenya

Scott M. Hammer, MD, Vice Chair
Columbia University College of Physicians and Surgeons
New York, NY, United States

Julie Overbaugh, PhD, Vice Chair
Fred Hutchinson Cancer Research Center
Seattle, WA, United States

Elaine J. Abrams, MD
Mailman School of Public Health
Columbia University College of Physicians and Surgeons
New York, NY, United States

Constance A. Benson, MD
University of California San Diego
San Diego, CA, United States

Bruce J. Brew, MD, MBBS
St. Vincent’s Hospital
Sydney, Australia

Susan P. Buchbinder, MD
San Francisco Department of Public Health
San Francisco, CA, United States

Andrew Carr, MD
St. Vincent’s Hospital
Sydney, Australia

Ellen G. Chadwick, MD
Northwestern University’s Feinberg School of Medicine
Chicago, IL, United States

Richard E. Chaisson, MD
The Johns Hopkins University School of Medicine
Baltimore, MD, United States

John M. Coffin, PhD
Tufts University
Boston, MA, United States

Judith S. Currier, MD
University of California Los Angeles
Los Angeles, CA, United States

Wafaa M. El-Sadr, MD, MPH
ICAP, Columbia University
New York, NY, United States

Courtney V. Fletcher, PharmD
University of Nebraska Medical Center
Omaha, NE, United States

Patricia M. Flynn, MD
St. Jude Children’s Research Hospital
Memphis, TN, United States

Dana H. Gabuzda, MD
Dana-Farber Cancer Institute and Harvard Medical School
Boston, MA, United States

Francisco González-Scarano, MD
University of Texas School of Medicine at San Antonio
San Antonio, TX, United States

Beatrice H. Hahn, MD
University of Pennsylvania
Philadelphia, PA, United States

James Hakim, MBChB, MMed, MMedSc, FRCP
University of Zimbabwe College of Health Sciences
Harare, Zimbabwe

Sharon L. Hillier, PhD
University of Pittsburgh School of Medicine
Magee-Womens Hospital
Pittsburgh, PA, United States

James A. Hoxie, MD
University of Pennsylvania
Philadelphia, PA, United States

Harold W. Jaffe, MD
Centers for Disease Control and Prevention
Atlanta, GA, United States

Richard A. Koup, MD
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
Bethesda, MD, United States

Nathaniel R. Landau, PhD
New York University School of Medicine
New York, NY, United States
James McIntyre, MBChB, FRCOG  
Anova Health Institute  
Johannesburg, South Africa

John W. Mellors, MD  
University of Pittsburgh  
Pittsburgh, PA, United States

Ronald T. Mitsuyasu, MD  
University of California Los Angeles  
Los Angeles, CA, United States

Jean-Michel Pawlotsky, MD, PhD  
Henri Mondor Hospital  
University of Paris-Est  
Créteil, France

Douglas D. Richman, MD  
University of California San Diego  
VA San Diego Healthcare System  
La Jolla, CA, United States

Robert T. Schooley, MD  
University of California San Diego  
San Diego, CA, United States

Guido Silvestri, MD  
Emory University and Yerkes National Primate Research Center  
Atlanta, GA, United States

Papa Salif Sow, MD, MSc  
Bill & Melinda Gates Foundation  
University of Dakar  
Dakar, Senegal

Mario Stevenson, PhD  
University of Miami  
Miami, FL, United States

Amalio Telenti, MD, PhD  
Institute of Microbiology, University of Lausanne  
Lausanne, Switzerland

David L. Thomas, MD  
The Johns Hopkins University School of Medicine  
Baltimore, MD, United States

Alexandra Trkola, PhD  
Institute of Medical Virology, University of Zurich  
Zurich, Switzerland

**Community Liaison Subcommitte**

Michael Marco, MPH, MPhil  
Columbia University School of Public Health  
New York, NY, United States

Heidi M. Nass, JD  
AIDS Treatment Activists Coalition  
Madison, WI, United States

Jeff Taylor  
AIDS Treatment Activists Coalition  
Palm Springs, CA, United States

Steven F. Wakefield  
HIV Vaccine Trials Network  
Fred Hutchinson Cancer Research Center  
Seattle, WA, United States

**Conference Secretariat**

International Antiviral (formerly AIDS) Society–USA (IAS–USA)  
San Francisco, CA, United States  
Donna M. Jacobsen, Executive Director
Overview

The 2014 Conference on Retroviruses and Opportunistic Infections (CROI) will be held at the John B. Hynes Veterans Memorial (Hynes) Convention Center from March 3 to 6, 2014. CROI was established in 1993 to provide a forum for basic scientists and clinical investigators to present, discuss, and critique their investigations into the epidemiology and biology of human retroviruses and associated diseases. The synergy of basic science and clinical investigation has been a major contributor to the success of the meeting. CROI is the preeminent HIV research meeting in the world and attracts more than 4000 HIV/AIDS research leaders internationally. The goal of the conference is to provide a forum for researchers to translate their laboratory and clinical findings into tangible progress against the HIV pandemic. CROI has facilitated the presentation of important discoveries in the field, thereby ultimately accelerating progress in HIV/AIDS research.

Americans with Disabilities Act

CROI 2014 endeavors to fully comply with the legal requirements of the Americans with Disabilities Act (ADA). If you require assistance onsite, please visit the Attendee Services booth on the Plaza level during the conference.

CROI Foundation

The CROI Foundation operates exclusively for the charitable and educational purpose of organizing, promoting, and presenting the Conference on Retroviruses and Opportunistic Infections (CROI).

IAS–USA

The International Antiviral Society–USA (IAS–USA) is a 501(c)(3) not-for-profit professional education organization. The IAS–USA serves as the CROI 2014 Conference Secretariat.

The mission of the IAS–USA is to improve the treatment, care, and quality of life for people with HIV, hepatitis C virus, or other viral infections through high-quality, relevant, balanced, and needs-oriented education and information for practitioners who are actively involved in medical care.

Continuing Medical Education (CME)

Objectives

After participating in CROI 2014, learners will be able to:

• Describe current basic science research on the pathogenesis of HIV and on advances toward a cure

• Discuss the most recent findings from clinical trials in the HIV field and the implications of these data for state-of-the-art treatment strategies

• Review current epidemiologic data on the prevalence of HIV infection, transmission, treatment, and linkage to and retention in care in populations worldwide and discuss the implications of these data for public health program planning

Statement of Need

Since HIV was identified, the scientific response to the global pandemic has been a coordinated effort among basic researchers, clinical investigators, health care providers, epidemiologists, and community leaders to move information and potential treatment options from research to clinical trials and out to affected communities as quickly as possible. CROI was founded in 1993 by research investigators working in HIV/AIDS and its complications as a science-focused forum for exchanging current research findings among their international peers. CROI continues to focus on scientific exchange, providing an environment in which basic science researchers, translational researchers, clinical investigators, epidemiologists, and public health experts meet to present and discuss the latest research on different facets of HIV and its complications.

Accreditation Statement

The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The IAS–USA designates this live activity for a maximum of 27.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Since 2006, the IAS–USA has had Accreditation with Commendation, being a member of an elite group of organizations in the United States that have been awarded this prestigious status, which is, in the words of the ACCME, “reserved for programs that are truly exceptional.”

Faculty Financial Disclosure

It is the policy of the IAS–USA to ensure balance, independence, objectivity, and scientific rigor in all its educational activities. All faculty members (speakers, presenters, moderators, conveners, etc) participating in IAS–USA-sponsored activities are required to disclose to the program audience any financial interests within the past 12 months that could be perceived to influence, or give the appearance of potentially influencing, the written or oral
presentation. (The ACCME defines a financial interest as an interest in any amount.) The information is intended to make our audience aware of author/contributor interests and commitments with commercial companies or other entities so that they may form their own judgments about such associations.

Each author or contributor is required to complete this financial disclosure declaration. In accordance with IAS–USA policy, the IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Disclosure information will be printed in the electronic Program and Abstracts eBook.

**Drug and Product Disclaimer**

This activity may contain information about the investigational uses of drugs or products that are not approved by the US Food and Drug Administration. Please consult full prescribing information before using any medication or product mentioned in this activity.

**Welcome Reception**

Please join us after the opening session, Monday, March 3rd, for an attendee welcome reception at the Hynes Convention Center. Light hors d’oeuvres and refreshments will be served. The reception will be held in Hall C.

**Meals**

Morning coffee breaks and afternoon snack breaks will be available to conference registrants in the Poster Hall. The Convention Center will open the permanent concession stands in Halls A, B, and D, as well as 2 Outtakes Express concession stands on Level 3, from 11 AM to 2 PM every day. The Outtakes Express stands will have cold items for purchase such items as wraps, sandwiches, salads, snacks, and chips as well as beverages. The permanent concession stands will offer these cold items as well as some hot items. **Attendees are on their own for lunch during the hours of approximately 12 noon to 1:30 PM each day.** Below is a list of food service options located in the Convention Center or within a short walking distance.

**At the Convention Center**

Towne Stove and Spirits  The Capital Grill

**At the Prudential Center**

(next to the South Lobby main entrance of the Convention Center)

5 Napkin Burger  Au Bon Pain
Ben & Jerry’s  Boston Chowda Co
California Pizza  Cheesecake Factory
Cheesecake Factory  Flamers
Flamers  Godiva
Gourmet India  Haru
Legal Sea Foods  Panda Express
Paradise Bakery  PF Chang’s
Pizzeria Regina  Poulet
Qdoba  Sarku Japan
Teavana  Tossed
Top of the Hub  Wagamama

**At the Sheraton Boston**

(next to the South Lobby main entrance of the Convention Center)

SideBar & Grille  Starbucks
Café Apropos

**At the Marriott Copley, Copley Place Mall, and Westin Copley Place**

(within 1 block of the Convention Center)

Bar 10  Champion’s Sports Bar
The Huntington  Legal Sea Foods
The Palm  Turner Fisheries
Starbucks  Osushi

**Overflow Accommodations for Session Rooms**

Most session rooms will have designated overflow areas. Should any session draw substantially higher attendance than can be accommodated, a nearby space will be available to provide a live audio and video feed.

**USB Flash Drive**

Each participant was supplied a blank 4Gbyte USB flash drive upon badge pick-up. The 2014 Program at a Glance and Agenda and Abstracts Book are available online to be loaded on to the USB flash drive. Downloads can be completed at the Cyber Cafe or directly from the conference website.

**Website**

For additional information about the conference please visit the website at: www.CROI2014.org

**Webcasts and Podcasts**

Plenaries, symposia, scientific overviews, oral abstract sessions, and themed discussions will be webcast and podcast. Webcasts are also available as streaming video for the Apple iPad and iPhone. Visit www.CROI2014.org or www.CROIwebcasts.org to access the CROI 2014 webcasts and podcasts. Webcasts will be available within 24 hours of the session.

**WiFi Access at the Conference**

Complimentary WiFi access is provided at the Hynes Convention Center. There are 2 network options:

- Hynes Wireless
- Hynes Wireless Fast (only for recent models of smart phones and tablets)

There is no login information required.
Badges
Badge pickup will be available at the registration lobby; please bring photo identification that clearly shows your name. You must wear your name badge to gain entry to all official meeting activities, including the poster sessions. **DO NOT LOSE YOUR BADGE.** Payment of an additional registration fee ($730) will be required to replace a lost badge.

Child Care
Children are not permitted entry into any meeting room, including the poster area. If you should require child care, please contact the concierge of your hotel.

Conference Etiquette
Please ensure all cell phones and pagers are off or are placed in SILENT mode.
No flash photography is permitted in session rooms.

Conference Services at the Hynes Convention Center

<table>
<thead>
<tr>
<th>Services</th>
<th>Location</th>
<th>Hours</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Boston Information</td>
<td>Main Lobby</td>
<td>Sunday 3 PM–5 PM</td>
<td>Local information and reservations assistance</td>
</tr>
<tr>
<td></td>
<td>Plaza Level</td>
<td>Monday 11 AM–7 PM</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tuesday to Thursday 10 AM–6 PM</td>
<td></td>
</tr>
<tr>
<td>Bag and Coat Check</td>
<td>Plaza Level</td>
<td>Monday 8 AM–9:30 PM</td>
<td>$3.00 per item</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tuesday/Wednesday 7:30 AM–6:30 PM</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Thursday 7:30 AM–6:30 PM</td>
<td></td>
</tr>
<tr>
<td>CyberCafe</td>
<td>Hall C</td>
<td>Sunday 3 PM–5 PM</td>
<td>Computers with Internet access available for webcasts, abstract searches, and messages</td>
</tr>
<tr>
<td></td>
<td>2nd Level</td>
<td>Monday to Wednesday 7 AM–7 PM</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Thursday 7 AM–6 PM</td>
<td></td>
</tr>
<tr>
<td>Media Center</td>
<td>Room 208</td>
<td>Monday 9 AM–7 PM</td>
<td>There is no onsite press registration. Registered press can pick up press kits and obtain location for press conferences.</td>
</tr>
<tr>
<td></td>
<td>2nd Level</td>
<td>Tuesday to Thursday 8 AM–6:30 PM</td>
<td></td>
</tr>
<tr>
<td>Message Center</td>
<td>Main Lobby</td>
<td>Sunday 3 PM–5 PM</td>
<td>Access to voice and text messages in addition to the CyberCafe</td>
</tr>
<tr>
<td></td>
<td>Plaza Level</td>
<td>Monday 7 AM–7 PM</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tuesday 7 AM–6 PM</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wednesday/Thursday 8 AM–6 PM</td>
<td></td>
</tr>
<tr>
<td>Badge Pickup</td>
<td>Main Lobby</td>
<td>Sunday 3 PM–6 PM</td>
<td>Location to pick up badges and conference materials</td>
</tr>
<tr>
<td>Attendee Services</td>
<td>Plaza Level</td>
<td>Monday 7 AM–7 PM</td>
<td></td>
</tr>
<tr>
<td>Housing Information</td>
<td></td>
<td>Tuesday 7 AM–6 PM</td>
<td></td>
</tr>
<tr>
<td>Scholarship Badge Pickup</td>
<td></td>
<td>Wednesday 8 AM–6 PM</td>
<td></td>
</tr>
<tr>
<td>Media Badge Pickup</td>
<td></td>
<td>Thursday 8 AM–12 PM</td>
<td></td>
</tr>
<tr>
<td>Speaker Ready Room</td>
<td>Room 200</td>
<td>Sunday 3 PM–6 PM</td>
<td>Oral abstract, invited, and themed discussion session speakers should drop off presentations at least 24 hours before their presentation. Poster presenters should submit an electronic version of their poster for placement on the CROI website before their assigned session.</td>
</tr>
<tr>
<td>and Poster Drop-off</td>
<td>2nd Level</td>
<td>Monday to Thursday 7:30 AM–6 PM</td>
<td></td>
</tr>
</tbody>
</table>
Hotel Information

CROI 2014 hotels are listed below. For more detailed housing information, please visit: www.CROI2014.org/housing.

**Omni Parker House**
60 School Street
Boston, MA 02108
PH: +1 617 227 8600

**The Boston Park Plaza Hotel & Towers**
50 Park Plaza at Arlington Street
Boston, MA 02116
PH: +1 617 426 2000

**Hyatt Regency Boston**
One Avenue de Lafayette
Boston, MA 02111
PH: +1 617 912 1234

**Taj Boston**
15 Arlington Street
Boston, MA 02116
PH: +1 617 536 5700

**Sheraton Boston Hotel**
39 Dalton Street
Boston, MA 02199
PH: +1 617 236 2000

**Marriott Boston Copley Place**
110 Huntington Avenue
Boston, MA 02116
PH: +1 617 236 5800

**The Westin Copley Place Boston**
10 Huntington Avenue
Boston, MA 02116
PH: +1 617 262 9600

**Hilton Boston Back Bay**
40 Dalton Street
Boston, MA 02115
PH: +1 617 236 1100

**The Colonnade Hotel**
120 Huntington Avenue
Boston, MA 02116
PH: +1 617 424 7000

**Mandarin Oriental Boston**
776 Boylston Street
Boston, MA 02199
PH: +1 617 535 8888

**The Midtown Hotel**
220 Huntington Avenue
Boston, MA 02115
PH: +1 617 262 1000

**Hampton Inn & Suites – Crosstown Center**
811 Massachusetts Avenue
Boston, MA 02118
PH: +1 617 445 6400
In the interest of objective, balanced, and scientifically rigorous activities, the IAS–USA seeks grant support from multiple commercial companies, particularly from companies with competing products. These companies have no input in or control over the selection of faculty or content of the presentations. CROI 2014 has received grant support commitments from the following commercial companies:

**Platinum**

MERCK, ViiV Healthcare

**Gold**

Bristol-Myers Squibb, Janssen

**Silver**

abbvie, Gilead, Salix Pharmaceuticals, Inc.

Additional support has been provided by Mylan, Inc.
MONDAY MARCH 3, 2014

Session W1 Workshop
9:00 AM – 1:15 PM  Ballroom B/C

Program Committee Workshop for New Investigators and Trainees

Target audience: This workshop is directed toward new trainees (e.g., undergraduate students, graduate students, postdoctoral fellows, and physician fellows) and new investigators (both international and domestic).

Level of knowledge: It is assumed that learners have been conducting active research in the field for less than 3 years.

Objectives: At the completion of the workshop, learners will be able to:

• Recognize the major areas of HIV investigation being presented at the conference
• Identify the top 3 to 5 research questions in the field of retroviruses and opportunistic infections today
• Describe some of the proposed solutions for addressing the challenges presented globally by a variety of retroviruses and opportunistic infections

Conveners
Judith S. Currier, University of California Los Angeles, Los Angeles, CA, United States
John W. Mellors, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States

1  HIV Pathogenesis: Current Understanding and Future Research  Dana H. Gabuzda, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States

2  HIV Cure Research  John W. Mellors, University of Pittsburgh, Pittsburgh, PA, United States

3  HIV Vaccine Immunology: Recent Progress and Continuing Challenges  Richard A. Koup, Vaccine Research Center, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD, United States

4  HIV Prevention Research: Progress and Challenges  Sharon L. Hillier, University of Pittsburgh School of Medicine, Magee-Womens Hospital, Pittsburgh, PA, United States

5  Pathogenesis and Control of HCV Infection  David L. Thomas, The Johns Hopkins University School of Medicine, Baltimore, MD, United States

Session MD Panel
1:30 PM – 2:30 PM  Ballroom B/C

6  Martin Delaney Panel: Hepatitis C Virus: From Trials and Tribulations To Triumph

The Martin Delaney Panel is held annually during the workshops for Young Investigators, International Scholars, and Community Educators in honor of pioneering HIV/AIDS activist Martin Delaney (1945-2009). It recognizes the important contributions of community advocacy and engagement to research.

Panel Leaders
Jeff Taylor, AIDS Treatment Activists Coalition, Palm Springs, CA, United States
Tracy Swan, Treatment Action Group, New York, NY, United States

Panelists
Isabelle Andrieux-Meyer, Médecins sans Frontières, Geneva, Switzerland
Jules Levin, National AIDS Treatment Advocacy Project (NATAP), New York, NY, United States
Lynn E. Taylor, Brown University, Providence, RI, United States

Session W2 Workshop
2:30 PM – 4:30 PM  Ballroom B/C

Clinical Trial Design and Analysis

Target audience: This session is directed to clinicians and scientists who are interested in designing or interpreting clinical trial results.

Level of knowledge: It is assumed that learners are familiar with the basic design of randomized and observational clinical studies.

Objectives: At the completion of the session, learners will be able to:

• Discuss one or more possible solutions to adherence challenges
• Define factorial designs and discuss their advantages and disadvantages
• Define meta-analyses and discuss their advantages and disadvantages

Conveners
Susan Buchbinder, San Francisco Department of Public Health, San Francisco, CA, United States
Richard Chaisson, The Johns Hopkins University School of Medicine, Baltimore, MD, United States

7  Adherence: The Achilles Heel for Trial Interventions  David R. Bangsberg, Massachusetts General Hospital Center for Global Health, Boston, MA, United States

8  Studying Multiple Interventions: Factorial Designs and Other Approaches  Richard J. Hayes, London School of Hygiene and Tropical Medicine, London, United Kingdom
Program and Agenda

9  So Many Trials, So Little Time: Meta-Analysis Dos and Don’ts
    Dean A. Follmann, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States

Session W3 Workshop
2:30 PM – 4:30 PM  Ballroom A
Frontiers in Laboratory Science Workshop

The purpose of this workshop is to present the main technological and conceptual developments in life sciences that are influencing HIV research or hold a significant potential for research. The presentation should educate and engage investigators and clinicians, and spark interest in emerging technologies. The workshop format is designed to provide in-depth views on technologies that define B and T cell development and characterization, progress in the study of host-pathogen interactions at molecular and cellular levels, and new approaches to genetic editing. Applications in HIV research will be discussed.

Conveners
Galit Alter, Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Cambridge, MA, United States
Amalio Telenti, Institute of Microbiology, University of Lausanne, Lausanne, Switzerland

10 Systems Immunology Approaches for Vaccine Profiling and Antibody Discovery
    Sai Reddy, Swiss Federal Institute of Technology Zurich, Basel, Switzerland

11 3-D Structural Analysis of HIV Using Correlative CryoEM and Live Cell Imaging
    Peijun Zhang, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States

12 Virus-Host Interactions Revealed Through Proteomics/Phosphoproteomics
    Beatrix Ueberheide, New York University Langone Medical Center, New York, NY, United States

13 CRISPRs and Other Genome Editing Systems
    Paul F. Bates, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, United States

Session W4 Workshop
2:30 PM – 4:30 PM  Room 304
Workshop for Clinicians Who Are New To Hepatitis C Management: A Case-Based Interactive Session

Target audience: This session is directed to persons newly engaged in the care of HCV-infected patients

Level of knowledge: It is assumed that learners are familiar with fundamental principles of medicine and antimicrobial therapy

Objectives: At the completion of the session, learners will be able to:

- List the practices routinely required for HCV-infected persons with cirrhosis
- Describe patients for whom HCV treatment is not currently advisable
- List the recommended therapies for persons with genotypes 1-4 HCV infection

Conveners
David L. Thomas, The Johns Hopkins University School of Medicine, Baltimore, MD, United States
Robert T. Schooley, University of California San Diego, San Diego, CA, United States

14 Liver Management
    Kenneth E. Sherman, University of Cincinnati College of Medicine, Cincinnati, OH, United States

15 Interactive Case Presentations
    David L. Wyles, University of California San Diego, San Diego, CA, United States
    Susanna Naggie, Duke Clinical Research Institute, Durham, NC, United States

Opening Session
5:00 PM – 7:00 PM  Auditorium
Welcome

Session NL1 Lecture
Bernard Fields Lecture

The Bernard Fields Lecture, named in tribute to the exemplary work of the esteemed microbiologist and virologist Bernard Fields, is given during the opening session, to recognize the speaker for their important and relevant contributions to the fields of virology and viral pathogenesis.

17 Making and Breaking Barriers To Cross-Species HIV-1 Transmission
    Paul D. Bieniasz, Aaron Diamond AIDS Research Center, Rockefeller University, New York, NY, United States

Session NL2 Lecture
N’Galy-Mann Lecture

The N’Galy-Mann Lecture, named in honor of Drs Bosenge N’Galy and Jonathan Mann for their pioneering work in HIV science in Africa, is given during the opening session and recognizes an HIV/AIDS researcher for his or her important and relevant work in the fields of epidemiology or clinical research.

18 Application of Scientific Knowledge and Evidence To Limit the Progression of HIV/AIDS and Fight Other Endemic Diseases in West Africa
    Souleymane Mboup, Centre Hospitalier Universitaire Aristide Le Dantec, Dakar, Senegal

Welcome Reception
7:00 PM – 9:00 PM  Hall C
TUESDAY MARCH 4, 2014

Session PL1 Plenary
8:30 AM – 9:00 AM  Auditorium
19  HPV Vaccines: Progress To Date and Future Worldwide Directions
    Douglas R. Lowy, National Cancer Institute, Bethesda, MD, United States

Session PL2 Plenary
9:00 AM – 9:30 AM  Auditorium
20  HIV in People Who Use Drugs
    Adeeba Kamarulzaman, University of Malaya, Kuala Lumpur, Malaysia

Session O-1 Oral Abstracts
10:00 AM – 12:15 PM  Ballroom B/C

Hepatitis

Moderators
Jürgen Rockstroh, University Hospital Bonn, Bonn, Germany
Kristen M. Marks, Weill Cornell Medical College, New York, NY, United States

21  Longitudinal Phenotypic Profiling of Early HCV-Specific CD4 T Cells in HIV- and HIV+ Individuals
    Diana Y. Chen1, Lyndok K. Matsubara1, Joelle Brown1, Stephanie S. Kula1a, Jasmeet Aneja1, Lisa Lewis-Ximena1, Eddie James2, William W. Kwok2, Arthur Y. Kim3, Georg M. Lauer4
    1Gastrointestinal Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States; 2Infectious Disease Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States; 3Laboratorio de Hepatitis Virales, Instituto Oswaldo Cruz, Fundacao Oswaldo Cruz, Rio de Janeiro, Brazil; 4Benaroya Research Institute at Virginia Mason, Seattle, WA, United States

22  Rapid Peripheral In Vivo Cellular Changes During Interferon–Free Treatment of Hepatitis C
    Eric G. Meissner1, Brian Santich1, Yu-Jin Lee1, Olga Prokunina1, Anuwulawpo Osumi2,3, Anita Kohli2,4, Henry Masur3, Susan Moin3, Shyamasundaran Kottill1
    1Laboratory of Immunoregulation, NIAID/NIH, Bethesda, MD, United States; 2SAIC-Frederick, Inc, Frederick, MD, United States; 3CCMO/NIH, Bethesda, MD, United States

23  Faldaprevir Plus Pegylated Interferon Alfa-2a/Ribavirin in HIV/HCV Coinfection: STARTVerso4
    Douglas Dieterich1, Cristina Turral2, Mark Nelson3, Keikawus Arasteh4, Vicente Soriano5, Josep Guardiola6, Sanjay Bhagani7, Jürgen K. Rockstroh7, Jerry O. Stern8, Anne-Marie Quinson9
    1Mount Sinai Medical Center, New York, NY, United States; 2Hospital Universitari Germans Trias i Pujol, Barcelona, Spain; 3Chearsle and Westminster Hospital, London, United Kingdom; 4EPIMED/Vivantes Auguste-Viktoria-Klinikum, Berlin, Germany; 5Hospital Carlos III, Madrid, Spain; 6Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 7The Royal Free Hospital, London, United Kingdom; 8Department of Medicine I, University of Bonn, Bonn, Germany; 9Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, United States

24  Simeprevir (TMC435) Plus PegIFN/Ribavirin in HCV Genotype-1/HIV-1 Coinfection (Study C212)
    Douglas Dieterich1, Jürgen K. Rockstroh2, Choe Orkin1, Félix Gutiérrez3, Marina B. Klein4, Jacques Reyl5, Lotte Tambuyzer4, Monika Peeters4, Alan Jenkins6, Wolfgang Jessner6
    1Incahn School of Medicine at Mount Sinai, New York, NY, United States; 2Medizinische Universitätsklinik I, Bonn, Germany; 3Royal London Hospital, London, United Kingdom; 4Hospital General de Elche and Universidad Miguel Hernández, Alicante, Spain; 5McGill University Health Centre, Montreal, QC, Canada; 6Guí De Chauliac University Hospital, Montpellier, France; 7Janssen Infectious Diseases BVBA, Beersel, Belgium; 8Janssen Research & Development, Raritan, NJ, United States

25  All–Oral Combination of Daclatasvir, Asunaprevir, and BMS–791325 for HCV Genotype 1 Infection
    Gregory T. Everson1, Paul J. Thuluvath2, Eric Lawitz2, Tarek Hassanein3, Maribel Rodriguez-Torres4, Trevor Hawkins5, Vinod Rustgi6, Federico Hinestrosa7, James Levin8, Karen Sim9
    1University of Colorado Denver, Aurora, CO, United States; 2Mercy Medical Center, Baltimore, MD, United States; 3The Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX, United States; 4Southern California Liver Centers, Coronado, CA, United States; 5Fundación de Investigación, San Juan, Puerto Rico; 6Southwest CARE Center, Santa Fe, NM, United States; 7Metropolitan Research, Arlington, VA, United States; 8Orlando Immunology Center, Orlando, FL, United States; 9Dean Foundation for Health, Research and Education, Inc, Madison, WI, United States; 10Bristol–Myers Squibb, Hopewell, NJ, United States

26  Sofosbuvir Plus Ribavirin for HCV Genotype 1-3 Infection in HIV Coinfected Patients (PHOTON-1)
    Susanna Naggie1, Mark Sulkowski2, Jacob Lalezari3, W. Jeffrey Fessel3, Karam Mounzer4, Margaret Shuhart5, Anne Lueckemeyer6, David Asmuth7, Douglas Dieterich8, Maribel Rodriguez-Torres2, and The Gilead PHOTON-1 Study Team
    1Duke Clinical Research Institute, Durham, NC, United States; 2The Johns Hopkins University, Baltimore, MD, United States; 3Quest Clinical Research, San Francisco, CA, United States; 4Kaiser Permanente, San Francisco, CA, United States; 5Philadelphia FIGHT, Philadelphia, PA, United States; 6Harborview Medical Center, Seattle, WA, United States; 7San Francisco General Hospital, San Francisco, CA, United States; 8University of California Davis Medical Center, Sacramento, CA, United States; 9Mount Sinai School of Medicine, New York, NY, United States; 10Fundacion De Investigacion, San Juan, PR, United States

27LB  Combination Oral, Hepatitis C Antiviral Therapy for 6 or 12 Weeks: Final Results of the SYNERGY Trial
    Anita Kohli1,2, Zayani Sims2, Amy Nelson3, Anu Osinusi1,4, Geb Tefari5, Phil Pang6, William Symonds5, John Mc Hutchison5, Henry Masur4, Shyam Kottili3
    1Critical Care Medicine Department, National Institutes of Health, Bethesda, MD, United States; 2Clinical Research Directorate/ Clinical Monitoring Research Program, Leidos Biomedical Research, Inc. (formerly SAIC–Frederick, Inc.), Frederick National Laboratory for Cancer Research, Frederick, MD, United States; 3Laboratory of Immunoregulation, National Institutes of Health, Bethesda, MD, United States; 4University of Maryland, Baltimore, MD, United States; 5Columbia University, New York, NY, United States; 6Dana Farber Cancer Institute, Boston, MA, United States; 7University of Florida, Gainesville, FL, United States
Program and Agenda

Oral Sessions • Tuesday, March 4, 2014

28LB Daclatasvir in Combination With Simeprevir ± Ribavirin for Hepatitis C Virus Genotype 1 Infection
Stefan Zeuzem1, Christophe Hezode1, Jean-Pierre P. Bronowicki1, Veronique Loustad-Ratti1, Francisco Gea1, Maria Buti1, Maria Beumont-Mauviel1, Navdeep Boparai1, Gaston Picchio2, Stephanie Noviello3, on behalf of the LEAGUE-1 Study Team
1JW Goethe University Hospital, Frankfurt a.m., Germany; 2Hôpital Henri Mondor, Paris, France; 3Centre Hospitalier Universitaire de Nancy, Vandoeuvre Les Nancy, France; 4Université Limoges, Limoges, France; 5University Hospital La Paz, Madrid, Spain; 6Hospital Vall Hebron, Barcelona, Spain; 7Janssen Infectious Disease BVBA, Beerse, Belgium; 8Bristol-Myers Squibb, Princeton, NJ, United States; 9Janssen Research and Development, Titusville, NJ, United States

29LB PEARL III: SVR >99% After 12 Wks of NAIVE HCV GT1b Infection
Peter Ferenci1, Anders Nyberg1, David Bernstein2, Yaacov Baruch1, Vladimir Chulamov2, Wangang Xie3, Daniel Cohen3, Thomas Podsadecki6, K Rajender Reddy4, on behalf of the PEARL-III Study Group
1Universitätsklinik fuer Innere Medizin III, Vienna, Austria; 2Kaiser Permanente, San Diego, CA, United States; 3North Shore University Hospital, Manhasset, NY, United States; 4Rambam Health Care Campus, Haifa, Israel; 5Federal Budget Institute of Science, Moscow, Russian Federation; 6AbbVie Inc., North Chicago, IL, United States; 7University of Pennsylvania, Philadelphia, PA, United States

Session 0-2 Oral Abstracts

10:00 AM – 12:00 PM Room 304
NeuroHIV: Developments in Treatment and Pathogenesis

Moderators
Edwina J. Wright, The Alfred Hospital, Monash University, Melbourne, Australia
Victor G. Valcour, University of California San Francisco, San Francisco, CA, United States

30 Early Antiretroviral Therapy Appears To Normalize Intrathecal Markers of Immune Activation
Julia Peterson1, Evelyn Lee1, Dietmar Fuchs2, Richard W. Price3, Serena Spudich1
1Neurology, University of California San Francisco, San Francisco, CA, United States; 2Innsbruck Medical University, Innsbruck, Austria; 3Neurology, Yale University, New Haven, CT, United States

31 Immediate Antiretroviral Therapy Mitigates the Development of Neuronal Injury in Acute HIV Michael J. Peluso1, Victor Valcour2, Jintanat Ananworanich3,4, Pasiri Sithinamsuwan2, Thep Chalermchai1, Nithya Chemchey4, Bonnie Slike5, Magnus Gisslen1, Henrik Zetterberg2, Serena Spudich1, on behalf of the RV254/SEARCH 010 and 011 Study Teams
1Department of Medicine, Brigham and Women’s Hospital, Boston, MA, United States; 2Memory and Aging Center, University of California San Francisco, San Francisco, CA, United States; 3Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; 4SEARCH, The Thai Red Cross AIDS Research Center, Bangkok, Thailand; 5Pramongkuk/Kiao Hospital, Bangkok, Thailand; 6US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, United States; 7University of Gothenburg, Gothenburg, Sweden; 8Yale University School of Medicine, New Haven, CT, United States

32 Replication of HIV-1 in the Central Nervous System of Adults Early After Infection
Christa Buckheit Sturdevant1, Gretja Schnell2, Richard W. Price3, Serena Spudich1, Ronald Swanstrom3
1UNC Chapel Hill, Chapel Hill, NC, United States; 2University of California San Francisco, San Francisco, CA, United States; 3Yale University, New Haven, CT, United States

33 Persistent CSF, But Not Plasma HIV RNA Is Associated With Increased Risk of New-Onset Depression
Edward R. Hammond1, Rosa M. Crum1, Glenn J. Treisman1, Shruti H. Mehta1, Ronald J. Ellis2, Igor Grant3, Scott L. Letendre2, Christina M. Marra1, Susan Morgello1, Justin C. McArthur1
1The Johns Hopkins University, Baltimore, MD, United States; 2University of California San Diego, San Diego, CA, United States; 3University of Washington, Seattle, WA, United States; 4icahn School of Medicine at Mount Sinai, New York, NY, United States

34 CSF Metabolomics Reveals Altered Waste Clearance and Accelerated Aging in HIV Patients With HAND
Edana Cassof1, Vikas Misra1, Anupriya Dutta1, Susan Morgello1, Dana Gabuzda1
1Cancer Immunology and AIDS, Dana-Farber Cancer Institute, Boston, MA, United States; 2The Mount Sinai Medical Center, New York, NY, United States

35 Cerebral Small Vessel Disease and HAND in ARV-Treated Subjects
Virawud Soontornpiyomki, Anya Umlauf, Benchawanna Soontornpiyomki, Ben Gouaux, Will Toperoff, David J. Moore, Eliezer Masiiah, Igor Grant, Cristian L. Achim
UC San Diego, San Diego, CA, United States

Session 0-3 Oral Abstracts

10:00 AM – 12:15 PM Ballroom A
Prevention and Epidemiology: Evolving Trends

Moderators
Rochelle P. Walensky, Harvard Medical School, Massachusetts General Hospital, Boston, MA, United States
Ian M. McGowan, University of Pittsburgh, Pittsburgh, PA, United States

36 Temporal Trends in Prognostic Markers of HIV-1 Virulence and Transmissibility
Nikos Pantazis1, Kholoud Porter2, Dominique Costagliola3, Andrea De Luca4, Jade Ghez5, Marguerite Guiguette6, Anthony D. Kelleher7, Charles Morrison8, Rodolphe Thiebaut9, Giota Touloumi1, on behalf of the CASCADE Collaboration in EuroCoord
Transmission Clusters, Recent Infection and STIs Among New HIV Cases: Implications for Prevention
Hong-Ha M. Truong1, Sharon Pipkin1, Kara O’Keefe1, Brian Louie1, Teri Liefger1, Willi McFarland1,2, Robert M. Grant1,2, Mark Pandori1, Kyle Bernstein3, Susan Scheer5
1University of California San Francisco, San Francisco, CA, United States; 2Gladstone Institute of Virology and Immunology, San Francisco, CA, United States; 3Department of Public Health, San Francisco, CA, United States

Race and Age Disparities in HIV Incidence and Prevalence Among MSM in Atlanta, GA
Eli S. Rosenberg1, Patrick S. Sullivan1, Colleen F. Kelley1, Travis H. Sanchez1, Nicole Luis1, Carlos del Rio1, Laura F. Salazar4, Paula F. Frew1, John L. Peterson1
1Epidemiology, Emory University Rollins School of Public Health, Atlanta, GA, United States; 2Infectious Diseases, Emory University School of Medicine, Atlanta, GA, United States; 3Hubert Department of Global Health, Emory University Rollins School of Public Health, Atlanta, GA, United States; 4Institute of Public Health, Georgia State University, Atlanta, GA, United States; 5Medicine, Emory University School of Medicine, Atlanta, GA, United States; 6Psychology, Georgia State University, Atlanta, GA, United States

Correlating GSK1265744 Plasma Levels To Prevention of Rectal SHIV Transmission in Macaques
Chasity D. Andrews1, William Spreen2, Yun Lan Yueh1, Agegnehu Gettie1, Kasi Russell-Lodrigue1, Hiroshi Mohri1, Cecilia Cheng-Mayer1, Zhi Hong2, Martin Markowitz1, David D. Ho1
1Aaron Diamond AIDS Research Center, The Rockefeller University, New York, NY, United States; 2GlaxoSmithKline, Research Triangle Park, NC, United States; 3Tulane National Primate Research Center, Covington, LA, United States

Monthly GSK744 Long-Acting Injections Protect Macaques Against Repeated Vaginal SHIV Exposures
Jessica Radzio1, William Spreen2, Yun Lan Yueh2, James Mitchell1, Lee Cresa Jenkins1, J. Gerardo Garcia-Lerma1, Walid Heneine1
1Division of HIV/AIDS Prevention, CDC, Atlanta, GA, United States; 2GlaxoSmithKline, Research Triangle Park, NC, United States

Safety and Pharmacokinetics/Pharmacodynamics of Dapivirine and Maraviroc Vaginal Rings
Beatrice A. Chen1, Lori Panther2, Craig Hoesley1, Craig Hendrix1, Ariane van der Straten3, Maria Hushik1, Lydia E. Soto-Torres4, Annalene Neil5, Sherri Johnson6, Charlene S. Dezzutti7
1University of Pittsburgh, Pittsburgh, PA, United States; 2The Fenway Institute, Boston, MA, United States; 3University of Alabama at Birmingham, Birmingham, AL, United States; 4The Johns Hopkins University, Baltimore, MD, United States; 5RTI International, San Francisco, CA, United States; 6Statistical Center for HIV/AIDS Research & Prevention, Fred Hutchinson Cancer Research Center, Seattle, WA, United States; 7Division of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, MD, United States

FAME-02: A Phase I Trial To Assess Safety, PK, and PD of Gel and Film Formulations of Dapivirine
Katherine E. Bunge1, Charlene S. Dezzutti2, Ingrid Macio3, Craig W. Hendrix4, Lisa C. Rohan3, Mark A. Marzinke3, Brid Devlin4, Leslie A. Meyn5, Hans M. L. Spiegel5, Sharon L. Hillier1
1Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh, Pittsburgh, PA, United States; 2Magee-Womens Research Institute, Pittsburgh, PA, United States; 3Department of Medicine, The Johns Hopkins University, Baltimore, MD, United States; 4International Partnership for Microbicides, Silver Spring, MD, United States; 5Division of AIDS, National Institutes of Health, Bethesda, MD, United States

Single-Agent TDF Versus Combination FTC/TDF PrEP Among Heterosexual Men and Women
Jared Baeten1, Deborah Donnell1, Patrick Ndase1, Nelly Mugo1, Connie Celum1, Partners PrEP Study Team
1University of Washington, Seattle, WA, United States; 2Fred Hutchinson Cancer Research Center, Seattle, WA, United States; 3Kenya Medical Research Institute, Nairobi, Kenya

Divergent Adherence Estimates With Pharmacokinetic and Behavioral Measures in VOICE (MTN003)
Ariane van der Straten1,2, Elizabeth R. Brown1, Jeanne M. Marrazzoi1, Zvavahera M. Chirenje3, Kailazarid Gomez2, Jeanna M. Piper1, Craig W. Hendrix3
1Women’s Global Health Imperative, RTI International, San Francisco, CA, United States; 2Department of Medicine, Center for AIDS Prevention Studies (CAPS), University of California San Francisco, San Francisco, CA, United States; 3Statistical Center for HIV/AIDS Research & Prevention (SCHARP), Fred Hutchinson Cancer Research Center, Seattle, WA, United States; 4Department of Medicine, Division of Infectious Diseases, University of Washington, Seattle, WA, United States; 5Department of Obstetrics and Gynecology, University of Zimbabwe, Harare, Zimbabwe; 6FHI 360, Research Triangle Park, NC, United States; 7Division of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, MD, United States; 8Department of Medicine, The Johns Hopkins University, Baltimore, MD, United States
153LB HIV Transmission Risk Through Condomless Sex: If HIV+ Partner On Suppressive ART: PARTNER Study
Alison Rodger¹, Tina Bruun², Valentina Cambianò³, Pietro Vernazza⁴, Vicente Estrada⁵, Jan Van Lunzen⁶, Simon Collins⁷, Anna Maria Geretti⁸, Andrew Phillips¹, Jens Lundgren⁹, for the PARTNER Study Group
¹Research Department of Infection & Population Health, University College London, London, United Kingdom; ²Copenhagen HIV Programme, University of Copenhagen, Copenhagen, Denmark; ³Infectious Diseases, Cantonal Hospital, St. Gallen, Switzerland; ⁴Department of Infectious Diseases, Hospital Clínico San Carlos, Madrid, Spain; ⁵Department of Infectious Diseases, University Medical Center, Hamburg, Germany; ⁶HIV i-Base, London, United Kingdom; ⁷Institute of Infection & Global Health, University of Liverpool, Liverpool, United Kingdom; ⁸Centre for Viral Diseases and the Copenhagen HIV Programme, University of Copenhagen, Copenhagen, Denmark

Session 0-4 Oral Abstracts
10:00 AM – 12:00 PM Room 312
Host Factors and HIV/SIV Replication

Moderators
Renate R. Köenig, Paul-Ehrlich-Institut, Langen, Germany
Alan N. Engelman, Dana-Farber Cancer Institute, Boston, MA, United States

45 Inhibition of Cul4A Neddylation Causes a Reversible Block To SAMHD1-Mediated Restriction of HIV-1
Henning Hofmann¹, Thomas D. Norton, Eric C. Logue, Megan L. Schultz, Sylvie B. Polsky, Nicole Sunseri, Nathaniel R. Landau
NYU School of Medicine, New York, NY, United States

46 MX2, an Interferon-Induced Inhibitor of HIV-1 Infection
Melissa Kane¹, Shalini S. Yadav¹, Julia Bitzegeio¹, Sebba B. Kutluay¹, Trinity Zang¹, Sam J. Wilson¹, Daniel Blanco-Melo¹, Masahiro Yamashita¹, Theodora Hatziioannou², Paul D. Bieniasz¹,²
¹The Rockefeller University, New York, NY, United States; ²Howard Hughes Medical Institute, New York, NY, United States; ³Aaron Diamond AIDS Research Center, New York, NY, United States

47 BCA2/Rabring7 Targets HIV-1 Gag for Lysosomal Degradation in a Tetherin-Independent Manner
Ruth Serra-Moreno
Harvard Medical School, Southborough, MA, United States

48 Crystal Structure of APOBC3F Elucidates HIV-1 Vif Interaction and Dynamic Oligomerization
Markus-Frederik Bohn¹, Shivender M. D. Shandilya, Mohan Somasundaran, Celia A. Schiffer
Biochemistry, UMass Medical School, Worcester, MA, United States

50 Global Identification of the RNA Targets of HIV-1 Gag During Particle Genesis
Sebia B. Kutluay¹, Daniel Blanco-Melo¹, Trinity Zang¹, Paul D. Bieniasz¹,²
¹The Rockefeller University AIDS Research Center, New York, NY, United States; ²Rockefeller University & Howard Hughes Medical Institute, New York, NY, United States

51 Gorillas Transmitted SIV To Humans: Identification of HIV-1 Group P and O Ancestors
Mirela D’arc¹, Anídiyo Ayoubi¹, Armandine Esteban¹, Avelin Aghokeng², Sabrina Locatelli², Lucie Etienne², Beatrice Hahn³, Eric Delaporte⁴, Etel Mpoudi Ngole⁵, Martine Peeters⁶, ¹Univeristé Federal do Rio de Janeiro, Rio de Janeiro, Brazil; ²UMI 233, IRD and University of Montpellier 1, Montpellier, France; ³Projet PENSICA and IMPP/CREMER, Yaoundé, Cameroon; ⁴University of Pennsylvania, Philadelphia, PA, United States; ⁵Projet PENSICA and IMPP/CREME, Yaoundé, Cameroon

52LB A Gorilla Reservoir for Human T-lymphotropic Virus Type 4 (HTLV-4)
Matthew LeBreton¹,², William M. Switzer¹, Cyrille F. Djoko², Amethyst Gillis³, Hongwei Jia³, Anupama Shankar³, HaoQiang Zheng⁴, Bradley S. Schneider¹, Nathan D. Wolfe⁴,⁵
¹Metabiota, San Francisco, CA, United States; ²Global Viral, San Francisco, CA, United States; ³CDC, Atlanta, GA, United States; ⁴Global Viral, San Francisco, CA, United States

Session TD1 Themed Discussion
1:30 PM – 2:30 PM Room 309
Acute HCV Infection

Discussion Leader
Georg M. Lauer, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States

676 Seminal HCV RNA Level May Mirror Dynamics of Plasma HCV RNA in HIV-Positive Men With Acute HCV
Daniel Bradshaw¹, François Lamoury¹, Beth Catlett², Tanya L. Applegate¹, John Mcallister², Gregory J. Dore³, Gail Matthews⁴, Mark Danta⁵
¹Kirby Institute, University of New South Wales, Sydney, Australia; ²St Vincent’s Hospital, Sydney, Australia; ³Faculty of Medicine, University of New South Wales, Sydney, Australia

675 Higher Risk of Sexually Acquired HCV Coinfection in MSM With Wide HIV Transmission Bottleneck
Roger D. Kouyos¹, Andri Rauch¹, Dominique Braun¹, Sabine Yerly², Jürg Böni³, Thomas Klimkait³, Vincent Aubert⁴, Bruno Ledergerber⁴, Huldrych Günthard⁵, The Swiss HIV Cohort Study (SHCS)
¹University Hospital Zurich, University of Zurich, Zurich, Switzerland; ²Inselspital Bern, Bern, Switzerland; ³University of Geneva, Geneva, Switzerland; ⁴University of Zurich, Zurich, Switzerland; ⁵University of Basel, Basel, Switzerland; ⁶University of Lausanne, Lausanne, Switzerland
Session TD2 Themed Discussion
1:30 PM – 2:30 PM  Ballroom A
Restriction Factors

Discussion Leader
Paul W. Spearman, Emory University, Atlanta, GA, United States

188 Degradation of SAMHD1 Specifically Decreases the Efficacy of Thymidine HIV RT Analog Inhibitors
Ester Ballana, Gerard Terradas, Eva Riveira-Muñoz, Bonaventura Clotet, Eduardo Palou, José A. Esté, IrsiCaixa AIDS Research Institute, Badalona, Spain

182 Characterizing Novel N-Terminal Domains of APOBEC3G
Meiling R. May1, Ann M. Sheehy2
1College of the Holy Cross, Worcester, MA, United States, 2Biology, College of the Holy Cross, Worcester, MA, United States

188A Natural Resistance To HIV-1 by Select APOBEC3H Haplotypes
Eric W.Refsland1, Judd F. Hultquist1, Elizabeth M. Luengas1, Rachel Prosser1, Keith Henry1, Michael Emerman1, Reuben S. Harris1
1Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, MN, United States, 2Hennepin County Medical Center, Minneapolis, MN, United States, 3Fred Hutchinson Cancer Research Center, Seattle, WA, United States

186 Nuclear Import of APOBEC3F-Labeled HIV-1 Preintegration Complexes
Ryan C. Burdick, Wei-Shau Hu, Vinay K. Pathak
HIV Drug Resistance Program, National Cancer Institute, Frederick, MD, United States

Session TD3 Themed Discussion
1:30 PM – 2:30 PM  Room 304
Heart Failure, Cardiac Steatosis, and HIV

Discussion Leader
Wendy S. Post, The Johns Hopkins University School of Medicine, Baltimore, MD, United States

725 ST2 and GDF-15 Are Associated With Structural Heart Disease and Mortality in HIV
Eric Secemsky, Rebecca Scherzer, Elaine Nitta, Alan Wu, David Lange, Steven Deeks, Jeffrey Martin, James Snider, Peter Ganz, Priscilla Hsu, University of California San Francisco, San Francisco, CA, United States

723 Elevated NT-proBNP Levels Predict Mortality in HIV-Infected Women
Matthew R. Gingo1, Kidane Ghebreahwariat1, Jong-Hyeon Jeong1, Yanxia Chu1, Quanwei Yang1, Lorrie Lucht1, David Hanna2, Jason Lazaara, Mark Gladwin1, Yingze Zhang1, Alison Morris1
1University of Pittsburgh, Pittsburgh, PA, United States, 2Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY, United States, 3SUNY Downstate Medical Center, Brooklyn, NY, United States, 4University of Pittsburgh, Pittsburgh, PA, United States

726 Depression and HIV Are Risk Factors for Incident Heart Failure Among Veterans
Jessica R. White1, Chung-Chou H. Chang1, Adeel A. Butt2,3, Hilary A. Tindall1, Maria C. Rodriguez Barradas1,4, David Rimland5,6, David Leaf7,8, Matthew Budoff10,11, Amy C. Justice1,2,3, Matthew S. Freiberg5
1University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, United States, 2University of Pittsburgh School of Medicine, Pittsburgh, PA, United States, 3Veteran Affairs Pittsburgh Healthcare System, Pittsburgh, PA, United States, 4Baylor College of Medicine, Houston, TX, United States, 5Veteran Affairs Greater Los Angeles Health Care System, Los Angeles, CA, United States, 6University of California San Francisco, San Francisco, CA, United States, 7University of Pittsburgh, Pittsburgh, PA, United States, 8University of Pittsburgh School of Medicine, Pittsburgh, PA, United States, 9University of Pittsburgh, Pittsburgh, PA, United States, 10Veteran Affairs Connecticut Healthcare System, West Haven, CT, United States, 11Yale University School of Medicine, New Haven, CT, United States, 12National Institutes of Health, Bethesda, MD, United States

724 Cardiac Steatosis Increased in HIV: Related To Gender, Visceral Fat and ARV Exposure
Julia B. Purdy1, Chia-Ying Liu2, Sabrina Mangat3, Horacio Duarte1, Diana Thiera6, Nancyanne Schmidt1, Jamie Hur3, Christopher T. Sibley1, Christopher T. Sibley1, David A. Bluemke1, Colleen Hadigan3, 1Critical Care Medicine, National Institutes of Health, Bethesda, MD, United States, 2Diagnostic Radiology Department, National Institutes of Health, Bethesda, MD, United States, 3Critical Care Medicine, National Institutes of Health, Bethesda, MD, United States, 4National Institutes of Health, Bethesda, MD, United States, 5National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States, 6University of Washington School of Medicine, Seattle, WA, United States, 7Vanderbilt University School of Medicine, Nashville, TN, United States, 8Stony Brook University School of Medicine, Stony Brook, NY, United States, 9Drexel University College of Medicine, Philadelphia, PA, United States
Session TD4 Themed Discussion
1:30 PM – 2:30 PM Room 312
Response To Early ART Initiation in Infants
Discussion Leader
Mark F. Cotton, Stellenbosch University, Cape Town, South Africa

925 Routine Antibody Tests Have No Place in Determining HIV Status After Early ART: Evidence From CHER
Helen Payne1,2, Nonhlanhla Mkhize1, Lynn Morris1, Kennedy Ot owombe1, Ravindre Panchia1, Avy Vi olari1, Nigel Klein1, Abdel G. Babiker1, Mark F. Cotton1, Diana M. Gibbi1
1Infectious Diseases and Microbiology, Institute of Child Health, London, United Kingdom; 2Children’s Infectious Diseases Clinical Research Unit, Faculty of Medicine and Health Sciences, University of Stellenbosch, Cape Town, South Africa; 3Centre for HIV and STIs, National Institute for Communicable Diseases, Johannesburg, South Africa; 4Clinical Trials Unit, Medical Research Council, London, United Kingdom

926 Early Cytomegalovirus Viraemia and Clinical Outcomes of HIV-Infected Children in the Early ART Era
Nei-yuan Hsiao1,2,3, Kennedy Otowombe2, Landon Myer3, Avy Volari2, Diana Gibb1, Ravindre Panchiar1, Abdel Babiker4, Patrick Jean-Phillip1, Mark Fredric Cotton6
1Clinical Laboratory Sciences, University of Cape Town, Cape Town, South Africa; 2Perinatal HIV Research Unit, Johannesburg, South Africa; 3Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa; 4Medical Research Council UK, London, United Kingdom; 5National Institute of Allergy and Infectious Diseases, Bethesda, MD, United States; 6Paediatrics and Child Health, Stellenbosch University, Cape Town, South Africa

Session TD5 Themed Discussion
1:30 PM – 2:30 PM Room 311
Treatment Cascade and Loss To Follow-Up
Discussion Leader
David R. Bangsberg, Massachusetts General Hospital Center for Global Health, Boston, MA, United States

1060 Comparative Effectiveness of HIV Care and Treatment Programs in East Africa
Elvin Geng1, Thomas Odeny2, Rita Lyamuya3, Alice Nkigwa-Muwanga4, Mwesia Bwana1, Paula Braithstein2, Andrew Kambugu2, Elizabeth Bukusi2, Geoffrey Somi3, Lameck Diero1, Jeffrey Martin1
1Pediatrics, University of Washington, Seattle, WA, United States; 2Epidemiology, Harvard School of Public Health, Boston, MA, United States; 3Northwestern University Feinberg School of Medicine, Chicago, IL, United States; 4National Institute of Child Health and Human Development, Bethesda, MD, United States; 5Children’s Hospital of Philadelphia, Philadelphia, PA, United States; 6University of California San Diego, La Jolla, CA, United States; 7University of Illinois at Chicago, Chicago, IL, United States

1063 HIV Care Cascade Among Hard To Reach Populations in India: Need To Expand HIV Counseling and Testing
Shruti H. Mehta1, Gregory M. Lucas2, Suniti Solomon2, Aylur K. Srikrishnan3, Allison McFall4, P. Nandagopali5, Pachamuthu Balakrishnan6, Muniratsam S. Kumar3, David D. Celentano2, Sunil S. Solomon1,3
1Epidemiology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States; 2The Johns Hopkins University School of Medicine, Baltimore, MD, United States; 3YR Gaitonde Centre for AIDS Research and Education, Chennai, India

1061 Loss To Follow-up: Determining Outcomes for Adults Enrolled in HIV Services in Kenya
William Reidy1, Mansi Agarwal1, Matthew Lamb2, Mark Hawken1, Duncan Chege3, Batya Eliu4, Elaine J. Abrams5, Elvin Geng6
1Columbia University, New York, NY, United States; 2University of Massachusetts Medical School, Worcester, MA, United States; 3Gombe National Park, East Africa; 4Idaho National Laboratory, Idaho Falls, ID, United States; 5University of Washington, Seattle, WA, United States; 6Pediatrics, University of Washington, Seattle, WA, United States
1 Mailman School of Public Health, ICAP-Columbia University, New York, NY, United States; 2 School of Medicine, University of California at San Francisco, San Francisco, CA, United States

1064 Unplanned Interruptions in HIV Care in Nigeria: Rates and Implications
Aima A. Ahonkhai1, Bolanle Banigbe2, Juliet Adeola2, Ifeyinwa Onwuatuol2, Ingrid V. Bassett3, Elena Losina4, Kenneth A. Freedberg1, Prospor Okonkwo2, Susan Regan1
1 Massachusetts General Hospital, Boston, MA, United States; 2 AIDS Prevention Initiative Nigeria, Abuja, Nigeria; 3 Infectious Disease, Massachusetts General Hospital, Boston, MA, United States; 4 Brigham and Women’s Hospital, Boston, MA, United States

1065 Using the Side Door: Non-Linear Patterns Within the HIV Treatment Cascade in Zambia
Charles B. Holmes1,2, Angela Bengtson1,2, Izukanji Sikazwe1,2, Carolyn Bolton-Moore1,2, Lloyd B. Mulenga1, Patrick Musonda1,3, Benjamin H. Chi1,2
1 Centre for Infectious Disease Research in Zambia, Lusaka, Zambia; 2 University of North Carolina School of Medicine, Chapel Hill, NC, United States; 3 University of East Anglia, East Anglia, United Kingdom

POSTER SESSIONS
2:30 PM – 4:00 PM
(Use the Poster Abstract section of the Program at a Glance, page 37 to 106, for specific posters in each session)

Session P-A1 SAMHD1
Session P-A2 Integration/Nuclear Import
Session P-B1 Transmission Networks
Session P-C1 The Gut and Lymph Nodes in HIV Pathogenesis
Session P-C2 Immune Activation and Pathogenesis
Session P-C3 NK Cells in HIV Pathogenesis
Session P-C4 CD8 T-Cell Pathogenesis
Session P-C5 Exhaustion Markers
Session P-D1 It’s All About the Gut
Session P-E1 Modulating Immune Activation
Session P-E2 Therapeutic Vaccines and Immunotherapies
Session P-F1 Mechanisms of HIV Latency
Session P-F2 Dynamics of Persistent and Rebound HIV
Session P-F3 Effect of ART Early in HIV Infection
Session P-G1 CNS Viral Escape and Neuroinflammation on ART
Session P-G2 HAND in Aging Populations
Session P-H1 Clinical Pharmacology of TB and HCV Co-infection
Session P-H2 Pharmacogenetics: Drug Disposition To Therapeutics
Session P-I1 Preclinical Studies of Novel ART Approaches: Entry
Session P-I2 Preclinical Studies of Novel ART Approaches: Post-Entry
Session P-K1 Viral Set Point and Elite Controllers
Session P-L1 Primary Drug Resistance
Session P-L2 Acquired HIV Drug Resistance
Session P-M1 HIV Early Detection: Application of New Assays
Session P-N1 HCV Testing and Epidemiology
Session P-N2 HCV Pre-Clinical Studies and Pharmacology
Session P-O1 Lymphoma/Liver/Gammopathy
Session P-O2 Cancer: Natural History and Epidemiology
Session P-P1 Heart Failure, Cardiac Steatosis, and HIV
Session P-P2 Immune Activation, Immunodeficiency, and CVD
Session P-Q1 Biomarkers and Non-AIDS Events
Session P-Q2 Frailty: Physical Function and Telomeres
Session P-Q3 Diabetes and Insulin Resistance
Session P-Q4 Reproductive Hormones in Women: Impact on Risk and Barrier Dysfunction
Session P-T1 Clinical Outcomes of HIV-Exposed Uninfected Infants
Session P-T2 Neonatal Sequelae of In Utero ART Exposure
Session P-U1 ART in Children and Adolescents
Session P-U2 HIV Drug Resistance and Tropism in Children and Youth
Session P-U3 ARV Pharmacokinetics, Pharmacogenetics, and Safety in Children and Adolescents
Session P-W1 Cascade of Care and Testing
Session P-W2 Cascade of Care, Linkage, and Retention
Session P-W3 Cascade of Care, Community Viral Load, and Viral Suppression
Session P-W4 Cascade of Care
Session P-X1 HIV Testing in Low-Income Settings
Session P-X2 HIV Treatment and Care

Session S1 Symposium
4:00 PM – 6:00 PM Ballroom B/C
Toward a Cure: A Challenging Game of Hide and Seek

Target audience: This session is directed to clinicians, basic researchers, and affected persons interested in the latest developments in HIV cure research.

Level of knowledge: It is assumed that learners are familiar with basic aspects of HIV replication and latency as well as standard therapeutic options.

Objectives: At the completion of the session, learners will be able to:

• Understand the effects of early treatment on the establishment of the latent reservoir
• Understand the roles of different T-cell subsets in maintaining the latent reservoir
• Describe how different animal models can be used to investigate cure strategies prior to clinical trials

Conveners
Christine Rouzioux, Université Paris Descartes, Paris, France
Hiroyu Hatano, University of California San Francisco, San Francisco, CA, United States

53 Impact of Early ART On HIV Eradication in Children
Katherine F. Luzuriaga
University of Massachusetts Medical School, Worcester, MA, United States

54 T Memory Stem Cells: The Stem Cell Reservoir for HIV?
Mathias Lichterfeld
Massachusetts General Hospital, Boston, MA, United States

55 Inflammation as an Obstacle for Remission: Lessons Learned From Non-Human Primate Models
Michaela Müller-Trutwin
Institut Pasteur, Paris, France

56 Humanized Mouse Models for Studies On HIV Latency, Reservoirs, and Eradication Strategies
J. Victor García-Martinez
University of North Carolina at Chapel Hill, Chapel Hill, NC, United States

Session S2 Symposium
4:00 PM – 6:00 PM Ballroom A
HCV and Beyond

Target audience: This session is directed to clinicians and researchers interested in viral hepatitis, including the latest information on the epidemiology of HEV, the biology of HCV, and efforts to cure HCV and HBV infections.

Level of knowledge: It is assumed that learners are familiar with basic principles of virology, epidemiology, and immunology.

Objectives: At the completion of the session, learners will be able to:
• Recognize the nonhuman reservoirs for HEV infection
• Compare the innate immune responses to HCV and HIV infections
• Compare efforts to cure HIV and HBV infections
• Identify the major strategies for interferon alfa–sparing treatment of HCV

Conveners
Arthur Y. Kim, Harvard Medical School, Boston, MA, United States
Camilla S. Graham, Beth Israel Deaconess Medical Center, Boston, MA, United States

57 HEV: State of the Art
Kenneth E. Sherman
University of Cincinnati College of Medicine, Cincinnati, OH, United States

58 HBV Eradication: Similarities To and Differences From HIV
Shyam Kottilil
National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States

59 Humoral Immunity and the Innate Response To HCV
Andrea L. Cox
The Johns Hopkins University School of Medicine, Baltimore, MD, United States

60 Interferon Alfa-Free Treatment of HCV
Jean-Michel Pawlotsky
Hôpital Mondor Hospital, University of Paris-Est, Créteil, France

Session S3 Symposium
4:00 PM – 6:00 PM Room 304
PrEP: Use It or Lose It

Target audience: This session is directed to clinicians and scientists who are interested in understanding the differences in pre-exposure prophylaxis (PrEP) trial results and how PrEP can best be implemented for populations at high risk of HIV acquisition.

Level of knowledge: It is assumed that learners are familiar with the current status of PrEP for HIV prevention, the results from major clinical trials, and the challenges associated with the success of PrEP.

Objectives: At the completion of the session, learners will be able to:
• Discuss potential reasons for differences in trial results
• Identify benefits and challenges in PrEP implementation in different settings
• Identify which populations may gain the greatest benefit from PrEP

Conveners
Lisa K. Fitzpatrick, United Medical Center, Washington, DC, United States
Suwat Chariyalertsak, Chiang Mai University, Chiang Mai, Thailand

61 HIV Pre-Exposure Prophylaxis: Clinical Pharmacology Insights
Craig W. Hendrix
The Johns Hopkins University School of Medicine, Baltimore, MD, United States

62 Notes From the Field: Implementing PrEP in Resource Constrained Settings
Nelly R. Mugo
Kenya Medical Research Institute, Nairobi, Kenya

63 A Community Perspective On PrEP
Christopher Bathazarr and London Dorris
Stroger Hospital of Cook County, Chicago, IL, United States

64 Choosing Populations for Maximal Impact
David V. Glidden
University of California San Francisco, San Francisco, CA, United States
WEDNESDAY MARCH 5, 2014

Session PL3 Plenary
8:30 AM – 9:00 AM    Auditorium
65  B-Cell Responses To HIV Infection: Challenges and Opportunities
Susan L. Moir, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States

Session PL4 Plenary
9:00 AM – 9:30 AM    Auditorium
66  NeuroHIV in 2014: Beyond Dementia
Serena S. Spudich, Yale University, New Haven, CT, United States

Session O-5 Oral Abstracts
10:00 AM – 12:15 PM    Room 304
Critical Issues in MTCT: Maternal Health and HIV Treatment in Children
Moderators
Amita Gupta, The Johns Hopkins University School of Medicine, Baltimore, MD, United States
A. Sarah Walker, Medical Research Council Clinical Trials Unit, London, United Kingdom

67  A 15-Year Review of Maternal Deaths in a Background of Changing HIV Management Guidelines
Coceka N. Mnyani1,2, Eckhart Buchmann2, Karlyn Frank2, Helen Struthers1, James McIntyre1
1Anova Health Institute, Johannesburg, South Africa
2University of the Witwatersrand, Johannesburg, South Africa

68  Incidence and Cofactors of Acute HIV During Pregnancy and Postpartum
John Kinuthia1, Alison Drake2, Daniel Matemo1, Barbra Richardson2, R. Scott McClelland3, Grace John-Stewart1
1Obstetrics and Gynaecology, University of Nairobi, Nairobi, Kenya
2Global Health, University of Washington, Seattle, WA, United States
3Biostatistics, University of Washington, Seattle, WA, United States

69  Efficacy and Safety of LPV/r Versus EFV in HIV+ Pregnant and Breast-Feeding Ugandan Women
Deborah Cohen1, Paul Natureeba2, Albert Plenty1, Flavia Luwadda Julia Mweuiga1, Veronica Ades1, Edwin Charlebois3, Tamara Clark Bridget Nzaruabara1, Moses Kamya1, Pius Okong1, Diane Havlir1
1OBGYN, University of California San Francisco, San Francisco, CA, United States
2Infectious Diseases Research Collaboration, Kampala, Uganda
3Medicine, University of California San Francisco, San Francisco, CA, United States

70  Infant Lopinavir/r Versus 3TC To Prevent Postnatal HIV-1 Transmission: The ANRS 12174 Trial
Chipepo Kankasa1, Nicolas Nago1,2, Nicolas Meda1,3, James K. Turnwine3, Amwe Aku1, Debra Jackson3, Roselyne Vallo1,2, Thorkild Tylleskär4, Philippe Van de Perre1,2, ANRS 12174 ANRS 12174 Trial Group
1Department of Paediatrics and Child Health, University Teaching Hospital, Lusaka, Zambia
2INSERM U1058, Montpellier, France
3CHU Montpellier, Montpellier, France
4Centre de Recherche Internationale pour la Santé (CRIS), Université de Ouagadougou, Ouagadougou, Burkina Faso
5Centre Muraz, Bobo-Dioulasso, Burkina Faso
6Department of Paediatrics and Child Health, Makerere University, Kampala, Uganda
7School of Public Health, University of Western Cape, Cape Town, South Africa
8Université de Montpellier I, Montpellier, France
9Centre for International Health, University of Bergen, Bergen, Norway

71  Lower Newborn Bone Mineral Content Associated With Maternal Use of Tenofovir Disoproxil Fumarate
George K. Siberry1, Denise L. Jacobson1, Heidi Kalkwarf1, Julia W. Wu1, Linda A. DiMeglio2, Ram Yogev3,4, Katherine M. Knapp5, Justin Wheeler6, Rohan Hazra1, Kenneth C. Rich10
1NICHHD, National Institute of Child Health and Human Development, Bethesda, MD, United States
2Pediatric Endocrinology/Diabetology, St. Jude Children’s Research Hospital, Memphis, TN, United States
3Division of General and Community Pediatrics, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, United States
4Department of Epidemiology, Harvard School of Public Health, Boston, MA, United States
5Pediatric Endocrinology/Diabetology, Riley Hospital for Children at Indiana University Health, Indianapolis, IN, United States
6Ann & Robert Lurie Children’s Hospital of Chicago, Chicago, IL, United States
7Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL, United States
8Department of Infectious Diseases, St. Jude Children’s Research Hospital, Memphis, TN, United States
9Gerald J. and Dorothy R. Friedeman School of Nutrition Science and Policy, Tufts University, Boston, MA, United States
10Department of Pediatrics, University of Illinois at Chicago, Chicago, IL, United States

72  Virologic Control by 1 Year of Age Significantly Reduces HIV-1 Reservoirs in Perinatal Infection
Deborah Persaud1, Kunjal Patel1, Brad Karaliuss, Carrie Ziemia1, Kaitlin Rainwater-Lovett1, Ya Chen1, Douglas D. Richman2, George K. Siberry2, Russell VanDyke7, Katherine Luzuriaga5, Pediatric HIV/AIDS Cohort Study (PHACS) and IMPAACT Network
1Pediatrics, The Johns Hopkins University School of Medicine, Baltimore, MD, United States
2Epidemiology, Harvard School of Public Health, Boston, MA, United States
3Pathology and Medicine, University of California San Diego, San Diego, CA, United States
4Eunice Kennedy Shriver National Institutes of Child Health and Human Development, Bethesda, MD, United States
5Pediatrics, Tulane University Health Sciences Center, New Orleans, LA, United States
6Pediatrics, University of Massachusetts Medical School, Boston, MA, United States
7Pediatrics, Indiana University School of Medicine, Indianapolis, IN, United States

73  Virologic Efficacy of Efavirenz Maintenance Therapy in Nevirapine Prophylaxis-Exposed Children
Ashraf Coovadia1, Elaine Abrams2, Renate Strehlau3, Stephanie Shiain4, Francoise Pinillos5, Leagh Martens6, Gillian Hunt4, Wei-Yann Tsai7, Lynn Morris8, Louise Kuhn8, NEVEREST 3 Study Team
1Division of Infectious Diseases, University College, Cape Town, South Africa
2MRC The HIV and Tobacco Research Group, University of the Witwatersrand, Johannesburg, South Africa
3Department of Pediatrics and Child Health, Guide Hospital, Cape Town, South Africa
4Pediatric Health Program, Medicine, Pediatrics, University of Cape Town, Cape Town, South Africa
5Infectious Diseases Research Collaboration, Kampala, Uganda
6Medicine, Makerere University, Kampala, Uganda
7OBGYN, Makerere University, Kampala, Uganda
8Pediatric AIDS Clinical Trials Unit, University of California San Diego, San Diego, CA, United States

Session O-6 Oral Abstracts

10:00 AM – 12:00 PM Room 312

HIV/SIV Pathogenesis

Moderators

Marcus Altfeld, Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Cambridge, MA, United States

R. Keith Reeves, Harvard Medical School, Boston, MA, United States

76 Pyroptosis Drives Both CD4 T Cell Death and Chronic Inflammation in HIV-Infected Lymphoid Tissues

Gilad Doitsh1, Nicole Galloway1, Xin Meng1, Kathryn Monroe1, Zhijuan Yang1, Orlando Zepeda1, Peter Hunt1, Hiroju Hatano1, Stefanie Sowinski1, Warner C. Greene1

1 Gladstone Institute of Virology and Immunology, San Francisco, CA, United States; 2 University of California, San Francisco, San Francisco, CA, United States

77 Early ART Initiation Prevents Disruption of the Mucosal Barrier and Subsequent T-Cell Activation

Alexandra Schuetz1, Yuwadee Phuang-Ngern1, Rungsun Rerknimitr1, Eugene Kroon1, Nitya Chomchevy1, Praphan Phanuphak1, Merlin Robb1, Jerome Kim1, Mark de Souza1, Jintanat Ananworanich2, on behalf of the RV254/SEARCH 010 and RV304 Study Groups

1 Retrovirology, USAMC-AFRIMS, Bangkok, Thailand; 2 Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; 3 SEARCH, Bangkok, Thailand; 4 US Military HIV Research Program, Silver Spring, MD, United States

78 Characterizing the IFNα Resistance of Transmitted Founder HIV-1

Shiha S. Iyer1, Angharad E. Fenton-May2, Andrew G. Smith1, Weiying Zhang1, John C. Kappes3, Feng Gao4, Frederic Bibollet-Ruche1, Hui Li1, George M. Shaw1, Persephone Borrow1, Beatrice Hahn1

1 Departments of Medicine and Microbiology, University of Pennsylvania, Philadelphia, PA, United States; 2Nuffield Department of Clinical Medicine, Oxford, United Kingdom

80 Central Memory and Effector Memory CD4 T Cells From HIV Controllers Harbor Distinct HIV Strains

Eli Boritz1, Luke Swasey1, Rebecca Hoh2, Jeffrey Martin3, Steven Deeks4, Daniel Douek1

1 Human Immunology Section, Vaccine Research Center, Bethesda, MD, United States; 2Department of Medicine, University of California San Francisco, San Francisco, CA, United States; 3Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, United States

Session O-7 Oral Abstracts

10:00 AM – 12:15 PM Ballroom B/C

Randomized Controlled Trials and Antiretroviral Resistance

Moderators

Urvil M. Parikh, University of Pittsburgh, Pittsburgh, PA, United States

Edmund C. Tramont, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States
84LB First-Line RAL + DRV/r Is Non-Inferior To TDF/FTC + DRV/r: The NEAT001/ANRS143 Randomised Trial
François Raffi1, Abdel G. Babiker2, Laura Richert1, Jean-Michel Molina4, Elizabeth C. George1, Andrea Antinori1, Jose Arribas6, Stefano Vella1, Genève à Chêne1, Antoine L. Pozniak4, NEAT001/ANRS143 Study Group
1University Hospital, Nantes, France; 2MRC Clinical Trials Unit at UCL, London, United Kingdom; 3INSERM U897, Bordeaux, France; 4ST Louis Hospital, Paris, France; 5INMI L Spallanzani, Rome, Italy; 6Hospital La Paz, Madrid, Spain; 7Istituto Superiore di Sanità, Rome, Italy; Chelsea and Westminster Hospital, London, United Kingdom

85 Efficacy and Tolerance of Atazanavir, Raltegravir, or Darunavir With FTC/Tenofovir: ACTG 5257
Raphael J. Landovitz2, Heather J. Ribaudo1, Ighovwerha Ofotokun1, Hongying Wang1, Bryan P. Baugh4, Randi Y. Leavitt1, James F. Rooney5, Daniel Seikins1, Judith S. Currier1, Jeffrey L. Lennox3
1Center for Clinical AIDS Research & Education, University of California Los Angeles, Los Angeles, CA, United States; 2Harvard Center for Biostatistics in AIDS Research, Boston, MA, United States; 3Division of Infectious Diseases, Emory University, Atlanta, GA, United States; 4Merck & Co, Whitehouse Station, NJ, United States; 5Gilead Sciences, Foster City, CA, United States; 6Bristol-Myers Squibb, Wallingford, CT, United States

86 Attachment Inhibitor Prodrug BMS-663068 in ARV-Experienced Subjects: Week 24 Analysis
Jacob Lalezari1, Gulam H. Latiff2, Cynthia Brinson3, Juan Echevarria1, Sandra Treviño-Pérez2, Johannes R. Bogner4, David Stock2, Samit R. Joshi2, George J. Hanna2, Max Lataillade1, for the AI438011 study team
1Quest Clinical Research, San Francisco, CA, United States; 2Maxwell Clinic, Durban, South Africa; 3Central Texas Clinical Research, Austin, TX, United States; 4Hospital Nacional Cayetano Heredia, Lima, Peru; 5Mexico Centre for Clinical Research, Mexico City, Mexico; 6Hospital of the University of Munich, Munich, Germany; 7Bristol-Myers Squibb, Wallingford, CT, United States; 8Bristol-Myers Squibb, Princeton, NJ, United States

87 Sensitive Screening Reveals Widespread Underestimation of Transmitted HIV Drug Resistance
Jin-fen Li, David Kim, Laurie Linley, Richard Kline, Walid Heneine, Jeffrey A. Johnson
Division of HIV/AIDS Prevention, CDC, Atlanta, GA, United States

88 Transmitted HIV-1 Drug Resistance Between Partner-Pairs
Joanne Stekler1, Rachel Payant2, Ingrid Beck2, Brandon Maust1, Sarah Holt1, Janine Maenza1, Claire E. Stevens1, James I. Mullins1, Ann C. Collier1, Lisa M. Frenkel1,2
1University of Washington, Seattle, WA, United States; 2Seattle Children’s Hospital, Seattle, WA, United States; 3Fred Hutchinson Cancer Research Center, Seattle, WA, United States

89 Silent Mutations in HIV-1 Subtype B Reverse Transcriptase Selected by ART Restore Viral Fitness
Sushama Telwattel3, Anna C. Hearps1,2, Adam Johnson3,4, Con Sonza5,6, Nicolas P. Sluis-Cremer6, Richard P. Harrigan6, Gilda Tachedjian1,2
1Centre for Biomedical Research, Burnet Institute, Melbourne, Australia; 2Department of Microbiology, Monash University, Melbourne, Australia; 3Department of Infectious Diseases, Monash University, Melbourne, Australia; 4Department of Microbiology and Immunology, University of Melbourne, Melbourne, Australia; 5Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, PA, United States; 6Drug Treatment Program, BC Centre for Excellence in HIV/AIDS, British Columbia, BC, Canada

90 Reduced In Vivo Replicative Capacity of Drug-Resistant SHIV During Acute Infection
Mian-er Cong, Chou-Pong Pau, Walid Heneine, J. Gerardo Garcia-Lerma
Division of HIV/AIDS Prevention, CDC, Atlanta, GA, United States

91LB 744 and Rilpivirine as Two-Drug Oral Maintenance Therapy: LAI116482 (LATTE) Week 48 Results
David Margsoli1, Cynthia Brinson1, Joseph Eron1, Gary Richardson2, Roger LeBlanc3, Sandy Griffith4, Marty St. Clair5, Marita Stevens6, Peter Williams7, William Spreen1
1GSK, RTP, NC, United States; 2Central Texas Clinical Research, Austin, TX, United States; 3University of North Carolina, Chapel Hill, NC, United States; 4HIV Clinic, Ft. Lauderdale, FL, United States; 5Clinique Opus Inc, Montreal, QC, Canada; 6Janssen, Beerse, Belgium

92LB Safety and Antiviral Effect of MK-1439, A Novel NNRTI (+FTC/TDF) in ART-Naive HIV-Infected Patients
Javier O. Morales-Ramirez1, Jose M. Gatell2, Debbie P. Hagens1, Melanie Thompson1, Keikawus Arastéh1, Christopher Hoffmann1, Charlotte Harvey1, Xiao Xu2, Heddy Teppeler1
1Clinical Research Puerto Rico, San Juan, Puerto Rico; 2University of Barcelona, Barcelona, Spain; 3Chatham County Health Dept, Savannah, GA, United States; 4AIDS Research Consortium of Atlanta, Atlanta, GA, United States; 5EPIMED/Vivantes Auguste-Viktoria-Klinikum, Berlin, Germany; 6ICH Study Center, Hamburg, Germany; 7Merck, Whitehouse Station, NJ, United States

Session 0-8 Oral Abstracts
10:00 AM – 12:00 PM Ballroom A

93 A Phase 2 Trial of a Rifapentine Plus Moxifloxacin-Based Regimen for Pulmonary TB Treatment
Marcus B. Conde1, Solange C. Cavalcante2,3, Margarette Dalcolmo4, Fernanda Mello5, Rafael Duarte1, Carla Loredo6, Valeria Rolla4, Betina Duvoiri2,3, Silvia Cohn6, Richard E. Chaisson1,2, Susan E. Dorman1,2
94  Tuberculosis Infection in Early Childhood in Uganda and the Influence of HIV Exposure
Carina Marquez1, Gabriel Chamie1, Jane Achain2, Anne F. Luetkemeyer1, Mary Kyohere3, Grant Dorsey4, Moses R. Kamya5, Edwin D. Charlebois1, Diane V. Havlir1
1University of California, San Francisco, San Francisco, CA, United States,2Makerere University College of Health Sciences, Kampala, Uganda,3Infectious Diseases Research Collaboration, Kampala, Uganda

95  Effect of Xpert MTB/RIF On Early Mortality in Adults With Suspected TB: A Pragmatic Randomized Trial
Gavin Churchyard1, Kerrigan McCarthy1, Katherine L. Fielding2, Wendy Stevens2, Violent Chihota3, Mark Nicol4, Norbert Ndjeka4, Alison D. Grant5, David Mamelka5
1Aurum Institute, Houghton, South Africa,2London School of Hygiene and Tropical Medicine, London, United Kingdom,3National Health Laboratory Service, Sandringham, South Africa,4University of Cape Town, Cape Town, South Africa,5South African Department of Health, Pretoria, South Africa

96LB  Xpert as the First-Line TB Test in South Africa: Yield, Initial Loss To Follow-Up, Proportion Treated
Katherine L. Fielding1, Kerrigan M. McCarthy2, Helen Cox3, Linda Erasmus4, Sibuse Ginindza4, Anna Vassall5, Lindwe Mvusi6, Chris Dye7, Alison D. Grant7, Gavin J. Churchyard7
1London School of Hygiene & Tropical Medicine, London, United Kingdom,2Aurum Institute, Johannesburg, South Africa,3University of Cape Town, Cape Town, South Africa,4National Health Laboratory Service, Johannesburg, South Africa,5South African Department of Health, Pretoria, South Africa,6Health Work Organization, Geneva, Switzerland

97LB  14 Day EBA Study of PA-824, Bedaquiline, Pyrazinamide and Clofazimine in Smear-Positive TB Patients
Andreas Diacon1, Rodney Dawson2, Christo Van Niekerk2, Jane Hutchings2, Stephen Murray2, Robert Schall3, Divan Burger3, Dan Everitt1, Carl Mendel1
1Department of Medical Biochemistry, Stellenbosch University, Cape Town, South Africa,2Medicine, University of Cape Town Lung Institute, Cape Town, South Africa,3Clinical Development, TB Alliance, Pretoria, South Africa,4Clinical Development, TB Alliance, New York, NY, United States,5Mathematical Statistics and Actuarial Science, University of the Free State, Bloemfontein, South Africa,6Mathematical Statistics and Actuarial Science, University of the Free State, Bloemfontein, South Africa

98 CTX Prophylaxis Discontinuation Among ART-Treated Adults: A Randomized Non-Inferiority Trial
Christina S. Polyak1, Krista Yuhas2, Benson Singa2, Monica Khaemba1, Judd Watson2, Barbra Richardson2, Grace John-Stewart2
1Military HIV Research Program, Walter Reed Army Institute of Research, University of Washington, Bethesda, MD, United States,2Global Health, University of Washington, Seattle, WA, United States,3Kenya Medical Research Institute/ University of Washington, Nairobi, Kenya

Session TD6 Themed Discussion
1:30 PM – 2:30 PM Room 309
Frailty and Functional Impairment
Discussion Leader
Kevin E. Yarasheski, Washington University School of Medicine, St Louis, MO, United States

766  Geriatric Syndromes Are Common Among Older HIV-Infected Adults
Meredith Greene1,2, Victor Valcour1,3, Yinghui Miao4,5, Ken Covinsky4,5, Joy Madamba5, Monica Mattes6, Harry Lempiris2,3, Jeffrey Martin2, Steven Deeks2,3
1Medicine-Geriatrics, University of California San Francisco, San Francisco, CA, United States,2San Francisco VA Medical Center, San Francisco, CA, United States,3Neurology, University of California San Francisco, San Francisco, CA, United States,4NCIRE, San Francisco, CA, United States,5Medicine-HIV/AIDS, University of California San Francisco, San Francisco, CA, United States,6University of Central Florida College of Medicine, Orlando, FL, United States

767  Physical Function Impairment On Quality of Life Among Persons Aging With HIV Infection
Kristine M. Erlandson, Amanda A. Allshouse, Catherine M. Jankowski, Samantha MaWhinney, Wendy M. Kohrt, Thomas B. Campbell
University of Colorado Anschutz Medical Campus, Aurora, CO, United States

764  Cell-Mediated CMV Responses in HIV-Infected Persons With Impaired Physical Function
Kristine M. Erlandson, Amanda A. Allshouse, Rick Rapaport, Brent E. Palmer, Cara C. Wilson, Samantha MaWhinney, Thomas B. Campbell
University of Colorado Anschutz Medical Campus, Aurora, CO, United States

762  Frailty, Inflammation and Mortality Among Aging HIV-Infected and At-Risk Injection Drug Users
Damani A. Piggott, Ravi Varadhan, Shrutiri Mehta, Todd T. Brown, Sean X. Leng, Gregory D. Kirk
The Johns Hopkins University, Baltimore, MD, United States

763  Brisk Walking Improves Inflammatory Markers in cART-Treated Patients
Valeria Longo1, Matteo Bonato1, Simona Bossolasco2, Laura Galli1, Andrea Caumo2, Gaspare Pavli3, Adriano Lazzarin1, Giampiero Merati1, Antonio La Torre4, Paola Cincu5
1Infectious Diseases, San Raffaele Scientific Institute, Milano, Italy,2Biomedical Sciences for Health, Università degli Studi di Milano, Milano, Italy,3Pathophysiology and Transplantation Department, Università degli Studi di Milano, Milano, Italy
Session TD7 Themed Discussion
1:30 PM – 2:30 PM  Ballroom A
Clinical Pharmacology in Patient Care

Discussion Leader
Stephen Taylor, Birmingham Heartlands Hospital, Birmingham, United Kingdom

496 Pharmacokinetics of Raltegravir 400 vs 800 mg BID With Intermittent Rifampicin Dosed Thrice Weekly
Helen E. Reynolds1, Deirdre Egan1, Laura Else1, Mas Chapondra2, Alexis Chrdle2, David J. Back3, Saye H. Khoo1
1University of Liverpool, Liverpool, United Kingdom, 2Royal Liverpool University Hospital, Liverpool, United Kingdom

494 Relationship Between Efavirenz Trough & CYP2B6 Genotypes With Rifampin-Based TB Therapy in STRIDE
Anne Luetkemeyer1, Susan L. Rosenkranz2, Darlene Lu3, Beatriz Grinsztejn4, Jorge Sanchez5, Michael Ssemmanda6, Ian Sanne7, Helen McCuller8, Diane Havlir9, David Haas10, ACTG A5221 & A5243 Study Teams
1HIV/AIDS Division, San Francisco General Hospital, University of California, San Francisco, San Francisco, CA, United States, 2Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, MA, United States, 3HIV/AIDS Division, Center for Biostatistics in AIDS Research, Harvard School of Public Health, San Francisco, CA, United States, 4Instituto de Pesquisa Clinica Evandro Chagas, Fundacao Oswaldo Cruz, Rio de Janeiro, Brazil, 5Asociacion Civil Impacta Salud y Educacion, Lima, Peru, 6Joint Clinical Research Center, Kampala, Uganda, 7Clinical HIV Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, 8Division of Clinical Pharmacology, University of Cape Town, Cape Town, South Africa, 9Vanderbilt University School of Medicine, Nashville, TN, United States

497 Pharmacokinetics of Faldaprevir and Antiretrovirals in Patients With HIV/HCV Coinfection
Jürgen K. Rockstroh1, Marc-Antoine Valantin2, Josep Mallolas3, Massimo Puel1, Juan Antonio Pineda4, Patrick Ingliz5, Marina Núñez5, Fenglei Huang6, Richard Vinisko6, Douglas Dieterich7
1Department of Medicine I, University of Bonn, Bonn, Germany, 2Service des Maladies Infectieuses et Tropicales, Hôpital Pité-Salpêtrière, Paris, France, 3Hospital Clinic-University of Barcelona, Barcelona, Spain, 4Department of Infectious Diseases, AO Ospedale Niguarda Ca’ Granda Milano, Milan, Italy, 5Unit of Infectious Diseases and Microbiology, Hospital Universitario de Valme, Seville, Spain, 6Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom, 7Faculty of Pharmacy, Obafemi Awolowo University, Ile-Ife, Nigeria

504 Relative Genetic Contribution To the Pharmacokinetics of Commonly Prescribed Antiretrovirals
Marco S. Siccardi1, Adeniyi Olajunju1,2, Marco Simiele3, Antonio D’Avolio1, Andrea Calcagno1, Giovanni Di Perri1, Stefano Bonora1, Andrew Owen1
1Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom, 2Faculty of Pharmacy, Obafemi Awolowo University, Ile-Ife, Nigeria, 3Amedeo di Savoia Hospital, University of Turin, Turin, Italy

505 Leveraging Genomics in HIV Treatment Decisions
Paul J. McLaren1, Margalida Rotger1, Manel Aouri1, Huldrych Günthard2, Catia Marzolini2, Laurent Decosterd3, Amalio Telenti2
1The Swiss HIV Cohort, Lausanne, Switzerland, 2The Swiss HIV Cohort, Zurich, Switzerland, 3The Swiss HIV Cohort, Basel, Switzerland

Session TD8 Themed Discussion
1:30 PM – 2:30 PM  Room 304
How Transmission Networks Drive Epidemics

Discussion Leader
Roger D. Kouyos, University Hospital Zurich, University of Zurich, Zurich, Switzerland

213 HIV Transmission in the United States: The Roles of Risk Group, Race/Ethnicity, and Geography
Alexandra M. Oster1, Joel O. Wertheim2, Angela L. Hernandez3, Marie C. B. Ocfemia4, Neeraja Sadavalu5, David Kim6, H. I. Hall7
1Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, GA, United States, 2ICF International and University of California San Diego, San Diego, CA, United States, 3ICF International, Atlanta, GA, United States

205 Ongoing HIV-1 Subtype B Transmission Networks in the Netherlands
Daniela Bezemer1, Oliver Ratmann2, Ard van Sighem1, Bas E. Duit3, Nuno Faria4, Rob van den Hengel5, Luuk Gras6, Peter Reiss5, Frank de Wolf2, Christophe Fraser1, ATHENA observational cohort
1Research, HIV Monitoring Foundation, Amsterdam, Netherlands, 2Imperial College, London, United Kingdom, 3Centre for Molecular and Biomolecular Informatics, Nijmegen, Netherlands, 4University, Oxford, United Kingdom

206 Using HIV Networks To Inform Real Time Prevention Interventions
Susan J. Little1, Sergei L. K. Pond1, Christy M. Anderson2, Jason A. Young3, Joel O. Wertheim1, Sanjay R. Mehta1, Susanne May2, Davey M. Smith1
1Medicine, University of California San Diego, San Diego, CA, United States, 2Biostatistics, University of Washington School of Public Health, Seattle, WA, United States

215 Large MSM Group and Local Heterosexual Transmission Are Major Concerns in the HIV Epidemic in Japan
Teichiro Shino1, Kenji Sadamasu2, Junko Hattori1, Mami Nagashima1, Yasumasa Iwatani1, Yoshiyuki Yokomaku2, Wataru Sugiuira3, The Japanese Drug Resistance HIV-1 Surveillance Network
1Infectious Diseases Surveillance Center, National Institute of Infectious Diseases, Tokyo, Japan, 2Tokyo Metropolitan Institute of Public Health, Tokyo, Japan, 3Clinical Research Center, Nagoya Medical Center, Nagoya, Japan
Session TD9 Themed Discussion
1:30 PM – 2:30 PM Room 312
Gut and Immune Activation

Discussion Leader
Peter W. Hunt, University of California San Francisco, San Francisco, CA, United States

312 Rapid Gut-Homing of Plasmacytoid Dendritic Cells During Acute SIV Infection
Haiying Li, Jacqueline Gillis, R. Keith Reeves
NEPRC, Harvard Medical School, Southborough, MA, United States

313 CCR6+ and CD161+ CD4 T Cell Loss Contributes To the Pathogenesis of SIV Infection in Rhesus Macaques
Colleen S. McGary1, Luca Micci1, Emily S. Ryan1, Maria J. Buzon2, Amy Shaw2, Mathias Lichterfeld2, Guido Silvestri1,2, Aftab A. Ansari1, Mirko Pairoddini1,3
1Department of Microbiology and Immunology, Emory University, Atlanta, GA, United States; 2Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, United States; 3Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, United States

315 Decreased Diversity of Gut Microbiota Is Associated With Immune Status During HIV-1 Infection
Piotr Nowak1, Babilonia Barqasho2, Ekatarina Avershina3, Kajsa Noyan4, Jan Vesterbacka1, Marius Trosseid1, Knut Rud1, Anders Sönnerborg1
1Department of Infectious Diseases, Karolinska Institute, Huddinge, Sweden; 2Department of Medicine, Karolinska Institute, Huddinge, Sweden; 3Department of Chemistry, Biotechnology and Food Science, Norwegian University of Life Sciences, As, Norway; 4Infectious Diseases, Oslo University Hospital, Oslo, Norway

Session TD10 Themed Discussion
1:30 PM – 2:30 PM Room 311
Reproductive Hormones in Women: Impact On Risk and Barrier Dysfunction

Discussion Leader
Susan Cu-Uvin, Brown University, Providence, RI, United States

844 Depot-Medroxypregesterone Acetate Does Not Increase Genital SHIV Shedding in Macaques
Jessica Radzio1, Kristzina Hanley1, Debra Hanson1, James Mitchell1, Leecresia Jenkins1, Sharon Ellis1, Frank Deyoung1, Walid Heneine1, J. Gerardo Garcia-Lerma1
1Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, GA, United States; 2Pathology, Emory University, Atlanta, GA, United States

846 Hormonal Contraceptives Increase Innate Immune Effector Molecules in Cervicovaginal Secretions
Brandon L. Guthrie1,2, Robert Y. Choi3, Alison C. Roxby2, Rose Bosire1, Barbara Lohman-Payne1,2, Taha Hirbod1, Carey Farquhar1,2, Kristina Broliden4
1Department of Global Health, University of Washington, Seattle, WA, United States; 2Department of Medicine, University of Washington, Seattle, WA, United States; 3Department of Medicine, University of Washington, Seattle, WA, United States; 4Center for Public Health Research, Kenya Medical Research Institute, Nairobi, Kenya

847 Injectable Contraception and HIV Acquisition in the VOICE Study (MTN-003)
Lisa M. Naguchi1,2, Barbra Richardson3, Z. Mike Chirenje4, Gita Ramjee5, Gonassagrie Nair6, Thesla Palanee7, Pearl Selepe8, Ravindra Panchia9, Kailazarid Gomez10, Jeanne Marrazzo11, on behalf of the VOICE Study Team
658 Protease Inhibitors To Treat Hepatitis C in the Swiss HIV Cohort Study: High Efficacy But Low Uptake
Sebastian Haubitz1, Verena Schraer2, Juan Ambrosioni3, Matthias Cavaissini1, Marcel Stoeckle1, Patrick Schmid4, Laurent Decosterd1, Karin Metzner2, Jan Fehr2, Andrei Rauch1
1Division of Infectious Diseases, Bern, Switzerland, 2Division of Infectious Diseases, Zurich, Switzerland, 3Division of Infectious Diseases, Geneva, Switzerland, 4Division of Infectious Diseases, Lausanne, Switzerland, 5Division of Infectious Diseases, Basel, Switzerland, 6Division of Infectious Diseases, St Gallen, Switzerland

655 Slow HCV-RNA Decay and Early Resistance Predict the Risk of Failure To TVR/BOC
Treatment
Francesca Ceccherini-Silberstein1, Valeria Cento1, Velia Chiara Di Maio1, Daniele Di Paolo2, Sergio Babudieri1, Antonio Di Biagio1, Massimo Andreoni3, Giustino Parruti4, Giuliano Rizzardi4, Carlo Federico Permon4
1Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy, 2Hepatology Unit, University Hospital of Rome Tor Vergata, Rome, Italy, 3Infectious Diseases Unit, Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy, 4Martino Hospital, Genoa, Italy, 5Infectious Diseases Unit, University Hospital of Rome Tor Vergata, Rome, Italy, 6Infectious Diseases Unit, Pescara General Hospital, Pescara, Italy, 7Division of Infectious Diseases, Hospital Sacco of Milan, Milan, Italy

661 Favorable Adverse Event Profile of Sofosbuvir/Ribavirin Versus Standard of Care for Hepatitis C Infection
Kerry Townsend1, Shivakumar Narayanan2, Amy Nelson3, Adrian Majid4, Luciano Kapelusznik2, Robert R. Redfield2, Shyamasundaran Kottili2, Rohit Talwani3, Anuoluwapo Osinusi2,1
1LIR, NIAID, NIH, Bethesda, MD, United States, 2Institute of Human Virology, Div. of Infectious Diseases, University of Maryland School of Medicine, Baltimore, MD, United States

641 Sustained Virologic Response and the Risk of Liver Decompensation in HCV and HIV/HeV Patients
Temitope O. Olufade1, Li Wang2, Scott Devine1, Onur Baser3, Vincent Lo Re3
1US Outcomes Research, Merck Sharpe & Dohme, North Wales, PA, United States, 2STATinMED Research, Dallas, TX, United States, 3Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States

650 Predicting Risk of ESLD in HIV/HCV Patients for Individualized HCV Therapy Decisions
Vincent Lo Re1, Janet P. Tate2, Adeel A. Butt3, Marina B. Klein4, Cynthia Gibert5, David Rimmel3, Matthew B. Goetz5, Jay R. Kostman1, Amy C. Justice2, Russell Localio3
1University of Pennsylvania, Philadelphia, PA, United States, 2STATinMED Research, Dallas, TX, United States, 3Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States, 4University of Pittsburgh School of Medicine, Pittsburgh, PA, United States, 5McGill University Health Centre, Montreal, QC, Canada, 6Washington DC VA Medical Center, Washington, DC, United States, 7Atlanta VA Medical Center, Atlanta, GA, United States, 8VA Greater Los Angeles Healthcare System, Los Angeles, CA, United States
POSTER SESSIONS

2:30 PM—4:00 PM

(Use the Poster Abstract section of the Program at a Glance, page 37 to 106, for specific posters in each session)

Session P-A4  Late Events in HIV Replication
Session P-A5  Apobec, Apobec, Apobec
Session P-B2  Application of NGS To Viral Profiling
Session P-C6  Clades and Pathogenesis
Session P-C7  Correlative Marker Studies
Session P-C8  Elite Controllers
Session P-C9  Pathogenesis: Insights From Clinical Trials
Session P-C10  Inmate Immunity and Pathogenesis
Session P-D2  New SIV Models
Session P-D3  SCID Mice
Session P-D4  Non-Pathogenic vs Pathogenic Hosts
Session P-E3  New Technologies in Immunology
Session P-E4  Monocytes, Dendritic Cells, NK Cells
Session P-E5  Pre-Clinical Vaccine Studies
Session P-F4  Methods for Measuring Reservoirs
Session P-F5  What and Where is the Reservoir?
Session P-F6  What Can We Learn From Bone Marrow Transplantation?
Session P-G3  Neuropathogenesis
Session P-G4  Host Genetics in HAND
Session P-G5  PML and Other CNS Infections
Session P-G6  CNS Viral Genetics
Session P-H3  ARV Pharmacokinetics, Drug Interactions, and Pharmacodynamics
Session P-K2  ART Initiation, Monitoring, and Outcomes
Session P-L3  Mechanisms of HIV Drug Resistance
Session P-L4  HIV Drug Resistance Variants
Session P-M2  HIV Diagnostics
Session P-N3  HCV: Prognosis and Impact of Treatment, Including Liver Transplantation
Session P-N4  HCV Treatment: Real-World Experience
Session P-N5  HCV: The Cascade
Session P-O4  Kaposi Sarcoma, PEL, and KSHV
Session P-P3  Alcohol, Smoking, and Atherosclerosis
Session P-P4  Risk Factors and Incidence: MI and Stroke
Session P-Q4  Lung Disease and HIV
Session P-Q5  Bone Disease: Osteopenia Fracture Risk and Osteoarthritis
Session P-Q6  Hepatic Fibrosis and Other Hepatic Complications
Session P-R1  Epidemiology and Transmission of TB
Session P-R2  TB Screening and Diagnosis
Session P-R3  Latent TB Screening and Treatment
Session P-R4  Inflammatory and Immune Activation Markers in TB
Session P-R5  Impact of ART on TB Risk and Disease
Session P-T3  Pregnancy Incidence and Outcomes Among Women in ART Programs
Session P-T4  Cellular and Immune Correlates of MTCT
Session P-T5  Characteristics of Pregnant Women in PMTCT
Session P-T6  Early Infant HIV Diagnosis
Session P-U4  Host and Immune Response in Children and Adolescents
Session P-U5  Complications of HIV and ART in Children and Adolescents
Session P-V1  Pre-Clinical Studies of Microbicides
Session P-V2  Animal Model of Clinical Studies and PrEP
Session P-V3  Identifying and Reducing HIV Risk
Session P-V4  PrEP, PEP, TasP
Session P-V5  Circumcision
Session P-W5  Acute Infection
Session P-W6  Incidence Assays
Session P-X3  The Treatment Cascade and Loss To Follow-Up
Session P-X4  Mental Health in HIV Care

Session O-11 Oral Abstracts

4:00 PM—6:00 PM Room 312 Malignancies and Pharmacology

Moderators
Kelly E. Dooley, The Johns Hopkins University School of Medicine, Baltimore, MD, United States
Margaret Z. Borok, University of Zimbabwe, Harare, Zimbabwe

99  HIV and Elevated Cancer-Specific Mortality Following Cancer Diagnosis in the United States
Anna E. Coghill, Meredith S. Shiels, Eric A. Engels
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Washington, DC, United States

100  Impact of Kaposi Sarcoma On Survival in HIV-Infected African Adults On Antiretroviral Therapy
Stephen B. Asiimwe1,2,3, Miriam Laker-Oketta1, John Bennett1, Adrienne Moccio1, David Glidden1, Jessica Haberer1, Mwebesa Bwana1, Peter Hunt1, David Bangsberg1, Edward Mbidde1, Jeffrey Martin1
1Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, United States;2Department of Internal Medicine, Mbarara Regional Referral Hospital, Mbarara, Uganda;3Infectious Diseases Institute, Kampala, Uganda;4Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States

101  Prospective Characterization of Kaposi Sarcoma Herpesvirus Inflammatory Cytokine Syndrome
Mark N. Polizzotto1, Thomas S. Ulidrick1, Kathleen M. Wyyill1, Karen Aleman1, Vickie Marshall1, Denise Whiby2, Stefania Pittaluga3, Seth Steinberg4, Irini Sereti5, Robert Yarchoan1
1HIV and AIDS Malignancy Branch, National Cancer Institute, Bethesda, MD, United States;2Viral Oncology Section, Frederick

Oral Sessions • Wednesday, March 5, 2014
102 Quadrivalent HPV Vaccine Demonstrates Immune Memory in HIV-1-Infected Men
Timothy Wilkin1, Shelly Lensing2, Mark Einstein3, Jeannette Lee1, Stephen Goldstone1, Elizabeth A. Stier4, Michael Berry3, Naomi Jay2, Ronald Mitsuyasu3, Joel Palefsky4
1Division of Infectious Diseases, Weill Cornell Medical College, New York, NY, United States; 2Department of Biostatistics, University of Arkansas for Medical Sciences, Little Rock, AR, United States; 3Department of Obstetrics & Gynecology and Women’s Health, Albert Einstein College of Medicine and Montefiore Medical Center, New York, NY, United States; 4University of Arkansas for Medical Sciences, Little Rock, AR, United States; 5Icahn School of Medicine at Mount Sinai, New York, NY, United States; 6Department of Obstetrics and Gynecology, Boston University Medical Center, Boston, MA, United States; 7University of California San Francisco, San Francisco, CA, United States; 8University of California San Francisco, San Francisco, CA, United States; 9UCLA CARE Center, University of California Los Angeles, Los Angeles, CA, United States

103 HIV-1 Infection Alters Intestinal Expression of Antiretroviral Drug Transporters and Enzymes
Olена Kisl1, Md. Tozammel Hogue1, Sharon L. Walmseley1,2,3,3, Sumathi Sankaran-Walters1, Satya Dandekar1, Reina Bendayan1
1Pharmaceutical Sciences, University of Toronto, Toronto, ON, Canada; 2University of Toronto, Toronto, ON, Canada; 3Division of Infectious Diseases, University Health Network, Toronto, ON, Canada; 4Medical Microbiology and Immunology, University of California, Davis, CA, United States; 5Medical Microbiology and Immunology, University of California, Davis, CA, United States

104 Tenofovir-Emtricitabine Directly Observed Dosing: 100% Adherence Concentrations (HPTN 066)
Craig W. Hendrix1, Adriana Andrade1, Angela D. Kashuba2, Mark Marzinke1, Peter L. Anderson2, Ayana Moor2, Vanessa Elharrar2, Lei Wang3, Kenneth H. Mayer2, Kristine B. Patterson2
1The Johns Hopkins University, Baltimore, MD, United States; 2University of North Carolina (Chapel Hill), Chapel Hill, NC, United States; 3University of Colorado, Aurora, CO, United States; 4FHI 360, Durham, NC, United States; 5National Institutes of Health, Rockville, MD, United States; 6SCHARP, Seattle, WA, United States; 7Fenway Health, Boston, MA, United States

105 Efavirenz Pharmacokinetics in HIV+ Persons Receiving Rifapentine and Isoniazid for TB Prevention
Anthony T. Podany1, Yajing Bao2, Richard E. Chaisson1, Susan Swindells3, Janet W. Andersen1, Thando Mwelase1, Khuanchai Supparatpinyo6, Amita Gupta1, Constance A. Benson1, Courtney V. Fletcher1
1College of Pharmacy, University of Nebraska Medical Center, Omaha, NE, United States; 2Statistical & Data Analysis Center, Harvard School of Public Health, Boston, MA, United States; 3Division of Infectious Diseases, The Johns Hopkins University, Baltimore, MD, United States; 4Infectious Diseases/Internal Medicine, University of Nebraska Medical Center, Omaha, NE, United States; 5Clinical HIV Research Unit, Wits Health Consortium, Johannesburg, South Africa; 6Chiang Mai University, Chiang Mai, Thailand; 7Antiviral Research Center, University of California San Diego, San Diego, CA, United States

106 Pharmacokinetic Variability in TB Therapy: Associations With HIV and Effect On Outcome
Derek J. Sloan1, Alessandro Schipani2, David Waterhouse3, Lisa Stone1, Henry C. Mwandumba1, Anthony E. Butterworth1, Robert S. Heyderman1, Elizabeth L. Corbett1, Saye H. Khoo1, Geraint R. Davies1
1Malawi Liverpool Wellcome Trust Clinical Research Programme, Blantyre, Malawi; 2University of Liverpool, Liverpool, United Kingdom; 3Liverpool School of Tropical Medicine, Liverpool, United Kingdom; 4College of Medicine, University of Malawi, Blantyre, Malawi

Session S4 Symposium
4:00 PM – 6:00 PM Ballroom B/C
TB: Looking To the Future: Resistance, Persistence, Monitoring, and Control

Target audience: This session is directed to clinicians and scientists interested in the pathogenesis, diagnosis, treatment, and prevention of TB.

Level of knowledge: It is assumed that learners are familiar with basic aspects of the disease, drug therapies, and development of resistance and with current tools available for disease monitoring on an individual and population basis.

Objectives: At the completion of the session, learners will be able to describe:
• Methods for sequencing MDR and XDR TB strains and factors beyond inadequate adherence that contribute to emergence of resistance
• The pathogenesis of latency, novel animal models of latency, and implications for treating latent TB infections
• Use of PET-CT, PET-MRI, and other novel imaging to detect mycobacterial replication, tissue inflammation, and responses to TB therapy
• Insights gained from population-based studies of TB prevention

Conveners
Neil A. Martinson, University of the Witwatersrand, Johannesburg, South Africa
Jean William Pape, Weill Cornell Medical College, New York, NY, United States, and Centres GHESKIO, Port-au-Prince, Haiti
109  Quantifying TB Treatment Response Using PET/CT  
Clifton E. Barry III  
National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States

110  Population-Level Control of HIV-Related TB  
Peter Godfrey-Faussett  
Joint United Nations Programme on HIV/AIDS (UNAIDS), Geneva, Switzerland

Session S5 Symposium  
4:00 PM – 6:00 PM  
Ballroom A  
Visualizing the Virus

Target audience: This session is directed to scientists and clinicians who are interested in current concepts of how the HIV viral particle is assembled and how it interacts with cellular proteins, particularly during entry. Learners will also learn about state-of-the-art technological approaches and breakthroughs that have enabled visualization and analysis of HIV virions and proteins in real time.

Level of knowledge: It is assumed that learners will have a basic understanding of the HIV virion components and virus life cycle.

Objectives: At the completion of the session, learners will be able to:
• Appreciate technological advances that are being applied to study HIV particles, viral proteins, and protein-protein interactions involved in viral entry
• Describe current views of how the HIV virion is assembled and how key cellular interactions contribute to infection and virus production
• Describe recent advances in structural biology that have enabled complex viral proteins to be visualized

Conveners  
Hans-Georg Kräusslich, University of Heidelberg, Heidelberg, Germany  
Eric O. Freed, National Cancer Institute, Frederick, MD, United States

111  An Ingenious Cloak for Subterfuge: The HIV Capsid Structure  
Angela M. Gronenborn  
University of Pittsburgh, Pittsburgh, PA, United States

112  Structure of a Soluble, Cleaved HIV-1 Env Trimer and Its Interaction With Broadly Neutralizing Antibodies  
Ian A. Wilson  
The Scripps Research Institute, La Jolla, CA, United States

113  Imaging the Molecular Dance of Single HIV-1 Env Molecules  
Walter H. Mothes  
Yale University, New Haven, CT, United States

114  Kill HIV by Starvation: SAMHD1 as a Potent Viral Restriction Factor and a Master Regulator of Cellular dNTP Metabolism  
Yong Xiong  
Yale University, New Haven, CT, United States

Session S6 Symposium  
4:00 PM – 6:00 PM  
Room 304  
Know Your Epidemic: From Data To Action

This session aims to inform the attendees of the value of data in furthering the understanding of the epidemiology of the HIV epidemic and the critical role that data and evidence can play in informing research as well as policy decisions regarding HIV. The availability of various population-level surveys and the wealth of other research findings allow for a more effective response to the HIV epidemic.

Target audience: This session is directed to clinicians, researchers and policy makers who are interested in use of data and evidence to inform their work

Level of knowledge: It is assumed that learners are familiar with the global HIV epidemic, basic epidemiology of HIV, and affected populations

Objectives: At the completion of the session, learners will be able to:
• Describe the complexity of the global epidemiology of HIV
• List available population surveys related to HIV
• Recognize the evolution of the HIV epidemic within subpopulations
• Identify ways in which data and evidence can be used to inform policy

Conveners  
John Stover, Futures Institute, Glastonbury, CT, United States  
Beatriz Grinsztejn, Instituto de Pesquisa Clinica Evandro Chagas-Fiocruz, Rio de Janeiro, Brazil

115  Population Surveys: What Do They Show?  
Peter D. Ghys  
Joint United Nations Programme on HIV/AIDS (UNAIDS), Geneva, Switzerland

116  MSM in the UK: Prevention Effects of ART in Perspective  
Andrew Phillips  
University College London, London, United Kingdom

117  Understanding Networks of HIV Transmission  
Stéphane Helleringer  
Columbia University, New York City, NY, United States

118  From Evidence To Policy: Experience From Swaziland  
Velephi J. Okello  
Swaziland National AIDS Programme, Mbabane, Swaziland
THURSDAY MARCH 6, 2014

Session PL5 Plenary
8:30 AM – 9:00 AM [Auditorium]

119 HIV-1 Infection and Type-1 Interferon
Michael H. Malim
King’s College London, London, United Kingdom

Session PL6 Plenary
9:00 AM – 9:30 AM [Auditorium]

120 PEPFAR/Global Fund at 10 years: Past, Present, and Future
Stefano M. Bertozzi
University of California Berkeley School of Public Health, Berkeley, CA, United States

Session 0-9 Oral Abstracts
10:00 AM – 12:15 PM Room 312

Interferon and Antibody at the Interface of Innate and Adaptive Immunity To HIV

Moderators
Xueling Wu, Aaron Diamond AIDS Research Center, New York, NY, United States
David T. Evans, University of Wisconsin, Madison, WI, United States

121 Cryo-EM Structures of the HIV-1 Env Trimer Reveal the Full Extent of Neutralizing Antibody Epitopes
Andrew B. Ward1, Dmitry Lyumkis1, Natalia de Val1, Jean-Philippe Julien1, Albert Cupo2, Per Johan Klasse2, Rogier Sanders3, John Moore4, Ian Wilson1
1Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, United States;2Weill Cornell Medical College, New York, NY, United States;3Academic Medical Center, Amsterdam, Netherlands

122LB Immunogenicity of Cleaved, Soluble BG505 SOSIP.664 Native-Like Trimers in Rabbits
John P. Moore
Microbiology/Immunology, Weill Medical College, New York, NY, United States

123 Identification of a New Neutralization Target at the N262/N448 Glycosylation Sites On HIV-1 gp120
Xueling Wu1, Tongqing Zhou2, Iveis S. Georgiev2, Siyy O’Dell2, Mark Louder3, Dennis R. Burton4, Wayne C. Koff5, Martin Markowitz6, Peter D. Kwong5, John R. Mascola7
1Aaron Diamond AIDS Research Center, New York, NY, United States;2Vaccine Research Center, Bethesda, MD, United States;3International AIDS Vaccine Initiative, New York, NY, United States

124 CD169 Mediates HIV-1 Evasion From Detection by α-gp120 Neutralizing Antibodies in Dendritic Cells
Hisashi Akiyama1, Nora G. P. Ramirez2, Manasa Gutheti3, Suryaram Gummuluru4
1Microbiology, Boston University School of Medicine, Boston, MA, United States;2Vutara Inc., Salt Lake City, UT, United States

125 Tetherin Antagonism by Vpu Protects HIV-Infected Cells From ADCC
Juan F. Arias1, Lisa N. Heyer2, Benjamin von Bredow1, Kim L. Weisgrau3, Brian Moldt4, Dennis R. Burton5, Eva G. Rakasz6, David T. Evans1
1Department of Pathology and Laboratory Medicine, University of Wisconsin, Madison, WI, United States;2Department of Microbiology and Immunobiology, Harvard Medical School, Southborough, MA, United States;3Wisconsin National Primate Research Center, University of Wisconsin, Madison, WI, United States;4Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA, United States

126 HIV Nef and Vpu Protect HIV-infected CD4+ T Cells From ADCC Through Downmodulation of CD4 and BST2
Tram N. Q. Pham1, Sabelo Lukhele1, Fadi Hajar1, Jonathan Richard1, Rajesh M. Valanparambil1, Halima Medjahed2, Mathieu Couto3, Andres Finzi4,5, Eric A. Cohen1
1Institut de Recherches Cliniques de Montréal, Montreal, QC, Canada;2Department of Medicine, McGill University, Montreal, QC, Canada;3Centre de Recherche du Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada;4Department of Microbiology, Infectiology and Immunology, Université de Montréal, Montreal, QC, Canada

127 Identification of HIV-infected CD4+ T Cells Using HIV RNA and Broadly Neutralizing Antibodies
Joseph P. Casazza1, Alexander C. Vostal2, Irene R. Primmer3, David R. Ambrozak4, Amarendra Pegu3, Eli Boritz2, Mark K. Louder3, Daniel C. Douek4, John R. Mascola5, Richard A. Koup1
1Immunology Laboratory, NIAID, Bethesda, MD, United States;2Virology Laboratory, NIAID, Bethesda, MD, United States;3Human Immunology Section, NIAID, Bethesda, MD, United States

128 Type I Interferon Signaling Is Critical for Early Control of Immune System Damage
Netanya G. Sandler1, Steven E. Bosinger2, Jacob D. Estes3, Eli Boritz4, Brandon F. Keele5, Jerome A. Langer6, Jeffrey D. Lifson7, Srin S. Rao8, Gideon Schreiber9, Daniel C. Douek4
1Internal Medicine, University of Texas Medical Branch at Galveston, Galveston, TX, United States;2Yerkes NHP Genomics Laboratory, Yerkes National Primate Research Center, Emory University, Atlanta, GA, United States;3Leidos Biomedical Research, Inc, AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, MD, United States;4NIAID Vaccine Research Center, National Institutes of Health, Bethesda, MD, United States;5Pharmacology, Robert Wood Johnson Medical School, Rutgers University, Piscataway, NJ, United States;6Biological Chemistry, Weizmann Institute of Science, Rehovot, Israel

129 mir-422a: A Solitary MicroRNA Biomarker of Interferon-α Anti-HIV-1 Activity In Vivo
Mohamed Abdel-Mohsen1,2, Xutao Deng1,2, Teri Liegler1, Andri Rauch1, Bruno Ledengerber2, Huldrych F. Günthard3, Joseph K. Wong4,5, Satish K. Pillai1,2
1Medicine, University of California, San Francisco, San Francisco, CA, United States;2Blood Systems Research Institute, San Francisco, CA, United States;3Infectious Diseases, Bern University Hospital and University of Bern, Bern, Switzerland;4Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
Session 0-10 Oral Abstracts
10:00 AM – 12:00 PM  Ballroom B/C
CV and Other Complications

Moderators
Jason V. Baker, University of Minnesota, Hennepin County Medical Center, Minneapolis, MN, United States
Cristina Mussini, University of Modena and Reggio Emilia, Modena, Italy

130 Increased Arterial Inflammation Relates to High-Risk Coronary Plaque Morphology in HIV+ Patients
Ahmed Tawakol1, Markella V. Zanni2, Janet Lo3, Ezinne J. Ihenacho4, Allison Han1, Megan MacNabb1, Bryan Wai1, Udo Hoffmann1, Suhny Abbara5, Steven Grinspoon6
1Cardiology Division, Massachusetts General Hospital/ Harvard Medical School, Boston, MA, United States, 2Program in Nutritional Metabolism, Massachusetts General Hospital/Harvard Medical School, Boston, MA, United States, 3Cardiovascular Radiology Division, Massachusetts General Hospital/Harvard Medical School, Boston, MA, United States

131 Arterial Inflammation in HIV as Measured by FDG-PET/CT Is Associated With Splenic Activity
Priscilla Y. Hsue1, Megan MacNabb1, Rebecca Kaplan2, Elaine Nitta1, Steven Deeks3, Jeffrey Martin3, Miguel Pampaloni3, Peter Ganz4, Ahmed Tawakol1
1Cardiology, University of California San Francisco, San Francisco, CA, United States, 2Massachusetts General Hospital, Boston, MA, United States, 3University of California San Francisco, San Francisco, CA, United States

132 Replicative Senescence of Circulating Osteogenic Cells and Low BMD in Perinatally Infected Men
John S. Manavarian, Stephen Arapdi, Jayesh Shah, Chiyuan A. Zhang, Marc Foca, Natalie Neu, Stavroula Kousteni, Michael T. Yin
Columbia University Medical Center, New York, NY, United States

133 High-Dose Vitamin D and Calcium Attenuates Bone Loss With ART Initiation: Results From ACTG A5280
Edgar T. Overton1, Ellen S. Chan2, Todd T. Brown3, Pablo Tebas4, Grace A. McComsey5, Kathleen M. Melbourne4, Andrew Napoli6, Royce Hardin6, Heather J. Ribaudo7, Michael T. Yin8, ACTG A5280 Study Team
1University of Alabama School of Medicine, Birmingham, AL, United States, 2Harvard School of Public Health, Boston, MA, United States, 3The Johns Hopkins University, Baltimore, MD, United States, 4Hospital of the University of Pennsylvania, Philadelphia, PA, United States, 5Pediatrics, Case Western Reserve University, Cleveland, OH, United States, 6Gilead Sciences, Foster City, CA, United States, 7Virology, Bristol-Myers Squibb, Plainsboro, NJ, United States, 8Duke University Community Advisory Board, Durham, NC, United States, 9Harvard School of Public Health, New York, NY, United States

134 Rosuvastatin Improves Hip Bone Mineral Density But Worsens Insulin Resistance
Grace A. McComsey1, Ying Jiang3, Kristine M. Erlandson2, Sara M. Debanne1
1Case Western Reserve University, Cleveland, OH, United States, 2University of Colorado Anschutz Medical Campus, Aurora, CO, United States

135 Effects of Tesamorelin On Hepatic Fat in HIV Patients: A Randomized, Placebo-Controlled Trial
Takara Stanley, Meghan Feldpausch, Jinhee Oh, Karen Branch, Martin Torrani, Steven Grinspoon
Massachusetts General Hospital, Boston, MA, United States

Session 0-12 Oral Abstracts
10:00 AM – 12:15 PM  Ballroom A
Persistence

Moderators
Nicolas Chomont, Vaccine and Gene Therapy Institute of Florida, Port St. Lucie, FL, United States
Mary Kearney, National Cancer Institute, Frederick, MD, United States

136LB Early Treatment in Acute SIV Infection Limits the Size and Distribution of the Viral Reservoir
Afam A. Okoye1, Mukta Rohankhedkar1, Matthew Reyes2, Joseph Clock1, Derick Duell1, Yoshinori Fukazawa1, Richard Lunn1, Haesun Park1, Jeffrey D. Lifson2, Louis J. Picker1
1Vaccine & Gene Therapy Institute and the Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR, United States, 2Frederick National Laboratory for Cancer Research, SAIC-Frederick, Inc, Frederick, MD, United States

137 CD4 T-Cell Subset Composition of HIV Reservoirs in Gut, Lymphnode, and Blood During HAART
Steven A. Yukl1,2, Teri Liegler1, Mohamed Abdel-Mohsen1, Elizabeth Sinclair1, Hiroyu Hatano1, Frederick Hecht1, Ma Somsouk1, Sarah Palmer1,2, Steven G. Deeks3, Joseph K. Wong1,2
1University of California San Francisco, San Francisco, CA, United States, 2San Francisco Veterans Affairs Medical Center, San Francisco, CA, United States, 3Karolinska Institute, Stockholm, Sweden, 4Westmead Millennium Institute for Medical Research, Sydney, Australia

138 Proliferation of Cells With HIV Integrated Into Regulatory Genes Is a Mechanism of Persistence
Thor A. Wagner1,2, Sherry McLaughlin1,2, Kavita Garg3, Hannah Huang4, Sheila Strycharz4, James I. Mullins1, Lisa M. Frenkel1,2
1University of Washington, Seattle, WA, United States, 2Seattle Children’s Hospital, Seattle, WA, United States, 3Fred Hutchinson Cancer Research Center, Seattle, WA, United States

139 Novel Ex Vivo Approaches Distinguish Effective and Ineffective Drugs for Reversing Latency In Vivo
Gregory M. Laird, C. Korin Bullen, Janet D. Siliciano, Robert F. Siliciano
The Johns Hopkins University School of Medicine, Baltimore, MD, United States
140 Effect of Vorinostat On Host Gene Expression in HIV Infected Patients On Antiretroviral Therapy
Khader Ghneim1, Jeff Ahiers2, Julian Elliot3, Miranda Smith4, Fiona Wightman1, Ajantha Solomon1, Miles Prince1, Steven Deeks2, Rafick Sekaly1, Sharon Lewin2

1VGX-110, 2Department of Infectious Diseases, Monash University, Melbourne, Australia, 3Department of Hematology, Peter MacCallum Hospital, Melbourne, Australia, 4Department of Medicine, University of California, San Francisco, CA, United States

141 Cyclophosphamide Enhances SB-728-T Engraftment To Levels Associated With HIV-RCNA
Gary Blick1, Jay Lalezari2, Ricky Hsu1, Edwin DeJesus1, Trevor Hawkins1, Ronald Mitsuyasu3, Steven Deeks2, Gary Lee4, Winson Tang5, Dale Ando4

1Circle Care Center, Norwalk, CT, United States, 2Quest Clinical Research, San Francisco, CA, United States, 3Private Practice, New York, NY, United States, 4Orlando Immunology Center, Orlando, FL, United States, 5Southwest Care, Santa Fe, NM, United States, 6UCLA David Geffen School of Medicine, Los Angeles, CA, United States, 7UCSF School of Medicine, San Francisco, CA, United States, 8Sangamo BioSciences, Richmond, CA, United States

142 Stimulation of Subdominant CTL Response Is Required for the Elimination of HIV-1 Latent Reservoir
Kai Deng, Mihaela Pertea, Liang Shan, Robert Siliciano

The Johns Hopkins University, Baltimore, MD, United States

143 Dendritic Cell-Based HIV Therapeutic Vaccine Increases Residual Viremia in Individuals On ART
Bernard J. Macatangay1, Mariam B. Lawani1, Sharon A. Riddler1, Nicole D. Wheeler1, Margaret A. Bedison1, Charles R. Rinaldo2, John W. Mellors3

1Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States, 2Infectious Disease and Microbiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, United States

144LB HIV-1 Rebound Following Allogeneic Stem Cell Transplantation and Treatment Interruption
Timothy J. Henrich1, Emily Hanhauser2, Michael N. Sirignano3, Jonathan Z. Li4, Mathias Lichterfeld1, Francisco M. Marty1, Philippe Armand5, Robert J. Soiffer3, Marcus Altfeld4, Daniel R. Kuntzkes1

1Brigham and Women’s Hospital, Harvard Medical School, Cambridge, MA, United States, 2Circle Care Center, Norwalk, CT, United States, 3Quest Clinical Research, San Francisco, CA, United States, 4Private Practice, New York, NY, United States, 5Department of Hematology, Peter MacCallum Hospital, Melbourne, Australia, 6Department of Medicine, University of California, San Francisco, CA, United States

145 Age-Disparate Relationships and HIV Incidence Amongst Rural South Africa Women
Guy Harling1, Marie-Louise Newell2,3, Frank Tanser1, Ichiro Kawachi1, SV Subramanian1, Till Bärnighausen1,3

1Global Health and Population, Harvard School of Public Health, Boston, MA, United States, 2University of Southampton, Southampton, United Kingdom, 3Africa Centre for Health and Population Studies, Mtubatuba, South Africa, 4Social and Behavioral Sciences, Harvard School of Public Health, Boston, MA, United States

146 Introduction of HIV into Stable Heterosexual Couples in Rakai, Uganda Before and After ART
Mary K. Grabowski1, Justin Lessler1, Fred Nalugoda1, Steve J. Reynolds1,4, Robert Seckubugu2, Xiangrong Kong1, Godfrey Kigozi1, Maria Wawer3,4, David Serwadda1, Ronald H. Gray1

1Epidemiology, The Johns Hopkins University, Baltimore, MD, United States, 2Epidemiology, Rakai Health Sciences Program, Kalisizo, Uganda, 3Medicine, The Johns Hopkins University, Baltimore, MD, United States, 4National Institutes of Health, Bethesda, MD, United States, 5Rakai Health Sciences Program, Kalisizo, Uganda, 6University of Makerere, Kampala, Uganda

147 One Year Outcomes Following Community-Based HIV Self-Testing: A Prospective Study in Malawi
Augustine T. Choko1, Peter MacPherson1,2, Emily L. Webb1, Helena Ball1, Rodrick Sambakunsi1, Aaron Mdolo1, Simon D. Makombe2, Nicola Desmond1,2, Richard Hayes3, Elizabeth L. Corbett1,3

1Malawi Liverpool Wellcome Trust Clinical Research Programme, Blantyre, Malawi, 2Liverpool School of Tropical Medicine, Liverpool, United Kingdom, 3London School of Hygiene & Tropical Medicine, London, United Kingdom, 4HIV Unit, Ministry of Health, Lilongwe, Malawi

148 Community HIV Testing and Linkage To Care Reduces Population Viral Load in South Africa and Uganda
Ruanne V. Barnabas1,2, Heidi van Rooyen3, Elioda Tumwesigye1, Meighan Krows1, Pam Murnane1, Hilton Humphries3, Bosco Turyamureeba4, James F. Hughes1,2, Jared Baeten1, Connie Celum1

1Global Health and Medicine, University of Washington, Seattle, WA, United States, 2Fred Hutchinson Cancer Research Center, Seattle, WA, United States, 3HIV/AIDS, STIs and Tuberculosis (HAST) Programme, Human Sciences Research Council, South Africa, 4Global Health and Epidemiology, University of Washington, Seattle, WA, United States

149 Enhanced HIV Surveillance To Evaluate the National Response To HIV/AIDS in Kenya
William Maina1, Davies Kimanga1, Ibrahim Mohammed1, Mamo Umuro2, Macdonald Obudu2, George Kichamu1, Patrick Mureithi1, Willis Aktionwe1, Kevin M. De Cock2, Andrea A. Kim1


140 Harriet Nuwagaba-Biribonwoha, International Center for AIDS Care and Treatment Programs (ICAP) in Swaziland, Columbia University Mailman School of Public Health, Mbabane, Swaziland

145
Oral Sessions • Thursday, March 6, 2014

150 Unequal Benefits From ART: A Growing Male Disadvantage in Life Expectancy in Rural South Africa
Till Barnighausen1,2, Abraham J. Herbst3, Frank Tanser4, Marie-Louise Newell5,6, Jacob Bor7,8
1Global Health and Population, Harvard School of Public Health, Boston, MA, United States; 2Africa Centre for Health and Population Studies, Mbabane, South Africa; 3University of Southampton, Southampton, United Kingdom; 4Department of International Health, Boston University School of Public Health, Boston, MA, United States

151 A New Paradigm for Evaluating the HIV Care Cascade
Margaret L. McNairy, Matthew Lamb, Batya Elul, Elaine Abrams, Wafaa El-Sadr, The Identifying Optimal Models of HIV Care in Africa Study
iCAP Columbia University, New York, NY, United States

152LB Moderate HIV Incidence and High ART Coverage in Rural Kwazulu-Natal: First Population-Based Survey
Helena Huerga1, Médécins Sans Frontières, Adrian Puren2, Malika Bouhenia1, Jihane Ben Farhat1, Alex Welle3, Lubbe Wiesner4, David Maman1, Jean-François Etard1,8
1Epicentre, Paris, France; 2National Institute for Communicable Diseases of the NHLS, Johannesburg, South Africa; 3South African DST/NRF Centre of Excellence in Epidemiological Modelling and Analysis (SACEMA), Stellenbosch, South Africa; 4Division of Clinical Pharmacology, Cape Town, South Africa; 5Institut de Recherche pour le Développement, Montpellier, France

Session TD11 Themed Discussion
1:30 PM – 2:30 PM Room 309
Kaposi Sarcoma
Discussion Leader
Thomas S. Uldrick, National Cancer Institute, Bethesda, MD, United States

709 Guidelines On Kaposi’s Sarcoma Treatment: Results From Two Cohort Systematic Reviews
Esther E. Freeman1, Charles Okwundu2, Oluwatoyin Gbabe3, Miriam Laker4, Philippa Easterbrook5, Toby Maurer1, Jeffrey Martin6
1Department of Dermatology, Harvard Medical School, Massachusetts General Hospital, Boston, MA, United States; 2Centre for Evidence-Based Health Care, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa; 3Centre for Evidence-Based Health Care, Faculty of Health Sciences, Stellenbosch University, Tygerberg, South Africa; 4Department of Epidemiology and Biostatistics, University of California at San Francisco, San Francisco, CA, United States; 5HIV Department, World Health Organization, Geneva, Switzerland; 6Department of Dermatology, University of California at San Francisco, San Francisco, CA, United States

711 Kaposi Sarcoma in the Era of Combination Antiretroviral Therapy
Natascha Wyss, Matthias Egger, Julia Bohlius, Malignancy Working Group for COHERE in EuroCoord
Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland

710 Randomized Trial of Protease Inhibitor-Based Antiretroviral Therapy for Kaposi Sarcoma in Africa
Jeffrey Martin1, Miriam Laker-Oketta1,2, Victoria Walusansa3, Jackson Orem3, John Bennett4, Adrienne Mocellin5, Toby Maurer1, Peter Hunt1, Andrew Kambugu2, Edward Mbindu1,4
1University of California San Francisco, San Francisco, CA, United States; 2Infectious Diseases Institute, Kampala, Uganda; 3Uganda Cancer Institute, Kampala, Uganda; 4Uganda Virus Research Institute, Entebbe, Uganda

708 The Effect of Protease Inhibitor Use On Kaposi Sarcoma Incidence in a cART-Experienced Cohort
Elizabeth Chiao, Marc Kowalkowski
Baylor College of Medicine, Houston, TX, United States

714 Indoleamine 2,3-Dioxygenase (IDO) Activity as a Determinant of Kaposi Sarcoma in Africa
Helen Byakwaga1,2, Peter W. Hunt1, Miriam Laker-Oketta1,2, David V. Glidden1, Yong Huang1, Mwebesa Mwebesa2, Victoria Walusansa3, David R. Bangsberg1, Edward Mbindu1,4, Jeffrey N. Martin1
1University of California San Francisco, San Francisco, CA, United States; 2Mbarara University of Science and Technology, Mbarara, Uganda; 3Uganda Cancer Institute, Kampala, Uganda; 4Harvard Medical School, Massachusetts General Hospital, Center for Global Health, Boston, MA, United States

Session TD12 Themed Discussion
1:30 PM – 2:30 PM Ballroom A
Pulmonary Complications of HIV Infection
Discussion Leader
Marshall J. Glesby, Weill Cornell Medical College, New York, NY, United States

775 HIV Infection and Related Biomarkers Are Independent Risk Factors for Radiographic Emphysema
Engi F. Attia1, Matthew B. Goetz2, María C. Rodriguez-Barradas3, David Rimland4, Sheldon T. Brown5, Guy Soo Hoo2, Joon Kim6, Cherry Wongtrakool7, Kathleen Akgun8, Kristina Crothers9
1Medicine, University of Washington, Seattle, WA, United States; 2Medicine, West Los Angeles Veterans Affairs Medical Center and David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA, United States; 3Medicine, Michael E. DeBakey Veterans Affairs Medical Center and Baylor College of Medicine, Houston, TX, United States; 4Medicine, Atlanta Veterans Affairs Medical Center and Emory University, Atlanta, GA, United States; 5Medicine, James J. Peters Veterans Affairs Medical Center and Icahn School of Medicine at Mt. Sinai, Bronx and NYC, NY, United States; 6Medicine, West Haven Veterans Affairs Medical Center and Yale University, West Haven, CT, United States
776 Factors Associated With Chronic Obstructive Pulmonary Disease in a High-Risk HIV-Infected Cohort
Alain Makinson1, Maurice Hayot2, Sabrina Eymard-Duvernay3, François Raiffi4, Laurence Thirard4, Fabrice Bonnet5, Pierre Tattevin6, Sophie Abgrall7, Jacques Reynes8, Vincent Le Moing9, ANRS EP48 HIV CHEST Study Team
1Infectious and Tropical Diseases Department, University Hospital Montpellier 1, UMI 233, Montpellier, France; Department of Clinical Physiology, INSERM U1046, University Hospital Montpellier, Montpellier, France; UMI 233, IRD, University Montpellier 1, Montpellier, France; Infectious and Tropical Diseases Department, Nantes University Hospital, Nantes, France; Tourcoing University Hospital, Tourcoing, France; Internal Medicine and Infectious Diseases Department, University Hospital Bordeaux, INSERM U897, Bordeaux, France; Infectious Diseases and ICU, Pontchaillou University Hospital, Rennes, France; Infectious and Tropical Diseases Department, Groupement Hospitalier Nord, Bobigny, France

777 HIV Infection Increases Risk of Acute Exacerbations of COPD
Allison A. Lambert, Gregory D. Kirk, Jacque Astemborski, Shruti H. Mehta, M. Bradley Drummond
The Johns Hopkins University, Baltimore, MD, United States

774 Association of HIV Infection and Immune Activation With Decline in Lung Function
Kristina Crothers1, Carla V. Rodriguez2, Cherry Wongtrakool2, Guy S. Hoo3, Joon Kim4, Sheldon T. Brown5, David Rimland6, Maria C. Rodriguez-Barradas7, Matthew B. Goetz8, Amy C. Justice9
1Department of Medicine, University of Washington, Seattle, WA, United States; 2Department of Medicine, Atlanta Veterans Affairs Medical Center and Emory University, Atlanta, GA, United States; 3Department of Medicine, West Los Angeles Veterans Affairs Medical Center and David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA, United States; 4Department of Medicine, University of California, Los Angeles, CA, United States; 5Department of Medicine, James J. Peters Bronx Veterans Affairs Medical Center and and Icahn School of Medicine at Mount Sinai, New York, NY, United States; 6Department of Medicine, Atlanta Veterans Affairs Medical Center and Emory University, Atlanta, GA, United States; 7Department of Medicine, University of California San Diego, La Jolla, CA, United States; 8Department of Biostatistics, University of California San Diego, La Jolla, CA, United States; 9Department of Biostatistics, University of California San Diego, La Jolla, CA, United States

Session TD13 Themed Discussion
1:30 PM – 2:30 PM Room 304
Incidence Assays
Discussion Leader
Christine M. Rousseau, Bill and Melinda Gates Foundation, Seattle, WA, United States

1006 Performance of the Limiting-Antigen Avidity EIA for Use With Dried Blood Spot Specimens
Erin K. Rottinghaus, Trudy Dobbs, Bharat S. Parekh, Yen T. Duong
Centers for Disease Control and Prevention, Atlanta, GA, United States

1008 Incorrect Identification of Recent HIV Infection Using a LAg-Avidity Assay in Adults in the US
Andrew F. Longosz1, Ron Brokmeier2, Shruti Mehta2, Greg D. Kirk3, Joseph B. Margolick3, Joelle Brown4, Thomas C. Quinn5,6, Susan H. Eshleman5, Oliver Laeyendecker1,7
1Brigham and Women’s Hospital, Harvard Medical School, Cambridge, MA, United States; 2Brigham and Women’s Hospital, Boston, MA, United States; 3Department of Biostatistics, University of California Los Angeles, Los Angeles, CA, United States; 4Department of Epidemiology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States; 5Department of Epidemiology, University of California Los Angeles, Los Angeles, CA, United States; 6Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, United States

1007 The Impact of HIV Subtype On Specificity of Cross-Sectional HIV Incidence Assays in Rakai, Uganda
Andrew F. Longosz1, David Serwadda2,3, Fred Nalugoda4, Godfrey Kigozi5, Veronica Franco6, Ronald H. Gray7,8, Thomas C. Quinn9,10, Susan H. Eshleman4, Oliver Laeyendecker1,11
1Brigham and Women’s Hospital, Harvard Medical School, Cambridge, MA, United States; 2Brigham and Women’s Hospital, Boston, MA, United States; 3Makerere University School of Public Health, Kampala, Uganda; 4Rakai Health Sciences Program, Rakai, Uganda; 5The Johns Hopkins University School of Medicine, Baltimore, MD, United States; 6The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States

1005 Independent Evaluation of Predicate Incidence Assays for HIV Surveillance
Resthma Kassanjee1, Christopher Pilcher2, Sheila Keating1, Shelley Facente3, Matt Price4, Jeffrey Martín5, Susan Little6, Alex Welte7, Michael Busch8, Gary Murphy9, Consortium for the Evaluation and Performance of HIV Incidence Assays (CEPHIA)
1The South African DST/NRF Centre of Excellence in Epidemiological Modelling and Analysis (SACEMA), Stellenbosch University, Stellenbosch, South Africa; 2University of California San Francisco, San Francisco, CA, United States; 3Blood Systems Research Institute, San Francisco, CA, United States; 4Department of Medical Affairs, International AIDS Vaccine Initiative (IAVI), New York City, NY, United States; 5Department of Medicine, University of California San Diego, La Jolla, CA, United States; 6Health Public England, London, United Kingdom
Program and Agenda

Session TD15 Themed Discussion
1:30 PM – 2:30 PM Room 311

CNS Viral Escape and Neuroinflammation in ART

Discussion Leaders
Dennis L. Kolson, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, United States
Scott L. Letendre, University of California San Diego, San Diego, CA, United States

447 CNS Outcomes of cART vs. cART plus Maraviroc and Raltegravir Intensification During Acute HIV
Victor Valcour1, Serena Spudich2, Napporn Sailasuta3, Sukalaya Lerdlim4, James L. K. Fletcher5, Eugene D. M. B. Kroon6, Peeriya Mangyu7, Bonnie Sliker8, Jerome Kim9, Jintanat Ananworanich10, on behalf of the SEARCH 010/RV254 Study Group
1Memory and Aging Center, UCSF, San Francisco, CA, United States
2Neurology, Yale University, New Haven, CT, United States
3Huntington Medical Research Institutes, Pasadena, CA, United States
4Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
5SEARCH, The Thai Red Cross AIDS Research Center, Bangkok, Thailand
6U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Springs, MD, United States
7Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

443 CSF Viral Escape in Patients Without Neurological Disorders: Prevalence and Associated Factors
Carmela Pinnetti1, Patrizia Lorenzinii, Federica Forbicii, Adriana Ammassariii, Raffaella Libertonei, Maria Letizia Giancolai, Maria Rosaria Capobianchii, Carlo Federico Pernoi, Andrea Antinori
1National Institute for Infectious Disease, Rome, Italy

445 Cerebrospinal Fluid Viral Blips and Persistent Escape in HIV-Infected Patients On ART
Arvid Eden1, Lars-Magnus Anderssoni, Dietmar Fuchsii, Lars Hagbergii, Staffan Nilssoni, Bo Svannerhomi, Aylin Yilmazi, Henrik Zetterbergi, Magnus Gisslen
1University of Gothenburg, Gothenburg, Sweden
2Innsbruck Medical University, Innsbruck, Austria
3Chalmers University of Technology, Gothenburg, Sweden

446 Mitochondrial DNA Is Associated With Inflammation and Neurocognitive Deficits in HIV Infection
Josué Pérez-Santiagoi, Sanjay R. Mehtai, Sara Gianellia, Rachel D. Schrieri, Mariana Cherneri, Susanna R. Varai, Tyler R. C. Dayii, Miguel Ramirez-Gaonaii, Davey M. Smithii, Scott L. Letendre1
1University of California San Diego, La Jolla, CA, United States
2Biometrics, University of Alberta, Edmonton, AB, Canada

444 Early Monocyte Inflammation Among Treatment-Naïve Acute HIV-Infected Thai Subjects
Lishomwa C. Ndholu1, Mary Margaret Byrons, Guangxiang Zhangi, Duangthai Surthichom1, Somprarthana Rattanamaneei, Rapee Trichavaroii, Nittaya Phanuphakii, Victor Valcourii, Merlin Robbi, Jintanat Ananworanichi
1Hawaii Center for AIDS, University of Hawaii, Honolulu, HI, United States
2University of Hawaii, Honolulu, HI, United States
3SEARCH, The Thai Red Cross AIDS Research Center, Bangkok, Thailand

Poster Sessions
2:30 PM – 4:00 PM

(Use the Poster Abstract section of the Program at a Glance, page 37 to 106, for specific posters in each session)

Session P-A6 HIV Entry
Session P-A7 Factor Potpourri
Session P-B3 Viral Subtype: Expansion, Migration, and Recombination
Session P-C11 CD4/CD8, Aging, and Immune Senescence
Session P-C12 Mucosal CD4 and TH17 Cells
Session P-C13 In Vitro Studies
Session P-C14 Genomics and Endogenous Retroviruses
Session P-D5 Compartmentalization
Session P-D6 New Themes in Host Control

Oral Sessions • Thursday, March 6, 2014

Page 34
Session P-E6  Human Vaccine Trial Results
Session P-E7  Immune Response To Infection
Session P-F7  Effect of ART on Persistence
Session P-F8  Immunology for Cure
Session P-F9  Toward A Cure...
Session P-G7  ART Effects on HAND and CNS Reservoirs
Session P-G8  CNS Inflammation, Immune Activation, and HAND Biomarkers
Session P-H4  New Clinical and Preclinical Formulations
Session P-J1  RCTs in Second-Line ART and Virologic Failure
Session P-J2  RCTs in First-Line ART in Treatment Naïve Patients
Session P-J3  ART Simplification, Intensification, and Switch Studies
Session P-K3  ART: Adherence and Retention
Session P-K4  Second-Line ART
Session P-K5  HIV-2
Session P-L5  Laboratory Detection of Drug Resistance and Tropism
Session P-L6  Cost Effectiveness Studies of ART and Drug Resistance Testing
Session P-N6  Acute HCV Infection: Pathogenesis
Session P-N7  HCV Infection and Cellular and Humoral Immune Responses
Session P-N8  HCV-Related Outcomes: Cardiac and Non-Liver
Session P-N9  HBV and HDV
Session P-N10  HEV
Session P-O5  Cervical Cancer, HPV, and HPV Vaccine
Session P-P6  Statins and ARV Effects in HIV
Session P-Q7  Renal Disease: ART, Genetic Factors, and Long-Term Outcomes
Session P-Q8  Obesity: ART and Animal Models
Session P-Q9  Genetic Factors and ART Outcomes
Session P-Q10  ART and Suicidality
Session P-R6  Cryptococcal Disease
Session P-R7  OIs other than TB and Cryptococcal Disease
Session P-S2  HIV in Women: Pregnancy, Progression, Pap, and Bones
Session P-S3  Immune Mediators and Immune Activation in Women
Session P-S4  Immune Response To Vaccination in HIV+ Women
Session P-T7  Risk Factors for MTCT
Session P-T8  PMTCT Approaches: Implementation and Outcome
Session P-T9  ART Pharmacokinetics During Pregnancy and Breast Feeding

Session P-U6  Response To Early ART Initiation in Infants
Session P-U7  Co-Infections and Treatment Responses in Children and Adolescents
Session P-U8  Outcomes Among Adolescents – Perinatally and Behaviorally Acquired HIV Infection
Session P-W7  Disease Progression/Mortality
Session P-W8  Co-Morbidities
Session P-W9  Transmission/Risk Factors

Session S7 Symposium
4:00 pm – 6:00 pm  Room 304
Interferon: Whatever Turns You On

Target audience: This session is directed to basic, translational, and clinical researchers interested in the role played by mechanisms of antiviral innate immunity — and, specifically, the type I interferons — in HIV-infected individuals in both protecting against virus replication and potentially inducing immunopathology in the host.

Level of knowledge: It is assumed that learners are familiar with the basic aspects of virology, immunology, and pathogenesis of HIV infection and AIDS.

Objectives: At the completion of the session, learners will be able to:

• Recognize the potential antiviral as well as pro-inflammatory roles of type I IFNs during HIV infection
• Understand the role of type I IFNs in HIV transmission and pathogenesis
• Describe the similarities and differences of the role played by type I IFNs in HIV and HCV infections

Conveners
Nina Bhardwaj, Icahn School of Medicine at Mount Sinai, New York, NY, United States
Michael M. Lederman, Case Western Reserve University, Cleveland, OH, United States

154  HIV-1 Evades Innate Immune Recognition Through Specific Co-Factor Recruitment
Greg J. Towers
University College London, London, United Kingdom

155  Interferon Treatments for Chronic Hepatitis C
Markus H. Heim
University Hospital Basel, Basel, Switzerland

156  Perturbing Interferon Signaling in SIV Infection
Daniel C. Douek
National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States

157  Type 1 Interferon-Mediated Selective Pressure On HIV-1 Transmission
Persephone Borrow
University of Oxford, Oxford, United Kingdom
Session S8 Symposium
4:00 PM – 6:00 PM Room 311
The Road To Elimination: Preventing and Treating HIV Infection in Infants

Target audience: This session is directed to individuals interested in prevention of perinatal transmission and early antiretroviral therapy for HIV-exposed infants at high risk for perinatal transmission.

Level of knowledge: It is assumed that learners are familiar with pathophysiology of perinatal HIV transmission, approaches to prevention of infant infection and HIV management of pregnant and breast-feeding women. In addition, learners should have a basic understanding of manifestations and treatment of HIV infection during infancy and early childhood.

Objectives: At the completion of the session, learners will be able to:

• Describe the rationale for and implementation experience with the Option B+ approach to prevention of perinatal HIV transmission
• Identify short- and long-term effects of antiretroviral exposure during pregnancy and breast-feeding
• Recognize new approaches to early diagnosis and treatment of HIV-exposed and -infected newborns

Conveners
Dalton C. Wamalwa, University of Nairobi, Nairobi, Kenya
Coceka N. Mnyani, University of the Witwatersrand, Anova Health Institute, Johannesburg, South Africa

158 Treatment of Pregnant and Breast-Feeding Women: Evidence and Rationale for Option B+
Saeed Ahmed
Baylor College of Medicine, Lilongwe, Malawi

159 Achievements and Challenges With Option B+ Implementation in the Field To Date
Edward Bitarakwate
Elizabeth Glaser Pediatric AIDS Foundation, Kampala, Uganda

160 No Free Rides: Consequences of Fetal & Infant ARV Exposure Among Children Remaining HIV Uninfected
Kathleen M. Powis
Harvard Medical School, Boston, MA, United States

161 Treatment of HIV-Infected Newborns: Why, When, and What To Start?
Ellen G. Chadwick
Northwestern University, Feinberg School of Medicine, Chicago, IL, United States

Session S9 Symposium
4:00 PM – 6:00 PM Room 312
Intimate Infections: What’s Love Got To Do With It?

Target audience: This session is directed to clinicians and scientists interested in sexually transmitted infections affecting HIV-infected and -at risk persons.

Level of knowledge: It is assumed that learners are familiar with basic HIV epidemiology and sexually transmitted infections.

Objective: At the completion of the session, learners will be able to:

• Describe the epidemiology, clinical manifestations, association with HIV infection, and approaches to prevention and treatment of human papilloma virus (HPV), bacterial vaginosis (BV), meningococcus, and lymphogranuloma venerium (LGV)

Conveners
Christine Katlama, Pitié-Salpêtrière Hospital, Paris, France
Bernard Liautaud, GHESKIO Centers, Port-au-Prince, Haiti

162 Oral Human Papillomavirus (HPV): Epidemiology and Role in Oropharyngeal Cancer
Gypsyamber DSouza
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States

163 Bacterial Vaginosis
Landon Myer
University of Cape Town, Cape Town, South Africa

164 Outbreak of Invasive Meningococcal Disease Among Men Who Have Sex With Men — New York City, 2010-2013
Alison Ridpath
New York City Department of Health and Mental Hygiene, New York, NY, United States

165 Lymphogranuloma venereum
David A. Lewis
National Institute for Communicable Diseases, Johannesburg, South Africa
POSTER ABSTRACTS

Session P-A1 Poster Session
Tuesday March 4, 2014, 2:30 PM–4:00 PM  Exhibit Hall A
SAMHD1

166 CDK2 But Not CDK1 Phosphorylates SAMHD1 in Primary Macrophages
Alba Ruiz1, Eduardo Paulus1, Ester Ballana1, Albert Gres2, Mar Alvarez3, Luis Menéndez-Arias3, Francesc Posas1, Bonaventura Clotet1, José A. Este1
1AIDS Research Institute - IRISCaixa, Badalona, Spain; 2Institute for Medical Virology, Frankfurt, Germany

167LB p21 Regulates the HIV-1 Restriction Factor SAMHD1
Alba Ruiz1, Eduardo Paulus1, Eva Rivera-Muñoz1, Marcel Permanyer1, Roger Badia1, Oliver T. Keppler1, Bonaventura Clotet1, Ester Ballana1, Jose Este1
1AIDS Research Institute - IRISCaixa, Badalona, Spain; 2Institute for Medical Virology, Frankfurt, Germany

Session P-A2 Poster Session
Tuesday March 4, 2014, 2:30 PM–4:00 PM  Exhibit Hall A
Integration/Nuclear Import

170 BET Proteins Mediate Integration Site Selection of MLV Much Alike LEDGF/p75 in HIV Integration
Jan De Rijck1, Christine de Kogel1, Jonas Demeulemeester1, Sofie Vets1, Nirar Malani1, Frederic Bushman2, Frauke Christ3, Rik Gijbers1, Zeger Debyser1
1Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium; 2Department of Microbiology, University of Pennsylvania, Philadelphia, PA, United States

171 Zinc-Finger Endonuclease Targeting LEDGF/p75 Inhibits HIV-1 Integration
Roger Badia1, Ester Ballana1, Bonaventura Clotet1, Jose Est1
AIDS Research Institute - IRISCaixa, Badalona, Spain; 2Institute for Medical Virology, Frankfurt, Germany

172 Small-Molecule Inhibits HIV-1 Replication by Interacting With HIV Capsid
Atsuko Hachiya1,2, Anna Gres3, Karen A. Kirby4, Michailidis Elefteriou2, Masami Maejima1, Wataru Sugiru1, Kyeongeun Lee5, Vineet KewalRamani1, Kamlendra Singh6, Stefan G. Sarafianos1,4,8
1Clinical Research Center, Laboratory of Infectious Diseases, National Hospital Organization, Nagoya Medical Center, Nagoya, Japan; 2C. S. Bond Life Sciences Center & Department of Molecular Microbiology and Immunology, University of Missouri School of Medicine, Columbia, MO, United States; 3HIV Drug Resistance Program, National Cancer Institute, Frederick, MD, United States; 4Department of Biochemistry, University of Missouri, Columbia, MO, United States

173 Resistance To HIV-1 Infection in PBLs From LGMD1F Patients Carrying a Genetic Defect in TNP03
Mercedes Bermejo1, Mayte Corrales1, Sara Rodriguez-Mora1, Elena Matos1, Ramón Martí1, Juan Vilchez1, Antonio Andreu1, José Alcami1,2
1AIDS Immunopathology Unit, Instituto de Salud Carlos III, El Centro Nacional de Microbiología, Majadahonda, Madrid, Spain; 2Research Group on Neuromuscular and Mitochondrial Disorders, Vall d’Hebron Institut de Recerca, VHIV and CIBERER, Barcelona, Spain; 3Hospital Universitari i Politecnic La Fe, Department of Neurology, Universitat de Valencia, and CIBERNED, Department of Medicine, Valencia, Spain

Session P-A4 Poster Session
Wednesday March 5, 2014, 2:30 PM–4:00 PM  Exhibit Hall A
Late Events in HIV Replication

175 SHAPE- Directed Discovery of a Novel Structure in the HIV-1 RNA Polyadenylation Signal
Nathan A. Siegfried1, Steven Busan1, Gregory M. Rice1, Christine E. Hajdin1, Julie A. E. Nelson2, Kevin M. Weeks1
1Chemistry, Univ of North Carolina at Chapel Hill, Chapel Hill, NC, United States; 2UNC Center for AIDS Research and Microbiology & Immunology, Univ of North Carolina at Chapel Hill, Chapel Hill, NC, United States

176 HIV-1 Assembly On Intracellular Plasma Membrane-Connected Compartments of Human Macrophages
David O. Nkwe1, Annikki Pelchen-Matthews2, Mark Marsh3, Mercedes Bermejo1, Rik Gijbers1, Zeger Debyser1
1AIDS Immunopathology Unit, Instituto de Salud Carlos III, El Centro Nacional de Microbiología, Majadahonda, Madrid, Spain; 2Research Group on Neuromuscular and Mitochondrial Disorders, Vall d’Hebron Institut de Recerca, VHIV and CIBERER, Barcelona, Spain; 3Hospital Universitari i Politecnic La Fe, Department of Neurology, Universitat de Valencia, and CIBERNED, Department of Medicine, Valencia, Spain

177 LEDGIN (ALLIN1) Disruption of HIV-1 Assembly Does Not Involve LEDGF/p75
Hind J. Fadel1, James Morrison1, Dyana Saenz1, Stephen C. Ekker2, James R. Fuchs2, Mamuka Kvaratskhelia1, Eric M. Pesochia3
1Division of Infectious Diseases & Department of Molecular Medicine, Mayo Clinic, Rochester, MN, United States; 2Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, United States; 3Ohio State University Center for Retrovirus Research, Columbus, OH, United States

178 Characterization of the Interaction Between Staufen-1 With HIV-1 Rev and HERV-K(HML-2) Rec
Katharina Fieddeke1, Alexander Rohde1, Kirsten Hanke1, Jula Wamara1, Oliver Hohn1, Norbert Bannert1
1HIV and Other Retroviruses, Robert Koch Institute, Berlin, Germany

179 The Role of RNA Interference in HIV-1-Infected Primary Human Monocyte-Derived Macrophages
Valentina Vondrad1, Jochen Imig1, Pejman Mohammad2, Shivendra Kishore3, Lukasz Jasikiewicz4, Mihaela Zavolan4, Jonathan Hall1, Niko Beerenwinkel1, Huldrych F. Günthard1, Karin J Metzner1
1Division of Infectious Diseases & Department of Molecular Medicine, Mayo Clinic, Rochester, MN, United States; 2ETH Zurich, D-BSSE, Basel, Switzerland; 3Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland; 4ETH Zurich, Zurich, Switzerland; 5Computational and Systems Biology, University of Basel, Basel, Switzerland

180 Induced Maturation of HIV-1 Virions
Barbara Mueller1, Simone Mattei1, Maria Anders1, John A. G. Briggs1, Hans-Georg Krausslich1
1Infectious Diseases, Virology, University of Heidelberg, Heidelberg, Germany; 2EMBL, Heidelberg, Germany
Poster Abstracts

181 Interplay of Cholesterol and Env Protein in the Lytic Deformation of HIV-1 by Peptide Triazoles
R Venkat Kalyana Sundaram1, 2, Huynhan Li3, Lauren Bailey4, A Rosemary Bastian1, 2, Steven Wrenn1, CameronAbrams1, Inrln Chalken1
1Biochemistry and Molecular Biology, Drexel University College of Medicine, Philadelphia, PA, United States; 2School of Biomedical Engineering, Science and Health Systems, Drexel University, Philadelphia, PA, United States; 3Shared Research Facility, West Virginia University, Morgantown, WV. United States; 4Biochemistry, Drexel University College of Medicine, Philadelphia, PA, United States

182 Characterizing Novel N-Terminal Domains of APOBEC3G
Melting R. May1, Ann M. Sheehy2
1College of the Holy Cross, Worcester, MA, United States; 2Biomedical Sciences, University of Massachusetts Medical School, Worcester, MA, United States

183 SLBP (Stem-Loop Binding Protein) Regulates the Expression of APOBEC3G
Ming Li, Lynne Tucker, Michelle Lally, Bharat Ramnath
Alpert Medical School of Brown University, Providence, RI, United States

184 Incomplete Apobec3g Neutralization by Vif Mutations Facilitates Evolution From CCR5 To CXCR4 Use
Claudia Altieri1, Matteo Surdo1, Patrizia Soccomandi1, Fabio Contiienza2, Daniele Armenia1, Luca Caroti1, Anna Artesse1, Francesca Ciccherini-Silberstein1, Carlo Federico Perno2, Valentina Siviero2
1Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy; 2Istituto Nazionale per le Malattie Infettive “Lazzaro Spallanzani”, Rome, Italy; 3Department of Pharmacological Sciences, Magna Graecia University of Catanzaro, Roccella di Borgia (CZ), Italy

185 17δ-Estradiol Protects Primary Macrophages Against HIV Through Induction of IFNc and APOBEC3A
Carley Tasker1, Jian Ding1, Mirco Schmolke2, Omaritib Rivera-Medina1, Adolfo Garcia-Sastre3, Theresa Chang1
1Department of Microbiology and Molecular Genetics, Rutgers Biomedical and Health Sciences, Newark, NJ, United States; 2Department of Microbiology, Mount Sinai School of Medicine, New York, NY, United States; 3Department of Medicine, Rutgers Biomedical and Health Sciences, Newark, NJ, United States

186 Nuclear Import of APOBEC3F-Labeled HIV-1 Preintegration Complexes
Ryan C. Burdick, Wei-Shau Hu, Vinay K. Pathak
HIV Drug Resistance Program, National Cancer Institute, Frederick, MD, United States

187 Non-Integrating HIV-1 Is Sensitive To Inhibition by Target Cell Apobec3a
Carsten Münk1, Akaterini Krikoni1, Wolfgang Goering1, Andre Franken1, Daniela Marini1, Gerald S. Schummann1, Renate König1, Wolfgang Schultz1, Dieter Haussinger2
1Clinic for Gastroenterology, Hepatology and Infectiology, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany; 2Clinic for Urology, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany

188 Degradation of SAMHD1 Specifically Decreases the Efficacy of Thymidine HIV RT Analog Inhibitors
Ester Ballana, Gerard Terradas, Eva Rivera-Muñoz, Bonaventura Clotet, Eduardo Paula, José A. Este
IrsiCaixa AIDS Research Institute, Badalona, Spain

188A Natural Resistance To HIV-1 by Select APOBEC3H Haplotypes
Eric W. Relfseld1, Judd F. Hultquist1, Elizabeth M. Luengas1, Rachel Proser1, Keith Henry3, Michael Emerman1, Reuben S. Harris1
1Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, MN, United States; 2Hennepin County Medical Center, Minneapolis, MN, United States; 3Fred Hutchinson Cancer Research Center, Seattle, WA, United States

Session P-A6 Poster Session
Thursday March 6, 2014, 2:30 PM – 4:00 PM Exhibit Hall A

189 The Sphingosine-1-Phosphate Receptor 1 Dimers With CCR5 and Enhances HIV Infection
Charline Duquenne1, Sandrine Gimenez1, Adeline Guitiues1, Laurent Prézeau1, Noelle Campos1, Jalal Tazi1, Pierre Corbeau1, Vincent François2
1Institute of Human Genetics, CNRS, Montpellier, France; 2Institute of Functional Genomics, CNRS, Montpellier, France; 3Institute of Molecular Genetics, CNRS, Montpellier, France

190 Puriﬁnger Receptor Antagonists as Potent Inhibitors of HIV-1 Infection by Blocking Early Entry
Talia H. Swartz, Anthony M. Esposito, Natasha D. Durham, Benjamin K. Chen
Icahn School of Mount Sinai, New York, NY, United States

191 Optical Sorting of HIV-1 Reveals the Minimum Number of Spikes Required for Optimal Viral Infectivity
Wei Cheng
University of Michigan, Ann Arbor, MI, United States

192 Application of an HIV Entry Assay To Identify HIV Target Cells in the Female Genital Tract
Vince R. Joag
University of Toronto, Toronto, ON, Canada

193 Early Non-Mac-Tropic HIV-1 RS EnvS Efficiently Trans- Infect T Cells and Infect Ectocervices
Paul J. Peters1, Olivia O’Connell1, Thomas Musich2, Maria Paz2, Gonzalez Perez2, Tiffany Moore-Simaz3, Cynthia Berderuy1, Paul R. Chlapman4
1Molecular Medicine, University of Massachusetts Medical School, Worcester, MA, United States; 2National Cancer Institute, Bethesda, MD, United States; 3Obstetrics & Gynecology, UMass Memorial Medical Center, Worcester, MA, United States; 4Emory Vaccine Center, Atlanta, GA, United States

194 Transmitter as Compared To Recipient Envelopes Caribbean Replication and c457 Utilization
Victor Pena-Cruz1, Bethedal Etemad1, Nikolaos Chatzandroureas, Shannon Stock1, Steven J. Reynolds1, Oliver Layendecker1, Ronald H. Gray2, David Seward3, Thomas C. Quinn2, Manish Sagar4
1Boston University, Boston, MA, United States; 2College of the Holy Cross, Worcester, MA, United States; 3The Johns Hopkins University, Baltimore, MD, United States; 4Makere University School of Public Health, Kampala, Uganda

195 Differences in HIV Receptor Activity of CXCR4 Isoforms: Consequences for X4 Strains Emergence
Charline Duquenne1, Christina Poasoma2, Sandrine Gimenez3, Marie-Josée Carlies3, Claudine Barbuat4, Jean-Philippe Lavigne1, Albert Sotto1, Jacques Reynes1, Vincent Francois2, Pierre Corbeau1
1Institute of Human Genetics, CNRS, Montpellier, France; 2Infectious Diseases, University Hospital, Montpellier, France; 3Microbiology, University Hospital, Nîmes, France; 4Infectious Diseases, University Hospital, Nîmes, France

196 Defining Interactions of HIV With Rectal Epithelial Barriers and Recetal Mucus
Luis M. Barcena1, Minh Do1, Peter A. Anton2, Thomas J. Hope1
1Northwestern University Feinberg School of Medicine, Chicago, IL, United States; 2UCLA, David Geffen School of Medicine, Los Angeles, CA, United States
Session P-A7 Poster Session Thursday March 6, 2014, 2:30 PM–4:00 PM Exhibit Hall A Factor Potpourri

197LB Platelet Factor 4 Oligomeric State Correlates With Antiviral Activity
Zahra F. Parker1, Ann Rua1, Fang-Hua Lee1, Amber Riblitt2, Mortimer Poncz3, Bruce Sachsai1, Robert Dom2
1Microbiology, University of Pennsylvania, Philadelphia, PA, United States;2Pathology, University of Pennsylvania, Philadelphia, PA, United States;3Hematology, The Children's Hospital of Philadelphia, Philadelphia, PA, United States;4Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, United States;5Pathology and Laboratory Medicine, The Children's Hospital of Philadelphia, Philadelphia, PA, United States

198 CRM-1: A Critical Regulator of HIV Replication in a Quest Towards a Small Animal Model for HIV
Hila Elina1, Yuanchi Wu1, Ayse Coskun2, Katarzyna Hryckiewicz2, Iris Kemler3, Yani Hu4, Bing Hao4, Choukri Ben Mamoun5, Eric Poeschla5
1Clinical Microbiology and Infectious Diseases, Hadassah Hebrew University Medical Center, Jerusalem, Israel;2Infectious diseases, Yale University, New Haven, CT, United States;3Department of Molecular Medicine, Mayo Clinic, Rochester, MN, United States;4Infectious Diseases, Yale University, New Haven, CT, United States;5Molecular Microbial and Structural Biology, University of Connecticut Health Center, Farmington, CT, United States

199 Analyses of the Sequence-Function Relationships Among HIV-1 Vpr, SIVagmVpr, and SIVmacVpx
Ana Beatriz DePaula-Silva1, Patrick A. Cassidy, Vicente Planelles
1Pathology, University of Utah, Salt Lake City, UT, United States

200 Elevated Expression of Anti-HIV-1 Restriction Factors in Effector Memory CD4+ T Cells In Vivo
Mohamed Abdel-Mohsen1, Xutao Deng1, Rui Andre Saraiva Raposo1, Teri Liegler1, Elizabeth Sinclair1, Rebecca Hon1, Douglas F. Nixon1, Joseph K. Wong1, Steven G. Deeks1, Yuanfei Wu2, Ayse Coskun2, Rui Andre Saraiva Raposo1, Thomas C. Dunn3, Aida Kukuzalaza, Don Teg5, Kung Tieg6
1Centre of Excellence for Research in AIDS (CERiA), Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia;2Institute of Infectious Disease and Epidemiology, Communicable Disease Centre, Tan Tock Seng Hospital, Novena, Singapore;3Division of Infectious Diseases, The Johns Hopkins School of Medicine, Baltimore, MD, United States;4Laboratory of Immunoregulation, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States

201LB TRIM5alpha Determinants for the Activation of Innate Immunity
Marie-Edith Nepeu-Transmission Clustering Among Newly Diagnosed HIV+ Patients in the United Kingdom
Jean L. Mbisa1, Esther Fearnhill1, David T. Dunn2, Deenan Pillay3, Satish K. Pillai1
1Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, GA, United States;2ICF International and University of California, San Diego, CA, United States;3International AIDS Vaccine Initiative, New York, NY, United States

202 HIV-1 Vpu Antagonizes Macaque and Chimpanzee BST-2 Through Cytoplasmic Domain Interactions
Takeshi Yoshida1, Yoshio Koyanagi2, Hirofumi Akari3, Klaus Strehl2
1Center for Human Evolution Modeling Research, Primate Research Institute, Kyoto University, Uiyama, Japan;2Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, United States;3Laboratory of Viral Pathogenesis, Institute for Virus Research, Kyoto University, Kyoto, Japan

203 Investigating the Requirement of a NOD-Like Receptor for Early HIV Replication
Manja Burgraff1, Prashant Jain2, Crystal Shi3, Nicole Esly4, John Mariett1, John A. Young5, Sumit K. Chandra6, Renate Koenig7
1Host-Pathogen-Interactions, Paul-Ehrlich-Institute, Langen, Germany;2Sanford-Burnham Medical Research Institute, La Jolla, CA, United States;3The Salk Institute, La Jolla, CA, United States

204 ITIH4: A Cellular Factor Targeted by HIV-1 Vpr
Steven Santos1, Yong-Hui Zheng2, Michael Bukrinsky1
1The George Washington University, NIH Washington, DC, United States;2Michigan State University, East Lansing, MI, United States

205 Ongoing HIV-1 Subtype B Transmission Networks in the Netherlands
Daniela Bezemer1, Oliver Ratmann2, Ard van Sighem3, Bas E. Dutilh3, Nuno Faria1, Rob van den Hengel4, Luuk Grass, Peter Reiss1, Frank de Wolf5, Christophe Fraser1
1ATHENA observational cohort 1Research, HIV Monitoring Foundation, Amsterdam, Netherlands;2Imperial College, London, United Kingdom;3Centre for Molecular and Biomolecular Informatics, Nijmegen, Netherlands;4University of Oxford, Oxford, United Kingdom

206 Using HIV Networks To Inform Real Time Prevention Interventions
Susan J. Little1, Sergei L. K. Pond2, Christy M. Anderson3, Jason A. Young4, Joel O. Wertheim5, Sanjay R. Mehta6, Susanne May7, Davey M. Smith1
1Medicine, University of California San Diego, San Diego, CA, United States;2Biostatistics, University of Washington School of Public Health, Seattle, WA, United States

207 Transmission Networks of HIV-1 Subtype B, CRF01_AE and CRF01_01B Among MSM in Singapore
Kim Tien Ng1, Kah Ying Ng2, Wei Xin Khong3, Olivier Luyendecker1,4, Thomas C. Dunn5, Adeeba Kamarulzaman1, Don Teg5, Kok Keng Tee1
1Centre of Excellence for Research in AIDS (CERiA), Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia;2Institute of Infectious Disease and Epidemiology, Communicable Disease Centre, Tan Tock Seng Hospital, Novena, Singapore;3Division of Infectious Diseases, The Johns Hopkins School of Medicine, Baltimore, MD, United States;4Laboratory of Immunoregulation, Division of Intramural Research, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD, United States

208 HIV-1 Phylogenetics and Phylogeography Among High-Risk and General Populations in Uganda
Gonzalo Yebra1, Manon Ragonnet-Cronin2, Deogratius Ssemwangi3, Chris M. Parry4, Pontiano Kaleebu4, Andrew J. Leigh Brown1, Darren L. curtains1,2,3,4,5,6,7,8
1Institute of Virology and Biotechnology, University of Edinburgh, Edinburgh, United Kingdom;2Research Unit on AIDS, MRC/Uganda Virus Research Institute, Entebbe, Uganda

209 Sustained Spread of HIV-1 Drug Resistance in Treatment-Naive Patients in the United Kingdom
Jean L. Mbisa1, Esther Fearnhill1, David T. Dunn2, Deenan Pillay3, David Asboe4, Patricia Anne Can5, on behalf of the UK HIV Drug Resistance Database
1Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, GA, United States;2ICF International and University of California, San Diego, CA, United States;3Laboratory of Viral Pathogenesis, Institute for Virus Research, Kyoto University, Kyoto, Japan

210 Transmission Clustering Among Newly Diagnosed HIV+ Patients in Chicago, 2008 To 2011
Sarah Hoenhen1, Anna Hotton2, Audrey L. French3, Stacey Kincaid4, David Barker1, Ronald Lumberch5,5
1Infectious Disease, Rush University Medical Center, Chicago, IL, United States;2Biostatistics, University of Washington School of Public Health, Seattle, WA, United States;3Research Department of Infection, University College London, London, United Kingdom;4Directorate of HIV Medicine and Sexual Health, Chelsea and Westminster Hospital, London, United Kingdom

211 Can Molecular HIV Surveillance Identify Groups To Prioritize for Prevention?
Alexandra M. Oster1, Joel O. Wertheim2, Angela L. Hernandez3, Marie C. B. Ocfemia1, Neeraja Sadulava1, David Kim1, H. I. Hall3
1Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, GA, United States;2ICF International and University of California, San Diego, CA, United States;3Division of HIV/AIDS Prevention, ICF International, Atlanta, GA, United States
212 Investigation of HIV Transmission Dynamics Reveals “Active” Clusters of Men Who Have Sex With Men
Philip A. Chan1, Austin Huang2, Allison Delong1, Joseph Hogan3, Marissa Rettsma1, Marco Saleni4, Rami Kantor5
1Medicine, Brown University, Providence, RI, United States, 2Computer Science, Brown University, Providence, RI, United States, 3Center for Statistical Sciences, Brown University, Providence, RI, United States, 4Pathology, University of Florida, Gainesville, FL, United States

213 HIV Transmission in the United States: The Roles of Risk Group, Race/Ethnicity, and Geography
Alexandra M. Oster1, Joel O. Wertheim2, Angela L. Hernandez2, Marie C. B. Ofernia3, Neeraja Sadakvala4, David Kim5, I. H. J. Hall6
1Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, GA, United States, 2ICF International and University of California San Diego, San Diego, CA, United States, 3ICF International, Atlanta, GA, United States

214 Risk Factor Predicts Geographic Spread Within New York City Joel O. Wertheim7, Sanjay R. Mehta8, Sergi L. Kosakovskyy Pond9, Davey M. Smith1, Lisa A. Forgie10, Lucia L. Torian11
7New York City Department of Health and Mental Hygiene, New York, NY, United States, 8Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States, 9Division of Neurology, Yale University, New Haven, CT, United States, 10Department of Neurology, University of California at San Francisco, San Francisco, CA, United States, 11Center For AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States

1Infectious Diseases Surveillance Center, National Institute of Infectious Diseases, Tokyo, Japan, 2Tokyo Metropolitan Institute of Public Health, Tokyo, Japan, 3Clinical Research Center, Nagoya Medical Center, Nagoya, Japan

Session P-B2 Poster Session
Wednesday March 5, 2014, 2:30 pm–4:00 pm Exhibit Hall A
Application of NGS To Viral Profiling

216 Full-Length HIV-1 Haplotype Reconstruction From Heterogeneous Virus Populations Armin Töpper1, Francesca Di Girolamo2, Melanie Rey3, Sandhya Prabathakaran4, Yannik Duport5, Christine Leemann6, Huldrych F. Günthard7, Volker Roth8, Niko Beerenwinkel9, Karin J. Metzner10
1D-BSSE, ETH Zurich, Basel, Switzerland, 2SIB Swiss Institute of Bioinformatics, Basel, Switzerland, 3University of Zurich, Zurich, Switzerland, 4Life Science Zurich Graduate School, Zurich, Switzerland, 5University of Basel, Basel, Switzerland

217 Limited HIV-1 Superinfection in Serconvereters From the CAPRISA 004 Microbicide Trial Andrew Redd1, Caroline Mullis2, Daniel Sheward3, Carolyn Williamson4, Lisa Werner5, Nigel Garrett6, Stephen Porcelli7, Guarraisha Abdool Karim8, Thomas Quinn9, Salim Abdool Karim10, TRAPS Study Team11
1NIAID, Baltimore, MD, United States, 2The Johns Hopkins, Baltimore, MD, United States, 3University of Cape Town, Cape Town, South Africa, 4CAPRISA, Durban, South Africa, 5NIAID, Hamilton, MT, United States

218 Analysis of PCR Bias Using Primer IDs and Illumina Sequencing of HIV RNA Populations Valerie F. Bets1, Wei Shao2, Mary F. Kearney3, John W. Mellors4, Frank Maldarelli5, John M. Coffin6
1Drug Resistance Program, National Cancer Institute, Frederick, MD, United States, 2Advanced Biomedical Computing Center, Leidos Biomedical Research, Inc, Frederick, MD, United States, 3Division of Infectious Disease, University of Pittsburgh, Pittsburgh, PA, United States, 4Department of Molecular Biology and Microbiology, Tufts University, Boston, MA, United States

219 HIV Surveillance and Parallel Virome Analysis Using Unbiased Next-Generation Sequencing Ka-Chung Luk1, Michael Berg2, Samia Nacacche3, Scot Federman3, Charlotte Nganso1, Dora Mbanya1, Lazare Kaptue4, Charles Y. Chi5, John Hackett1
1Abbott Diagnostics, Abbott Park, IL, United States, 2University of California, San Francisco, San Francisco, CA, United States, 3Université de Yaounde, Yaounde, Cameroon, 4Université des Montagnes, Bangangte, Cameroon

220 Primer ID Deep Sequencing of HIV-1 env Region To Reveal Genetic Structure of Viral Population Shuntai Zhou1, Maria Bednar2, Christa Sturdevant3,4, Serena Spudich5, Richard Price6, Ronald Swanstrom7,8
1Lineberger Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States, 2Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States, 3Department of Neurology, Yale University, New Haven, CT, United States, 4Department of Neurology, University of California at San Francisco, San Francisco, CA, United States, 5Center For AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States, 6Department of Biocomputation and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States

221 Using RNAsSeq To Characterize Viral Genetic Diversity in a Cohort of HIV-2 Monoinfected Individuals Katherine L. James1, Louis-Marie Yendom2, Thuathan De Silva3, Shokouh Makvandi-Nejad4, Stephen Taylor5, Hilton Whittle6, Tim Vincent7, Gilean McVean8, Sarah Rowland-Jones9
1NMD, University of Oxford, Oxford, United Kingdom, 2University of Sheffield, Sheffield, United Kingdom, 3Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom, 4London School of Hygiene and Tropical Medicine, London, United Kingdom, 5Medical Council Research Unit, Fajara, Gambia, 6Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom

222 Next Generation Sequencing of Full-Length HIV-1 env During Primary Infection Melissa E. Laird1, N. Lance Helper2, Colleen Ludka3, Michael Brown4, Stephen Esposita5, Yen Guo6, Douglas D. Richman7, Sergei Kosakovskyy Pond8, Ellen E. Paxinos9, Davey M. Smith10
1University of California, San Diego, La Jolla, CA, United States, 2Applications and Collaborations, Pacific Biosciences, Menlo Park, CA, United States, 3Bioinformatics, Pacific Biosciences, Menlo Park, CA, United States, 4Veterans Affairs San Diego Healthcare System, San Diego, CA, United States

Session P-B3
Thursday March 6, 2014, 2:30 pm–4:00 pm Exhibit Hall A
Viral Subtype: Expansion, Migration, and Recombination

223 Spread of CRF33_01B and Emergence of Novel Recombinants Among People Who Inject Drugs in Malaysia Wei Zhen Chow1, Lai Yee Ong1, Hui Ting Cheong2, Nur Ezreen Syafina3, Maryam Nabil Al-Khannaq4, Yutaka Takebe5, Clayton Koh6, Haider Al-Darraji7, Adeeba Kamarulzaman8, Kok Keng Tee1
1Centre of Excellence for Research in AIDS (CERIA), Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia, 2AIDS Research Center, National Institute of Infectious Diseases, Toyama, Shinjuku-ku, Tokyo, Japan

224 AHI Detection Among People WhoInject Drugs in Russia Reveals the HIV-1 Transmission Bottleneck Elena Dukhovninova1, Alexey Masharsky2,3, Sergei Verevochkin4, Olga Tousova5,6, Andrey Shevchenko7,8, David Montefiori9, Irving Hoffman10, William Miller11, Andrei Kozlov12, Ronald Swanstrom1,9,2
1CFAR and Lineberger CCC, University of North Carolina, Chapel Hill, NC, United States, 2Saint Petersburg State University, Saint Petersburg, Russian Federation, 3the Biomedical Center, Saint Petersburg, Russian Federation, 4Pavlov State Medical University, Saint Petersburg, Russian Federation, 5Theodosius Dobzhansky Center for Genome Bioinformatics, Saint Petersburg, Russian Federation, 6Laboratory for AIDS Vaccine Research and Development, Duke University, Durham, NC, United States, 7Center for Infectious Diseases, University of North Carolina, Chapel Hill, NC, United States, 8Gilling School of Global Public Health, University of North Carolina, Chapel Hill, NC, United States, 9Department of Biochemistry and Biophysics, University of North Carolina, Chapel Hill, NC, United States
225 Migration of HIV-1 Subtypes in East Africa Is Associated With Proximity To Highway Corridor

Nuno R. Faria, Kim C. E. Sigaloff1, David A. M. C. van de Vijver1, Andrew J. Tatem1, Andrea C. Pirined1, Karolinska Wallis1, Marc A. Suchard1, Tobias F. Rinke de Wit1, Raph L. Hamers1, Philippe Lemaey1, Nicaise Ndemb1
1Department of Zoology, University of Oxford, Oxford, United Kingdom; 2Department of Global Health, PharmAccess Foundation, Academic Medical Center of the University of Amsterdam, Amsterdam, Netherlands; 3Department of Virology, Erasmus Medical Center, Rotterdam, Netherlands; 4Department of Geography and Environment, University of Southampton, Southampton, United Kingdom; 5Department of Microbiology and Immunology, Rega Institute for Medical Research, Leuven, Belgium; 6Lancet Laboratories, Johannesburg, South Africa; 7Department of Biomatics and Human Genetics, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, United States; 8Institute of Human Virology, Baltimore, MD, United States

226 Ongoing Cross-Species Transmission of Simian Retroviruses and High HIV Prevalence in Cameroon

Julius Chia1, Avelin Aghokeng1, Emilande Guichet1, Ahidjo Ayoub2, Steve Ahuka-Mundeke1, Nicole Vidal1, William Switzer1, Eric Delport1, 1Epile Mpuogi Nkou1, Martine Peeters1
1Loep Presica and AIM / CREMER, Yaounde, Cameroon, 2IRD, Montpellier, France, 3Centers for Disease Control and Prevention, Atlanta, GA, United States

227 An Emerging HIV-1 Recombinant (CRF58_01B) Disseminating Among People Who Inject Drugs in Malaysia

Wei Zhen Chow1, Yutaka Takebe2, Nur Ezreen Syafina3, Malarveli Soorya Prakash4, Haider Al-Darajai5, Clayton Koh6, Adeeba Kamaruzaman7, Kon Keng Tee1
1Centre for Excellence in Research for AIDS (CERIA), Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia; 2National Institute of Infectious Diseases, AIDS Research Center, Toyama, Shinjuku-ku, Tokyo, Japan

228 Exploring the Hidden Interrelationship of HIV-1 Epidemics in Asia and Beyond

Yutaka Takebe1, Makiko Kondo2
1AIDS Research Center, National Institute of Infectious Diseases, Tokyo, Japan; 2Department of Microbiology, Kanagawa Prefectural Institute of Public Health, Chigasaki, Japan

229 CRF01 AE and Subtype B Transmission Networks Cross Over; A New AE-B Recombinant Emerges in Japan

Masumi Hosaka1, Seichiro Fujisaki2, Junko Hattori3, Teiichiro Shinno1, Atsuko Hachiya4, Masakazu Matsuoka5, Yasumasa Iwatai6, Yeesiul Kwon7, Yotowar Sujiro8
1National Organization Hospital Nagoya Medical Center, Nagoya, Japan; 2National Institute of Infectious Diseases, Tokyo, Japan; 3Nagoya Graduate School of Medicine, Nagoya, Japan

230 Phylodynamic Analysis of a Regional HIV Epidemic Jeffrey B. Joy1, Richard Liang1, Conan K. Woods1, Susan Shurgold1, Guillaume Colley1, Chanson Brumme1, Robert S. Hogg2, Julio S. G. Montaner1, P. Richard Harrigan1, Art F. Y. Poont4,2
1Department of Medicine, BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada

Session P-C2 Poster Session

Tuesday March 4, 2014, 2:30 PM–4:00 PM Exhibit Hall A Immune Activation and Pathogenesis

264LB An SMS Intervention To Improve HIV Linkage To Care: A Randomized, Comparative Effectiveness Trial

Mark J. Siedner1, Data Santorino2, Alexander J. Lankowsk1, Michael Kanyesige3, Bosco Mwebesa5, Jessica E. Haberer1, David R. Bangsberg1
1Medicine, Massachusetts General Hospital, Boston, MA, United States; 2Mbarara University of Science and Technology, Mbarara, Uganda; 3University of Philadelphia, Philadelphia, PA, United States; 4AIDS Research Center, National Institute of Infectious Diseases, Tokyo, Japan; 5Nagoya Graduate School of Medicine, Nagoya, Japan

265 CD4 T-Cell Responses in Relationship With Immune Activation and Viral Load in Primary HIV Infection

Matthieu F. Chevalier1, Céline Didier1, Gaël Petitjean1, Pierre-Marie Girard1, Françoise Barré-Sinoussi2, Daniel Scott-Algara1, Laurence Weiss1, 1Institut Pasteur, Paris, France; 2AP-HP, Hôpital Saint-Antoine, Paris, France; 3University Paris Descartes, Paris, France; 4AP–HP, Hôpital Évreux Georges Pompidou, Paris, France

266 Herpesvirus Infections in HIV+ Individuals On ART Are Not Associated With Immune Activation

Bernard J. Macintyre1, Yue Chen1, Arielle Bullotta1, Aarika Yates2, Eric Fialkovich2, Luann Borowski2, William Buchanan3, Phalguni Gupta2, Charles Rinaldo2
267 Chronic Inflammation in HIV-1 Infected Individuals Reduces T-Cell Responsiveness To Vaccines
Jean Boyer1, Lorenzo Ramirez2, Ian Frank1, Pablo Tebas2
1University of Pennsylvania, Philadelphia, PA, United States; 2Hospital of the University of Pennsylvania, Philadelphia, PA, United States

268 Persistently Activated CD27+CD69+ B Cells Following ART Correlate With Macrophage Activation
Stephanie N. Hudey1, Bret J. Rudy2, Xinrui Zhang2, Susan Lukas4, Maureen Goodenow2, John Sleasman3
1University of South Florida Morsani College of Medicine, Tampa, FL, United States; 2New York University School of Medicine, New York City, NY, United States; 3University of Florida, Gainesville, FL, United States; 4University of South Florida Morsani College of Medicine, St. Petersburg, FL, United States

269 Novel Exosomal HIV miRNAs may Contribute To Chronic Immune Activation
Mark A. Bernard1, Simon C. Yue1, Asha Anandathal1, Henry Koziel2, Souvenir D. Tachado2
1University of South Florida Morsani College of Medicine, Tampa, FL, United States; 2Research Institute of the McGill University Health Centre, Montreal, QC, Canada

270B Interleukin-21 Reduces Residual Immune Activation in ART-Treated SIV-Infected Rhesus Macaques
Luca Micci1, Emily Ryan1, Colleen McGarry1, Sara Paganini1, Guido Silvestri1, Jason Brechley1, Francois Villingier1, Mirko Paiardini4
1Department of Microbiology and Immunology, Emory University, Atlanta, GA, United States; 2National HIV/AIDS Clinical and Prevention Research Program, National Institute of Health, Bethesda, MD, United States

271 Immune Activation and Risk of HIV-1 Transmission Among HIV-1 Serodiscordant Couples
Erin M. Kahle1, Michael Bolton3, James Hughes4, Deborah Donnell5, Connie Celum2, Jairam Lingappa1, Allan Ronald2, Guy de Bruyn6, Julie McElrath2, Jared M. Baeten3
1University of Washington, Seattle, WA, United States; 2Fred Hutchinson Cancer Research Center, Seattle, WA, United States; 3University of Makerere, Kampala, Uganda; 4University of Witwatersrand, Johannesburg, South Africa

272 Inflammation in Acute HIV Infection Correlates With Blood and Gut CD4 T-Cell Loss and Viral Burden
Netanya G. Sandler1, Jintanat Ananworanich2, Suteearporn Pinyakorn1,1, Adam Rupert1, Alexander Schuetz2, James L. K. Fisher1, Daniel C. Douek3, Nicholas Chomont1, Jerome H. Kim4, Irini Sereti5
1Internal Medicine, University of Texas Medical Branch at Galveston, Galveston, TX, United States; 2SEARCH, The Thai Red Cross AIDS Research Center, Bangkok, Thailand; 3HIV-NAT, The Thai Red Cross AIDS Research Center, Bangkok, Thailand; 4AIDS Monitoring Laboratory, Leids Biomedical Research, Inc., Frederick, MD, United States; 5Armed Forces Research Institute of Medical Sciences – US Component, Bangkok, Thailand; 6NIADDK Vaccine Research Center, National Institutes of Health, Bethesda, MD, United States; 7Vaccine and Gene Therapy Institute Florida, Port St. Lucie, FL, United States; 8Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, United States; 9Vaccine Research Center, National Institutes of Health, Bethesda, MD, United States

Session P-C3 Poster Session
Tuesday March 4, 2014, 2:30 PM–4:00 PM Exhibit Hall A

273 NK Cell Subsets Responding To HIV-Infected Autologous CD4 T Cell in Protective KIR/HLA Genotypes
Irene Lisovsky1, Rujun Song1, Bertrand Lebouche2, Jean-Pierre Routy1,2, Julie Bruneau1, Nicole F. Bernard1,3
1Division of Experimental Medicine, McGill University, Montreal, QC, Canada; 2Research Institute of the McGill University Health Centre, Montreal, QC, Canada; 3Medicine Division of Experimental Medicine, McGill University, Montreal, QC, Canada

274 Siglec-7 Binds HIV-1 GP120 and Facilitates Infection of CD4pos T Cells and Macrophages
Stefania Varchetta1, Paolo Lusso2, Dalila Mele2, Stefania Paolucci2, Raffaello Cimbro2, Mauro Malnati3, Agostino Riva3, Renato Maserati3, Mario U. Mondelli4, Domenico Mavilio2
1Department of Infectious Diseases, Fondazione IRCCS Policlinico, Pavia, Italy; 2Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, Bethesda, MD, United States; 3Unit of Human Virology, San Raffaele Scientific Institute, Milan, Italy; 4Dipartimento di Scienze Cliniche (DISC), Luigi Sacco Hospital and University of Milan, Milan, Italy; 5Department of Medical Biotechnologies and Translational Medicine, Humanitas Research Center and University of Milan, Rozzano (Milan), Italy

275 Monocyte and NK Cell Dysfunctional Responses To Mycobacteria During Chronic HIV-1 Infection
Melanie A. Gasper1,2, David R. Sherman1, Donald L. Sodora1
1Seattle Biomedical Research Institute, Seattle, WA, United States; 2Pathobiology Graduate Program, University of Washington, Seattle, WA, United States

276 Identification of a New Isoform of MLL5: A Surrogate Marker of the CD4 Depletion in HIV-1
Vincent Viellard1, Florence Baycheler2, Alexis Semenpin2, Myriam Ermonval2, Karim Dorghami1, Patrice Debre1
1INSERM UMR S 945, Paris, France; 2Département de Virologie, Institut Pasteur, Paris, France

277 Do KIR3DL1/HLA-B Combinations Influence ADCC Responses of HIV-1 Infected Slow Progressors?
Ganze Iseitan1,2, Zoya Padamasi3, Pilar Zanoni4, Matthew Parsons1, Marianne Harris1, Jean-Pierre Routy1,2, Cecile L. Tremblay1, Nicole F. Bernard3,4
1Division of Experimental Medicine, McGill University, Montreal, QC, Canada; 2Research Institute of the McGill University Health Centre (RI-MUHC), Montreal, QC, Canada; 3Microbiology and Immunology, University of Melbourne, Melbourne, Australia; 4St Paul’s Hospital, Vancouver, BC, Canada; 5Division of Hematology, Royal Victoria Hospital, Montreal, QC, Canada; 6Centre de Recherche du Centre Hospitalier de l’Université de Montréal, Montréal, QC, Canada

278 CD8+ NK Cells in HIV-1 Infection Are Associated With Slower Disease Progression Towards AIDS
Fareed Ahmad1,2, Hencoh S. Hong1,3, Na Lu1, Marc Jäckel1, Nupur Bhatnagar1, Johanna M. Eberhardt2, Benjamin A. Bolming3, Reinhold E. Schmidt1, Dirk Meyer-Olson4,5
1Clinic for Immunology and Rheumatology, Hannover Biomedical Research School (HBRS), Medizinische Hochschule Hannover (MHU), Hannover, Germany; 2Division of Immunology, Harvard Medical School, Southborough, MA, United States; 3Clinic for Immunology and Rheumatology, Medizinische Hochschule Hannover (MHU), Hannover, Germany; 4Rheumatologie, KVG Klinik in Bad Pyrmont Versorgungs GmbH & Co Betriebs KG, Bad Pyrmont, Germany

Session P-C4 Poster Session
Tuesday March 4, 2014, 2:30 PM–4:00 PM Exhibit Hall A

279 HLA-B*35:05 is a Protective Allele With a Unique Structure Amongst CRF01_AE-Infected Thais.
Masahiko Mori1,2, Nuanjun Wichukchinda1,2, Peiko Miyahara1, Archawan Rejanawiwat1, Panita Pathipvanich1, Tomoyuki Maekawa3, Philip Goulder1, Michio Yasunami1, Koya Ariyoshi1, Pathom Sawanpanyalert1,2, Rujun Song2,3, Bertrand Lebouche4, Jean-Pierre Routy5,6, Zoya Padamasi1,2, Pilar Zanoni4, Matthew Parsons1, Marianne Harris1, Jean-Pierre Routy1,2, Cecile L. Tremblay1, Nicole F. Bernard1,2
1Department of Clinical Medicine, Nagasaki University, Institute of Tropical Medicine, Nagasaki, Japan; 2Department of Paediatrics, University of Oxford, Oxford, United Kingdom; 3Department of Medical Sciences, Ministry of Public Health, Nonthaburi, Thailand; 4Day Care Centre, Lampang Hospital, Lampang, Thailand

280 Novel Exosomal HIV miRNAs may Contribute To Chronic Immune Activation
Mark A. Bernard, Simon C. Yue, Asha Anandathal, Henry Koziel, Souvenir D. Tachado
1University of South Florida Morsani College of Medicine, Tampa, FL, United States; 2Research Institute of the McGill University Health Centre, Montreal, QC, Canada; 3Medicine Division of Experimental Medicine, McGill University, Montreal, QC, Canada
293  **TNFα in Viral Control and Early Disease Progression in Patients With HIV Infection**

Sagar A. Vaidya1,2, Christian Konrath2, Michael Sirignano3, Molly Amer2, Sue Banzer2, Jenna Rychert2, Todd Allen3, Eric S. Rosenberg2, Ronald J. Bosch4, Marcus Affield1,4

1The Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, United States; 2Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, United States; 3Harvard School of Public Health, Boston, MA, United States; 4Department of Viral Immunology, Heinrich Pette Institute, Hamburg, Germany

294  **Monocyte Activation Markers in HIV-Infected Subjects: A Biomarker for HIV Immunotherapy**

Joumana Zeidan1,2, Elizabeth Sinclair1, Gary Lee1, Shelley Wang2, Martin Giedlin2, Geoff Nichol3, Winne Tang4, Steven Deeks2, Dale Ando2, Rafick-Pierre Sekaly1

1VGTI Florida, Port St. Lucie, FL, United States; 2UCSF, San Francisco, CA, United States; 3Sangamo Biosciences, Richmond, CA, United States

295  **Down-Regulation of CD39/CD73 On B Cells of HIV Patients Coincides With a Disturbed Ig Class Switch**

Eun-Seong Kim2, Ionu Toth1, Claudia Beisel1, Johanna Eberhardt1, Silke Kummer2, Ansgar W. Lohse1, Friedrich Haag1, Jan van Lunzen1, Julian Schulte zur Wiesch1

1Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 2Institute of Immunology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Session P-C8 Poster Session

**Wednesday March 5, 2014, 2:30 pm–4:00 pm**  
**Exhibit Hall A**

**Elite Controllers**

296  **Transcriptional Signatures of CD4 T Cell Subsets and Control of HIV Reservoirs in Elite Controllers**

Adele de Masson1,2, Amos Kirkovska1, Rima Zoorob1, Veronique Avettand-Fenoel1, Veronique Morin1, Anne Oudin1, Benjamin Descours2, Christine Rouzioux2, Brigitte Autran2, the ALT ANRS-Co15 Study Group

1Immunoology, Université Pierre et Marie Curie - Paris 6, UMR S945, Laboratory Immunity and Infection, INSERM, U945, Laboratory Immunity and Infection, Paris, France; 2Immunology, Paris-Descartes University, Sorbonne Paris-Cité, EA 3620, Virology Laboratory, Necker-Enfants-Malades Hospital, Paris, France

297  **Elite Suppressor CD4+ and CD8+ T Cells Suppress Viral Replication in Monocyte-Derived Macrophages**

Victoria E. K. Walker-Sperling1, Robert W. Buckheit2, Robert F. Siliciano3,4, Joel N. Blankson3,4

1The Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, United States; 2Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, United States; 3Harvard School of Public Health, Boston, MA, United States; 4Department of Neurology, Boston Children’s Hospital, Boston, MA, United States

298  **Effective Control of Virus Replication in HIV-1 Elite Controllers by Active SAMHD1**

Eduardo Pauls1, Alba Ruiz2, Beatriz Mothe2, Manel Crespo1, Mercedes Arias1,2, Bonaventura Clotet2, Charles Rice1,2, Michael Ho1,2, Angel Rubio1,2, Ramon Espinosa1,2, Miguel Aliberti1,2,3

1IrsiCaixa AIDS Research Institute, Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain; 2Infectious Diseases, Hospital Universitari Vall d’Hebron, Barcelona, Spain; 3Centre de Biologia Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas, Universidad Autónoma de Madrid, Madrid, Spain; 4Institute of Medical Virology, University of Frankfurt, Frankfurt, Germany; 5Cell Signaling Unit, Department de Biomecànica de Barcelona, Barcelona, Spain; 6Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain

Session P-C9 Poster Session

**Wednesday March 5, 2014, 2:30 pm–4:00 pm**  
**Exhibit Hall A**

**Pathogenesis: Insights From Clinical Trials**

300  **Effect of Raltegravir Intensification in the Cytokine Profile of Treated HIV+ Individuals**

Marta Massanella1, Josep M. Llibre1, Silvia Marti1, Maria C. Puertas2, Jordi Puig3, Eugenia Negredo2, Douglas D. Richman1,4, Javier Martinez-Picado5, Bonaventura Clotet6,7, Julia Blanco1,4,9

1Pathology, University of California San Diego, La Jolla, CA, United States; 2Ulltra contra la Sida Foundation, Badalona, Spain; 3AIDS Research Institute IrsiCaixa, Institut d’Investigació en Ciències de la Salut Germans Trias i Pujol, IGTP, Badalona, Spain; 4University of California San Diego, La Jolla, CA, United States; 5Veterans Affairs San Diego Healthcare System, La jolla, CA, United States

301  **Analyses of HIV-1 Viral Dynamics During Treatment**

With a Regimen Including an Integrase Inhibitor

Jeremie Guedj1, Ruy Ribeiro2, Adriana Andrade3, Susan L. Rosenberg4, Darlene Ly5, Douglas Richman1, Matthew Straw1, John Mellors6, Daniel R. Kuritzkes7, Alan S. Perelson8

1UMR-0738, INSERM, Paris, France; 2Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM, United States; 3The Johns Hopkins University, Baltimore, MD, United States; 4University of California San Diego, La Jolla, CA, United States; 5Centre for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, MA, United States; 6University of California, San Diego, San Diego, CA, United States; 7School of Medicine, University of Pittsburgh, Pittsburgh, PA, United States; 8Brigham and Women’s Hospital, Boston, MA, United States

302  **Characterization of Functional Profile of HIV-Specific CD4+ T Cells in VISCONTI Group of Patients**

Asa Samii1,2, Charline Bacchus1, Laurent Hawrylowicz5, Asier Saez-Cirion1,2, Amandine Emarre1, Brigitte Autran2, and VISCONTI ANRS Study

1Immunology, UPMC Univ Paris 06, UMR S945, Laboratory Immunity and Infection, Inserm, U945, Laboratory Immunity and Infection, Paris, France; 2Immunology, Paris-Descartes University, Sorbonne Paris-Cité, EA 3620, Virology Laboratory, Necker-Enfants-Malades Hospital, Paris, France

303  **Immune Activation and Defective pTFHs Are Associated With Impaired Immunity in Aging HIV+ Persons**

Varghese K. George1, Suresh Pawlikuth2, Anita Parmigiani3, Maria L. Alcaide1, Margaret Fisch1, Savita Pawha1

1Microbiology and Immunology, University of Miami, Miami, FL, United States; 2Human & Molecular Genetics, Virginia Commonwealth University, Richmond, VA, United States

304  **Fresh Cohort: Acute HIV-1 Infection in Cohort of High Risk HIV Negative Women in KZN, South Africa**

Krista Dong1,2, Amber Moodley1,2, Thumbi Ndungu1,3, Bruce Walker1,4,5

1Ragon Institute, Massachusetts General Hospital, Boston, MA, United States; 2Harvard Medical School, Boston, MA, United States; 3University of KwaZulu-Natal, Durban, South Africa; 4The Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, United States

305  **Vitamin D Significantly Changes the Immune Transcriptome and Augments CD4 Recall Responses in HIV**

Raskit Lachmann1,2, Margaret-Anne Bevan1, Sangmi Kim1, Nishma Patel1, Siddhima Banga1, Nagasuma Chandra1, Sudha Rao1, Catherine Hawrylowicz1, Annapurna Vyakarnam1, Barry Peters1

1Infectious Diseases, Kings College London, London, United Kingdom; 2GU Medicine and HIV, Guys and St Thomas’ Hospital Trust, London, United Kingdom; 3Indian Institute of Science, Bangalore, India; 4Genotypic Technology Limited, Bangalore, India; 5Division of Allergy & Lung Biology, Kings College London, London, United Kingdom
2014 Impact of Methamphetamine Use On Immunologic and Virologic Markers During Suppressive ART
Marta Masana1, Dougal D. Richman1,2, Susan J. Little1, Constanze B. Benson1, Eric S. Darai3, Michael D. Dube4, Richard H. Hamborich1, Davey M. Smith1,5, Sheldon R. Morris5, the CCG 592 Team
1University of California San Diego, La Jolla, CA, United States; 2Veterans Affairs San Diego Healthcare System, La Jolla, CA, United States; 3Les Angeles Biomedical Research Institute, Torrance, CA, United States; 4University of Southern California Keck School of Medicine, Los Angeles, CA, United States; 5Veterans Affairs San Diego Healthcare System, La Jolla, CA, United States

207 Vitamin D-Receptor Gene Polymorphisms: Association With Virological Failure and Mortality
Simbarashe Takwava1,2, Lynne McNamara3, Tobias Chimwa4, Ian Sanne4, Adrian R. Martinet4, Patrick A. MacPhail4
1Centre for HIV and STIs, National Institute for Communicable Diseases, MHL5, Johannesburg, South Africa; 2Department of Internal Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; 3Clinical HIV Research Unit, Department of Internal Medicine, University of the Witwatersrand, Johannesburg, South Africa; 4School of Public Health, University of the Witwatersrand, Johannesburg, South Africa; 5Barts and the London School of Medicine and Dentistry, Queen Mary-University of London, London, United Kingdom

208 Statins Use is Associated With Greater CD4 Gains in HIV-Infected US Veterans
Henning J. Drechsler1,2, James Cutrell1,2, Pablo Tebas, Roger Bedimo3,4
1Medicine, North Texas VA Health Care System, Dallas, TX, United States; 2Medicine, UT Southwestern Medical School, Dallas, TX, United States; 3Medicine, University of Pennsylvania, Philadelphia, PA, United States

209 Maraviroc Intensification in HIV-Infected Patients Induces Increased CCR5 Expression On T Cells
Assa Samri1, Gael Moullot1, Christina Fosma2, Melanie Lavenu2, Selma Trabelsi3, Lise Cuzin4, Pierre Corbeau5, Brigitte Autran6, Philippe Flandre7
1Immunology, UPMC Univ Paris 06, UMR-S945, Laboratory Immunology and Infection, INSERM, UMR-S945, Paris, France; 2Immunology and Infectious Diseases Department, University Hospital, Institute for Human Genetics, CNRS UPR1142, Montpellier, France; 3Immunology, INSEERM U 943 and University Pierre and Marie Curie, UMRS 943, Paris, France; 4Immunology, Infectious Diseases Department, University Hospital, Toulouse, France; 5Immunology, Immunology Department, University Hospital, Allins, Institute for Human Genetics, CNRS UPR1142, Montpellier, France

Session P-C11 Poster Session
Thursday March 6, 2014, 2:30 PM–4:00 PM Exhibit Hall A
CD4/CD8, Aging, and Immune Senescence

240 CD4:CD8 Ratio Remains Significantly Decreased Despite Viral Suppression With Effective ART
Brinda Emu1, Jeffrey Martin2, Douglas Nixon2, Steven G. Deeks2, Joseph M. McCune3
1Yale University, New Haven, CT, United States; 2University of California, San Francisco, San Francisco, CA, United States

241 CMV Reactivation and Immune Aging in HIV-Infected Individuals Virologically Suppressed On ART
Helen M. McGuire1, Philip M. Grant2, Holden Macek3, Jorg J. Goronzy4, Mark M. Davis5, Andrew R. Zolopa6
1Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA, United States; 2Division of Infectious Diseases, Stanford University School of Medicine, Stanford, CA, United States; 3Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford, CA, United States; 4Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, United States; 5The Howard Hughes Medical Institute, Chevy Chase, MD, United States

242 A Low CD4/CD8 Ratio During Effective ART Predicts Immunosenescence and Morbidity/Mortality
Sergio Serrano-Vilar1, Talia Sainz2, Sulgi A. Lee3, Peter W. Hunt3, Elizabeth Sinclair3, April L. Ferre4, Vivek Jain5, Frederick M. Hetch1, Santiago Moreno1, Steve G. Deeks3
1Infectious Diseases, University Hospital Ramón y Cajal, Madrid, Spain; 2Infectious Diseases, University Hospital Gregorio Marañón, Madrid, Spain; 3University of California San Francisco, San Francisco, CA, United States; 4University of California Davis, Davis, CA, United States

243 CMV and HIV: A Double Hit On the CD4/CD8 Ratio
Talia Sainz1, Sergio Serrano-Vilar2, Sulgi A. Lee3, Peter W. Hunt3, Elizabeth Sinclair2, Jeffrey N. Martin4, Joseph M. McCune3, Steven G. Deeks3
1Molecular Immune Biology Laboratory, University Hospital Gregorio Marañón, Madrid, Spain; 2Molecular Immune Biology Laboratory, University Hospital Ramón y Cajal, Madrid, Spain; 3University of California San Francisco, San Francisco, CA, United States

Session P-C12 Poster Session
Thursday March 6, 2014, 2:30 PM–4:00 PM Exhibit Hall A
Mucosal CD4 and TH17 Cells

244 Severe Depletion of Lung CD4 T Cells During HIV Infection Impairs Alveolar Macrophage Function
Bjorn Corleis1,2, Maud Derauza1,3, Melanie N. Ananth1,3, Gregory Olson1, Brittany Bowman1, Vladimir Vrabcan1, Andrew M. Tager2, Douglas S. Kwon1, Ragon Institute of MGH, Harvard and MIT, Cambridge, MA, United States; 3Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States

245 Impaired IL-23 Signalling and TH17 Dysfunction in HIV Infection
Jason R. Fernandes1, Ashok Kumar2,3, Jonathan B. Angel1,2
1Chronic Diseases, The Ottawa Hospital Research Institute, Ottawa, ON, Canada; 2Pathology, Children’s Hospital of Eastern Ontario Research Institute, Ottawa, ON, Canada; 3Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada
246  Th17 and Tregs at Early HIV Infection Influence Disease Progression and HIV Specific CD8+ Responses
Juliana Faivre1, Yanina A. Greigione2, Natalia L. Laufer4, María E. Socias2, María J. Ruiz2, Pedro Cahn2, Omar Sued2, Horacio Salomón1, Gabriela Turk1, María M. Gherardini1
1Instituto de Investigaciones Biomédicas en Retrovirus y SIDA, UBA-CONICET, Buenos Aires, Argentina; 2Hospital Juan A. Fernández, Unidad Enfermedades Infecciosas, Buenos Aires, Argentina; 3Fundación Huésped, Buenos Aires, Argentina

247  Profound Lung CD4+ T-Cell Depletion in HIV-Associated Chronic Obstructive Pulmonary Disease
Iulia Popescu1, M. Bradley Drummond1, Lucio Gama1, Christian Marlo2, Robert Wise1, Janice Clements1, Gregory D. Kirk2, John F. McDyer2
1Medicine, University of Pittsburgh, Pittsburgh, PA, United States; 2School of Public Health, The Johns Hopkins University, Baltimore, MD, United States; 3School of Public Health, The Johns Hopkins University, Baltimore, MD, United States

248  Site Specific HIV-Infection of Th17 Cells in the Human Female Reproductive Tract
Marta Rodriguez-Garcia1, Fionia D. Barr1, John V. Fahey1, Charles R. Wira2
Physiology and Neurobiology, Geisel School of Medicine at Dartmouth, Lebanon, NH, United States

249  Transcriptional Profiling Identifies New Mechanisms of HIV Permissiveness in Primary Th17 Cells
Aurélie Cleret-Buhot1, Jean-Philippe Goulet2, Patricia Monteiro2, Annie Bernier2, Annie Gosselin2, Mohammad-Al Jenabian2, Jean-Pierre Rouxty1, Elías Hassadat1, Rafick Pierre Sekaly1, Cécile Tremblay1, Petronella Ancuta1
1Microbiology, Infectology and Immunology, University de Montréal, Montréal, QC, Canada; 2CHUM-Research Centre, Montréal, QC, Canada; 3CHUM-CNRS UMR 9100, Montréal, QC, Canada; 4McGill University Health Centre, Montréal, QC, Canada; 5Vaccine and Gene Therapy Institute, Port St Lucie, FL, United States

Session P-C13 Poster Session
Thursday March 6, 2014, 2:30 PM–4:00 PM Exhibit Hall A

250  Elevated Soluble CD40 Ligand During HIV Infection Suppresses Dendritic Cell Function
Meagan O’Brien1, Elizabeth Miller1, Nina Bhardwaj2
Mount Sinai School of Medicine, New York, NY, United States

251  Chronic Exposure To Type-I IFN Under Lymphopenic Conditions Alters CD4 T Cell Homeostasis
Cécile Le Saout1, Rebecca B. Hasley1,6, Suzanne M. Anahtar2,3, John V. Fahey1, Charles R. Wira2
1Medicine, University of Pittsburgh, Pittsburgh, PA, United States; 2Pathology, University of Texas Medical Branch, Galveston, TX, United States; 3School of Public Health, The Johns Hopkins University, Baltimore, MD, United States; 4Medicine, University of Washington, Seattle, WA, United States; 5Medicine, University of California -San Diego, San Diego, CA, United States; 6Science, Department of Microbiology and Molecular Genetics, Rutgers University-New Jersey Medical School, Newark, NJ, United States; 7Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, United States

252  IL-15 Induces Id2 To Drive Effector Differentiation of CD8 TM and EM Cells While Maintaining CM Pools
Alessandra Note1, Francesco A. Procopio2, Julien van Grevenynghe3, Cheryl Cameron1, Courtney steel1, Amrit Sabnis2, Hiroshi Takata1, Franck Dupuy4, Jeff Ahlers1,6, Franck Dupuy1,6, Maria Catalafano1
1Laboratory of Immunoregulation, NIAID/NIH, Bethesda, MD, United States; 2Biology, University of California -San Diego, San Diego, CA, United States; 3Medicine, University of Texas Medical Branch, Galveston, TX, United States; 4Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, United States; 5Neurology, University of California -San Diego, San Diego, CA, United States; 6Medicine, University of California -Santa Barbara, Santa Barbara, CA, United States; 7Neurology, The Johns Hopkins University, Baltimore, MD, United States; 8Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, United States; 9Neurology, Washington University, Saint Louis, MO, United States; 10Psychiatry, University of California -San Diego, La Jolla, CA, United States; 11Family and Preventive Medicine, University of California -San Diego, San Diego, CA, United States

253  Double Stranded RNA Stimulates IL-1β Secretion in Cervical Epithelial Cells via the Inflammasome
Melis N. Anartha1, Maud Deruaz1, Andrew M. Tager1, Douglas S. Kwon1, Fang Li1, John V. Fahey1, Charles R. Wira2
1Department of Microbiology and Immunology, University of Pittsburgh, Pittsburgh, PA, United States; 2Pathology, University of Texas Medical Branch, Galveston, TX, United States

254  Alpha-Defensins Modulate HIV Transcytosis: Role of STI-Mediated Enhancement of HIV Transmission
Kimiya Valera1, April Aceve1, Alison J. Guay1, Wuyan Lu1, Eileen Eugeninan, Theresa Changn
1Public Health Research Institute, Department of Microbiology and Molecular Genetics, Rutgers University-New Jersey Medical School, Newark, NJ, United States; 2Public Health Research Institute, Newark, NJ, United States; 3Louisiana State University Health Sciences Center, New Orleans, LA, United States; 4Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, United States

255  Exposure To IFNα Leads To Generation of IL-10-Producing Tr1 Cells
Clara Lehmann1, Kristina Kochi2, Nora Kochi3, Pia Hartmann4,5, Gerd Falkenheuer6, Fabio Romero7
1First Department of Internal Medicine, University of Cologne, Cologne, Germany; 2Institute for Medical Microbiology, Immunology and Hygiene, University of Cologne, Cologne, Germany; 3Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, United States

256  TNF Drives Foam Cell Formation by Monocytes From HIV+ Donors in an In Vitro Atherosclerosis Model
Anna Maisa1, Candida F. Pereira1,2, Thomas A. Angelovich3, Jing-Ling Zhou1, William A. Muller2, Anna C. Heaps3,4, Suzanne M. Crowe5,6, Anthony Jaworowski7,8
1Burnet Institute, Melbourne, Australia; 2Centre for Biomedical Research, Burnet Institute, Melbourne, Australia; 3Department of Infectious Diseases, Monash University, Melbourne, Australia; 4School of Applied Sciences, RMII Fund, Melbourne, Australia; 5Northwestern University, Chicago, IL, United States; 6Department of Infectious Diseases, Monash University, Melbourne, Australia

257  HIV-Altered mRNA Expressions of Type 1 IFN Pathway Related To Activation/Exhaustion in CD4+ T Cells
Chi-Lin Lee1,2, Eric Serrao3,4, Toni Frederic3, Chia-Hao Wang1, Andrea Kovacs1
1Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States; 2Medicine, Harvard University, Boston, MA, United States; 3Pharmacology and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA, United States

258  Dysfunctional High Density Lipoprotein Directly Upregulates T Cell Activation in HIV-1 Infection
Theodora Kelesidis1, Judith Currier1, Diana Huyyn2, Sangeun Park3, Hwee Ng4, Otto O. Yang5
1Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, United States

259  Dysfunctional High Density Lipoprotein Directly Reduces HIV-1-Specific Antiviral Responses
Theodora Kelesidis1, Judith Currier1, Diana Huyyn2, Sangeun Park3, Hwee Ng4, Otto O. Yang2
1Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, United States

Session P-C14 Poster Session
Thursday March 6, 2014, 2:30 PM–4:00 PM Exhibit Hall A

260  HLA Gene Loci Associated With HIV Load in CSF and Blood Plasma in the CHARTER Cohort
Benjamin B. Gelman1, Sunil K. Ahuja1, Ronald J. Ellis2, Scott Lefendre3, Christina M. Marra2, Justin McArthur3, Sunan Morgello2, David B. Clifford1, Igor Grant4, Florin Vaida5,6, The CHARTER Group7
1Pathology, University of Texas Medical Branch, Galveston, TX, United States; 2Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, United States; 3Neurology, University of California - San Diego, San Diego, CA, United States; 4Medicine, University of California -San Diego, San Diego, CA, United States; 5Neurology, University of Washington, Seattle, WA, United States; 6Medicine, University of California -San Diego, San Diego, CA, United States; 7Neurology, The Johns Hopkins University, Baltimore, MD, United States; 8Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, United States; 9Neurology, Washington University, Saint Louis, MO, United States; 10Psychiatry, University of California -San Diego, La Jolla, CA, United States; 11Family and Preventive Medicine, University of California -San Diego, San Diego, CA, United States
261 GUAVA: A Compendium of Host Genetic Data in HIV Biology and Disease
Istvan Bartha1,2, Paul J. McLaren2,3, Angela Ciuffi2, Jacques Fellay1,2, Amalio Telenti1
1École Polytechnique Fédérale De Lausanne, Lausanne, Switzerland; 2Institute of Microbiology, University Hospital Lausanne, Lausanne, Switzerland

HIV-1 Infection Leads To Increased Expression of HML-2 Proviruses In Vivo But Not Virion Production
Neeru Bhardwaj, Frank Maidarelli, John Mellors, John M. Coffin1
1Tufts University, Boston, MA, United States; 2National Cancer Institute, Frederick, MD, United States; 3University of Pittsburgh, Pittsburgh, PA, United States

Exome Sequencing To Evaluate the Impact of Rare Coding Variation On HIV-1 Control
Paul J. McLaren1, Patrick R. Shea2, David B. Goldstein, Jacques Fellay1
1Life Sciences, École Polytechnique Fédérale De Lausanne, Lausanne, Switzerland; 2Center for Human Genome Variation, Duke University School of Medicine, Durham, NC, United States

Session P-D1 Poster Session
Tuesday March 4, 2014, 2:30 PM–4:00 PM
Exhibit Hall A
It’s All About the Gut

310 Increased Immune Activation After Gut Permeabilization in SIV-Infected African Green Monkeys
Jan Kristoff1, Thaidra Gaufin2, Rajeev Gautam2, Dongzh Ma3, Jacob Estes4, Russell Tracy5, Cristian Apetrei1, Steve Nelson6, Gregory Bagby7, Ivona Pandrea1
1Center for Vaccine Research, University of Pittsburgh, Pittsburgh, PA, United States; 2UCLA, Los Angeles, CA, United States; 3Center for Vaccine Research, NIAD/NIH, Bethesda, MD, United States; 4NCI/NIH, Frederick, MD, United States; 5University of Vermont, Colchester, VT, United States; 6Louisiana State University, New Orleans, LA, United States

311 Breaches in Colonic Claudin-4 Expression Correlate With T-Cell Activation in HIV-1 Infection
Louise Greathead1, Anna Mroz2, Hiromi Kudo3, Brian Gazzard4, Mark Nelson1, Robert D. Goldin4, Alan Steel5, Peter Kelleher6
1Imperial College, London, United Kingdom; 2Chelsea and Westminster Hospital NHS Trust, London, United Kingdom

312 Rapid Gut-Homing of Plasmacytoid Dendritic Cells During Acute SIV Infection
Halying Li, Jacqueline Gillis, R. Keith Reeves
NEPRC, Harvard Medical School, Southborough, MA, United States

CCR6+ and CD161+ CD4 T Cell Loss Contributes To the Pathogenesis of SIV Infection in Rhesus Macaques
Colleen S. McGary1, Luca Micci2, Emily S. Ryan3, Maria J. Buzon1, Amy Shaw2, Mathias Lichterfeld1, Guido Silvestri1,2, Aftab A. Ansari4, Minko Pardan1
1Department of Microbiology and Immunology, Emory University, Atlanta, GA, United States; 2Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, United States; 3Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, United States

SIV Vaccine Controllers Prevent Aberrant Accumulation of Follicular CD4 T Cells in Rectal Mucosa
Geetha H. Mylakaganam1, Vijaayakumar Velu2, Jung-Joo Hong3, Shannugala Pradeepa, Suifen Kwa4, Rahul Basu5, Benton Lawson1, Francois Villinger6, Rama R. Amara1
1Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA, United States; 2Emory Vaccine Center, Yerkes National Primate Center, Atlanta, GA, United States; 3Department of Pathology, Emory University School of Medicine, Atlanta, GA, United States

Decreased Diversity of Gut Microbiota Is Associated With Immune Status During HIV-1 Infection
Piotr Nowak1, Bablilonia Barqasho2, Ekatarina Avershina1, Kajsa Noyan3, Jan Vesterbacka1, Marius Trossel1, Knut Rud1, Anders Sonnemberg1
1Department of Infectious Diseases, Karolinska Institute, Huddinge, Sweden; 2Department of Laboratory Medicine, Karolinska Institute, Huddinge, Sweden; 3Department of Chemistry, Biotechnology and Food Science, Norwegian University of Life Sciences, As, Norway; 4Infectious Diseases, Oslo University Hospital, Oslo, Norway

315 Dysregulated miR-34a-SIRT1-Acetyl-p65 Axis Induces Immune Activation in Chronic SIV-Infection
Maahes Mohan, Andrew Alan Lackner, Xavier Alvarez
Comparative Pathology, Tulane National Primate Research Center, Covington, LA, United States

316 Dysbiotic Bacteria Translocate in Progressive SIV Infection
Zachary Kiasa1, Elias Schwartzman1, Alexandra Ortiz2, Lauren Canning1, Mariam Quinones2, Jason Brenchley1
1Laboratory of Molecular Microbiology, NIAID/NIH, Bethesda, MD, United States; 2National Institutes of Health, Bethesda, MD, United States

Session P-D2 Poster Session
Wednesday March 5, 2014, 2:30 PM–4:00 PM
Exhibit Hall A
New SIV Models

318L Viral Suppression Was Induced by Anti-PD-L1 Following ARV-Interuption in SIV-Infected Monkeys
Stephen W. Mason, Srisomwraya Sanisety1, Christa Osvio, Gutierrez2, So-Yon Lim1, Susan Chianiewski1, Shalyn Campellone1, Daniel Tenney1, Scott Baltis1, James B. Whitney2
1Discovery Virology, Bristol-Myers Squibb, Wallingford, CT, United States; 2Center for Virology and Vaccine Research, Bristol-Myers Squibb, Boston, MA, United States; 3Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States

319 A Novel HIV-1mt Encoding CCR5-Tropic Env Established Persistent Infection in Cynomolgus Macaques
Akatsuki Saito1, Kazuhiro Matsaoka2, Hirota Oda3, Hirooyuki Otsuki4, Takeda Yoshida5, Yasumasa Iwata6, Wataru Sugiiura7, Tetsuo Matano8, Tomoyuki Miura8, Hirofumi Akari9
1Center for Human Evolution Modeling Research, Primate Research Institute, Kyoto University, Inuyama, Japan; 2Japan Foundation for AIDS Prevention, Chiyoda-ku, Japan; 3Clinical Research Center, National Nagoya Medical Center, Nagoya, Japan; 4Laboratory of Primate Model, Institute for Virus Research, Kyoto University, Kyoto, Japan; 5AIDS Research Center, National Institute of Infectious Diseases, Shinjuku-ku, Japan

320 New SIVsmm Strains To Achieve Control of Virus Replication With Conventional ART in Rhesus Macaques
George Hare-Richter1, Donghu Ma1, Hui Li2, Samantha Ross1, Rachit Anand1, Cuiling Xu1, George M. Shaw2, Beatrice H. Hahn3, John W. Mellors4, Ivona Pandrea5, Cristian Apetrei1
1Center for Vaccine Research, University of Pittsburgh, Pittsburgh, PA, United States; 2Institute of Biophysics, Chinese Academy of Sciences, Beijing, China; 3Baylor Research Institute, Dallas, TX, United States

Program and Agenda

Poster Abstracts
323 Characterizing the Acute Spread of Cell-Associated HIV in Humanized Mice
Kenneth M. Law, Alice W. Yewdall, Benjamin K. Chen
Infectious Disease, Icahn School of Medicine at Mount Sinai, New York, NY, United States

Session P-D4 Poster Session
Wednesday March 5, 2014, 2:30 PM–4:00 PM
Exhibit Hall A
Non-Pathogenic vs Pathogenic Hosts

324 Differential TCR Activation and TRAIL Regulation in Sooty Mangabeys and Rhesus Macaques
Shan Yu1, Kenneth Robeson1, Francois Villinger2, Amtilnder Kaur3
1Division of Immunology, Harvard Medical School, Southborough, MA, United States; 2Division of Pathology, Emory University, Atlanta, GA, United States; 3Harvard Medical School, Southborough, MA, United States

325 Divergent CD4+ T Memory Stem Cell Dynamics in Pathogenic and Nonpathogenic SIV Infections
Emily K. Cartwright1, Collette McGary1, Barbara Cervat1, Benton Lawson1, Steven E. Bosinger2, Thomas H. Vanderford3, Mirko Piaardi4, Ann M. Chahroudi5, Guido Silvestri6
1Yerkes National Primate Research Center, Emory Vaccine Center, Atlanta, GA, United States; Department of Pediatrics, Emory University, Atlanta, GA, United States

326 Double-Negative T Cells Are Functionally Distinct and Maintained in SIV-Infected Sooty Mangabeys Namita Rout1, James M. Billingsly2, Shan Yu1, Alexandra Gryzynska2, Premeela A. Rajakumar1, Arnaud Colantonio1, Robert P. Johnson1, Jim Else1, Amtilnder Kaur3
1Immunology, NIEHS, Southborough, MA, United States; 2Wellesley College, Wellesley, MA, United States; 3Animal Resources, Yerkes National Primate Research Center, Atlanta, GA, United States

327 CD39/CD73/Adenosine Pathway in Progressive vs Non-Progressive Infections
Tianyu He1, Egidio Brocca-Cofano2, Cuiling Xu2, Jan Kristoff3, Samantha Ross3, Dongzhou Ma4, Charles R. Rinaldo5, Bernard J. C. Macatangay6, Cristian Apetrei7, Ivona Pandrea8
1Pathology, University of Pittsburgh, Pittsburgh, PA, United States; 2University of Pittsburgh, Pittsburgh, PA, United States; 3Microbiology and Molecular Genetics, University of Pittsburgh, Pittsburgh, PA, United States; 4Infectious Diseases and Microbiology, University of Pittsburgh, Pittsburgh, PA, United States

328 Dynamics of B Cell Subpopulations in Pathogenic and Nonpathogenic SIV Infections
Egidio Brocca-Cofano1, Basile Siewe2, Dave Kurt3, Xu Cuiling1, Jan Kristoff3, Dongzhou Ma4, George S. Haref-Richter5, David C. Montefl6, Alan Landy7, Ivona Pandrea8, Cristian Apetrei9
1Pathology, University of Pittsburgh, Pittsburgh, PA, United States; 2University of Pittsburgh, Pittsburgh, PA, United States; 3Microbiology and Microbiology, Rush University Medical Center, Chicago, IL, United States; 4Centre for Vaccine Research, University of Pittsburgh, Pittsburgh, PA, United States; 5Microbiology, University of Pittsburgh, Pittsburgh, PA, United States; 6Duke Human Vaccine Institute, Duke University, Durham, NC, United States

Session P-D5 Poster Session
Thursday March 6, 2014, 2:30 PM–4:00 PM
Exhibit Hall A
Compartmentalization

329 Transient Compartmentalization of SIV Variants in the Breast Milk of African Green Monkeys Carrie Ho
Human Vaccine Institute, Duke University Medical Center, Durham, NC, United States

330 HIV Migrates Bi-Directionally Between Blood and Cerebrospinal Fluid and Between Blood and Semen
Antoine Chaillet1, Sara Gianella1, Joel G. Wertheim1, Sergei L.K. Pond2, Douglas D. Richman3, Saniya R. Mehta4, David M. Smith3
1Pathology, University of California San Diego, La Jolla, CA, United States; 2INSERM UMR U966, Tours, France; 3Veterans Affairs San Diego Healthcare System, San Diego, CA, United States

331 Pol Versus Env Genetics in SHIV-Infected Macaques
Highlights Importance of Phylogenetic Signal
Chad Coomer1, Elizabeth M. Anderson2, Luke Smith2, Wei Shao3, Jonathan Spindler4, John W. Mellors5, John M. Coffin6, Zandrea Ambrose7, Mary F. Kearney8
1National Cancer Institute, NIH, Frederick, MD, United States; 2Division of Infectious Disease, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, United States; 3Department of Molecular Biology and Microbiology, Tufts University, Boston, MA, United States; 4Division of Infectious Diseases, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, United States

Session P-D6 Poster Session
Thursday March 6, 2014, 2:30 PM–4:00 PM
Exhibit Hall A
New Themes in Host Control

332 Low Social Rank Prior To SIV or SHIV Infection Associates With Higher Viral Load in Chronic Infection
Brett Chen1, Timothy Hayes2, Ronald Tribble3, Thomas H. Vanderford4, Diane G. Carnathan5, Constance S. Harrell6, Kirk Easley7, Mirko Piaardi8, Guido Silvestri9
1Physiology, Emory University, Atlanta, GA, United States; 2Yerkes National Primate Research Center, Atlanta, GA, United States; 3Emory University, Atlanta, GA, United States; 4Biostatistics, Emory University, Atlanta, GA, United States

333 Modulation of Natural Killer Cell Activity by Simian Immunodeficiency Virus Peptides
Jamie L. Schafer1, Natasha Guha2, Nancy A. Wilson3, David T. Evans2
1Harvard University, Southborough, MA, United States; 2University of Wisconsin, Madison, WI, United States

Session P-E1 Poster Session
Tuesday March 4, 2014, 2:30 PM–4:00 PM
Exhibit Hall A
Modulating Immune Activation

334 Rosuvastatin Reduces Immune Activation and Inflammation in Treated HIV Infection
Nicholas Funderburg1, Brian Clagett2, Ying Jiang3, Sara M. Debanne4, Norma Storer5, Danielle Lobbato6, Steven Juchnowski7, Brian Ferrari8, Michael Lederman9, Grace A. Comessy9
1Health and Rehabilitation Sciences, The Ohio State University, Columbus, OH, United States; 2Case Western Reserve University/Case Medical Center, Cleveland, OH, United States; 3Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, OH, United States; 4University Hospitals Case Medical Center, Cleveland, OH, United States

335 Effects of Prednisolone On CD4 Counts and HIV Disease Progression: A Two-Year Clinical Trial
Christa Kasang1, Samuel Kalluyua2, Charles Majine2, Gilbert Kongola3, Mathias Miwia4, Irene Massawe4, P. Kabyemela5, K Magambo6, H Klinker7, E Koutsilieri8, W Praier9, D Hofmann9, J Hain9, A Müller9, Weisbrich9, Albrecht Ulmer9, Axel Retwilm10, August Stich11, Carsten Scheller11
1Institute of Virology and Immunobiology, University of Wuerzburg, Wuerzburg, Germany; 2Institute of Virology and Immunobiology, Bugando Medical Centre, Mwanza, United Republic of Tanzania; 3Bugando Medical Centre, Mwanza, United Republic of Tanzania

337 Sevelamer Does Not Decrease Plasma LPS or sCD14 But Does Decrease Soluble Tissue Factor and LDL
Netanya G. Sandler1, Kianyu Zhang2, Ronald J. Boschi3, Nicholas T. Funderburg4, Janet K. Robinson5, Daniel C. Douek6, Cara C. Wilson7, Steven G. Deeks8, Michael M. Lederman9, Rajesh T. Gandhi10, for the AS296 Study Team
1Internal Medicine, University of Texas Medical Branch at Galveston, Galveston, TX, United States; 2Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, MA, United States; 3Case Western Reserve University, Cleveland, OH, United States; 4NIADD Vaccine Research Center, National Institutes of Health, Bethesda, MD, United States; 5Internal Medicine, University of Colorado, Aurora, CO, United States; 6San Francisco General Hospital, San Francisco, CA, United States; 7Massachusetts General Hospital and Ragon Institute, Boston, MA, United States

Poster Abstracts
338 Reduction of sCD163, SP and PD1+ Th Cell Levels in a Phase 1B Trial of the NK1R Antagonist Aprepitant.  
Pablo Tebas1, Serguei Spitsin2, Jeffrey Barrett1, Florin Tuluc1, Okan Erci3, James Kortels2, Wayne Wagner1, Deborah Kim1, Renae Catalano1, Steven D. Douglas1  
1University of Pennsylvania, Philadelphia, PA, United States; 2Children’s Hospital of Philadelphia Research Institute, Philadelphia, PA, United States; 3Westat, Rockville, MD, United States

339 Rifaximin Has Marginal Impact On Immune Activation in Immune Non-Responders To ART - ACTG 5286  
Alien R. Tenorio1, Cara C. Wilson2, Ellen S. Charn3, Ronald J. Bosch4, Bernard J. Macatangay1, Sara Yessim1, Sarah W. Read5, David M. Margolis2, Jeffrey M. Jacobson5, Alan L. Landay5  
1Medicine, Rush University Medical Center, Chicago, IL, United States; 2Medicine, University of Colorado Health Sciences Center, Aurora, CO, United States; 3Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, MA, United States; 4Center for Biostatistics Research in AIDS, Harvard School of Public Health, Boston, MA, United States; 5Medicine, University of Pittsburgh, Pittsburgh, PA, United States; 6Frontier Sciences, Amherst, NY, United States; 7Division of AIDS, National Institutes of Health, Bethesda, MD, United States; 8Medicine, University of North Carolina, Chapel Hill, NC, United States; 9Medicine, Drexel University, Philadelphia, PA, United States; 10Immunology and Microbiology, Rush University Medical Center, Chicago, IL, United States

340 Reduced Immune Activation During Tenofovir-Emtricitabine Therapy in HIV-Negative Individuals  
Jose R. Castilla-Mancilla1, Amia Meditte2, Sharon Sefter1, Jia-Hua Zheng1, Becky J. Kerr1, Edward M. Gardner1, Brent E. Palmer1, Lane Bushman1, Samantha Mawhinney4, Peter L. Anderson2  
1Infectious Diseases, University of Colorado, Aurora, CO, United States; 2Pharmaceutical Sciences, University of Colorado, Aurora, CO, United States; 3Infectious Diseases, Denver Health Hospital, Denver, CO, United States; 4Allergy and Immunology, University of Colorado, Aurora, CO, United States; 5Biostatistics and Informatics, University of Colorado, Aurora, CO, United States

341 Mesalazine To Reduce Immune Activation During HIV Infection: A Randomized Controlled Trial  
Ma Somsouk1, Richard M. Dunham1, Michelle Cohen1, Rebecca Albright1, Teri Liegler1, Yuanner Wu1, Jeffrey N. Martin1, Priscilla Y. Hsue1, Steven G. Deeks1, Joseph M. McCune1, Peter W. Hunt1  
1University of California San Francisco, San Francisco, CA, United States

342 Decreased Levels of D-Dimer After Probiotic Supplementation in Patients Receiving ART  
Birgitte Stiksrud1, Pirot Nowak2, Birgitte Stiksrud1, Piotr Nowak2, Dag Kvale1, Anders Thalme2, Marit Ous3  
1Oslo University Hospital, Oslo, Norway; 2Karolinska University Hospital, Stockholm, Sweden; 3TINE SA, Oslo, Norway

Session P-E2 Poster Session  
Tuesday March 4, 2014, 2:30 PM–4:00 PM  
Exhibit Hall A

Therapeutic Vaccines and Immunotherapies

343 Immune Function and Viral Load Post AGS-004 Administration To Chronic HIV Subjects Undergoing STI  
Mark DeBenedette1, Irina Tcherepanova1, Alicia Gamble1, Joe Horatovitch1, Jason Harris1, Jean-Pierre Routy1, Charles Nicolle2, AGS-004-001 Study Team  
1Immunology, Argos Therapeutics, Durham, NC, United States; 2McGill University Health Centre, Montreal, QC, Canada

344 Immunogenicity of AGS-004 Dendritic Cell Therapy in Patients Treated During Acute HIV Infection  
Cynthia L. Gay1, Nance Archin1, Irina Tcherepanova1, Esther Viliardi2, Charles Hicks1, Mary Kearney1, John Coffin1, Mark DeBenedette2, Joseph Eron1, Charles Nicolle2, David M. Margolis1  
1Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States; 2Research and Development, Argos Therapeutics, Inc, Durham, NC, United States; 3Argos Therapeutics, Inc, Durham, NC, United States; 4Medicine, Duke University, Durham, NC, United States; 5Translational Research Unit, National Cancer Institute, Frederick, MD, United States; 6National Cancer Institute, Frederick, MD, United States

345 Immunogenicity and VL Rebound After ATI in Chronic HIV Infected Patients Receiving MVA-B  
Beatriz Mothe1, Miriam Rosas1, Montserrat Plana2, Nuria Climent1, Jose Luis Jimenez2, Judith Pich2, Mariano Esteban1, Felipe Garcia1, Christian Brander1  
1IrsiCaixa AIDS Research Institute-HIVACAT, Badalona, Spain; 2Hospital Clinic-HIVACAT, IDIBAPS, University of Barcelona, Badalona, Spain; 3Hospital Gregorio Maranon, Madrid, Spain; 4Centro Nacional de Biotecnologia, Madrid, Spain; 5Hospital Clinic-HIVACAT, IDIBAPS, University of Barcelona, Barcelona, Spain

346 Dynamics of VL Rebound After cART Interruption in HIV Patients Receiving MVA-B Plus Disulfram  
Beatriz Mothe1, Sonsoles Sanchez-Palomino2, Jose Luis Jimenez3, Jose M. Gatell2, Bonaventura Clotet1, Mariano Esteban1, Montserrat Plana1, Juan Carlos Lopez Bernaldo de Quiros1, Christian Brander1, Felipe Garcia1  
1IrsiCaixa-HIVACAT, Hospital Germans Trias i Pujol, Badalona, Spain; 2Hospital Clinic-HIVACAT, IDIBAPS, University of Barcelona, Barcelona, Spain; 3Hospital Gregorio Maranon, Madrid, Spain; 4Centro Nacional de Biotecnologia, Madrid, Spain

347 Vaccination With Autologous Dendritic Cells Pulsed With Autologous HIV-Infected Apoptotic Cells  
Bernard J. Macatangay1, Sharon A. Riddler1, Nicole D. Wheeler1, Mary J. Butto1, Aarika Yates1, Luann Borowski1, Theresa L. WhITLESE1, Charles R. Rinaldo1  
1Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States; 2University of Pittsburgh Cancer Institute, Pittsburgh, PA, United States; 3Infectious Disease and Microbiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, United States
Session P-E4 Poster Session  
Wednesday March 5, 2014, 2:30 PM—4:00 PM  Exhibit Hall
Monocytes, Dendritic Cells, NK Cells

352 Identification of Pattern Recognition Receptor for HIV-1 in Human Dendritic Cells  
Sunnie M. Yoh, Monika Schneider, Stephen Soonthornvacharin, Kevin Olivier, Sourav Bandopadhyay, Elisa Decastro, Adolfo G. Sastry, Sunil C. Chanda  
1Inflammatory Diseases, Sanford Burnham Medical Institute, La Jolla, CA, United States; 2Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, United States; 3Department of Microbiology, Mount Sinai School of Medicine, New York, NY, United States

353 Plasmacytoid Dendritic Cell Phagocytosis of IgG Anti-p24 Associates With Control of HIV Infection  
Christian Tjiaji, James Taylor, Maznah A. Morshidi, Jeffrey N. Martin, Steven G. Deeks, Dino Tan, Silvia Lee, Sonia Fernandez, Martyn A. French  
1School of Pathology and Laboratory Medicine, University of Western Australia, Perth, Australia; 2School of Medicine, University California San Francisco, San Francisco, CA, United States; 3Lung Institute of Western Australia, University of Western Australia, Perth, Australia

354 Recruitment of Functionally Different NK Cells To the Rectal Mucosa in Vaccinated Macaques  
Namal P. M. Liyanage, Shari N. Gordon, Monika Vaccari, Poornam Perug, Melvin Doster, David Venzon, James Tartaglia, Susan W. Barnett, Nelson Michael, Genoveffa Franchini  
1National Cancer Institute, National Institutes of Health, Bethesda, MD, United States; 2Department of Research and Development, Sanofi Pasteur, Swiftwater, PA, United States; 445 Sidney Street, Novartis Vaccines & Diagnostics, Cambridge, MA, United States; 5U.S. Military HIV Research Program, Rockville, MD, United States

355 HIV Myeloid-Derived Suppressor Cells Inhibit the Protective Response To Cytomegalovirus  
Ankita Garg, Stephen A. Spector  
1Pediatrics, University of California San Diego, La Jolla, CA, United States; 2Rady Children's Hospital, San Diego, CA, United States

Session P-E5 Poster Session  
Wednesday March 5, 2014, 2:30 PM—4:00 PM  Exhibit Hall
Pre-Clinical Vaccine Studies

356 Induction of Gut Anti-HIV Immune Response via Dendritic Cell Targeted Intranasal Vaccination  
Darren Huang, Yoonkyung Doh, Akash Greg, Haeyoung Lee, Thomas Kraus, Jordan Poels, Lucas Brane, Christine Trumpfthiere, Andres Salazar, Ralph Steinman, Saurabh Mehandru  
1Gastroenterology, Mt Sinai School of Medicine, New York, NY, United States; 2School of Nano-Bioscience and Chemical Engineering, Ulsan National Institute of Science and Technology, Korea, Republic of Korea; 3Mt Sinai School of Medicine, New York, NY, United States; 4Rockefeller University, New York, NY, United States; 5Oncovir, Inc, New York, NY, United States

357 Conserved Element DNA Vaccine based On HIV-1 or SIV sequences Increases T-Cell Breadth  
Barbara K. Felber  
NCI, Frederick, MD, United States

358 DNA and Protein Co-Immunization Improves the Magnitude and Longevity of Humoral Immune Responses  
George N. Pavlakis  
National Cancer Institute, Frederick, MD, United States

359 The Adjuvant Used in an ALVAC/gp120 Regimen Alters Plasmablast Homing Markers in Macaques and Humans  
Luca Schitanella, Shari Gordon, Monica Vaccari, Georgia Tomaras, Mangala Rao, David Venzon, Susan Barnett, James Tartaglia, Silvia Ratto Kim, Genoveffa Franchini  
1National Cancer Institute, National Institutes of Health, Bethesda, MD, United States; 2Duke University, Durham, NC, United States; 3Veteran's Administration Medical Center, Medical Center, National Institutes of Health, Bethesda, MD, United States; 4Novartis Vaccines and Diagnostics, Cambridge, MA, United States; 5Sanofi Pasteur, Swiftwater, PA, United States; 6United States Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, United States

360 ALVAC-SIV/gp120 Efficacy Is Not Improved by the Increase of Anti-Envelope B and T-Cell Responses  
Monica Vaccari, Shari N. Gordon, Brandon F. Keele, Georgia D. Tomaras, Mangala Rao, Mario Roederer, Donald M. Stabile, Sanjay Phogat, Susan W. Barnett, Genoveffa Franchini, NICH, NCI, Bethesda, MD, United States; 2Duke Human Vaccine Institute, Durham, NC, United States; 3UMSHRP, Walter Reed Army Institute of Research, Silver Spring, MD, United States; 4NIH, NIAID, Bethesda, MD, United States; 5The EMMES Corporation, Rockville, MD, United States; 6Sanofi Pasteur, Swiftwater, PA, United States; 7Novartis Vaccines and Diagnostic, Cambridge, MA, United States

361 Altering the Prime Affects ALVAC-SIV/gp120 Immunogenicity and Efficacy  
Shari N. Gordon, Monica Vaccari, Georgia D. Tomaras, Mario Roederer, David Venzon, Dan H. Barouch, Barbara Felber, Nelson L. Michael, James Tartaglia, Genoveffa Franchini  
1Animal Models and Retroviral Vaccine Section, NCI, National Institutes of Health, Bethesda, MD, United States; 2Duke Human Vaccine Institute, Durham, NC, United States; 3Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, MD, United States; 4Biostatistics and Data Management Section, NCI, National Institutes of Health, Bethesda, MD, United States; 5Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, United States; 6Human Retrovirus Pathogenesis Section, Vaccine Branch, NCI, National Institutes of Health, Bethesda, MD, United States; 7Walter Reed Army Institute of Research, US Military HIV Research Program, Silver Spring, MD, United States; 8Sanofi Pasteur, Swiftwater, PA, United States

362 Immunization of Humanized BLT Mice Against HIV Influences Early Immune Responses and Viral Loads  
Timothy E. Dudek, Colby R. Maldini, Vladimir D. Vrbancic, Elizabeth F. Mellors, Damien Tully, Marcus Altfield, David M. Knipe, Andrew M. Tager, Todd M. Allen  
1Ragon Institute of MIT, Harvard, Cambridge, MA, United States; 2Massachusetts General Hospital, Boston, MA, United States; 3Harvard Medical School, Boston, MA, United States

Session P-E6 Poster Session  
Thursday March 6, 2014, 2:30 PM—4:00 PM  Exhibit Hall
Human Vaccine Trial Results

363 Antibody Responses in Anogenital Secretions of RV305, a Late Boost Vaccination of RV144 Volunteers  
Srirat Atakarin, Chitrapporn Karnasuta, Viseth Ngauy, Robert J. O'Connell, Funnene Pitsathutthum, Supachai Rerk-Angam, Nelson L. Michael, Mark S. De Souza, Jerome H. Kim, Nicos Karasavvas, Retrovirology, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand; 2Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; 3Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; 4Disease Control, Ministry of Public Health, Nonthaburi, Thailand; 5Retrovirology, Walter Reed Army Institute of Research, Silver Spring, MD, United States

364 Divergent HIV-Specific CD4 T-Cell Response Profiles in HIV Vaccine Trials  
Franco Pissani, Sebastien Maloveste, Bruce Shultz, Sorachai Nittayaphaph, Prasert Thongcharoen, Funnene Pitsathutthum, Michael Eler, Silvia Ratto Kim, Mary Marovich, Hendrik Streeck  
1Cellular Immunology, Military HIV Research Program, Silver Spring, MD, United States; 2Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand; 3Department of Microbiology, Siriraj Hospital, Mahidol University, Bangkok Noi, Thailand; 4Clinical Tropical Medicine, Mahidol University, Nakronsawan, Thailand; 5Military HIV Research Program, Silver Spring, MD, United States; 6Division of AIDS, National Institutes of Health, Bethesda, MD, United States
365 Immunogenicity and Reactogenicity of Cervarix® Versus Gardasil® in HIV-Infected Adults: An RCT
Lars Toft1, Merete Stengaard2, Martin Müller1, Peter Soini3, Jesper Bonde4, Martin Tolstrup1, Lars Østergaard5, Ole S. Søgaard6
1Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark; 2Research Program Infection and Cancer, German Cancer Research Center, Heidelberg, Germany; 3Chemical Biology Core Facility, European Molecular Biology Laboratory, Heidelberg, Germany; 4Department of Pathology, Copenhagen University Hospital, Værløse, Denmark;
5The Specificity of V3 Antibodies in RV144 Plasma Implicated in Reducing HIV Infection
Susan Zolla-Pazner1, Constance Williams2, Morgane Rolland3, Paul Edleson4, Xiang-Peng Kong5, Arthur Nadasi6, S. Tovanabutra7, Supachai Rekhs-Ngarm8, Merlin Robb1, Nelson Michael1, Jerome Kim1
1Pathology, VA and New York University Medical Centers, New York, NY, United States; 2Pathology, New York University Medical Center, New York, NY, United States; 3Military HIV Research Program, Bethesda, MD, United States; 4Fred Hutchinson Cancer Research Institute, Seattle, WA, United States; 5New York University Medical Center, New York, NY, United States; 6Military HIV Research Program and HM Jackson Foundation, Bethesda, MD, United States; 7Ministry of Public Health, Bangkok, Thailand

Session P-E7 Poster Session
Thursday March 6, 2014, 2:30 PM-4:00 PM Exhibit Hall

367 HIV Cell Tropism Dependent Impact of CTL Escape Mutations in Gag On Viral Replicative Capacity
Benedikt Grandel1, Sara Wenning1, Franziska Winter2, Sven Breitwieser3, Bernd Sattberger1, Arne Schneidewind4
1Internal Medicine I, University of Regensburg, Regensburg, Germany; 2Internal Medicine I, University of Bonn, Bonn, Germany

367LB Epitope Targeting and the Antibody-Dependent Cell Cytotoxicity Response Against HIV-1
Priyamvada Acharya1, William D. Tobert1, Lei Yu2, James E. Robinson1, Lois Martin1, Peter D. Kwong3, Yongjun Guan4, Anthony L. DeVico5, George K. Lewis2,4, Marzena Pazgier2,3
1Vaccine Research Center, National Institutes of Health, Bethesda, MD, United States; 2Institute of Human Virology, Baltimore, MD, United States; 3Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD, United States; 4Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD, United States; 5Department of Pediatrics, Tulane University Medical Center, New Orleans, LA, United States; 6Service d’Ingénierie Moléculaire des Protéines, CEA, GIF-sur-Yvette, France; 7Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, United States

369 Complex Impact of Reversion Mutations and CD8+ T Cell Escape Mutations On HIV-1 Fitness
Hongsu Song1, Tannoy Bhattacharya2, Nuu Goonetilleke1, Kevin Wiehe1, Andrew McMichael1, George Shaw4, Beatrice Hahn5, Alan Perelson6, Stanton Haynes1, Feng Gao3
1Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, United States; 2Los Alamos National Laboratory, Los Alamos, NM, United States; 3Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom; 4Department of Microbiology, University of Pennsylvania, Philadelphia, PA, United States

371 Linkage Between Disease Status and a Naturally Arising Mutation in Functional Region of HIV-1 Nef
Stanley C. Meribe1, Zafra Hasan2, Hiroyuki Gatanaga3, Toshiyuki Miura4,5, Akisaka-Tachikawa3, Akichi Iwamoto3, Shinichi Oka6, Takamasa Ueno7
1Center for AIDS Research, Kumamoto University, Kumamoto, Japan; 2AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan; 3Institute of Medical Science, University of Tokyo, Tokyo, Japan; 4Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan

Poster Abstracts

372 Characterizing Acute HIV-1B CTL Escape by Full-Genome “Deep” Sequencing
Karen Power, Aaron Seese, Michael Sirignano, Marcus Alfitt, Todd M. Allen
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, United States

373 HIV-1 gp120-Specific Antibody Dependent Cell-Mediated Cytotoxicity in HIV-1 Elite Controllers
Marina M. Mata1, Fareeha Mahmood1, Elizabeth T. Golub2, Ruth M. Greenblatt1, Kathryn Anastas3, Marek Nowicki2, Mary Young4, Helen Durkin5, Seema N. Desai6, Linda Hole7, Robert W. Buckheit2,3, Robert F. Christopher W. Pohlmeyer2,3
1Immunology/Microbiology, Rush University Medical Center, Chicago, IL, United States; 2Epidemiology, The Johns Hopkins University, Baltimore, MD, United States; 3Clinical Pharmacy, Medicine, Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, United States; 4Medicine, Epidemiology and Population Health, Montefiore Medical Center, Bronx, NY, United States; 5Medicine, University of Southern California, Los Angeles, CA, United States; 6Medicine, Division of Infectious Disease, Georgetown University Medical Center, Washington, DC, United States; 7Pathology, SUNY Downstate Medical Center, Brooklyn, NY, United States

374 CD8 T Cell Responses Emerging During Acute HIV Infection Drive Long-Term Control
Hendrik Streeck1, Jean-Pierre Routy1, Heiko Jessen2, Anthony Kellner2, Friedrich Hecht2, Rafick-Pierre Sekaly3, Eric Rosenberg3, Todd Allen4, Mary Garrington5, Marcus Alfitt6
1US Military HIV Research Program, Silver Spring, MD, United States; 2Chronic Viral Illness Service, McGill University Health Centre, Montreal, QC, Canada; 3Practice Jessen + Jessen, Berlin, Germany; 4Centre for Immunology, St. Vincent’s Hospital, Darlinghurst, Australia; 5School of Medicine, University of California San Francisco, San Francisco, CA, United States; 6VGTI, Port St Lucie, FL, United States; 7Massachusetts General Hospital, Boston, MA, United States; 8Ragon Institute, Cambridge, MA, United States; 9National Cancer Institute, Frederick, MD, United States; 10Heinrich-Pette Institut, Hamburg, Germany

375LB Modification of Antibody 10E8 To Improve HIV-1 Neutralization
Gilad Olek1, Gabriel Lu1, Baoshan Zhang3, Amy Baol1, Yongping Yang1, McKee Krishna1, Brett Zirkle1, Jinde Huang1, Mark Connors1, John R. Mascola1, Peter D. Kwong3
1Vaccine Research Center, National Institutes of Health, Bethesda, MD, United States; 2Laboratory of Immunoregulation, National Institutes of Health, Bethesda, MD, United States

376 Association of Gag-Specific CD28+CD95+ CD8+ T-Cell Responses in Lymph Nodes With Lower Viral Loads
Hiroshi Ishii1, Saori Matsuoka2, Tetsuro Matano1
1AIDS Research Center, National Institute of Infectious Diseases, Tokyo, Japan; 2The Institute of Medical Science, The University of Tokyo, Tokyo, Japan

377 Distinct Functional Properties of HIV-Specific Cytolytic CD4 T Cells Compared To Th1 or CD8 T Cells
Susan Johnson1, Richard Lu2, Alexander Oster3, Franco Pissani4, Mary A. Marovich5, Diane L. Bolton2, Hendrik Streeck3
1US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, United States; 2Division of AIDS, NIH/NAID, Bethesda, MD, United States

378 CD8+ T Cells From HLA-B*57 Elite Suppressors Inhibit Replication of HIV-1 Escape Mutants
Christopher W. Pohlmeyer1, Robert W. Buckheit1,2, Robert F. Siliciano1, Joel N. Blankson1,4, Mary A. Marovich2, Diane L. Bolton1, Hendrik Streeck3
1School of Medicine, The Johns Hopkins Medical Institution, Baltimore, MD, United States; 2National Cancer Institute, Frederick, MD, United States; 3The Johns Hopkins Medical Institution, Baltimore, MD, United States; 4Howard Hughes Medical Institute, Baltimore, MD, United States
Session P-F1 Poster Session
Tuesday March 4, 2014, 2:30 pm–4:00 pm

Exhibit Hall A
Mechanisms of HIV Latency

379LB The Tat Inhibitor, Cortalentin A, Suppresses Transcription and Reactivation of HIV Latent Cells
Guillaume Mousseau1, Remi Fromentin2, Nicolas Chomont3, Susana T. Valente
1The Scripps Research Institute, Jupiter, FL, United States, 2Vaccine and Gene Therapy Institute, Port Saint Lucie, FL, United States

380 Mechanisms by Which Negative Elevation Factor (NELF) Establishes and Maintains HIV Latency
Gillian M. Schiralli Lestere, Malini Natarajane, Andrew J. Henderson1
1Medical, Infectious Disease, Boston University Medical Center, Boston, MA, United States, 2Stowers Institute for Medical Research, Kansas City, MO, United States

381 Differential Role of Bromodomain Proteins in HIV-1 Latency
Daniela Boehm, Pao-Chen Li, Hendrik Sy, Melanie Ott
Gladstone Institute of Virology and Immunology, Gladstone Institute University of California San Francisco, San Francisco, CA, United States

382 The NCO2-RuN1-CoREST Axis Impairs HIV Reactivation in Latently Infected Microglial Cells
David Alvarez1, Biswajit Das, Yoeil Garcia-Mesa, Curtis Dobrowolski, Jonathan Kam
Molecular Biology and Microbiology, Case Western Reserve University, Cleveland, OH, United States

383 Repression of HIV Transcription in Memory CD4+ T Cells by Blimp-1
Katarzyna Kaczmarek1, Malini Natarajan2, Zelda Euler3, Gailt Alter3, Andrew J. Henderson1
1Molecular and Translational Medicine, Boston University School of Medicine, Boston, MA, United States, 2Stowers Institute for Medical Research, Kansas City, MO, United States, 3Ragon Institute of MGH, MIT and Harvard, Boston, MA, United States

384 HIV-1 Reactivation and Autophagy Inhibition Synergize To Cell Death via Amino Acid Deprivation
Metodi V. Stankov1, Diana Panayotova-Dimitrova2, Georg M. N. Behrens1
1Department for Clinical Immunology and Rheumatology, Hannover Medical School, Hannover, Germany, 2Department of Dermatology, Venerology and Allergology, Mannheim Clinic of University of Heidelberg, Mannheim, Germany

385 JAK Inhibitors Tofacitinib and Ruxolitinib Block T-Cell Activation and Reactivation of HIV-1 Replication
Franck R. Mpony1, Jessica Brehm1, Christina Gavegnano2,3, Raymond F. Schinaizi,2,3, Rafick P. Sekaly1
1Vaccine and Gene Therapy Institute VGTI-FL, Port Saint Lucie, FL, United States, 2Department of Pediatrics, Center for AIDS Research, Laboratory of Biochemical Pharmacology, Atlanta, GA, United States, 3Gene Therapy Institute, Port Saint Lucie, FL, United States

386LB Human Genome shRNA Screen Identifies Cellular Factors Controlling Latency
Shweta Hakre1, Martin Kampmann2, Nina N. Hosmane3, Michael C. Bassik4, Erik Verschueren5, Emilie Battivel6, Robert F. Siliciano7, Nevan J. Krogan8, Jonathan S. Weissman9, Eric W. Verdin2
1Virology and Immunology, Department of Medicine, UCSF, Gladstone Institutes, UCSF, San Francisco, CA, United States, 2Cellular and Molecular Pharmacology, Howard Hughes Medical Institute, University of California, San Francisco, San Francisco, CA, United States, 3Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States, 4Genetics, Stanford University School of Medicine, Stanford, CA, United States, 5Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, United States, 6Genetics, Stanford University School of Medicine, Stanford, CA, United States, 7Virology and Immunology, Gladstone Institutes, UCSF, San Francisco, CA, United States, 8Virology and Immunology, Department of Medicine, UCSF, Gladstone Institutes, UCSF, San Francisco, CA, United States, 9Virology and Immunology, Department of Medicine, UCSF, Gladstone Institutes, UCSF, San Francisco, CA, United States

Session P-F2 Poster Session
Tuesday March 4, 2014, 2:30 pm–4:00 pm

Exhibit Hall A
Dynamics of Persistent and Rebound HIV

387 Incomplete Adherence To cART Is Associated With Higher Levels of Residual HIV-1 Viremia
Jonathan Z. Li1, Sebastien Gallien1, Heather Ribaudo2, Andrea Helsey2, David Bangsberg3, Daniel R. Kuritzkes3
1Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, United States, 2Hôpital Saint Louis, Paris, France, 3Harvard School of Public Health, Boston, MA, United States, 4Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States

388 Viral Dynamics of HIV-1 Rebound Viremia
Benjamin Scheinfield, Katharine J. Bar
Medicine, University of Pennsylvania, Philadelphia, PA, United States

389 Transcripts Associated With the HIV Reservoir Correlate With the Pool Size of Long-Lived CD4 T Cells
Maria J. Buzon1,2, G. Yuanyu Zheng1, Amy Shaw1, Hong Sun1, Forencia Pareyra1,2, Nadine Zangger1,2, Xu Yu3, Amaliao Telen3, Eric S. Rosenberg1,2, Mathias Lichterfeld1,2
1Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, United States, 2Infectious Disease Division, Massachusetts General Hospital, Boston, MA, United States, 3AIDS Research Center, The First Affiliated Hospital of China Medical University, Shenyang, China, 3Infectious Disease Division, Brigham and Women’s Hospital, Boston, MA, United States, 4Institute of Microbiology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

390 Massive Expansion of HIV Infected Cells With Identical Provirus in Patients On Suppressive ART
Mary Kearney1, Luke Smith1, Johnathan Spindler2, Charles Coo, Guillaume J. Besson1, Elizabeth M. Anderson3, Wei Shao3, John M. Coffin4, John W. Mellors5, Frank Maldarelli7
1National Cancer Institute, NIH, Frederick, MD, United States, 2University of Pittsburgh, Pittsburgh, PA, United States, 3Advanced Biomedical Computing Center, SAIC, Frederick, MD, United States, 4Department of Molecular Biology and Microbiology, Tufts University, Boston, MA, United States, 5Department of Medicine, University of Pittsburgh, Pittsburgh, PA, United States

391 Effects of CCR5-Δ32 Heterozygosity On HIV-1 Reservoir Size and Immune Activation
Charliene Wang1,2, Mohamed Abdel-Mohsen3,4, Matthew C. Strain1,2, Steven M. Lada1,2, Leslie Cockerham1, Steven Yuki1,2, Teri Liegler3, Douglas R. Richman4,1, Steven G. Deeks3, Satosh K. Pillai2,3
1Emory University, Atlanta, GA, United States, 2Blood Systems Research Institute, San Francisco, CA, United States, 3University of California, San Francisco, San Francisco, CA, United States, 4University of California, San Diego, La Jolla, CA, United States, 5Veterans Affairs San Diego Healthcare System, San Diego, CA, United States, 6Veterans Affairs Medical Center, San Francisco, CA, United States

392 Seminal CMV Replication, Immune Activation, and Higher Provirial HIV DNA During Suppressive ART
Sara Gianella1, Marta Massanet1, Douglas R. Richman2, Susan J. Little3, Celsa A. Spina1, Eric S. Daar4, Michael P. Dube4, Richard H. Haubrich5, Sheldon P. Morris1,5, Daniel R. Kuritzkes1, and the CCGT 592 Team
1Medicine, University of California San Diego, La Jolla, CA, United States, 2Veterans Affairs San Diego Healthcare System, San Diego, CA, United States, 3Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, United States, 4University of Southern California Keck School of Medicine, Los Angeles, CA, United States, 5Veterans Affairs San Diego Healthcare, San Diego, CA, United States

393 Persistent HIV in Plasma On During cART Can Lead To Rebound Viremia After Treatment Interruption
Junko Hattori1, Wei Shao2, Shawn Hill3, Francesco R. Simonetti4, Elizabeth M. Anderson1, Catherine A. Rehm1, Sara E. Jones4, Richard T. Davey5, Frank Maldarelli7
1National Cancer Institute, NIH, Frederick, MD, United States, 2Veterans Affairs Medical Center, San Francisco, CA, United States, 3Infectious Disease Division, Massachusetts General Hospital, Boston, MA, United States, 4University of California, San Francisco, CA, United States, 5Veterans Affairs San Diego Healthcare System, San Diego, CA, United States, 6Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, United States
Effect of ART Early in HIV Infection

Ulmer7, Lothar Schneider 8, Hans Jaeger 9, New Era Study Group
France,5Isarpraxis - Private practice Dr. Becker/Dr. Pauli, Munich,
Laboratoire de Virologie, Hôpital Necker, Enfants malades, Paris,
Francisco, CA, United States,3Vaccine and Gene Therapy Institute of
Central Memory Cells and Can Induce HIV Remission

Lack of Detectable HIV DNA in a PrEP Study Participant

Mice

Establishment of HIV-1 Infection in Humanized-BLT

Early Antiretroviral Therapy Prevents the
Establishment of HIV-1 Infection in Humanized-BLT

Mice

Loss of HIV Serological Markers Following Early
Treatment of Acute HIV Infection

Mark M. Manak1, Sheila Peel1, Jennifer Malia2, Ashley Stutt3,
Sriwat Akapirat4, Tippawan Pankam4, Tippawan Pankam 4, James Fletcher 4,
Merlin Robi1, Jerome Kim1, Jintanat Ananworanich5,
US Military HIV Research Program, HUF, Silver Spring, MD, United States,
US Military HIV Research Program, WRAIR, Silver Spring, MD, United States,
Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand,
Thai Red Cross AIDS Research Center, Bangkok, Thailand

A Scalable RNA RT-PCR Based Assay To Quantify
Latency Disruption in HIV-1 Infected Cells

Jason M. Hataye1, Joseph P. Casazza2, David R. Ambrozak3, Eli Boritz4,
Takuya Yamamoto1, Daniel C. Doiuek, Richard A. Koup
Vaccine Research Center, National Institute of Allergy and Infectious
Diseases, Bethesda, MD, United States

Antibodies To Detect HIV Persistence in
Treatment Intensification and Eradication Studies

Sheila M. Keating1, Christopher D. Filcher2, Gary Murphy3, Alex
Welsh4, Reetsha Kasiangjee5, David Matten6, Mia Labeveda7,
Shelley N. Facente8, Steve G. Deeks9, Michael P. Busch10,11,12,13,
Consortium for Evaluation of Performance of HIV Incidence Assays (CEPIHA)
Blood Systems Research Institute, San Francisco, CA, United States,
UCSF, San Francisco, CA, United States,
Public Health England, London, United Kingdom,
SACEMA, Stellenbosch, South Africa,
University of California, San Francisco, CA, United States

HIV DNA in PHI Associates With T Cell Immunity and
Predicts Disease Progression and Rebound Viremia

Jacob Hurst1, James Williams2, Elisabeth Hamrin3, Kersten Koebsch4,
Sarah Felder5, Abdel Babiker6, Jonathan Weber7, Tony Kelleher8,
Rodney Phillips9, John Frater10, Spartac Trial Investigators
University of Oxford, Oxford, United Kingdom,
Imperial College, London, United Kingdom,
University of New South Wales, Sydney, Sydney, United Kingdom,
MRC Clinical Trials Unit, London, United Kingdom,
University of New South Wales, Sydney, Australia

Next Generation Plasma HIV-1 RNA Single Copy Assays
Anthony R. Cillo1, David Vagratian2, Margaret Bedison1, Elizabeth
Anderson3, Mary Kearney4, Elizabeth Fyne5, Dianna Koontz6, John
Coffin7, Michael Piatak8, John Mellors9
School of Medicine, University of Pittsburgh, Pittsburgh, PA, United States,
University of Pittsburgh, Pittsburgh, PA, United States,
NIH-Frederick, Frederick, MD, United States,
Tufts University, Boston, MA, United States

Assessment and Quantification of Cell Associate
Unspliced HIV-1 RNA Using RT-ddPCR

Zixin Hu1, Carlos Bocorri1, Nina H. Lin1, Jonathan Li1, Andrea Hseisy1, 
Atte M. Tisbrir1, Daniel R. Kuritzkes
Division of Infectious Diseases, Brigham and Women’s Hospital and
Harvard Medical School, Boston, MA, United States

Measuring HIV Latency Over Time: Reservoir Stability
and Assessing Interventions

Nancie M. Archin1, Amanda M. Crooks2, Rosalie Bateson1, Anna B.
Cope2, Noelle P. Dahl3, Joseph J. Eron1, Cynthia L. Gay4, John D.
Kuruc5, David M. Margulis2, Ronald J. Bosch2
Department of Medicine, University of North Carolina at Chapel
Hill, Chapel Hill, NC, United States,
Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States,
Department of Microbiology & Immunology, Department of
Session P-F5 Poster Session
Wednesday March 5, 2014, 2:30 pm–4:00 pm Exhibits Hall A
What and Where Is the Reservoir?

407LB The Role of HIV Integration Sites in Extensive Clonal Expansion of Infected Cells in Patients
Frank Maldarelli1, Xiaolin Wu1, Mary Kearney1, Ling Su2, Wei Shao3, Shawn Hill4, Francesco Simonetti1, Jon Spindler1, John Coffin1, Stephen H. Hughes1
1HIV Drug Resistance Program, NIMH, Frederick, MD, United States; 2Leidos, Inc, Frederick, MD, United States; 3ISP/Advanced Biomedical Computing Center, Leidos, Inc., Frederick, MD, United States; 4Department of Molecular Biology and Microbiology, Tufts University School of Medicine, Boston, MA, United States

408 Identification of a New Th17 Subset That Contributes To HIV-1 Persistence in ART-Treated Subjects
Vanessa S. Wacleche1,2, Annie Gosselin1, Patricia Monteiro1, Aurélie Cleret-Buhod1,2, Sandrine DaFonseca3, Mohammad-Ali Jenabian1, Jean-Pierre Routy1, Petronela Ancuta1,2
1CR-CHUM, Montréal, QC, Canada; 2Université de Montréal, Montréal, QC, Canada; 3McGill University Health Centre, Montréal, QC, Canada

409 Identifying Defective and Identical Viral Genomes in HIV Reservoirs During Effective HIV Therapy
Susanne von Stockenstrom1, Lina Odevall1, Elizabeth Sinclair2, Rui A. Raposo1, Douglas F. Nixan1,2, Hiroyu Hatanaka3, Peter Hunt1, Peter Bacchetti1, Steven G. Deeks3, Frederick M. Hecht1, Sarah Palmer4
1Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden; 2Department of Medicine, University of California San Francisco, San Francisco, CA, United States; 3Division of Experimental Medicine, University of California San Francisco, San Francisco, CA, United States; 4Department of Microbiology, Immunology and Tropical Medicine, The George Washington University, Washington, DC, United States

410 Healthy HIV-Infected Subjects Harbor HIV in Alveolar Macrophages, Which Can Impair Lung Function
Sushma K. Gribbs1,2, David M. Guidott1, Angela M. Callendo2, Lou Ann Brown3, Jeffrey Lennox4
1Pulmonary/Critical Care Medicine, Emory University, Atlanta, GA, United States; 2Brown University, Providence, RI, United States; 3Pediatrics, Emory University, Atlanta, GA, United States; 4Infectious Diseases, Emory University, Atlanta, GA, United States

411 Quantitative and Phylogenetic Analyses of Persistent HIV in Blood and GALT During Long-Term CART
Francesco R. Simonetti1, Shawn Hill2, Shao Wei3, Robert Gorelick2, Michael Piatak4, Mark Voellinger4, Stephen H. Hughes1, Joe Kovacs1, Frank Maldarelli1
1HIV Drug Resistance Program, National Cancer Institute, Frederick, MD, United States; 2Advanced Biomedical Computing Center SAIC-Frederick, Frederick National Laboratories for Cancer Research, Frederick, MD, United States; 3AIDS and Cancer Virus Program, Frederick National Laboratories for Cancer Research, Frederick, MD, United States; 4National Institute of Digestive and Kidney Diseases, Digestive Disease Branch, National Institutes of Health, Bethesda, MD, United States; 5Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD, United States

412 The Immune Checkpoint Blockers PD-1, LAG-3 and TIGIT Are Associated With HIV Persistence During ART
Remi Fromentin1, Sandrina Da Fonseca1, Wendy Bakeman1, Gabriela Khoury1, Elizabeth Sinclair2, Frederick Hecht1, Steven G. Deeks3, Sharon R. Lewin2, Rafick P. Sekaly1, Nicolas Chomont1
1VGTI, Florida, Port St Lucie, FL, United States; 2Infectious Diseases, Alfred Hospital and Monash University, Melbourne, Australia; 3Medicine, UCSF, San Francisco, CA, United States; 4Centre for Biomedical Research, Bame Institute, Melbourne, Australia

413 Distinct Patterns of TLR-Mediated HIV Reactivation in Latently-Infected Microglia vs Monocytes
David Alvarez1, Yeovies Garcia-Mesa, Biswajit Das, Curtis Dobrowolski, Stephanie Milne, Roxana Rojas, Jonathan Karn2
Molecular Biology and Microbiology, Case Western Reserve University, Cleveland, OH, United States

414 CXCR3 and CCR5 Expression Are Associated With 2LTR Circles in Patients On Antiretroviral Therapy
Gabriela Khoury1, Jenny Anderson2, Rémi Fromentin1, Nicolas Chomont1, Elizabeth Sinclair2, Wendy Hartogensen1, Peter Bacchetti1, Frederick M. Hecht1, Steven G. Deeks3, Sharon R. Lewin2
1Infectious Diseases, Monash University & Alfred Hospital, Melbourne, Victoria, Australia; 2Burnet Institute, Melbourne, Victoria, Australia; 3Vaccine and Gene Therapy Institute of Florida, Port St Lucie, FL, United States; 4Medicine, University of California San Francisco, San Francisco, CA, United States; 5University of California San Francisco, San Francisco, CA, United States

CD4+ and CD8+ T Cell Activation Are Strongly Associated With HIV-1 DNA in Resting CD4+ T Cells
Leslie Cockerham1, Janet D. Siliciano, Elizabeth Sinclair1, Una O’Doherty1, Sarah Palmer1, Steven A. Yuki1, Matt C. Strain1, Robert F. Siliciano2, Douglas R. Richman3, Steven G. Deeks4
1HIV/AIDS Division, University of California - San Francisco, San Francisco, CA, United States; 2Department of Medicine, Johns Hopkins University, Baltimore, MD, United States; 3Division of Experimental Medicine, University of California - San Francisco, San Francisco, CA, United States; 4Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, United States; 5The University of Sydney, Sydney, Sydney, Australia; 6San Francisco VA Medical Center, San Francisco, CA, United States; 7University of California - San Diego, San Diego, CA, United States; 8Johns Hopkins University, Baltimore, MD, United States

Session P-F6 Poster Session
Wednesday March 5, 2014, 2:30 pm–4:00 pm Exhibits Hall A
What Can We Learn From Bone Marrow Transplantation?

415 Targeting SIV Reservoirs via Autologous Hematopoietic Stem Cell Transplant in Rhesus Macaques
Maud Maguire1, Benjamin Watkins2,3,4, Berton O. Lawson5, Ann Chahroudi1,2, Leslie S. Kean3,4, Guido Silvestri1,2
1Yerkes National Primate Research Center, Emory University, Atlanta, GA, United States; 2Department of Pediatrics, Emory University, Atlanta, GA, United States; 3Emory Transplant Center, Emory University, Atlanta, GA, United States

417 Dynamics of HSPC Repopulation in Non-Human Primates Revealed by a Decade-Long Clonal Tracking
Sanggu Kim1, Namshin Kim2, Angela Presson1, Dong Sung An1, Robert E. Donahue1, Irvin S. Y. Chen1
1University of California, Los Angeles, Los Angeles, CA, United States; 2Korean Bioinformatics Center, Daegoe, Republic of Korea; 3National Heart, Lung and Blood Institute, Bethesda, MD, United States

418 Impact of Systemic Cytotoxic Chemotherapy for Malignancies On HIV-1 Reservoir Persistence
Timothy J. Henrich1, Emily Hanhauser2, Jonathan Z. Li1, Andrea Heisey1, Jeremy S. Abramson, Ayad Hamdan1, Philippe Armand2, Ann S. LaCasce1, Daniel R. Kuritzkes1
1Brigham and Women’s Hospital, Harvard Medical School, Cambridge, MA, United States; 2Korean Bioinformatics Center, Daegoe, Republic of Korea; 3Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States; 4Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States
419 Modeling Functional Cure of HIV in Nonhuman Primates Using Gene-Modified Hematopoietic Stem Cells Hans-Peter Kogelnik1, Christopher W. Peterson1, Patrick M. Younan1, Shi-Lok Hu1, Patricia Palacino2, Michael Holmes3, Phillip Gregory4, Jianbin Wang5

1Transplantation Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, United States; 2University of Washington, Seattle, WA, United States; 3Sangamo Biosciences, Richmond, CA, United States

Session P-F7 Poster Session
Thursday March 6, 2014, 2:30 PM–4:00 PM Exhibit Hall A

Effect of ART On Persistence

420 Patterns of Persistent Viremia After 10 Years of Suppressive ART: ACTG A5276s Rima Zoorob1, Laura Papagno1,6, Francois Lecardonnel 6, Vincent Calvez3,4, Christine Katlama1,2, Lambert Assoumou 5,7, Brigitte Autran 1, The Eramune-01 Study Group 1UPMC University Paris 06, UMR-S943, Epidemiology, Therapeutic Strategies and Clinical Virology in HIV Infection, Laboratory of Virology, Paris, France, 2University of Oxford, Oxford, United Kingdom, 3Innunocure Ltd., Abingdon, Oxon, United Kingdom, 4Laboratory Animal Sciences Program, Leidos Biomedical Research, Inc., Foster City, CA, United States, 5Social & Scientific Systems, Inc., Silver Spring, MD, United States, 6ORVACS, Pitié-Salpêtrière Hospital, Paris, France, 7AP-HP, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States, 7AP-HP, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States

421LB Comparison of Combination ART Regimens for Viral Suppression in SIV-Infected Rhesus Macaques

422 Impact of RAL/MVC Intensification With or Without HIV-RA5s Vaccination On HIV DNA: ERAMUNE 02 Study

423 Impact of Three Different ART Regimens On the GALT: A Randomized Clinical Trial

424 HIV Reservoir Changes in Resting CD4 Subsets in the IL7 Plus ART Intensification Eramune-01 Study

425LB Pre-ART HIV-1 RNA as well as On-Treatment CD8 Count and CD4/CD8 Ratio Predict Residual Viremia On ART

426 Eradication of HIV-1 Reservoirs With Antibody Mediated Killing

427LB Maraviroc Reverts Latent HIV-1 in ART Suppressed Patients Through NFKB Without Viral Load Increase

428 Regulatory B cells Attenuate Anti-HIV CTL Responses After Reactivation of Latent Reservoirs

429 Evaluation of HIV-1 Reservoir Characteristics in a Therapeutic HIV-1 Gag Vaccine Trial

430LB Engineered TCR-Redirected Clearance of Gag-Positive Reservoir Cells From ART-Treated Subjects

Poster Abstracts
432LB Ing-B is a Potential PKC Activator for HIV Eradication Is Active in SIVmac251-Infected Macaques
Amilcar Tanuri1,2, Lucio Gama1, Renato Santana1,2, Mark Lewis3, Andrea Savarino1, Iart Shyta4, Janice E. Clements1, Luiz F. Pianowski1
1Genetics, UFRJ, Rio de Janeiro, Brazil, 2UFRJ, Rio de Janeiro, Brazil, 3Johns Hopkins School of Medicine, Baltimore, MD, United States, 4BioQual, Inc, Rockville, MD, United States, 5Istituto Superiore di Sanità, Rome, Italy

434 LAUSANNE Toward A Cure...
Thursday March 6, 2014, 2:30 PM–4:00 PM  Exhibit Hall A

435LB HIV-1 Expression Within Resting CD4 T-Cells Following Multiple Doses of Voninostat In Vivo
Yang Kuo-Hsiung1, Nancie M. Archin2, Christopher H. Woelk3, Matthew C. Strain4, Douglas D. Richman5, JoAnn D. Kuruc6, Richard J. O. Barnard1, Daria J. Hazuda7, Joseph J. Eron8, David M. Margolis1
1School of Pharmacy, UNC Chapel Hill, Chapel Hill, NC, United States, 2School of Medicine, UNC Chapel Hill, Chapel Hill, NC, United States, 3University of Southampton, Southampton, United Kingdom, 4School of Medicine, UCSD and San Diego VAMC, San Diego, CA, United States, 5Merck Research Laboratories, White Horse Junction, PA, United States

436 Autophagy Induction by Histone Deacetylase Inhibitors Inhibits HIV-1 Infection in Macrophages
Grant R. Campbell1, Rachel S. Bruckman2, Stephen A. Spector1
1University of California San Diego, La Jolla, CA, United States, 2University of Utah School of Medicine, Salt Lake City, UT, United States

437 An In Vitro Compound Screen for Selective Apoptosis Induction in HIV-1 Infected Resting CD4+ T Cells
Adam M. Spivak1, Alberto Bosque2, Vicenta Planelles3
1Medicine, University of Utah School of Medicine, Salt Lake City, UT, United States, 2Pathology, University of Utah School of Medicine, Salt Lake City, UT, United States

438LB Panobinostat Induces HIV Transcription and Plasma Viremia in HIV Patients on Suppressive cART
Thomas Rasmussen1, and the CLEAR study group
1Dept. of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark

439 Failure of HIV-1 To Replicate in Human T Cells Expressing a Tat Mutant
David Harich1, Hongjiang Jin2, Riku Raittia3, Simo Nikunen4, Anna Virta5, Lars Söderberg6, Tapio Mäkelä7, Henryk Zetterberg8, Magnus Gisslen9
1University of Gothenburg, Gothenburg, Sweden, 2Innsbruck Medical University, Innsbruck, Austria, 3Chalmers University of Technology, Gothenburg, Sweden

440 Hepatitis C Therapy Reduces CD4 T-Cell-Associated HIV DNA in HIV-1/HCV Coinfected Patients
Hong Sun1, Maria Buzon1, Amy Shaw2, Randi Berg3, Xu G. Yu2, Sara Ferrando-Martinez2, Manuela Leal3, Ezequiel Ruiz-Mateos3, Mathias Lichterfeld4
1Ragon Institute of MGH, MIT, and Harvard, Boston, MA, United States, 2National Institute for Infectious Disease, Rome, Italy, 3Lausanne University Hospital and University of Lausanne, Institute of Microbiology, Lausanne, Switzerland

441 HIV-1 Nef Inhibits Autophagy in Macrophages Through Transcription Factor EB Sequestration
Grant R. Campbell1, Pratima Rawat2, Rachel S. Bruckman2, Stephen A. Spector1
1University of California San Diego, La Jolla, CA, United States, 2University of Utah School of Medicine, Salt Lake City, UT, United States

442 HIV-1 RNA Detection in CSF in ART-Treated Subjects With Incomplete Viral Suppression in Plasma
Sam Nightingale1, the PARTITION Study Group
1Institute of Infection and Global Health, University of Liverpool, Liverpool, United Kingdom

443 CSF Viral Escape in Patients Without Neurological Disorders: Prevalence and Associated Factors
Carmela Pinnetti1, Patrizia Lorenzini2, Federica Forbici, Adriana Ammassari3, Raffaella Libetbone1, Maria Letizia Giancola1, Maria Rossaria Capobianchi1, Carlo Federico Perno2, Andrea Antonini1
1National Institute for Infectious Disease, Rome, Italy, 2University of Rome, Rome, Italy

444 Early Monocye Inflammation Among Treatment-Naïve Acute HIV-Infected Thai Subjects
Lishomwa C. Ndhlovu1, 2, Mary Margaret Byron1, Guangxiang Zhang2, Duangnathai Suttichom3, Somprarthana Rattanamanee4, Rapee Trichavari4, Nittaya Phanuphak5, Victor Valcour1, Merlin Robbi, Jintanat Ananworanich1
1HIV/AIDS center for AIDS, University of Hawaii, Honolulu, HI, United States, 2School of Medicine, UCSD and San Diego VAMC, San Diego, CA, United States, 3Merck Research Laboratories, White Horse Junction, PA, United States

445 Cerebrospinal Fluid Viral Blips and Persistent Escape in HIV-Infected Patients On ART
Arvid Eden1, Lars-Magnus Andersson1, Dietmar Fuchs2, Lars Hagberg1, Staffan Nilsson1, Bo Svennerholm1, Aylin Yilmaz2, Henrik Zetterberg1, Magnus Gisslen3
1University of Gothenburg, Gothenburg, Sweden, 2Innsbruck Medical University, Innsbruck, Austria, 3Chalmers University of Technology, Gothenburg, Sweden

446 Mitochondrial DNA Is Associated With Inflammation and Neurocognitive Deficits in HIV Infection
Josué Pérez-Santiago1, Sanjay R. Mehta2, Sara Gianella2, Rachel D. Schrier3, Mariana Cherrier4, Susanna R. Var1, Tyler R. C. Day1, Miguel Ramirez-Gaona2, Davey M. Smith1,3, Scott L. Letendre1,2
1University of California San Diego, La Jolla, CA, United States, 2National Institute for Infectious Disease, Rome, Italy, 3Veterans Administration San Diego Healthcare System, San Diego, CA, United States

447 CNS Outcomes of CART vs. CART plus Maraviroc and Raltegravir Intensification During Acute HIV
Victor Valcour2, Serena Spudich1, Napaporn Sallasita3, Suklaya Lerduum4, James L. K. Fletcher5, Eugene D. M. B. Kroon6, Peeriya Mangyu6, Bonnie Silke7, Jerome Kim7, Jintanat Ananworanich1, on behalf of the SEARCH 010/RV254 Study Group
1Memory and Aging Center, UCSF, San Francisco, CA, United States, 2Neurology, Yale University, New Haven, CT, United States, 3Huntington Medical Research Institutes, Pasadena, CA, United States, 4Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand, 5SEARCH, The Thai Red Cross AIDS Research Center, Bangkok, Thailand, 6U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Springs, MD, United States, 7Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
Session P-G2 Poster Session  
Tuesday March 4, 2014, 2:30 PM–4:00 PM  
Exhibit Hall A  
HAND in Aging Populations

448 The Effects of Age and Study Cohort On Brain Structure Among Men With HIV Disease James T. Becker, Lawrence A. Kingsley, Mikhail Popov, Nisha Shafi, Andrew J. Levine, Eileen M. Martin, Eric N. Miller, Cynthia A. Munro, Andrew Raffin, Ned Sacktor  
Psychiatry, Neurology and Psychology, University of Pittsburgh, Pittsburgh, PA, United States; Infectious Diseases and Microbiology, Epidemiology, University of Pittsburgh, Pittsburgh, PA, United States; Psychiatry, University of Pittsburgh, Pittsburgh, PA, United States; The John Hopkins Bloomberg School of Public Health, Baltimore, MD, United States; Neurology, University of California Los Angeles, Los Angeles, CA, United States; Psychiatry, Rush University School of Medicine, Chicago, IL, United States; Psychiatry, University of California Los Angeles, Los Angeles, CA, United States; Psychiatry, The Johns Hopkins University School of Medicine, Baltimore, MD, United States; Radiology, Northwestern University, Evanston, IL, United States; Neurology, The Johns Hopkins University School of Medicine, Baltimore, MD, United States

449 FMRI Reveals Asymptomatic Deficits Among HIV+ Older Adults On cART When Compared To HIV- Controls Manya Magnus, Rebecca Baraasks, Halli Olsen, Xiong Jiang  
Epidemiology and Biostatistics, George Washington University, Washington, DC, United States; Georgetown University, Washington, DC, United States

450 Longitudinal Progression of Cortical Atrophy in HIV-Patients On Stable Treatment Michael R. Nowak, Bradford Navia, Jaroslav Harezk, Constantin Yannoutsos, Charles Guttmann, Elyse Singer, Thomas Campbell, Eric Daar, Giovanni Schifitto, David Tate  
Department of Computer Science and Engineering, Texas A&M University, College Station, TX, United States; UTsuFs University Medical School, Boston, MA, United States; Indiana University School of Medicine, Indianapolis, IN, United States; Brigham and Women's Hospital, Boston, MA, United States; University of California Los Angeles, Los Angeles, CA, United States; University of Colorado Denver, CO, United States; University of Rochester Medical Center, Rochester, NY, United States; HUF for the Advancement of Military Medicine, San Antonio, TX, United States

451 FMRI Evidence for HIV-Induced Acceleration of Aging in Middle-Aged Women Xiong Jiang, Chenglong Liu, Matthew Lelctair, Cuivel Wang, Xiaohan Xu, Pilar Hamilton, Lakshmi Goparaju, Mary Young  
Neuroscience, Georgetown University Medical Center, Washington, DC, United States; Georgetown University School of Medicine, Washington, DC, United States

452 Factors Related To Brain Atrophy in a Cohort of HIV Infected Patients: ANRS CO3 Aquitaine Cohort Carole Dufouil, Laura Richert, Rodolphe Thibault, Mathias Bruyant, Frederic Dauchy, Michele Allard, Didier Neau, Francois Dabis, Fabrice Bonnet, Genevieve Chene  
HIV and associated disease team, INSERM Centre 897, Bordeaux, France; Services de Maladies Infectieuses et Tropicales, Bordeaux Hospital, Bordeaux, France; Bordeaux Hospital, Bordeaux, France

Infectious Diseases, Sahlgrenska Academy, Gothenburg, Sweden; Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden; Neurology, University of California San Francisco, San Francisco, CA, United States; Mathematical Sciences, Chalmers University of Technology, Gothenburg, Sweden; Infectious Diseases, San Raffaele Hospital, Milan, Italy

Session P-G3 Poster Session  
Wednesday March 5, 2014, 2:30 PM–4:00 PM  
Exhibit Hall A  
Neuropathogenesis

454 Efavirenz Produces a Differential Bioenergetic Response in Neurons and Gial Cells Haryes A. Funes, Nadezda Apostolova, Fernando Alegre, Miriam Polo, Ana Blas-Garcia, Juan V. Esplugues  
Departamento de Farmacologia, Facultad de Medicina, Universitat de Valenica, Valencia, Spain; University Hospital Dr. Peset, Valencia, Spain; University Hospital Dr. Peset, Valencia, Spain

455 Corneal Sensory Nerve FiberLoss in SIV-Infected Macaques: Tracking HIV PNS Damage Jamie Dorsey, Lisa Mangus, Jonathan Oakley, Joseph Mankowski  
Molecular and Comparative Pathobiology, Johns Hopkins University, Baltimore, MD, United States; Voxeleron, Pleasanton, CA, United States; Neurology, Johns Hopkins University, Baltimore, MD, United States

456 HIV-Tat Protein in Inflammatory Infiltrates of CNS-IRIS and in CSF of Patients On ART Gloria von Geldern, Cory P. Johnson, Richa Tyagi, Ned Sacktor, Justin C. McArthur, Scott Letendre, Avindra Nath  
NINDS, NIH, Bethesda, MD, United States; Dept. of Neurology, Johns Hopkins University, Baltimore, MD, United States; Dept. of Neurology, Johns Hopkins University, Baltimore, MD, United States; Dept. of Neurology, University of California, San Diego, San Diego, CA, United States

457 Central Nervous System Demyelination in Pediatric SIV Infection Herman Kamboj, Kimberly Curtis, Heather Caryl, Hayford Agyemang, Koen Van Rompay, Kristina Abel, Mark Burke  
Physiology & Biophysics, Howard University, Washington, DC, United States; University of California Davis, Davis, CA, United States; University of North Carolina at Chapel Hill, Chapel Hill, NC, United States

Genomic Medicine, Cleveland Clinic Foundation/Lerner Research Institute, Cleveland, OH, United States; Neurosurgery, Penn State Milton S. Hershey Medical Center, Hershey, PA, United States; Psychology, University of Wisconsin, Madison, WI, United States; Pathology, University of Texas Medical Branch, Galveston, TX, United States

Pharmacology and Expt. Neuroscience, University of Nebraska Medical Center, Omaha, NE, United States; Radiology, University of Nebraska Medical Center, Omaha, NE, United States; University of Rochester Medical Center, NY, NY, United States

462 SIV Dynamics in the CD8-Depleted vs Non-CD8-Depleted Rhesus Macaque Model for NeuroAIDS Susanna L. Lammers, David J. Nolan, Brittany D. Rife, Gary B. Fogel, Tricia Burdo, Kenneth C. Williams, Marco Salemi  
Virology and Immunology, and Laboratory Medicine, University of Florida, Gainesville, FL, United States; University of Florida, Gainesville, FL, United States; Natural Selection, San Diego, CA, United States; Boston College, Boston, MA, United States
463 Vascular Endothelium and Neurological Performance Among People Living With HIV: A Longitudinal Study

Seymour Urdal1,2, Kevin Robertson1,2, Fang-yong Li1, Felicia C. Chow3, Julia Peterson4, Elaine M. Nitta4, Richard W. Price1, Pricila Y. Hsue1, Serena Spudich1

1Yale University, New Haven, CT, United States; 2University of North Carolina, Chapel Hill, NC, United States; 3University of California, San Francisco, San Francisco, CA, United States

Session P-G4 Poster Session

Wednesday March 5, 2014, 2:30 PM–4:00 PM Exhibit Hall A

466 Host Genetics in HAND

464 Heme Oxygenase-1 Polymorphism and Protein Deficiency Associated With Neurological Disease in HIV

Alexander J. Gill1, Suren S. Ambegaokar1, Colleen E. Kovacs1, Stephanie A. Cross2, Benjamin B. Gelman3, Dennis L. Kolson1

1Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States; 2Department of Pathology, University of Texas Medical Branch, Galveston, TX, United States

Session P-G5 Poster Session

Wednesday March 5, 2014, 2:30 PM–4:00 PM Exhibit Hall A

465 Mitochondrial DNA Haplogroups and Neurocognitive Impairment in the CHARTER Cohort

Todd Hulgan1, David Samuels2, William Bush3, Ronald Ellis4, Scott L. Letendre2, Peter Straub2, Deborah Murdock2, Donald Franklin2, Igor Grant1, Asha Kallianpur5

1Department of Biostatistics, Indiana University, Indianapolis, IN, United States; 2Foundation/Lerner Research Institute, Cleveland, OH, United States; 3Department of Neurology, University of Texas Medical Branch, Galveston, TX, United States

467 MBL2 Promoter Polymorphism rs7096206 Predicts Brain Metabolite Anomalies in HIV-Infected Adults

Kumud K. Singh1, Qianqian Deng1, Christine Fennema-Notestine2, Florin Vaida1, Ronald J. Ellis3, Scott L. Letendre2, Donald Franklin2, Debraale Rosario1, Robert K. Heaton2, Igor Grant1, and CHARитет Group

University of California San Diego, La Jolla, CA, United States

Session P-G6 Poster Session

Wednesday March 5, 2014, 2:30 PM–4:00 PM Exhibit Hall A

468 Pathogenesis of JC Virus Reactivation During Nalizumab Treatment

Spyridon Chalkias1, Xin Kang2, Marion Bort3, Philip Kinker4, Jacob Sloan4, Maria Houtchen3, Guy Buckle1, Carolina Ionteti1, Igor Korahni1

1Harvard Medical School, Center for Vaccine Research, Boston, MA, United States; 2Department of Neurology, BidMC, Boston, MA, United States; 3Department of Neurology, BWH, Boston, MA, United States; 4Department of Neurology, UMass, Worcester, MA, United States

469 Impaired T. pallidum OspC Antibody Function in HIV-Infected Patients With Neurosyphilis

Christina Marra, Lauren Tantalo, Sharon Sahl, Emily Ho, Shelia Dunaway, Trudy Jones, Sheila Lukhart

University of Washington, Seattle, WA, United States

470 CD4-Independent Infection in the CNS of R5 SHIV+ Macaques Is Associated With Severe Neuropathology

Ana Rachel Leda1,2, Ke Zhuang1, Lily Tsai1, Agegeneh Gettie2, Heather Knight4, Carole Harbison2, Susan Westmoreland2, Cecilia Cheng-Mayer1

1Aaron Diamond AIDS Research Center, New York, NY, United States; 2Federal University of Sao Paulo, Sao Paulo, Brazil; New England Primate Research Center, Southborough, MA, United States

471 HIV-Associated Neurocognitive Disorder Is Associated With HIV-1 Dual Infection

Gabriel A. Wagner1,1, Antoine Chailli2, Donald R. Franklin2, Gemma Caballero3, Sergio L. Kossakovsky Pond1, Robert K. Heaton3, Douglas D. Richman3,1, Davey M. Smith3,1, CHARитет Group

1Infectious Diseases, University of California San Diego, La Jolla, CA, United States; 2University of California San Diego, La Jolla, CA, United States; 3Veterans Affairs San Diego Healthcare System, San Diego, CA, United States

472 Single Genome Analysis Reveals Genetic Characteristics of Neuroadaptation Across HIV-1 Envelope

Teresa H. Evering, Leslie St. Bernard, Charles Farmer, Markus Markowitz

The Aaron Diamond AIDS Research Center, New York, NY, United States

Session P-G7 Poster Session

Thursday March 6, 2014, 2:30 PM–4:00 PM Exhibit Hall A

473 HIV-1 Replication in Central Nervous System Increases Over Time On Protease Inhibitor Only Therapy

Christoph Stephan1, Maximilian Donath1, Timo Wolf2, Annette Haber1, Markus Bickel1, Siri Göpel1, Pavel Khaykin1, Annemarie Berger1, Dimitria Bon1, Reinhard Brodt1

1Infectious Diseases, Goethe-University Hospital, Frankfurt, Germany; 2Medical Virology Institute, Goethe-University Hospital, Frankfurt, Germany; 3Biomathematics, Goethe-University Hospital, Frankfurt, Germany


Tanja Su1, Judith Schouten2,3, Gert J. Geurtsen1, Ferdinand W. Wit1,2, Ireen G. Stolte2, Peter Portegies3,4, Matthias W. A. Caan1, Peter Reiss4,4, Charles B. Majoe1, Ben A. Schmand1

1Radboud University Medical Center, Nijmegen, Netherlands; 2Psychiatry, Radboud University Medical Center, Amsterdam, Netherlands; 3Amsterdam Institute for Global Health and Development, Amsterdam, Netherlands; 4Internal Medicine, Academic Medical Center, Amsterdam, Netherlands; 5GGD Amsterdam, Amsterdam, Netherlands; 6Neurology, Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands; 7Psychology, University of Amsterdam, Amsterdam, Netherlands

475 Improvement of Depression and Anxiety After Discontinuation of Long-Term Efavirenz Treatment

Khusto M. Mthotho1, Arnt Schelleken2, Reinout van Crevel3, Karin Grintjes-Huisman1, Monique Keuter4, Peter Koopmans5, Andre van der Ven1

1Internal Medicine and Nijmegen Institute for Infection, Inflammation and Immunity, Radboud University Medical Center, Nijmegen, Netherlands; 2Psychiatry, Radboud University Medical Center, Nijmegen, Netherlands

476 New Advanced EEG Technique To Monitor Early Brain Damage in Naïve HIV and Its Recovery During ART

Massimo Andreoni1, Claudio Babiloni2,3, Paolo Maria Rossini1, Paolo Onorati1,2, Stefano Ferrucci1, Francesco Di Campli1, Antonio Aceti8, Elisabetta Teti1, Alfredo Pennica1
HIV-Replication Control Rates Needed To Prevent Neurocognitive Performance (NP) Decline
Ignacio Pérez-Valero, Robert Heaton, Donald Franklin, Scott Letendre, Reena Deutsch, Bernard Gelman, David Simpson, Ann Collier, Igor Grant, and the CHARTER Group
Hospital Universitario La PAZ, Madrid, Spain; University of California, San Diego, San Diego, CA, United States; University of California, San Diego, San Diego, CA, United States; Hospital Universitario La PAZ, Galveston, TX, United States; Mount Sinai Hospital, New York, NY, United States; University of Washington, Seattle, WA, United States

CSF Biomarker Profile in HIV Patients With and Without CSF Viral Escape
Ignacio Pérez-Valero, Scott Letendre, Robert Heaton, Ronald Ellis, Allen McCutchan, David Simpson, Reena Deutsch, Igor Grant, and the CHARTER Group
Hospital Universitario La PAZ, Madrid, Spain; University of California, San Diego, San Diego, CA, United States; University of California, San Diego, San Diego, CA, United States; Mount Sinai School of Medicine, New York, NY, United States

Accuracy of NEU Screen for Detecting Cognitive Impairment in Virologically Suppressed HIV Patients Jose A. Muñoz-Moreno, Anna Prats, Núria Pérez-Álvarez, Inmaculada Nieto-Verdugo, Carmina R. Fumaz, Maria J. Ferrer, Maite Garoaura, Bonaventura Clotet
Lluita contra la SIDA Foundation - Germans Trias i Pujol University Hospital, Badalona, Barcelona, Catalonia, Spain; Consorci Sanitari - Terrassa Hospital, Terrassa, Barcelona, Catalonia, Spain; Institut per la Recerca de la SIDA IrisCaixa, Badalona, Barcelona, Catalonia, Spain

Determinants of Cognitive Impairment in HIV-Positive Men On cART and Uninfected Controls Judith Schouten, Tanja Sui, Ferdinand W. Wit, Neeltje A. Koolstra, Matthias W. A. Caan, Gert J. Geurtsen, Ben A. Schmandt, Charles B. Majoe, Peter Portegies, Peter Reiss, for the CHARTER group
University of Gothenburg, Gothenburg, Sweden; University of California San Diego, La Jolla, CA, United States; Center for Clinical Research, Copenhagen, Denmark; University of California San Diego, La Jolla, CA, United States; University of California San Diego, La Jolla, CA, United States; University of California San Diego, La Jolla, CA, United States

HIV Reactivation by the Histone Deacetylase Inhibitor Panobinostat: Effects On CNS Thomas A. Rasmussen, Ole S. Søgaard, Holger J. Møller, Thomas A. Rasmussen, Dietmar Fuchs, Igor Grant, J. Allen McCutchan, for the CHARTER Group
Academic Medical Center, Amsterdam, Netherlands; Amsterdam Institute for Global Health and Development, Amsterdam, Netherlands; Radiology, Academic Medical Center, Amsterdam, Netherlands; Internal Medicine, Academic Medical Center, Amsterdam, Netherlands; Experimental Immunology, Academic Medical Center, Amsterdam, Netherlands; Psychology, University of Amsterdam, Amsterdam, Netherlands; Neurology, Ozie Lieve Vrouwe Gasthuis, Amsterdam, Netherlands

University of Gothenburg, Gothenburg, Sweden; University of California San Diego, La Jolla, CA, United States; Innsbruck Medical University, Innsbruck, Austria; Chalmers University of Technology, Gothenburg, Sweden; University of California San Diego, San Diego, CA, United States

Genomic Medicine, Lerner Research Institute, Medicine Institute, Cleveland, OH, United States; Biomedical Informatics, Vanderbilt University School of Medicine, Nashville, TN, United States; Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, United States; Neurology/Pathology, Mount Sinai School of Medicine, New York, NY, United States; Medicine/Allergy and Infectious Diseases, University of Washington, Seattle, WA, United States; Pathology, University of Texas Medical Branch, Galveston, TX, United States; Neurology, Washington University School of Medicine, St Louis, MO, United States; Medicine/Infectious Diseases, University of California San Diego, La Jolla, CA, United States; Psychiatry, University of California San Diego, La Jolla, CA, United States

Abdominal Obesity, Inflammation, Immune Activation and Neurocognitive Impairment Fred R. Sattler, Jiaxue He, Scott Letendre, Carla Wilson, Chelsea Sanders, Robert K. Heaton, Ronald Ellis, Donald Franklin, Igor Grant, J. Allen McCutchan, for the CHARTER Group
University of California-San Diego, La Jolla, CA, United States; Preventive Medicine, University of Southern California, Los Angeles, CA, United States; University of Washington, Seattle, WA, United States; University of Texas Medical Branch, Galveston, TX, United States; Johns Hopkins University, Baltimore, MD, United States; Mount Sinai School of Medicine, New York, NY, United States

CNS Inflammation, Immune Activation, and HAND Biomarkers
Julia Peterson, Sheila Keating, Dietmar Fuchs, Phillip Norris, Henrik Zetterberg, Barbara Shacklett, Serena Spudich, Magnus Gisslen, Richard W. Price
University of Gothenburg, Gothenburg, Sweden; University of California San Diego, La Jolla, CA, United States; Innsbruck Medical University, Innsbruck, Austria; Chalmers University of Technology, Gothenburg, Sweden; University of California San Diego, San Diego, CA, United States

Neurology, University of California San Diego, San Diego, CA, United States; Blood Systems Research Institute, San Francisco, CA, United States; Center for Chemistry and Biomedicine, Innsbruck Medical University, Innsbruck, Austria; Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden; University of California Davis, Davis, CA, United States; Neurology, Yale University, New Haven, CT, United States

486L Neuroinflammation in Asymptomatic HIV-Infected Subjects On Effective cART Jaime H. Vera, Qi Guo, Ilan Rabiner, Paul Matthews, Roger Gunn, and Alan Winston
Infectious Diseases, Imperial College London, London, United Kingdom; Institute of Psychiatry, King’s College London, London, United Kingdom; Imamova Centre for Imaging Sciences, London, United Kingdom; Division of Brain Sciences, Imperial College London, London, United Kingdom

487 CSF Biomarkers Correlate With Magnetic Resonance Spectroscopy Metabolites During HIV Disease Albert M. Anderson, Christine Fennema-Notestine, Anya Umlauf, David Clifford, Cristina Marras, Benjamin Gelman, Justin McArthur, Allen McCutchan, Susan Morgello, Scott Letendre, for the CHARTER group
Emory University School of Medicine, Atlanta, GA, United States; University of California—San Diego, San Diego, CA, United States; Washington University at St. Louis, St. Louis, MO, United States; University of Washington, Seattle, WA, United States; University of Texas Medical Branch, Galveston, TX, United States; Johns Hopkins University, Baltimore, MD, United States; Mount Sinai School of Medicine, New York, NY, United States

488 Abdominal Obesity, Inflammation, Immune Activation and Neurocognitive Impairment Fred R. Sattler, Jiaxue He, Scott Letendre, Carla Wilson, Chelsea Sanders, Robert K. Heaton, Ronald Ellis, Donald Franklin, Igor Grant, J. Allen McCutchan, for the CHARTER Group
University of California-San Diego, La Jolla, CA, United States; Preventive Medicine, University of Southern California, Los Angeles, CA, United States; University of Texas Medical Branch, Galveston, TX, United States; Johns Hopkins University, Baltimore, MD, United States; Mount Sinai School of Medicine, New York, NY, United States

Genomic Medicine, Lerner Research Institute, Medicine Institute, Cleveland, OH, United States; Biomedical Informatics, Vanderbilt University School of Medicine, Nashville, TN, United States; Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, United States; Neurology/Pathology, Mount Sinai School of Medicine, New York, NY, United States; Medicine/Allergy and Infectious Diseases, University of Washington, Seattle, WA, United States; Pathology, University of Texas Medical Branch, Galveston, TX, United States; Neurology, Washington University School of Medicine, St Louis, MO, United States; Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, United States; Neurology/Pathology, Mount Sinai School of Medicine, New York, NY, United States; Medicine/Allergy and Infectious Diseases, University of Washington, Seattle, WA, United States; Pathology, University of Texas Medical Branch, Galveston, TX, United States; Neurology, Washington University School of Medicine, St Louis, MO, United States; Medicine/Infectious Diseases, University of California San Diego, La Jolla, CA, United States; Psychiatry, University of California San Diego, La Jolla, CA, United States

University of Gothenburg, Gothenburg, Sweden; University of California San Diego, La Jolla, CA, United States; Innsbruck Medical University, Innsbruck, Austria; Chalmers University of Technology, Gothenburg, Sweden; University of California San Diego, San Diego, CA, United States

Session P-G8 Poster Session
Thursday March 6, 2014, 2:30 PM–4:00 PM Exhibit Hall A
CNS Inflammation, Immune Activation, and HAND Biomarkers

484 Differences Between Cerebrospinal Fluid and Blood Biomarkers of Inflammation in HIV Infection
Julia Peterson, Sheila Keating, Dietmar Fuchs, Phillip Norris, Henrik Zetterberg, Barbara Shacklett, Serena Spudich, Magnus Gisslen, Richard W. Price
University of Gothenburg, Gothenburg, Sweden; University of California San Diego, La Jolla, CA, United States; Innsbruck Medical University, Innsbruck, Austria; Chalmers University of Technology, Gothenburg, Sweden; University of California San Diego, San Diego, CA, United States

Poster Abstracts
program and agenda

poster abstracts

491 CNS Inflammation During Treatment-Induced Viral Suppression
Julia Peterson1, Sheila M. Keating1, Viktor Dahl1, Phillip J. Norris2, Sarah Palmer3;4, Dietmar Fuchs5, Henrik Zetterberg4, Magnus Gisslén1, Richard W. Price1
1Neurology, University of California San Francisco, San Francisco, CA, United States; 2Blood Systems Research Institute, San Francisco, CA, United States; 3Karolinska Institute, Stockholm, Sweden; 4Westmead Millennium Institute for Medical Research and University of Sydney, Westmead NSW, Australia; 5Innsbruck University, Innsbruck, Austria; 6Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden

492 CSF Viremia and Inflammatory Markers in Pts With NCI On TDF/FTC/EFV and After Switch To ABC/3TC/MVC
Juan M. Tiraboschi1, Jose Muñoz-Moreno2, MC Puerto3, Carlos Alonso4, Anna Prats-Paris5, Elena Ferrer6, Nerea Rozas7, Marga Maso-Serra8, Javier Martinez-Pico9, Daniel Podzamczer10
1HIV Unit, Infectious Disease Service, Hospital Universitari de Bellvitge, Barcelona, Spain; 2Fundació Lluita contra laSIDA - Unitat de VH, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain; 3Institut de Recerca de la SIDa IrsaiCaixa, Barcelona, Spain; 4Complex Sanitari Santa Tecla, URV, Tarragona, Spain

Session P-H1 Poster Session
Tuesday March 4, 2014, 2:30 pm–4:00 pm

Exhibit Hall B

Clinical Pharmacology of TB and HCV Coinfection

493 Rifapentine Once-Weekly Dosing Effect On Efavirenz, Emtricitabine and Tenofovir PKs
Christine Farenc1, Severine Doroumain1, Cathy Cantalloube2, Laurent Perrin3, Virginie Esposito4, Isabelle Clerier-Puiseux5, Xavier Boulenc6, Marilyn Maroni7
1Disposition Safety Animal Research, Sanofi, Montpellier, France; 2Clinical Exploratory Pharmacology, Sanofi, Montpellier, France; 3Clinical Exploratory Pharmacology, Sanofi, Paris, France; 4Complex Sanitari Santa Tecla, URV, Tarragona, Spain

494 Relationship Between Efavirenz Trough & CYP2B6 Genotypes With Rifampin-Based TB Therapy in STRIDE
Anne Luetcemeyer1, Susan L. Rosenkranz1, Darlene Lu2, Beatriz Grinstejn1, Jorge Sanchez1, Michael Ssemmanda3, Ian Sanne4, Helen McIlleron5, Diane Havlir6, David Haas7, ACTG A5221 & A5243 Study Group
1HIV/AIDS Division, San Francisco General Hospital, University of California, San Francisco, San Francisco, CA, United States; 2HIV/AIDS Division, Harvard School of Public Health, Boston, MA, United States; 3HIV/AIDS Division, Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, MA, United States; 4HIV/AIDS Division, Center for Biostatistics in AIDS Research, Harvard School of Public Health, Cambridge, MA, United States; 5HIV/AIDS Division, Center for Biostatistics in AIDS Research, Harvard School of Public Health, Cambridge, MA, United States; 6Clinical Pharmacology/Clinical Research, Merck Research Laboratories, Upper Gwynedd, PA, United States; 7Clinical Pharmacology/Clinical Research, Merck Research Laboratories, Rahway, NJ, United States; 8Clinical Drug Metabolism, Merck Research Laboratories, West Point, PA, United States; 9Clinical Pharmacology, Merck Research Laboratories, Upper Gwynedy, PA, United States; 10Clinical Pharmacology/Clinical Research, Merck Research Laboratories, Upper Gwynedy, PA, United States; 11Celerion, Lincoln, NE, United States

495 Concentrations of Nevirapine or Efavirenz On and Off Anti-Tuberculosis Therapy (ANRS12214)
Nilesh Bhatt1, Elisabeth Baudin1, Bindiya Meggi2, Carlota Silva3, Valerie Furián4, Aurelie Barrai-Tran5, Marie Bonnet6, Anne-Marie Taburet7
1Instituto Nacional de Saúde, Ministry of Health, Maputo, Mozambique; 2Clinical Research Department, Epicentre, MSF, Paris, France; 3Clinical Pharmacology, Hospital Bicêtre, Paris-Sud University, Kremlin Bicêtre, France; 4Éa4123, Faculty of Pharmacy, Paris-Sud University, Chatenay Malabry, France

496 Pharmacokinetics of Raltegravir 400 vs 800 mg BID With Intermittent Rifampicin Dosed Thrice Weekly
Helen E. Reynolds1, Deirdre Eggen1, Laura Else1, Mas Chandonés2, Ales Chrdle3, David J. Back4, Saye K. Kho1
1University of Liverpool, Liverpool, United Kingdom; 2Royal Liverpool University Hospital, Liverpool, United Kingdom

497 Pharmacokinetics of Faldaprevir and Antiretrovirals in Patients With HIV/HCV Coinfection
Jürgen R. Rockstroh1, Marc-Antoine Vaillant2, Josep Mallorés3, Massimo Puoti4, Juan Antonio Pineda5, Patrick Ingiliz6, Marina Núñez7, Fenglei Huang8, Richard Vinisko9, Douglas Dieterich10
1Department of Medicine I, University of Bonn, Bonn, Germany; 2Service des Maladies Infectieuses et Tropicales, Hôpital Pitié-Salpêtrière, Paris, France; 3Hospita Clinic-University of Barcelona, Barcelona, Spain; 4Department of Infectious Diseases, AO Ospedale Niguarda Ca’Granda Milan, Milan, Italy; 5Unit of Infectious Diseases and Microbiology, Hospital Universitario de Valme, Seville, Spain; 6Medical Center for Infectious Diseases, Berlin, Germany; 7Wake Forest University Health Sciences, Winston-Salem, NC, United States; 8Boehringer Ingelheim Pharmaceutical, Inc, Ridgefield, CT, United States; 9Mount Sinai Medical Center, New York, NY, United States

498 Pharmacokinetic Interactions Between the HCV NS5A Inhibitor MK-8742 and Efavirenz
Wendy Yeh1, William Marshall2, Eric Margin3, Xiaobi Huang4, Yali Zhu5, Susanne Langley1, Patricia Jumes1, Stephen Youngberg6, Joan Butterton7
1Merck, Sharpe and Dohme, Whitehouse Station, NJ, United States; 2Celerion, Lincoln, NE, United States

499 Effect of Faldaprevir On Atazanavir Pharmacokinetics in Patients With HIV/HCV Coinfection
Mark Nelson1, Keikawus Arastéh2, Mamta K. Jain3, Vicente Soriano4, José Valdez Madruga5, Juvencio Furtado1, Manuel Battegay6, Fenglei Huang7, Montserrat Mariner8, Douglas Dieterich9
1Chelsea and Westminster Hospital, London, United Kingdom; 2EPIMED/Vivantes Auguste-Viktoria-Klinikum, Berlin, Germany; 3UT Southwestern Medical Center, Dallas, TX, United States; 4Hospital Carlos III, Madrid, Spain; 5Centro de Referencia e Treinamento DST/AIDS, Sao Paulo, Brazil; 6Faculdade de Medicina do ABC and Hospital Helipolita, Sao Paulo, Brazil; 7University Hospital Basel, Basel, Switzerland; 8Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT, United States; 9Boehringer Ingelheim España, Barcelona, Spain; 10Mount Sinai Medical Center, New York, NY, United States

500 No Meaningful PK Interaction Between HCV Protease Inhibitor MK-5172 and Tenofovir or Raltegravir
Wendy Y. Yeh1, Iain P. Fraser1, Luzelena Caro2, Jennifer Talaty1, Zifang Guo3, Henry Davis4, Stephen P. Youngberg5, Joan R. Butterton6
1Clinical Pharmacology/Clinical Research, Merck Research Laboratories, Boston, MA, United States; 2Clinical Pharmacology/Clinical Research, Merck Research Laboratories, Rahway, NJ, United States; 3Clinical Drug Metabolism, Merck Research Laboratories, West Point, PA, United States; 4Statistics, Merck Research Laboratories, Upper Gwynedy, PA, United States; 5Clinical Pharmacology/Clinical Research, Merck Research Laboratories, Upper Gwynedy, PA, United States; 6Celerion, Lincoln, NE, United States

501 Effect of Faldaprevir On Raltegravir Pharmacokinetics in Healthy Volunteers
David Joseph1, Peter Rose2, Natalja Strelikova3, Armin Schutz4, Jeanette Garcia1, Mabrouk Elgadi5, Fenglei Huang6
1Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, United States; 2Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany; 3CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany; 4Boehringer Ingelheim (Canada), Ltd, Burlington, ON, Canada

502 No Clinically Relevant Interactions Between Daclatasvir and Cyclosporine or Tacrolimus
Marc Bifano1, Robert Adamiczak2, Carey Hwang3, Hamza Kandoussi4, Alan Marion5, Richard J. Berta6
1Research and Development, Bristol-Myers Squibb, Hopewell, NJ, United States; 2Research and Development, Bristol-Myers Squibb, Lawrenceville, NJ, United States; 3ICON Development Solutions, Omaha, NE, United States
517 Tenofovir Concentrations and Prophylactic Effect in a Macaque Model of Rectal SHIV Transmission
Peter L. Anderson1, David V. Giilden2, Lane R. Bushman1, Jia-Hua Zheng1, L. Anthony Guida1, Waldl Heneine1, J. Gerardo Garcia-Lerma1
1Pharmaceutical Sciences, University of Colorado Denver, Aurora, CO, United States; 2Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States

Session P-H4 Poster Session
Thursday March 6, 2014, 2:30 PM–4:00 PM

New Clinical and Preclinical Formulations

518 Optimisation of Intramuscular Sustained Release Nano-Formulations Using In Silico Modelling
Rajith Kumar Reddy Rajal1, David Back2, Steve Rannard3, Andrew Owen3
1Department of Clinical & Molecular Pharmacology, University of Liverpool, Liverpool, United Kingdom; 2Department of Chemistry, University of Liverpool, Liverpool, United Kingdom

519 Macrophage Targeted Nanomedicines for Mycobacterial Infections
Benson Edaga1, Dongwei Guo2, Pavan Puligujja3, JoEllyn McMillan4, Ximing Liu5, Howard Gandelman6, Prabagaran Narayanasamy7
1University of Nebraska Medical Center, Omaha, NE, United States; 2Pharmaceutical Science, University of Nebraska Medical Center, Omaha, NE, United States

520 Fluorescent Magnetic Nanoparticle as Anti-HIV Drug Carrier for Rodent Brain Targeting
Upal Roy1, Hong Ding1, Sudheesh P. Kanthikeel1, Elena M. Kattanovskaya1, Andrea Raymond1, Karla Munoz-Caamaño1, Madhavan Nadar1
1Immunology, Florida International University, Miami, FL, United States; 2Department of Human and Molecular Genetics, Florida International University, Miami, FL, United States

521LB A Novel Anti-HIV Particle Provides Sustained Plasma and Cell Drug Levels in Lymph Nodes in Primates
Jennifer Freeling1, Josefin Koehn1, Cuiling Shu1, Rodney JY Ho2,3
1Pharmaceutics, University of Washington, Seattle, WA, United States; 2Pharmaceutics, University of Washington, Seattle, WA, United States; 3Clinical Pharmacology, Fred Hutchinson Cancer Research Center, Seattle, WA, United States

522 NanoART Facilitated HIV-1 Clearance by a Mixed- Lineage Kinase 3 Inhibitor
Gang Zhang1, Prasanta K. Dash2, Dongwei Guo1, Jayme L. Wiederin3, Pawan S. Ciborowski2, Val S. Goodfellow3, JoEllyn M. McMillan4, Santhi Gorantla1, Harris A. Gelbard5, Howard E. Gendelman1
1Pharmacology and Experimental Neurosciences, University of Nebraska Medical Center, Omaha, NE, United States; 2MRC Laboratory of Molecular Biology, Cambridge, UK; 3Behavioral and Clinical Neuroscience, University of Colorado School of Medicine, Aurora, CO, United States; 4University of Rochester Medical Center, Rochester, NY, United States

523 A Multiple Dose Study of Raltegravir (RAL) Formulations
Matthew L. Rizk1, Rajesh Krishna2, Valerie Schultz1, Jolanda ten Bruggencate-Broeders1, Patrick Larson2, Larissa Wenning2, Merrck & Co., Inc., West Point, PA, United States

524 In Vivo Effects of Solid Drug Nanoparticle and Conventional Efavirenz On Anxigenesis in Rodents
Paul Curley1, Marco Guardaballe1, Neil Liprot2, Philip Martin3, Tom McDonald4, Marco Siccardi5, Juliet McAdams1, Steve Rannard6, Tim Kirkham7, Andrew Owen1
1Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom; 2Chemistry, University of Liverpool, Liverpool, United Kingdom; 3Institute of Psychology, Health and Society, University of Liverpool, Liverpool, United Kingdom

525 Atazanavir/Cobicistat Fixed-Dose Combination Is Bioequivalent To the Separate Agents
Xiaol Tu1, Heather Senevsky1, Reena Wang1, Palanikumar Ravindran2, Karen Sims1, Xiaohui Xu3, Navin Jarwal4, Richard Bertz1
1Bristol-Myers Squibb, Pennington, NJ, United States; 2Bristol-Myers Squibb, Princeton, NJ, United States

Session P-11 Poster Session
Tuesday March 4, 2014, 2:30 PM–4:00 PM

Preclinical Studies of Novel ART Approaches: Entry

526 Non-Integrating Lentivirus Delivered CCR5-ZFNs Can Inhibit HIV-1 Infection in Humanized Mice
Guohua Yi1, Jang-Gi Choi1, Preeti Bhayr2, Sojan Abraham1, Manjunath Swamy1, Premila Shankar2
Department of Biomedical Sciences, Center of Excellence in Infectious Disease, Texas Tech University Health Sciences Center El Paso, TX, United States

527 Role of Sulfhydryl in Causing Lytic Inactivation of HIV-1 by Env Targeting Peptide Triazole Thiol
Lauren D. Bailey1, Caitlin Duffy1, Huyuqan Li2, Ali Emileh1, Arangassery R. Bastian1, Irwin Challen1
1Biochemistry and Molecular Biology, Drexel University College of Medicine, Philadelphia, PA, United States; 2West Virginia University, Morgantown, WV, United States; 3Dartmouth College, Hanover, NH, United States; 4Biomedical Engineering, Drexel University College of Medicine, Philadelphia, PA, United States

528 eCD4-Ig is a Highly Potent HIV-1 Entry Inhibitor
Matthew Gardner1, Lisa Kattenhorn1, Jessica Chang1, Michael Farzan2
1Department of Infectious Diseases, The Scripps Research Institute, Jupiter, FL, United States; 2Division of Comparative Pathology, Harvard Medical School, Southborough, MA, United States; 3Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA, United States

529 Computational Design of Novel Potent Inhibitors of HIV-1 Entry
Marina Tyuyshina, Simon Cocklin
Biochemistry, Drexel College of Medicine, Philadelphia, PA, United States

530 Cenicriviroc Achieves High CCR5 Receptor Occupancy at Low Nanomolar Concentrations
Emile Jalbert1, Mary Margaret Byron1, Cecilia Shikuma2, Helen Jenkins3, Eric Lefebvre4, Jason D. Barbour5
1University of Hawaii Manoa, Honolulu, HI, United States; 2Tobira Therapeutics, South San Francisco, CA, United States

Session P-12 Poster Session
Tuesday March 4, 2014, 2:30 PM–4:00 PM

Preclinical Studies of Novel ART Approaches: Post-Entry

531 Identification of a Novel HIV-1 Inhibitor Targeting Vif-Dependent Degradation of Human APOBEC3G
Erez Perry1, Andrew Jay Brazier1, Ann Sheehy1, Vikas Misra1, Kottampatty S. Rajendran1, Marie K. Mankowski2, Lynn Rasmussen1, E. Lucile White1, Roger G. Putat1, Dana Gabuzda3
1Cancer Immunology and AIDS, Dana Farber Cancer Institute, Boston, MA, United States; 2Department of Pathology, Harvard Medical School, Boston, MA, United States; 3Department of Biology, College of the Holy Cross, Worcester, MA, United States; 4Department of Infectious Diseases Research, Southern Research Institute, Frederick, MD,
United States; High Throughput Screening Center, Southern Research Institute, Birmingham, AL, United States; Department of Neurology (Microbiology), Harvard Medical School, Boston, MA, United States

532 Drugging HIV Vif as a Rational Approach To Eradication
Harold C. Smith, Ryan P. Bennett
OyaGen, Inc, Rochester, NY, United States

533 A Novel Class of Multimerization Selective Inhibitors of HIV-1 Integrase
Amir Sharma, Alison P. Slaughter, Nivedita Jena, Lei Feng, Jacques J. Kessl, Li Wu, James R. Fuchs, Mamuka Kvaratskhelia
College of Pharmacy, The Ohio State University, Columbus, OH, United States; Center for Retrovirus Research, The Ohio State University, Columbus, OH, United States

534 PF74 Inhibits Multiple HIV Capsid Functions Independent of Host Cyclophilin A and CPSF6
Stephen R. Yant, Luong Tsai, Debji Jin, Rajuta A. Ban, Andrew Mulato, Maggileene Hung, Chien-hung Chou, Randall Halcomb, Tomas Chiarl
Angiogenesis Center, The Ohio State University, Columbus, OH, United States; Biology, Gilead Sciences, Foster City, CA, United States; Medicine, University of Alabama at Birmingham School of Medicine, Birmingham, AL, United States

535 Recent Progress in Developing Potent and Broadly Active HIV-1 Maturation Inhibitors
Emiko Urano, Sherrimy D. Abian, David Martin, Ritu Gaur, Paul W. Keller, Aliassad C. Steven, Theodore Nitz, Carl Wild, Eric O. Freed
HIV Drug Resistance Program, NCI-Frederick, Frederick, MD, United States; DFH Pharma, Inc, Gaithersburg, MD, United States; Center for Retrovirus Research, The Ohio State University, Columbus, OH, United States; South Asian University, New Delhi, India; National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH, Bethesda, MD, United States

Session P-J1 Poster Session
Thursday March 6, 2014, 2:30 PM–4:00 PM

537 Mortality Among HIV+ Participants Randomized To Omit NRTIs vs. Add NRTIs in OPTIONS (ACTG A5241)
Karen Tashima, Laura Smeaton, Karin Klingman, Adriana Andrade, Joseph Eron, Carl Fichtenbaum, Rajesh Gandhi, Victoria Johnson, Richard Hambuch
Medicine, Warren Alpert Medical School of Brown University, Providence, RI, United States; Center for Biostatistics in AIDS Research, Boston, MA, United States; HIV Research Branch, NIAID, NIH, Bethesda, MD, United States; Medicine, Johns Hopkins University, Baltimore, MD, United States; Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States; Medicine, University of Cincinnati, Cincinnati, OH, United States; Medicine, Massachusetts General Hospital and Ragon Institute, Boston, MA, United States; Medicine, Birmingham VA Medical Center and University of Alabama at Birmingham School of Medicine, Birmingham, AL, United States; Medicine, University of California at San Diego, San Diego, CA, United States

538 Partner-Based Intervention for Adherence To Second-Line ART: A Multinational Trial (ACTG A5234)
Robert Gross, Lu Zheng, Alberto La Rosa, Xin Sun, Susan Rosenkranz, Sandra Cardoso-Wagner, Francis Sassi, Robert Camp, Catherine Godfrey, Ann Collier, ACTG Team A5234
Medicine (ID), University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, United States; Biostatistics, Harvard School of Public Health, Boston, MA, United States; IMPACTA, Lima, Peru; FIOCruz, Rio de Janeiro, Brazil; Joint Clinical Research Centre, Kampala, Uganda; Eurodis, Barcelona, Spain; National Institute of Allergy and Infectious Diseases, Bethesda, MD, United States; University of Washington, Seattle, WA, United States

539 Predictors of Late Virological Failure After Initial Successful Suppression On EFV-Based ART
Isaac Singini, Thomas Campbell, Laura Smeaton, Nagalingeswaran Kamarasamy, Karin Klingman, Sineenat Taeranomkul, Timothy Flanigan, Alberto La Rosa, James Hakim, Michael Hughes
for the ACTG A5175/PEARLS Study Team
Johns Hopkins Research Project, Blantyre, Malawi; University of Colorado Denver, Aurora, CO, United States; Harvard School of Public Health, Boston, MA, United States; VIRGARE Medical Centre, Chennai, India; NIH, NIAID, DAIDS, Bethesda, MD, United States; Chiang Mai University, Chiang Mai, Thailand; Miriam Hospital, Brown University, Providence, RI, United States; Associação Civil Impacta Saúde e Educação, Lima, Peru; University of Zimbabwe College of Health Sciences, Harare, Zimbabwe

540Raltegravir Non-Inferior To Standard of Care in SECOND-LINE Therapy Over 96 Weeks
Janaki Amin, on behalf of the SECOND-LINE study team
The Kirby Institute, University of New South Wales, Sydney, Australia

541B Randomized Comparison of Three Second Line ART Regimens in Africa: The 2 Lady/ANRS/EDCTP Study
Sinatou Koutla-Shiro, Laura Caffi, Vincent Le Moing, Cheikh Tidiane Nдуndur, Adrien Sawadogo, Sabrina Eymard-Duvermay, Avelin Aho-Rantakangas, Jacques Reyne, Alexandra Calmy, Eric Delaporte, on behalf of the SLADY study group
Service Maladies Infectieuses, Central Hospital Yaounde, FMSB/UY, Yaounde, Cameroon; Site ANRS Cameroon, Yaounde, Cameroon; UM233, IRD, Montpellier, France; Service Maladies Infectieuses, Hospital de Fann, CRCF, Dakar, Senegal; CHU Sanou Souro, HDJ, Bobo Dioulasso, Burkina Faso; UM233/IRD, IMPP, CREMER, Yaounde, Cameroon; Infectious Diseases, University Hospital Geneva, Geneva, Switzerland

Session P-J2 Poster Session
Thursday March 6, 2014, 2:30 PM–4:00 PM

542 First-Line Therapy With LPV/r vs NVP and 2 NRTIs in a Developing Country: W144 of a Randomized Trial
Nathan Cumeck, Claire Mwambwa, Kabamba Kabeya, Serge Matanda, Doreline Vaira, Eric Kasamba, Coca Ncozi, David Kadetwe, Chantal Milolo, Jo Ilunga, Lévin Kapendi
Infectious diseases, CHU Saint-Pierre, Brussels, Belgium; Lubumbashi Network & PNMLs, Lubumbashi, Congo, Democratic Republic of the; CHU Liège, Liège, Belgium

543 Dolutegravir Regimen Statistically Superior To Tenofovir/Emtricitabine/Efavirenz: 96-Wk Data
Sharon Walmsey, Juan Berenguera, Marie-Aude Khoung-Josses, Michael Kilby, Thomas Lutz, Daniel Potzmaczer, Norman Roth, Catherine Graenier, Brian Wynne, Keith Pappa
University Health Network, Toronto, ON, Canada; Hospital General Universitario Gregorio Marañón, Madrid, Spain; CHG – Hôpital Delafontaine, Paris, France; Medical University of South Carolina, Charleston, SC, United States; Infektiologium, Frankfurt, Germany; Bellville University Hospital, Barcelona, Spain; Prahan Market Clinic, Melbourne, Australia; GSK, London, United Kingdom; GSK, Philadelphia, PA, United States; GSK, Research Triangle Park, NC, United States

544B A Randomized, Placebo-Controlled, Double-Blind Study of VM-1500 in HIV-NAïve Patients
Winai Ratasanuwat, Peerawong Weraarak, Robert L. Murphy, Vadim Bicko
Preventive and Social Medicine, Faculty of Medicine Siriraj Hospital, Bangkok, Thailand; Northwestern University, Chicago, IL, United States; ChemDiv, Inc, San Diego, CA, United States

545 The Oral Exam: A Simple Tool To Identify HIV-Infected Patients in Need of Antiretroviral Therapy
Ashta S. Batavia, Rode Secours, Patrice Espinosa, Marc A. Jean-Jeste, Patrice Severé, Jean W. Pape, Daniel W. Fitzgerald
Department of Medicine, New York Presbyterian Hospital, New York, NY, United States; The GHEKSIO Center, Port-au-Prince, Haiti; University of California San Francisco Medical Center, San Francisco, CA, United States

546 Efficacy of First-Line ARV Regimens: An Exploratory “Target Not Detected” Analysis
Kirsten L. White, Xuelian Wei, Lihe Zhong, Martin S. Rhee, Marshall W. Fordye, Javier Swartzberg, John Mellors, Michael D. Miller
Clinical Virology, Gilead Sciences, Inc, Foster City, CA, United States; University of Pittsburgh, Pittsburgh, PA, United States
554 Blunted Response To cART in Elite Controllers
Fadrotte Boufassa1, Jerome La Chenadec2, Laurence Meyer3,
Dominique Costagliola4, Peter W. Hunt5, Florecia Pereyra6, Steve
Deeks7, Gianfranco Pannico8, Olivier Tauerna9, Mathias Lichtfeldera,
Martin Markowitz2, Anthony Mills3, Hans-Juergen Anton Pozniak7,8,
Julian H. McArthur3,4, Bill Guyer9, Julie E. Myers1,2, Qiang Xia1,
Lucia V. Torian1, Mary K. Irvine1, Blayne Singini7, Javier R. Lama8,
Rosie Mngqibisa9, Rosie Ngumbi10, Samira Zaid11.

555 HIV Elite Controllers Are Hospitalized More Often Than
Persons With Medically Controlled HIV
Trevor A. Crowell1, Kelly A. Gebo1, Joel N. Blankson1, Baligh R.
McCready5, Don Warren6, Edward Mills8,9.

551LB Randomised Controlled Trial of a PI Monotherapy
Switch Strategy for Long-Term HIV Management
Nicholas Paton1,2, Wolfgang Stohr1, Alejandro Arenas-Pintor, David
Dunne1, the PIVOT Trial Group
1National University of Singapore, Singapore, Singapore, Singapore;
2MRC Clinical Trials Unit at UCL, London, United Kingdom

552LB Effect of Selenium Supplementation On CD4 depletion in
Rwandan HIV Patients: A Randomized Trial
Julius Kamwesiga1, Vincent Mubtabarker, Jean-Claude Tayari2,
Heather Fay3, Dugald Seely3, Cara Silva4, Steve Kantere5, Douglas J.
McCready6, Don Warren1, Edward Mills8,9.

553LB Switch From NNRTI plus FTC/TDF To E/C/F/TDF
Maintains HIV Suppression and Is Well Tolerated
Anton Pozniak1, Martin Markowitz2, Anthony Mills3, Hans-Juergen
Stellbrinck4, Antonio Antela5, Pere Domingo6, Pierre-Marie Girard7,
Keith Henry3, Will Garner3, Bill Guyer9, Chelsea and Westminster NHS Foundation Trust Hospital, London, United
Kingdom; 1Aaron Diamond AIDS Research Center, New York, NY, United States; 2Anthony Mills MD Inc., Los Angeles, CA, United States;
3ICH Study Center, Hamburg, Germany; 4Hospital Clinico Universitario, Santiago de Compostela, Spain; 5Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 6Hospital Saint-Antoine, Paris, France; 7HIV Program Hennepin County Medical Center, Minneapolis, MN, United States; 8Gilead Sciences, Inc., Foster City, CA, United States

Session P-J3 Poster Session
Thursday March 6, 2014, 2:30 PM–4:00 PM Exhibit Hall B
ART Simplification, Intensification, and Switch Studies

549LB Paradoxical Impact of Maraviroc/Raltegravir Added To
HAART in Acute HIV Infection: ANRS 147 Trial
Antoine Cheret1,2, Georges Nembot1, Adeline Milord1, Camille
Leclercoux1, Caroline Lascoux1, Isabelle Ravaux1, Jacques Reynes1,
Patrick Mailhe1,2, Laurent Meyer1, Christine Rouzioux1
1EA 3620 Virology Laboratory, Université Paris-Descartes Sorbonne
Paris Cité, Paris, France; 2Department of Infectious Diseases, DRON
Hospital, Tourocoing, France; 3INSERM U1018, APHP Bicêtre Hospital,
Faculty of Medicine Univ Paris-Sud, Le Kremlin-Bicêtre, Paris, France;
4INSERM U1012, Univ Paris-Sud, Paris, France; 5Department of Infectious Diseases, AP-HP, Saint-Louis Hospital, Paris, France;
6Department of Infectious Diseases, La Timone Hospital, Marseille, France; 7Department of Infectious Diseases, Guy de Chauliac Hospital, Montpellier, France; 8Department of Infectious Diseases, Croix Rouge Hospital, Lyon, France; 9INSERM U1018, Univ Paris-Sud, Paris, France

550LB Randomised Controlled Trial of a PI Monotherapy
Switch Strategy for Long-Term HIV Management
Nicholas Paton1,2, Wolfgang Stohr1, Alejandro Arenas-Pintor, David
Dunne1, the PIVOT Trial Group
1National University of Singapore, Singapore, Singapore, Singapore;
2MRC Clinical Trials Unit at UCL, London, United Kingdom

551LB Simplification of PI+RTV+FTC/TDF To E/C/F/TDF
Maintains HIV Suppression and Is Well Tolerated
Jose Arribas1, Gilles Pialoux2, Joseph Gatine3, Giovanni Di Perri4,
Jacques Reynes1, Pablo Tebas1, Thai Nguyen5, Eram Bramhiri6,
Kirsten White7, David Priolkowski8
1Hospital La Paz, Madrid, Spain; 2UPMC, Hôpital Tenon APHP,
Paris, France; 3Baylor College of Medicine, Houston, TX, United States;
4University of Turin, School of Medicine, Turin, Italy; 5Royal de Chauliac University Hospital, Montpellier, France; 6University of Pennsylvania, Philadelphia, PA, United States; 7Gilead Sciences, Inc., Foster City, CA, United States

552LB Effect of Selenium Supplementation On CD4 depletion in
Rwandan HIV Patients: A Randomized Trial
Julius Kamwesiga1, Vincent Mubtabarker, Jean-Claude Tayari2,
Heather Fay3, Dugald Seely3, Cara Silva4, Steve Kantere5, Douglas J.
McCready6, Don Warren1, Edward Mills8,9.
1Stanford Prevention Research Center, Rwanda Biomedical Centre,
Kigali, Rwanda; 2Rwanda Biomedical Center, Kigali, Rwanda; 3Rwanda Supplementation Study Team, Kigali, Rwanda; 4University of British Columbia, Vancouver, BC, Canada; 5Wilfrid Laurier University, Windsor, ON, Canada; 6Stanford Prevention Research Center, Stanford University, Stanford, CA, United States

553LB Switch From NNRTI plus FTC/TDF To E/C/F/TDF
Maintains HIV Suppression and Is Well Tolerated
Anton Pozniak1, Martin Markowitz2, Anthony Mills3, Hans-Juergen
Stellbrinck4, Antonio Antela5, Pere Domingo6, Pierre-Marie Girard7,
Keith Henry3, Will Garner3, Bill Guyer9, Chelsea and Westminster NHS Foundation Trust Hospital, London, United
Kingdom; 1Aaron Diamond AIDS Research Center, New York, NY, United States; 2Anthony Mills MD Inc., Los Angeles, CA, United States;
3ICH Study Center, Hamburg, Germany; 4Hospital Clinico Universitario, Santiago de Compostela, Spain; 5Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 6Hospital Saint-Antoine, Paris, France; 7HIV Program Hennepin County Medical Center, Minneapolis, MN, United States; 8Gilead Sciences, Inc., Foster City, CA, United States

Session P-K1 Poster Session
Tuesday March 4, 2014, 2:30 pm–4:00 pm Exhibit Hall B
Viral Set Point and Elite Controllers

554 Blunted Response To cART in Elite Controllers
Fadrotte Boufassa1, Jerome La Chenadec2, Laurence Meyer3,
Dominique Costagliola4, Peter W. Hunt5, Florecia Pereyra6, Steve
Deeks7, Gianfranco Pannico8, Olivier Tauerna9, Mathias Lichtfeldera,
Martin Markowitz2, Anthony Mills3, Hans-Juergen Anton Pozniak7,8,
Julian H. McArthur3,4, Bill Guyer9, Julie E. Myers1,2, Qiang Xia1,
Lucia V. Torian1, Mary K. Irvine1, Blayne Singini7, Javier R. Lama8,
Rosie Mngqibisa9, Rosie Ngumbi10, Samira Zaid11.

555 HIV Viral Set Point After Cessation of Anti retroviral Therapy
Initiated in Acute Primary HIV Infection
Christine Durier1, Cécile Goujard2,3, Caroline Roussillion4, Isabelle
Fournier5, Catherine Fagard6, Isabelle Charrreau7, Gilles Pialoux8,9,
Bruno Hoen10, Christine Rouzioux11,2, Jean-Pierre Aboulker11, ANRS
100 PRIMOST & 112 INTERPRIM study group
1INSERM SC10-US019, Villejuif, France; 2Hôpital Bicêtre, Kremlin-Bicêtre, Paris, France; 3INSERM CESP U1018, Univ Paris Sud, Le Kremlin-
Bicêtre, France; 4Epidemiology, INSERM CESP U1018, Le Kremlin-
Bicêtre, France; 5Epidemiology, INSERM CESP U1018, AP-HP, Univ Paris Sud, Le Kremlin-Bicêtre, France; 6UPMC Univ U06, INSERM
UMR 943, Paris 75013, France; 7Department of Medicine, University of California San Francisco, San Francisco, CA, United States;
8The Ragon Institute, Cambridge, MA, United States; 9Institut Pasteur, Paris 75015, France; 10Hospital Saint Louis, Paris 75010, France;
11Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, United States; 12Service des Maladies Infectieuses et Tropicales, INSERM UMR1043, Toulouse, France;
13Service de Medecine Interne, AP-HP, Le Kremlin-Bicêtre, France

556 HIV Elite Controllers Are Hospitalized More Often Than
Persons With Medically Controlled HIV
Trevor A. Crowell1, Kelly A. Gebo1, Joel N. Blankson1, Baligh R.
McCready5, Don Warren6, Edward Mills8,9.
1Division of Infectious Diseases & HIV Medicine, Johns Hopkins
University School of Medicine, Baltimore, MD, United States; 2Division
of Infectious Diseases, University of Pennsylvania Perelman School
of Medicine, Philadelphia, PA, United States; 3Division of General
Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, United States

Session P-K2 Poster Session
Wednesday March 5, 2014, 2:30 pm–4:00 pm Exhibit Hall B
ART Initiation, Monitoring, and Outcomes

557 CD4 Cell Count Monitoring Frequency Among HIV+
Persons in New York City (NYC), 2007-2011
Julie E. Myers1,2, Qiang Xia1, Lucia V. Torian1, Mary K. Irvine1, Blayne
H. Cutler1, Graham Harriman1, Kent A. Sepkowitz2, Colin W. Shepard1
Session P-K4 Poster Session
Thursday March 6, 2014, 2:30 PM–4:00 PM Exhibit Hall B
Second-Line ART

569 Virologic Suppression With Second-Line Therapy: Does the Initial Regimen Matter?
Kevin L. Aria1, Le Huu2, Camlin Tierney2, Eric S. Daar1, Paul E. Sax1
1Brigham and Women’s Hospital, Boston, MA, United States; 2Harvard School of Public Health, Boston, MA, United States

570 Favorable Long-Term Outcomes of 2nd-Line ART Despite Drug-Resistant HIV-1 in Sub-Saharan Africa
Tamara S. Boender1, Kim C. E. Sigaloff1, Raph L. Hamers2, Cissy Kityo3, Margaret Siwalie4, Mariette E. Botes5, Kishor Mandalya5, Maureen Wellington4, Suleiman Akanmu6, Tobias F. Rinke de Wit7
1Department of Global Health, Amsterdam Institute for Global Health and Development, Amsterdam, Netherlands; 2Department of Global Health, Department of Internal Medicine, Amsteram Institute for Global Health and Development, Amsterdam, Netherlands; 3Joint Clinical Research Centre, Kampala, Uganda; 4Lusaka Trust Hospital, Lusaka, Zambia; 5Muelned Hospital, Pretoria, South Africa; 6Coast Province General Hospital, Mombasa, Kenya; 7Newlands Clinic, Harare, Zimbabwe; 8Lagos University Teaching Hospital, Lagos, Nigeria

Session P-K5 Poster Session
Thursday March 6, 2014, 2:30 PM–4:00 PM Exhibit Hall B
HIV-2

572 Dolutegravir in the French Early Access Program in Integrase HIV-2-Resistant Infected Patients
Diane Descamps1, Gilles Peytavin1,2, Florence Damond1,2, Roland Tubiana3, Pauline Campa6, Marie-Aude Khboui7, Claudine Duviuier8, Marina Karmochkine9, Tuna Lukianua10, Sophie Matheron10,11
1Virology, APHP-Hôpital Bichat-Claude Bernard, Paris, France; 2IAME UMR 1137 INSERM and Paris Diderot University, Paris, France; 3Pharmacology, APHP-Hôpital Bichat-Claude Bernard, Paris, France; 4Service des Maladies Infectieuses et Tropicales, APHP-Hôpital Pitié-Salpêtrière, Paris, France; 5Service des Maladies Infectieuses et Tropicales, APHP-Groupe Hôpitalier Pitié-Salpêtrière, Paris, France; 6Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, Clinical HIV Research Unit, Johannesburg, South Africa; 7Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, Clinical HIV Research Unit, Johannesburg, South Africa; 8Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, Clinical HIV Research Unit, Johannesburg, South Africa; 9Infectious Diseases Center, Pasteur Institut, Medical Care Center, Necker-Pasteur Infectious Diseases Center, APHP-Necker Hospital, Paris, France; 10Medical Care Center, Necker-Pasteur Infectious Diseases Center, Pasteur Institut, Medical Care Center, Necker-Pasteur Infectious Diseases Center, Paris, France; 11Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, Clinical HIV Research Unit, Johannesburg, South Africa

Session P-L1 Poster Session
Tuesday March 4, 2014, 2:30 PM–4:00 PM Exhibit Hall B
Primary HIV Drug Resistance

577 Current First-Line Regimens Are Effective in Patients With Single Transmitted TAM
Claire M. F. Van Nispen tot Panneker1, Abdelilah El Barzouhi2, Ard I. van Sighem3, Jan M. Prins4, Suzanne Jerriau5, Nicole K. Back2,3, Kees Brinkman1, Charles A. Boucher1, Marchina E. Van der Ende1, Martin Schutten1
1Medical Microbiology and Infectious Diseases, Erasmus Medical Center, Rotterdam, Netherlands; 2Erasmus Medical Center, Rotterdam, Netherlands; 3Stichting HIV Monitoring, Amsterdam, Netherlands; 4Department of Internal Medicine, Division of Infectious Diseases, Amsterdam Medical Center, Amsterdam, Netherlands; 5Department of Virology, Academic Medical Center, Amsterdam, Netherlands; 6Department of Internal Medicine, Erasmus Medical Center, Rotterdam, Netherlands; 7Department of Internal Medicine, Erasmus Medical Center, Rotterdam, Netherlands

578 Drug Resistance Mutations in Treatment-Naïve HIV-Infected Patients 2000-2013
Nicolas A. Margot1, Ross Martin2, Michael D. Miller3, Christian Cellebaert1
1Clinical Virology, Gilead Sciences Inc., Foster City, CA, United States; 2Harvard School of Public Health, Boston, MA, United States; 3AIDS Prevention Initiative in Nigeria, Ltd. /Gtie, Abuja, Nigeria
583 Persistance of Transmitted HIV-1 Drug Resistance Mutations Associated With Fitness Costs

Wan-Lin Y. Yang, Roger Koury, Jürg Böni, Sabine Yerly, Thomas Klimkait, Vincent Aubert, Christos Petropoulos, Mogan Haddad, Sebastian Bonhoeffer, Huldrych F. Günthard, Swiss HIV Cohort Study (SHCS)
1University Hospital of Zurich, Zurich, Switzerland; 2University of Zurich, Zurich, Switzerland; 3University of Geneva, Geneva, Switzerland; 4University of Basel, Basel, Switzerland; 5Lausanne University Hospital, Lausanne, Switzerland; 6Monogram Biosciences, San Francisco, CA, United States; ETH, Zurich, Switzerland

Session P-L2 Poster Session
Tuesday March 4, 2014, 2:30 pm–4:00 pm Exhibit Hall B
Acquired HIV Drug Resistance

584 High HIV Resistance and Mutation Accumulation at Low Viral Loads Upon 2nd-Line Failure in Western Kenya

Lameck Diero, Allison DeLong, Leann Schreier, Emmanuel Kemboi, Millicent Oriko, Mary Rono, Marissa Reitman, Wilfred Emmony, Nathan Buciba, Joseph Hogan, Rami Kantor
1Medicine, Moi University, College of Health Sciences, School of Medicine, Eldoret, Kenya; 2Academic Model Providing Access to Healthcare, Eldoret, Kenya; 3Center for Statistical Sciences, Brown University, Providence, RI, United States; 4Medicine, Brown University, Providence, RI, United States

585 Drug Resistance After 2nd-Line Failure Can Be Managed Using WHO–Recommended Regimens in Nigeria

Nicaise Ndembali, Rawlings W. Daturi, Danjuma Sada, David A. M. van de Vijver, Christopher Akolo, Alash'le G. Abimikini, William A. Blattner, Obina Ogbanufe, Okyei C. Nwanyanwu, Patrick Dakum
1Institute of Virology Nigeria, Abuja, Nigeria; 2Virology, Erasmus Medical Center, Erasmus University, Rotterdam, Netherlands; 3Epidemiology and Prevention, Institute of Human Virology, Baltimore, MD, United States; 4US Centers for Disease Control and Prevention, Abuja, Nigeria

586 Sociodemographic Determinants of HIV Drug Resistance in British Columbia, Canada

1BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada; 2Vancouver Island Health Authority, Victoria, BC, Canada; 3School of Public Health and Social Policy, University of Victoria, Victoria, BC, Canada; 4Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada; 5Division of AIDS, University of British Columbia, Vancouver, BC, Canada

587 Week 144 Resistance Analyses of the Phase 3 EVG/COBI/FTC/TDF Studies

Rima Kulkarni, Michael E. Abram, Martin S. Rhee, Marshall W. Fordyce, Javier Szwarzberg, Michael D. Miller, Kirsten L. White
Clinical Virology, Glilead Sciences, Inc., Foster City, CA, United States

588 Emergent and Detectable Proviral DNA Drug Resistance in a Community Treatment Program

Anne Derache, Hyoung Shik Shin, Elizabeth White, Dennis Israelki, Jeffrey D. Klausner, David Katzenstein, Peninsula AIDS Research Collaboration
1Medical School / Infectious Diseases, Stanford University, Stanford, CA, United States; 2Center for Infectious Disease, National Medical Center, Seoul Korea, Seoul, Republic of Korea; 3David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, United States

589 Acquired Drug-Resistance Mutations and Mortality Among HIV Patients On First-Line ART

Julia W. Wu, Hui Xing, Eric Tchetgen Tchetgen, Lingjie Liao, Julia W. Wu, Frederick Matsen, the Partners PrEP Study Team
1Department of Epidemiology, Harvard School of Public Health, Boston, MA, United States; 2National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China; 3Department of Biostatistics, Harvard School of Public Health, Boston, MA, United States; 4Department of Biostatistics, Harvard School of Public Health, Boston, MA, United States

590LB PrEP Exposure and the Risk of Low-Frequency Drug Resistance

Dara A. Lehman, Jared Baeten, Connor McCoy, Julie F. Weis, Dylan Peterson, Connie Celum, Nelly Muguiro, Julie Overbaugh, Frederick Matsen, the Partners PrEP Study Team
1BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada; 2Center for Infectious Disease, National Medical Center, Seoul Korea, Seoul, Republic of Korea; 3David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, United States
Poster Abstracts

591 Ripilivirine-Associated Resistance in HIV-1 DNA in Suppressed Patients Pretreated by NNRTIs
Sebastien Gallien1, Isabelle Charreau2, Marie-Laure NERE2, Nadia Mahjoub2, Nathalie de Castro2, Jean-Pierre Aboulken3, Jean-Michel Molina1, Constance Delaugerre1
1Infectious Diseases, Hôpital Saint Louis, Paris, France; 2Esaiss Thérapeutiques et Maladies Infectieuses, INSERM SC10 - US019, Villejuif, France; 3Virology, Hôpital Saint Louis, Paris, France; 4INSERM SC10 - US019, Villejuif, France

592 Etravirine/Ripilivirine-Specific Mutations Selected by EFV and NVP in Kenyan Patients Failing ART
Keith W. Crawford1, Dorothy Njeru2, Jonah Maswai2, Milton Omondi3, Jane Kinetto4, Duncan Apoloo5, Appolonia Ako6, Raphael Langat1, Lawrence Gitano1, Jemutai Tarus7, Tiffany E. Hamm8
1Global Health Programs, US Military HIV Research Program, Bethesda, MD, United States; 2US Army Military Research Unit-Kenya, Nairobi, Kenya; 3Population Health, Fred Hutchinson Cancer Research Center, Seattle, WA, United States; 4Department of Global Health, University of Nairobi, Nairobi, Kenya

593 Detection of NNRTI Resistance Mutations After Interrupting NNRTI-Based Regimens
Valentina Cambiano1, Hannah Castro1, David Chadwick2, Erasmus Smith3, Anna M. Gerotti1, David Dunn1, Andrew Phillips1, on behalf of UK HIV Drug Resistance Database & UKCHIC study
1UCL, London, United Kingdom; 2Medical Research Council Clinical Trials Unit, London, United Kingdom; 3University of Newcastle, Newcastle, United Kingdom; 4HFA Heartlands Hospital, Birmingham, United Kingdom; 5University of Liverpool, Liverpool, United Kingdom

594 HIV-1 Resistance Outcomes in Seroconverters From MTN 003 (VOICE)
Urvi M. Parikh1, Krista A. Eskay1, Russell L. Hardesty1, Cliff Kelly1, Craig A. Magaret2, Cindy Mollitor2, Zvavahera M. Chirenje3, Jeanne Marrazzo3, John W. Mellors2, on behalf of the VOICE Study Team
1Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States; 2Fred Hutchinson Cancer Research Center/SCHARP, Seattle, WA, United States; 3Population Sciences, Fred Hutchinson Cancer Research Center/Vaccine and Infectious Disease Institute, Seattle, WA, United States; 4UZ-UCSF Collaborative Research Programme in Women’s Health, Harare, Zimbabwe; 5Division of Allergy & Infectious Diseases, University of Washington, Seattle, Washington, United States

595 Impact of Raltegravir/Elvitegravir Selected Mutations On Dolutegravir Cross-Resistance
Wei Huang1, Hong-Tao Xu, Susan Colby-Germinario, Maureen Oliveira, Yingshan Han, Yudong Quan, Mark Wainberg, Chen Liang
1McGill AIDS Centre, Lady Davis Institute, Montreal, QC, Canada

596 Analyses of Accessory Mutations in HIV-1 Protease Reveal Interdependent Mechanisms of Resistance
Debra A. Ragland1, Madhavi N.L. Natam1, Aysegül Ozen1, Yufeng Cai1, Hong Cao1, Celia A. Schiffer1, Veronica Zanchelli2, Hong-Tao Xu, Susan Colby-Germinario, Maureen Oliveira, Yingshan Han, Yudong Quan, Mark Wainberg, Chen Liang
1Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, MA, United States 2McGill AIDS Centre, Lady Davis Institute, Montreal, QC, Canada

598LB Two Distinct Mechanisms of Resistance To Allosteric HIV-1 Integrase Inhibitors
Alison Slaughter1, Kellie Jurado2, Lei Feng1, Nanjie Deng1, Nivedita Jena1, Jacques J. Kessl1, James R. Fuchs1, Ronald M. Levy1, Alan Engelmann1, Mamuka Kvaratskhelia1
1Ohio State University, Columbus, OH, United States; 2Harvard University, Boston, MA, United States; 3Temple University, Philadelphia, PA, United States

599 Impact of CD4 Mimetics-Resistant Mutations On Susceptibilities To Anti-Env nMABs
Shigeoyoshi Harada1, Samatchaya Boonchawai1, Tetsuo Narumi2, Hirokazu Tamamura2, Shuzo Matsuhashi3, Kazuhisa Yoshimura1
1AIDS Research Center, National Institute of Infectious Diseases, Shinjuku, Tokyo, Japan; 2Kumamoto University, Kumamoto, Japan; 3Tokyo Medical and Dental University, Tokyo, Japan

600 M184I and M230I Minority Variants in ART-Naïve Patients Are Linked To APOBEC3G/F Activity
Marc Noguera-Julian1, Alessandro Cozzi-Leprì2, Francesca di Giallonardo1, Rob Schuurman1, Martin Daiemer1, Sue Atkenson1, Huldryck F. Günther1, Françoise Brun-Vezinet1, Roger Paredes2, Karin J. Metzner3, CHAIN Minority HIV-1 Variants Working Group
1IRIsCaixa Retrovirology Lab, Badalona, Spain; 2University College, London, United Kingdom; 3Institute of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland; 4Utrecht Medical Centre, Utrecht, Netherlands; 5Institut für Immunologie und Genetik, Kaiserslautern, Germany; 6Association de Recherche en Virologie et Hematologie, Paris, France

601 Characterising the Complex Mutational Pathways Associated With Maraviruc-Resistant HIV-1
Xiaowei Jiang1, Felix Feyertag1, Conor Meehan1, Simon Travers4, Charles Craig1, Mike Westby1, Marilyn Lewis1, David L. Robertson2, on behalf of the UK CHIC study
1AIDS Research Center, National Institute of Infectious Diseases, Tokyo, Japan; 2University College, London, United Kingdom; 3Faculty of Life Sciences, University of Manchester, Manchester, United Kingdom; 4National University of Ireland Galway, Galway, Ireland; 5South African National Bioinformatics Institute, Bellville, South Africa; 6The Research Network, Sandwich, United Kingdom; 7Pfizer R&D, Sandwich, United Kingdom

602 Impact of Minority Drug-Resistant and X4 Variants in Naïve Patients Starting ART With <100 CD4+/µm²
Maria Casadelia1, Christian Manzardo2, Susana Perez-Alvarez1, Daniel Podzamczer1, Pere Domingo1, Christian Pou1, Marc Noguera-Julian2, Josep M. Gatell1, Josep M. Miró1, Roger Paredes2
1IRIsCaixa AIDS Research Institute, Universitat Autònoma de Barcelona, Badalona, Spain; 2Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona, Spain; 3Hospital Bellvitge-IDIBELL, University of Barcelona, Barcelona, Spain; 4Hospital de Sant Pau, Universitat Autònoma de Barcelona, Badalona, Barcelona, Spain; 5HIV Unit, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain

603 Antiretroviral-Naïve and -Treated Patients Can Harbor Viruses in CSF More Resistant Than in Plasma
Cathia Soulie1, Diane Descamps1, Maxime Grude2, Véronique Schneider3, Mary-Anne Traubaud1, Laurent Morand-Joubert1, Constance Delaugerre1, Vincent Calvez1, Philippe Flandre4, Anne-Geneviève Marcellin5, ANRS Resistance AC11 Group
1U943, Virology Laboratory Pitié Salpêtrière Hospital, Paris, France; 2Virology Laboratory Bichat Hospital, Paris, France; 3Virology Laboratory Tenon Hospital, Paris, France; 4Virology Laboratory Centre de Biologie Nord Croix Rousse Hospital, Lyon, France; 5U943, Virology Laboratory Saint Antoine Hospital, Paris, France; 6Virology Laboratory Saint Louis Hospital, Paris, France

604 Retention and Decay of HIV-1 Drug Resistance Mutations in Proenional DNA
Justin De La Cruz1,2,3,4, Saran Vardhanabhuti2,5, Robert M. Rovner2,5, Benjamin Pinsky3,2, Ronald Bosch2,5, David Katzenstein1,2,5
605 Prevalence of Minority Resistant Variants To ETR, DRV, and RAL at Baseline in the ANRS 139 TRIO Trial
Charlotte Charpentier1,2, Lee O. Guinevere3, Christophe Rodriguez4, Benoit Viseux5, Christine Fagard3, Jean-Michel Molina5, Christian Kattama6, Yazdan Yazdanpanah7,8, Richard P. Harrigan9, Diane Descamps-2
1Laboratoire de Virologie, Hôpital Bichat-Claude Bernard, Paris, France; 2Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, MA, United States; 3Botswana-Harvard AIDS Institute, Gaborone, Botswana; 4Beth Israel Deaconess Medical Center, Boston, MA, United States

Session P-L5 Poster Session
Thursday March 6, 2014, 2:30 PM–4:00 PM Exhibit Hall B Laboratory Detection of Drug Resistance and Tropism

606 Pan Degenerate Amplification and Adaptation for Highly Sensitive Detection of ARV Drug Resistance
Iain J. MacLeod1,2, Christopher F. Rowley1,3, M. Essex1
1Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, MA, United States; 2Botswana-Harvard AIDS Institute, Gaborone, Botswana; 3Department of Medicine, University of California San Francisco, San Francisco, CA, United States

607 Genotypic Tropism Testing of Proximal DNA To Guide Maraviroc Initiation in Aviremic Subjects
Federico García1, Eva Poveda1, María Ángeles Ribas1, María Jesús Pérez-Elias1, Onofre J. Martínez-Madrid1, Jordi Navarro2, Antonio Ocampo1, Félix Guibertévez3, Miguel García-Deltoro4, Roger Paredes10, PROTEST Study Group
1Hospital Universitario de Canarias, La Laguna, Spain; 2INIBIC-Complejo Hospitalario Universitario de La Coruña, A Coruña, Spain; 3Hospital Son Espases, Palma de Mallorca, Spain; 4Hospital Ramón y Cajal, Madrid, Spain; 5Hospital General Universitario Santa Lucía, Cartagena, Spain; 6Hospital Universitari Vall d’Hebron, Barcelona, Spain; 7Hospital Xeral de Vigo, Vigo, Spain; 8Hospital de Elche, Elche, Spain; 9Hospital General Universitario de Valencia, Valencia, Spain; 10Hospital Universitari Germans Trias i Pujol, Badalona, Spain

608 Characterization of NRRTI Mutations in HIV-1 RT Using Single Molecule, Real-Time SMRT® Sequencing
Anand Sethuraman1, Michael P. S. Brown2, Colleen Ludka3, Yan Guo4, Ellen E. Paxinos3
1Applications and Collaborations, Pacific Biosciences, Menlo Park, CA, United States; 2Massachusetts General Hospital, Division of General Medicine, Boston, MA, United States; 3School of Medicine, Boston University, Boston, MA, United States; 4Department of Medicine, University of California San Francisco, San Francisco, CA, United States; 5Department of Medicine, Brigham and Women’s Hospital, Division of Infectious Disease, Boston, MA, United States; 6Yale School of Public Health, New Haven, CT, United States

609 Celera RUO Integrase Resistance Assay Performs Well Across Several Subtypes
Carole L. Wallis1, Raquel V. Viana1, Elias Konstantine Halvas2, John W. Mellors3
1Molecular Pathology, Lancet Laboratories, Johannesburg, South Africa; 2Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, PA, United States

610 Feasibility and Clinical Utility of HIV-1 Genotype Testing in the Setting of Low-Level Viremia
Maria Mercedes Santoro1, Daniele Armenia1, Claudia Alterri1, Lavinia Fabeni1, Domenico Di Pinto1, Federica Forticci2, Ada Bertolli1, Caterina Gori1, Andrea Antinori1, Carlo Federico Perino1
1University of Rome Tor Vergata, Rome, Italy; 2University Hospital Tor Vergata, Rome, Italy

611 Tropism Testing by MiSeq Is Comparable To 454-Based Methods But Exhibits Contamination Issues
BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada

612 A Proposed HIV Reference Sample Characterized by Three Next-Generation Sequencing Platforms
Alejandro Gonzalez-Serna1, Charison J. Brumme1, Winnie Dong1, Eric Cai2, Art F. Y. Poon1, Kelly D. Huber2, Nicolas Sluis-Cremer3, Ellen E. Paxinos4, Luke C. Swenson5, Paul Richard Harrigan3
1School of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States; 2Applications and Collaborations, Pacific Biosciences, Menlo Park, CA, United States; 3Department of Medicine, Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States; 4School of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States; 5British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada

Cost Effectiveness Studies of ART and Drug Resistance Testing

613 Antiretroviral Switch Strategies for Lowering Costs of Therapy: 48-Week Cost-Efficacy Analysis
Josep M. Liblé1, Gloria Cardona2, Jose R Santos3, Anges Andreu4, Xavier Bonfanton5, Bonaventura Clotet6
1HIV Unit, University Hospital Germans Trias i Pujol, Badalona, Spain; 2Pharmacy, University Hospital Germans Trias i Pujol, Badalona, Spain; 3University Hospital Germans Trias i Pujol, Badalona, Spain; 4British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada; 5Health Strategies International, Oakland, CA, United States; 6BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada

Cost Effectiveness of Genotype Testing for Primary Resistance in Brazil
Paula M. Luz1, Bethany L. Morris2, Beatriz Grinsztejn3, Kenneth A. Freedberg4, Valédia G. Veloso5, Rochelle P. Walensky6, Yoriko M. Nakamura7, Paul E. Sax8, Claudio J. Struchiner9, A. David Paltiel10
1Fundação Oswaldo Cruz, Instituto de Pesquisa Clinica Evandro Chagas, Rio de Janeiro, Brazil; 2Massachusetts General Hospital, Medical Practice Evaluation Center, Boston, MA, United States; 3Massachusetts General Hospital, Division of General Medicine, Boston, MA, United States; 4Massachusetts General Hospital, Division of Infectious Disease, Boston, MA, United States; 5Harvard Medical School, Boston, MA, United States; 6Brigham and Women’s Hospital, Division of Infectious Disease, Boston, MA, United States; 7Yale School of Public Health, New Haven, CT, United States

Cost Effectiveness of Adding 4th-Generation Assay for Detection of Recent HIV Infections
Sheila M. Keating1,2, Gary Murphy3, Alex Welte4, Reshma Kassanjee5, David Matten4, Shelley N. Facente6, Mila Lebedeva7, Michael P. Busch1,2, Christopher D. Pilcher5, Consortium for Evaluation of Performance of HIV Incidence Assays (CEPHIA)
1Blood Systems Research Institute, San Francisco, CA, United States; 2University of California San Francisco, San Francisco, CA, United States; 3Biostatistics, Harvard University, Cambridge, MA, United States; 4Health Strategies International, Oakland, CA, United States; 5Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States; 6Pathology, Stanford University, Stanford, CA, United States; 7San Francisco Department of Public Health, San Francisco, CA, United States

Cost Effectiveness of Adding 4th-Generation Immunoassay Screening After a Negative Rapid HIV Test
Angela B. Hutchinson1, Stephanie Cohen2, Emily Westheimer1, Cynthia Gay3, Elliott Marselle4, Laura Hall1, Lisa Hightow-Weidman5, Benjamin Teo6, Mark Pandoroi7, Philip J. Peters7
1Centers for Disease Control and Prevention, Atlanta, GA, United States; 2San Francisco Department of Public Health, San Francisco, CA, United States; 3New York City Department of Health and Mental Hygiene, New York, NY, United States; 4University of North Carolina at Chapel Hill, Chapel Hill, NC, United States; 5Health Strategies International, Oakland, CA, United States; 6ICF International, Atlanta, GA, United States; 7San Francisco Department of Public Health Laboratory, San Francisco, CA, United States

Performance of HIV Rapid Tests To Identify Serocounters in MTN 003 (VOICE)
Urvi M. Parikh5, Edward Livant4, Cliffy Kelly3, Rashika Maharaj2, Marshall W. Munjomla1, Patrick Karugaba1, Natasha Samsunder6
1University of Rome Tor Vergata, Rome, Italy; 2L Spallanzani Hospital, Rome, Italy; 3Centers for Disease Control and Prevention, Atlanta, GA, United States; 4British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada; 5Health Strategies International, Oakland, CA, United States; 6BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada
623LB A Recombinant HIV-1 Gag Virus Panel for the Evaluation of p24-Antibodies and HIV Diagnostic Tests
Beatrice N. Vetter, Vanessa Orlovski, Cyrin Shah, Jürg Böni, Jörg Schüpbach
National Center for Retroviruses, Zurich University, Zurich, Switzerland

624 Evaluation of Pima CD4 Point-Of-Care Device in Western Kenya for Potential Use in Field Settings
Clement Zeh, Seth C. Inzulea, Fredrick Otieno, Boaz Goyaro, Richard Ndibo, Rose CE, Mitesh Desai, Robert Chen, Lisa A. Mills, Taraz Samandari
1CDC, Kisumu, Kenya; 2KEMRI/CDC, Kisumu, Kenya; 3CDC, Atlanta, GA, United States

625 Comparison of Central and Local HIV-1 RNA Quantification From Two International Clinical Trials
Janaiki Amin, Matthew Law, Anthony Kelleher, Rebekah Puls, David Cooper, Sean Emery
The Kirby Institute, University of New South Wales, Sydney, Australia

626 HIV-1 Can Be Confirmed by Bio-Rad Genius™ HIV 1/2 Confirmatory Assay Using Dried Blood Spots
Carolina Fernández McPhee, Patricia Alvarez, Luis Prieto, Jacinta Obiang, Pedro Avedillo, Antonio Vargas, Pablo Rojo, José Tomás Ramos, Africa Holguín
1Microbiology and Parasitology, Hospital Ramón y Cajal, Madrid, Spain; 2Hospital de Getafe, Madrid, Spain; 3Ministerio de Sanidad y Bienestar Social, Hospital Provincial de Getafe, Madrid, Equatorial Guinea; 4Instituto de Salud Carlos III-Madrid, RICET, Centro Nacional de Medicina Tropical, Madrid, Spain; 5Hospital Doce de Octubre, Madrid, Spain

627 Standard Diagnostics Bioline HIV/Syphilis Duo Test: Multi-Site Laboratory Evaluation
Claire C. Bristow, Yaw Adu-Sarkodie, Raphael O. Ondondo, Elizabeth Anne Bukusi, Claver Anoumou Dagnra, Khin Yi Oo, Jeffrey D. Klausner
1Fielding School of Public Health, University of California Los Angeles, Los Angeles, CA, United States; 2Department of Clinical Microbiology, School of Medical Science, College of Health Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana; 3Kenya Medical Research Institute, Kisumu, Kenya; 4Centre National de Référence des Tests VIH, Laboratoire de Microbiologie, Lomé, Togo; 5Virology Section, National Health Laboratory, Yangon, Myanmar; 6Department of Medicine, University of California Los Angeles, Los Angeles, CA, United States

Session P-M2 Poster Session
Wednesday March 5, 2014, 2:30 PM–4:00 PM
Exhibit Hall B

HIV Diagnostics

620 Evaluation of the Hologic Aptima HIV-1 Quant Dx Assay With HIV-1 Subtypes
Mark M. Manak, Holly Hack, Tracy Triscic, Sangeetha Nair, Andrew Worlock, Sheila A. Peet, Jennifer Malia, Linda Jagodzinski
1OFLDM, US Military HIV Research Program, Walter Reed Army Institute of Research/Henry M. Jackson Foundation, Bethesda, MD, United States; 2AFRIMS, Bangkok, Thailand; 3Walter Reed Project, Kericho, Kenya, Kenya, Mbuya Medical Research Centre, Mbuya, Tanzania, United Republic of; 4Makerere University Walter Reed Project, Kampala, Uganda; 5US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, United States

621 CAP/CTM V. 2.0 Using Dried Blood Spots Ineffective at Diagnosing Antiretroviral Treatment Failure
Souleymane Sawadogo, Andreas Shiningavanwaye, Joy Chang, Maher Andrew, Chunfu Yang, Esegiel Gaeb, Harold Kaura, Dennis Ellenberger, David Lowrance
1CDC-Namibia, Windhoek, Namibia; 2Namibia Institute of Pathology, Windhoek, Namibia; 3DHGA/CGH/CDC, Atlanta, GA, United States

622 Reliable and Accurate CD4 T Cell Count and Percent of the New Portable Flow Cytometer CyFlow MiniPOC
Milena Nasi, Sara De Biasi, Elena Bianchini, Lara Gibellini, Marcello Pinti, Tiziana Scacchetti, Tommaso Trenti, Vanni Boirghi, Cristina Mussini, Andrea Cozzarizza
1University of Modena and Reggio Emilia, Modena, Italy; 2Division of Clinical Pathology, NOCSAE Baggiovara, Modena, Italy; Infectious Diseases Clinic, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy

629 Prevalence and Risk Factors of Hepatitis C Virus Infection in China’s National Methadone Program
Cynthia X. Shi, Aozhou Wu, Keming Rou, Enwu Liu, Yan Zhao, Xiaobin Cao, Changhe Wang, Wei Luo, Zunyou Wu
1National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China; 2Epidemiology, Harvard University, Boston, MA, United States; 3Health Science Center, Peking University, Beijing, China; 4Epidemiology, Johns Hopkins University, Baltimore, MD, United States

630 The Burden of Hepatitis C Infection in Pennsylvania State Prisons and Implications for Treatment
Madeline Mahowald, Sarah Larney, Nicholas Scharff, Curt Beckwith, Lynn E. Taylor, Nick Zaller, Timothy Flanigan
1The Warren Alpert Medical School at Brown University, Providence, RI, United States; 2National Drug and Alcohol Research Centre, Sydney, Australia; 3Bureau of Health Care Services, Mechanicsburg, PA, United States; 4Division of Infectious Diseases, The Miriam Hospital, Providence, RI, United States
631 Impact of Rapid Hepatitis C Testing On Receipt of Hepatitis C Results in a Public STD Clinic
Oluwaseun Falade-Nwulia1, Shruti Mehta1, Mark Sukowski1, Jackline Lasola1, Khalil Ghanem1, Patrick Chauik2, David Thomas1
1Division of Infectious Diseases, Johns Hopkins University, Baltimore, MD, United States;2Baltimore City Health Department, Baltimore, MD, United States;3Department of Epidemiology, Johns Hopkins University, Baltimore, MD, United States

632 Hepatitis C Antigen Testing: A Reliable Alternative for Diagnosing Acute HCV Infection
Simon George Shaw, Fiona Cresswell, Gary Homer, Mohammed Hassan-Ibrahim, Martin Fisher
HIV Medicine, Brighton and Sussex University Hospitals NHS Trust, Brighton, United Kingdom

Session P-N2 Poster Session
Tuesday March 4, 2014, 2:30 PM–4:00 PM Exhibit Hall B
HCV Pre-Clinical Studies and Pharmacology

635 Longitudinal Analysis of RAVs by PrimerID 454-Seqencing in the Boceprevir P-05063 Study
Richard J. O. Barnard1, Abha Cheprie1, Mark Watson2, Don Cooper3, Cassandra Jabara4, Daria Hazuda5, Stanley Lemon6, Simon Maltas7
1Infectious Disease, Merck and Co, West Point, PA, United States;2Institute for Immunology & Infectious Diseases, Murdoch, Australia;3University of North Carolina, Chapel Hill, NC, United States

636 ABT-493, a Potent HCV NS3/4A Protease Inhibitor With Broad Genotype Coverage
Teresa Ng1, Thomas Reichel1, Tim Middleton1, Keith McDaniel1, Dale Kemp1, Liangjun Lu1, Guoqiang Wang1, Lijuan Jiang2, Yat Sun Or3, Tami Pilot-Matias4
1AbbVie Inc., North Chicago, IL, United States;2Enanta Pharmaceuticals Inc., Watertown, MA, United States

637 Use of Dried Blood Spots for Measuring Intracellular Ribavirin-Triphosphate
Leah C. Jimmerson, Jia-Hua Zheng, Lane R. Bushman, Kyle P. Hammond, Peter L. Anderson, Jennifer J. Kiser
Pharmaceutical Sciences, University of Colorado, Denver, Aurora, CO, United States

638 Ritonavir-Boosted Atazanavir, Lopinavir, & Darunavir Increase HCV NSSA Inhibitor MK-8742 Levels
Wendy Y. Yeh1, William Marshall1, Joanne Ma2, Eric Margin1, Xioadi Huang2, Patricia Jumes1, Stephen Youngberg3, Joan Butterton1, Merck Sharp and Dohme, Whitehouse Station, NJ, United States;4Celerion, Lincoln, NE, United States

639 ABT-530, an HCV NS5A Inhibitor With Potent Pangentotypic Activity and High Barrier To Resistance
Teresa Ng1, Preethi Krishnan, Warren Carter, Thomas Reichis, Liangjun Lu, Tanya Dekhtyar, Akhter Molla, Christine Collins, Tami Pilot-Matias5, AbbyVie Inc., North Chicago, IL, United States

Session P-N3 Poster Session
Wednesday March 5, 2014, 2:30 PM–4:00 PM Exhibit Hall B
HCV: Prognosis and Impact of Treatment Including Liver Transplantation

640 FIB-4 Outperforms Liver Biopsy in the Assessment of Prognosis in HCV/HIV Coinfection
Juan Berenguer1, Francisco X. Zamora2, Ana Carrero1, Miguel Angel von Wichmann1, José López-Aldayeguer3, María J. Téllez1, José Sanz4, Herminia Esteban5, José M. Bellon1, Juan Gonzalez-Garcia1, and GESISDA 3603 Study Group
1Hospital General Universitario Gregorio Marañón, Madrid, Spain;2Hospital Universitario La Paz, Madrid, Spain;3Hospital Donostia, San Sebastián, Spain;4Hospital La Fe, Valencia, Spain;5Hospital Clínico San Carlos, Madrid, Spain;6Hospital Principe de Asturias, Alcalá de Henares, Spain;7Fundación SEIMC/GEISDA, Madrid, Spain

641 Sustained Virologic Response and the Risk of Liver Decompensation in HCV and HIV Patients
Temitope O. Olufade1, Li Wang1, Scott Devine1, Onur Baser2, Vincent Lo Re2
1US Outcomes Research, Merck Sharp & Dohme, North Wales, PA, United States;2STATinMED Research, Dallas, TX, United States;3Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States

642LB GWAS Reveals New Genetic Associations With Liver Fibrosis Progression
Stephanie Dominguez1, Sigrid Le Clerc2, Damien Ullevil3, Taoufik Labib1, Maria Winnick1, Ioannis Theodorou1, Laurent Abeil1, Yves Levy1,2, Dominique Salmon1, Jean Francois Zagury1
1Clinical Immunology and Infectious disease, Henri Mondor Hospital, Paris, France;2INSERM U 055, Creteil, France;3Chaire de Bioinformatique, Conservatoire des Arts et Métiers, Paris, France;4INSERM U 987 ISPED, Bordeaux Segalen University, Bordeaux, France;5INSERM U 945, Pierre et Marie Curie University, Paris, France;6Laboratory of Human Genetics of Infectious Diseases INSERM U980, University Paris Descartes Imagine Institute, Paris, France;7Infectious and Tropical diseases, Cochin Hospital, Paris, France

643 Incident HCV Infections in the Swiss HIV Cohort Study: Natural History and Treatment Outcomes
Gilles Wandel1, Arnaud Vanhove1, Janine Rohrbach1, Karin Metzner1, Jan Fehr1, Marcel Stöckler1, Matthias Cassavini1, Juan Ambrosioni1, Olivia Keiser1, Hansjakob Furrer1, Andri Rauch1,2
1Bern University Hospital, Bern, Switzerland;2University of Bern, Bern, Switzerland;3University Hospital Zurich, Zurich, Switzerland;4University Hospital Basel, Basel, Switzerland;5University Hospital Lausanne, Lausanne, Switzerland;6University Hospital Geneva, Geneva, Switzerland

644 Is There Long-Term Evidence of Advanced Liver Fibrosis After Acute Hepatitis C Infection in HCV Coinfection?
Christoph Boesecke1, Patrick Ingilliz2, Matthias Mandorfer3, Carolynne Schwarze-Zander1, Florian Berger1, Marc-Antoine Valatyn1, Jan-Christian Wasnuth2, Thomas Reiberger3, Stefan Mau3,4, Juergen K. Rockstroh5, and the NEAT study group 1Department of Internal Medicine I, Bonn University Hospital, Bonn, Germany;2MIB, Berin, Germany;3Medical University of Vienna, Vienna, Austria;4Center for HIV and Hepatogastroenterology, Düsseldorf, Germany;5Hôpital La Pitié Salpêtrière, AP-HP, Paris, France

645 Hepatic Decompensation in HIV/HBV/HCV Patients and the Impact of HBV Therapy
Temitope O. Olufade1, Li Wang1, Scott Devine1, Onur Baser2, Vincent Lo Re2
1US Outcomes Research, Merck Sharp & Dohme, North Wales, PA, United States;2STATinMED Research, Dallas, TX, United States;3Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States

646 Short-Term Risk of Decompensation Among HIV/HCV-Coinfected Patients With Significant Fibrosis
Juan Macias1, Manuel Marquez2, Dolores Merino3, Francisco Téllez2, Antonio Rivero1, Luis López Cortés2, Maria Mancebo1, Juan A. Pineda2,1 Hospital Universitario de Valme, Seville, Spain;3Hospital Universitario Virgen de la Victoria, Málaga, Spain;4Hospital Juan Ramón Jimenez, Huelva, Spain;5Hospital La Línea, La Línea de la Concepción, Spain;6Hospital Universitario Reina Sofia, Córdoba, Spain;7Hospital Universitario Virgen del Rocío, Seville, Spain

647 Differential Immune Marker Levels Linked to Liver Fibrosis in HIV/Hepatitis C (HCV) Coinfection
Nasheed Moqueet1, Cynthia Kanagaratham2, Danuta Radzioch1, Sahar Saeed1, Marina B. Klein1, Canadian Co-infection Cohort 1Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, QC, Canada;2McGill University, Montreal, QC, Canada

648 Outcome of 215 C/HCV-Coinfected Liver Transplant Recipients: A Prospective Multicenter Study
Jose M. Miro1, Miguel Montejano2, Marino Blanes2, Abradelo Manuel1, Santos del Campo1,2, Lluís Castells1, Antoni Rafecas1,2, Christian Manzano3, Iñaki Perez1,2, Antonio Rímon1, and FIPSE investigators 1Hospital Clinico-IDIBAPS, University of Barcelona, Barcelona, Spain;2Hospital Universitario de Cruces, Bilbao, Spain;3Infectious Diseases, Hospital la Fe, Valencia, Spain;4Hospital Doce de Octubre, Madrid, Spain;5Hospital Universitario Ramon y Cajal, Madrid, Spain;6Hospital Universitario Vall d’Hebron, Barcelona, Spain;7Hospital Bellvitge-IDIBELL, University of Barcelona, L’Hospitalet de Llobregat, Spain
649 Liver Fibrosis Progression Among Persons With Recently Acquired HCV Infection
Adée A. Boccia1, Peng Yan1, Vincent Lo Re3, Marina B. Klein2, Matthew B. Goetz4, David Leaf5, Matthew S. Freiberg6, Kenneth E. Sherman7
1University of Pittsburgh, VA Pittsburgh Healthcare System, Pittsburgh, PA, United States;2Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates;3University of Pittsburgh, Pittsburgh, PA, United States;4University of Pennsylvania, Philadelphia, PA, United States;5McGill University Health Center, Montreal, QC, Canada;6VA Greater Los Angeles Healthcare System, Los Angeles, CA, United States;7University of Cincinnati School of Medicine, Cincinnati, OH, United States

650 Predicting Risk of ESLD in HIV/HCV Patients for Individualized HCV Therapy Decisions
Vincent Lo Re1, Janet P. Tater2, Adeel A. Butt3, Marina B. Klein4, Cynthia Gibert5, David Rimland6, Matthew B. Goetz7, Jay R. Kostman7, Amy C. Justice3, Russell Locati4
1University of Pennsylvania, Philadelphia, PA, United States;2VA Connecticut Healthcare System, West Haven, CT, United States;3University of Pittsburgh School of Medicine, Pittsburgh, PA, United States;4McGill University Health Centre, Montreal, QC, Canada;5Washington DC VA Medical Center, Washington, DC, United States;6Atlanta VA Medical Center, Atlanta, GA, United States;7VA Greater Los Angeles Healthcare System, Los Angeles, CA, United States

651 Level of Alcohol Use and Advanced Hepatic Fibrosis in HIV-Infected and Uninfected Patients
JP Tate1, JK Lim2, KJ Bryant3, CL Gibert4, D. Rimland5, MB Goetz6, MB Klein7, DA Fellig1, AC Justice8, V. Lo Re9
1Yale University School of Medicine, New Haven, CT, United States;2National Institute on Alcohol Abuse and Alcoholism (NIAAA), Washington, DC, United States;3George Washington University School of Medicine, Washington, DC, United States;4Emory University School of Medicine, Atlanta, GA, United States;5David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, United States;6Department of Medicine, McGill University, Montreal, QC, Canada;7University of Pennsylvania School of Medicine, Philadelphia, PA, United States

652 Liver-Related Death in HIV/HCV Coinfected Individuals: Who Should Be Targeted for HCV Treatment?
Daniel Grint1, Lars Peters2, Juergen K. Rockstroh2, Aza Rakhmanova3, Igor Karpov4, Massimo Galli5, Pere Domingo6, Ole Kirk7, Jens D. Lundgren8, Amanda Mocroft9
1University College London, London, United Kingdom;2Copenhagen HIV Programme, Copenhagen, Denmark;3University of Bonn, Bonn, Germany;4Medical Academy Botkin Hospital, St. Petersburg, Russian Federation;5Belarus State Medical University, Minsk, Belarus;6Luigi Sacco Hospital, Milan, Italy;7Hospital de Sant Pau, Barcelona, Spain

653 Significant Decrease of Liver Fibrosis in HIV-HCV Coinfected Patients Treated for HCV Infection
Marc Arthur Loko1, Camille Gilbert2, Karine Lacombe2, Caroline Lascoux-Combe3, Gilles Pliaux4, Linda Witrkop5, Christine Katama6, François Dabis7, Dominique Salmon8
1INSERM, Bordeaux, France;2Assistance Publique Hôpitaux de Paris, Paris, France

655 Slow HCV-RNA Decay and Early Resistance Predict the Risk of Failure To TVR/BOC Treatment
Francesca Ceccherini-Silberstein1, Valeria Centro2, Velia Chiara Di Maio3, Daniela Di Paol04, Sergio Babulderi5, Antonio Di Biagio6, Massimo Andreoni7, Giustino Parruti8, Giuliano Rizzardini9, Carlo Federico Pereno1
1Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy;2Hepatology Unit, University Hospital of Rome Tor Vergata, Rome, Italy;3Infectious Diseases Unit, Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy;4S. Martino Hospital, Genoa, Italy;5Infectious Diseases Unit, University Hospital of Rome Tor Vergata, Rome, Italy;6Infectious Diseases Unit, Pescara General Hospital, Pescara, Italy;7Division of Infectious Diseases, Hospital Sacco of Milan, Milan, Italy

656LB Global Origin of HCV NS3 Substitution Q80K That Is Associated With Lower Simeprevir Susceptibility
Art F. Poov1, Richard H. Liang2, Jeffrey B. Joy2, Thi Nguyen3, Rosemary M. McCloskey4, Mel Krajden5, Julio S. G. Montaner6, P. Richard Harrigan7
1BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada;2BC Centre for Disease Control, Vancouver, BC, Canada

659LB Boceprevir for Previously Treated HCV-HIV Coinfected Patients: The ANRS-HC27 BoceprevIH Trial
Isabelle Poizot-Martin1,2, Eric Bellissant2,3, Philippe Colson2,4, Alain Renaud4,5, Lionel Piroth1,5, Caroline Sola6,7, Marc Bourlière6,7, Rodolphe Garraffo1,8, Philippe Haffon9,10, Jean-Michel Molina11,12, and the ANRS HC27 BOCEPREVH Study Group.
1Immun-Hematological Clinical Unit, Aix Marseille University, APHM Sainte-Marguerite, Marseille, France;2Inserm U912 (SESTIM), Marseille, France;3Department of Clinical Pharmacology, Rennes University Hospital, Rennes, France;4INSERM 0203 CIC-P Clinical Investigation Centre, Rennes, France;5Fédération de Microbiologie Hospitalière, Aix Marseille Université, AP-HP Timone, Marseille, France, 6URMITE, UM 63, CNRS 7279, IRD 198, INSERM 1095, Marseille, France;7Infectious Diseases Department, University Hospital,Hôpital du Bocage, Dijon, France;8Department of Pharmacology and Toxicology, Aix Marseille Univ, APHM Timone, Marseille, France;9CRO2, INSERM U911, Marseille, France;10Hepatogastroenterology Department, Saint Joseph Hospital, Marseille, France;11Laboratoire de Pharmacologie, Faculty of Medicine of Nice, Hôpital Pasteur, Nice, France;12Medicine, European Hospital, Marseille, France;13Infectious Diseases Unit, Assistance Publique Hôpitaux de Paris (AP-HP) - Saint-Louis Hospital, Paris, France;14Pompei VII - Denis Diderot University, Paris, France

660 Boceprevir/Telaprevir-Based Therapy in HIV-Infection: Interim Analysis of a Multicenter Cohort
Karim Neukam1, Daniela Munteanu2, Antonio Rivero3, Annette Haber4, Manuel Marquez5, Patrick Inglis6, Ignacio de los Santos-Gil7, Thomas Lutz8, Juergen K. Rockstroh9, Juan A. Pineda10
1Unit of Infectious Diseases and Microbiology, Hospital Universitario de Valme, Seville, Spain;2University of Liverpool, Liverpool, United Kingdom;3Bonn University Hospital, Bonn, Germany;Matei Bals National Institute of Infectious Diseases, Bucharest, Romania;4Hospital Universitario Reina Sofia, Cordoba, Spain;5Frankfurt University Hospital, Frankfurt am Main, Germany;6Hospital Virgen de la Victoria, Malaga, Spain;7Medical Center for Infectious Diseases, Berlin, Germany;8Hospital Universitario de la Princesa, Madrid, Spain;9InfeKlinikum, Frankfurt am Main, Germany
661 Favorable Adverse Event Profile of Sofosbuvir/Ribavirin Versus Standard of Care for Hepatitis C
Kerry Townsend1, Shivakumar Nagarajan2, Anne Nelson3, Adrian Majid4, Luciano Kapeluszniak5, Robert R. Redfield6, Shyamasundaran Kottilit7, Rohit Talwani7, Anuoluwapo Osinusi2,3
1U of R, NIAID, NIH, Bethesda, MD, United States, 2Institute of Human Virology, Div. of Infectious Diseases, University of Maryland School of Medicine, Baltimore, MD, United States

662LB IFN-Free 3 DAA Regimen in HCV Genotype 1-Infected Patients On Methadone or Buprenorphine
Jacob Lalezari1, J Greg Sullivan1, Peter Vanunok1, Edward Galen1, Kris V. Kowdley1, Vinod Rustgi1, Humberto Aguilar1, Franco Felizarta1, Daniel Cohen1, Hui Tang1,2
1Quest Clinical Research, San Francisco, CA, United States, 2Parkway Medical Center, Birmingham, AL, United States

663 Teleaprevir Treatment of HIV/HCV G1 Patients With Severe Fibrosis: Efficacy Results To Week 16
Andrea Gori1, Manuela Doroa2, Oksana Chernova3, Jürgen Rockstroh1, Denes Bánhegyi4, Cilm Bergin5, Gabriella Verucchi6, Andrew Hill1,7, Blanca Hadden7, Mark Nelson7,8,9
1Division of Infectious Diseases, San Gerardo Hospital, Monza, Italy, 2Service de Doenças Infecciosas, Hospital de Santa Maria, Lisbon, Portugal, 3State Healthcare Institution, Tolyatti, Russian Federation, 4Department of Internal Medicine, University Hospital Bonn, Bonn, Germany, 5Szent László Hospital, Budapest, Hungary, 6Department of Genitourinary Medicine and Infectious Diseases, St James Hospital, Dublin, Ireland, 7Division of Infectious Diseases, University of Bologna, Bologna, Italy, 8Janssen R&D, High Wycombe, United Kingdom, 9Janssen Pharmaceuticals, Paris, France

664LB Teleaprevir Increases Ribavirin Toxicity Through eGFR Decrease in HIV-HCV Coinfected Patients
Laurent Cotte1,2, Aurélie Barrall-Trani1,4, Corinne Vincent1, Marc-Antoine Valantin1,3, Isabelle Fournier1, Karine Lacombe1, Jean-Pierre Aboulker5,2, Anne-Marie Taburet1,4, Jean-Michel Molina1,2,3
1Infectious Diseases, Hospices Civils de Lyon, Lyon, France, 2U1052, INSERM, Lyon, France, 3Clinical Pharmacy, Kremlin Bicêtre, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France, 4E4123, Faculty of Pharmacy, Paris-Sud University, Chatenay Malabry, France, 5SC10-US019, INSERM, Villejuif, France, 6Pitié-Salpêtrière Faculty of Pharmacy, Paris-Sud University, Chatenay Malabry, INSERM, Lyon, France, 7Assistance Publique - Hôpitaux de Paris, Paris, France, 8PARIS Descartes University, Paris, France, 9Saint Jean Hospital, Pepignan, France, 10Assistance Publique - Hôpitaux de Paris, Garches, France, 11Centre Hospitalier Intercommunal, Créteil, France, 12Assistance Publique - Hôpitaux de Paris, Créteil, France, 13INSERM, Villejuif, France, 14University of Paris VII Denis Diderot, Paris, France

665LB Safety and Efficacy of IFN-Free, Sofosbuvir/RBV Therapy in HIV/HCV Liver Transplanted Patients
Ana Moreno1, Maria J. Pérez-Elias1, Rafael Sánchez2, Carmen Quereda1, Jose L. Casado1, Fernando Dronda1, Santos del Campo2, Maria L. Mateos1, Alberto Diaz1, Santiago Moreno1,2
1Infectious Diseases, Hospital Ramón y Cajal, Madrid, Spain, 2Liver Transplant Unit, Hospital Ramón y Cajal, Madrid, Spain, 3Microbiology, Hospital Ramón y Cajal, Madrid, Spain

666 ss469415590 Variant Is a Better Predictor Than IL28B rs12979806 of PegIFN-α/RBV Therapy Failure
Sandra Franco1, Ester Aparicio1, Mariona Pareda1, Bonaventura Clotet2,3, Cristina Tur1, Miguel Ángel Martínez4,5
1IrsiCaixa, Hospital Universitat Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain, 2Fundació de la Lluita contra la SIDA, Badalona, Spain

667 Pill Burden & Treatment Length Reduce Adherence To IFN-Free Hepatitis C Therapy in an Urban Cohort
Tess Petersen1, Lori A. Gordon2, Kerry Townsend3, Monica Calderon4, Sreetha Sidhatharan4, Rachael Silk5, Anu Osinusi1,2,3, Henry Masur1, Shyam Kotttil,1, Anita Kohli4,5
1Critical Care Medicine Department, National Institutes of Health Clinical Center, Bethesda, MD, United States, 2Clinical Center Pharmacy Department, National Institutes of Health, Bethesda, MD, United States, 3National Institute of Allergy and Infectious Diseases, Laboratory of Immunoregulation, National Institutes of Health, Bethesda, MD, United States, 4Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc (formerly SAIC-Frederick, Inc), Frederick National Laboratory for Cancer Research, Frederick, MD, United States, 5Department of Infectious Diseases, University of Maryland, Baltimore, MD, United States

668 Teleaprevir in Treatment-Experienced HIV-HCV G1 Coinfected Patients (ANRS HC26 TeleapriVH)
Laurent Cotte1, Corinne Vincent1, Philippe Sogre2, Isabelle Fournier3, Hugues Aumable4, Pierre De Truchis4, Isabelle Rosal, Jean-Pierre Aboulker5, Jean-Michel Molina1,2
1Infectious Diseases, Hospices Civils de Lyon, Lyon, France, 2Liver Diseases, Université, Paris, France, 3Clinical Pharmacy, Kremlin Bicêtre, Assistance Publique Hôpitaux de Paris (AP-HP), Paris, France, 4Centre Hospitalier Intercommunal, Créteil, France, 5Assistance Publique - Hôpitaux de Paris, Créteil, France, 6INSERM, Villejuif, France, 7Assistance Publique Hôpitaux de Paris, Garches, France, 8University of Paris VII Denis Diderot, Paris, France

Session P-N5 Poster Session
Wednesday March 5, 2014, 2:30 PM – 4:00 PM

HCV: The Cascade
669 The Treatment Cascade for People With Chronic Hepatitis C Virus Infection in the United States
Baligh R. Yehia1, Asher Schrauz1, Craig Umscheid1, Vincent Lo Re1,2
1University of Pennsylvania, Philadelphia, PA, United States, 2New York University, New York, NY, United States

670 Initial Results of a Community-Based Rapid Hepatitis C Testing and Linkage To Care Program
Christian B. Ramers1, Robert Lewis2, Letty Reyes2, Alexander Kuo2, David L. Wyles3
1Special Populations, Family Health Centers of San Diego, San Diego, CA, United States, 2Hepatology and Liver Transplantation, University of California San Diego Health Sciences, San Diego, CA, United States, 3Infectious Diseases, University of California San Diego Health Sciences, San Diego, CA, United States

671 The CORE HCV Cascade a Decade Later: Looking Ahead To an IFN-Free Era
Oluwatoyin M. Adegymi1, Stephen Effinger, Benjamin Go, Sonia Vithakkar, Maureen Gallagher, Deborah Wolen, Becky Goldberg, Mike Demetria, David Barker, Gregory Huhn
1Ruth M Rothstein CORE Center, Cook County Health and Hospitals System, Chicago, IL, United States

672 The Hepatitis C Cascade of Care Among HIV-Infected Patients Following Diagnosis of HCV Infection
Edward R. Cachay1, Lucas Hill2, David Wyles1, Francesca Torriani1, Bradford Colwell2, Craig Ballard2, William Christopher Mathews3
1Medicine, University of California San Diego, La Jolla, CA, United States, 2Pharmacy, University of California San Diego, La Jolla, CA, United States

Session P-N6 Poster Session
Thursday March 6, 2014, 2:30 PM – 4:00 PM

Acute HCV Infection: Pathogenesis
673 Hepatitis C Virus Incidence in the Amsterdam Cohort Study Among Men Who Have Sex With Men: 1984-2011
Joost W. Vanhommerig1,2, Irene G. Stolte1, Femke E. A. Lambers2, Ronald B. Geskus1, Thijs J. W. van de Laar1, Martien W. Borgdorf1,2,3, Sylvia M. Brusisten1, Janke Schinkel1, Marja Prins4,5
1Department of Infectious Diseases, Public Health Service, Amsterdam, Netherlands, 2Department of Medical Microbiology,
Assessing HCV Acquisition Routes in HIV-Infected MSM Using Single Genome Sequencing—A Pilot Study

Daniel S. Frierer 1, Andrew H. Talal 1, Kristen M. Marks 1, Wouter van Seggelen 1, Andrea D. Branch 1, Shirish Huprikar 1, Shujie Wang 1, George M. Shaw 1,1 Hui Li 1
1 Infectious Diseases, Mount Sinai School of Medicine, New York, NY, United States; 2Gastroenterology, University of Buffalo School of Medicine, Buffalo, Buffalo, NY, United States; 3Infectious Diseases, Weill Cornell Medical College, New York, NY, United States; 4Liver Diseases, Mount Sinai School of Medicine, New York, NY, United States; 5Microbiology, University of Pennsylvania, Philadelphia, PA, United States

Higher Risk of Sexually Acquired HCV Coinfection in MSM With Wide HIV Transmission Bottleneck

Roger D. Koyou 1, Andri Rauch 1, Dominique Braun 1, Sabine Yerly 1, Jürg Böni 1, Thomas Klimkait 5, Vincent Aubert 6, Bruno Ledergerber 1, Karine Lacombe 4,5, Jeremie Guedj 1, Jürgen K. Rockstroh 2, Hulrdrych Günthard 1, The Swiss HIV Cohort Study (SHCS) 2
1University Hospital Zurich, University of Zurich, Zurich, Switzerland; 2Inselspital Bern, Bern, Switzerland; 3University of Geneva, Geneva, Switzerland; 4University of Zurich, Zurich, Switzerland; 5University of Basel, Basel, Switzerland; 6University of Lausanne, Lausanne, Switzerland

Seminal HCV RNA Level May Mirror Dynamics of Plasma HCV RNA in HIV-Positive Men With Acute HCV

Daniel Bradshaw 1, Francois Lamoury 2, Beth Catlett 3, Tanya L. Applegate 3, John McCallister 3, Gregory J. Dore 1, Gail Matthews 1, Mark Danta 1
1Kirby Institute, University of New South Wales, Sydney, Australia; 2St Vincent’s Hospital, Sydney, Australia; 3Faculty of Medicine, University of New South Wales, Sydney, Australia

HCV Viral Load Kinetics During Acute Hepatitis C in HIV-Infected Patients: A Model-Based Analysis

Romain Ragonnet 1, Christoph Boesecke 1, Marguerite Guiguet 1, Karine Lacombe 1, Jürgen K. Rockstroh 1,2, Jacob Nattermann 1, Esther Voigt 3, Patrick Ingiliz 4, Andreas Glässner 1,2, Ulrich Spengler 1,2, Andreas Glässner 1,2, Ulrich Spengler 1,2, Ulrich Spengler 1,2, Ulrich Spengler 1,2
1Inserm U1137, Paris, France; 2Department of Internal Medicine I, Johann Wolfgang Goethe University, Frankfurt, Germany; 3INSERM U912 (SESSTIM), Marseille, France; 4Inserm U912 (SESSTIM), Marseille, France

Immuno-Hematological Clinical Unit, Aix Marseille University, APH, Sainte Marguerite Hospital, Marseille, France; 5Service d’Hematologie et de Biologie Vasculaire, Aix Marseille University, APH, Conception Hospital, Marseille, France; 6Fédération de Microbiologie Hospitalière, Aix Marseille University, APH, Timone Hospital, Marseille, France; 7URMITE CNRS-IRDUMR 6236, Marseille, France; 8INSERM U912 (SESSTIM), Marseille, France

CD3+CD56+ Natural Killer-Like T Cells in HIV (+) Patients With Acute Hepatitis C

Pavlos Kokoreidis 1,2, Benjamin Krämer 1,2, Christoph Boesecke 1,2, Esther Voigt 3, Patrick Ingiliz 4, Andreas Glässner 1,2, Ulrich Spengler 1,2, Jürgen K. Rockstroh 1,2, Jacob Nattermann 1,2
1Internal Medicine I, University of Bonn, Bonn, Germany; 2German Center for Infection Research (DFZ), Bonn, Germany; 3Internal Medicine I, Praxis am Ebertplatz, Cologne, Germany; 4Medical Center for Infectious Diseases (MIZ), Berlin, Germany

The Effect of Hepatitis C (HCV) Clearance On Macrophage Activation in HIV/HCV CoInfection

Kara W. Chew 1, Lei Hu 1, Debika Bhattacharya 1, Adel A. Butt 1, Martha Lewis 2, Raymond T. Chung 3, Janet W. Andersen 4, Judith S. Currier 5
1David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, United States; 2Harvard School of Public Health, Boston, MA, United States; 3University of Pittsburgh School of Medicine, Pittsburgh, PA, United States; 4Harvard Medical School, Boston, MA, United States

HIV Patients Develop High Levels of Broadly Neutralizing Antibodies Against Hepatitis C Virus

Quentin Laplier 1,2, Catherine Fauvelle 1, Laura Heydman 1, Christiane Mouo 1, David Rey 1, Olivier Lambert 1, Nicolas Mayer 1, Heidi Barth 1,2, François Stoll-Keller 1,2, Samira Fafi-Kremer 1,2
1Institut de Virologie, FMTS, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, 2INSERM, U1110, Université de Strasbourg, Strasbourg, France; 3HIV Care Center, Hôpitaux Universitaires de Strasbourg, Strasbourg, France; 4Internal Medicine and Infectious Diseases, Hôpital Bicêtre, INSERM, 1012, Université Paris-Sud, France; 5Biostatistics, Hôpitaux Universitaires de Strasbourg, Strasbourg, France; 6Université de Strasbourg, Strasbourg, France

Activation and Senescence Markers in HIV-Infected Patients On PegIFN/RBV/Telaprevir Tritherapy

Isabelle Pellegrin 1, Céline Cognet 1, Pascale Trimoulet 1, Juliette Foucheur 1, Julien Vergnol 1, Wasiel Merrouche 1, Jean-Luc Taupin 1, Linda Wittke 1,2, Victor de Lelignes 1,2
1Immunology, Bordeaux Hospital, Bordeaux, France; 2Virology, Bordeaux Hospital, Bordeaux, France; 3Hepato-gastroenterology, Bordeaux Hospital, Bordeaux, France; 4Immuno-virology, CNRS UMR 5164, Bordeaux Hospital, Bordeaux, France; 5INSERM 897, ISPED, Public Health Unit, Bordeaux Hospital, Bordeaux, France

HCV Viremia and the Risk of Acute Myocardial Infarction at Various Lipid Levels

Adeel A. Butt 1,2, Kara W. Chew 1, Kathleen Corey 1, Raymond T. Chung 1, Javed Butler 1, Kenneth E. Sherman 2, Matthew S. Freiberg 1, Sebhat Erqou 7
1University of Pittsburgh School of Medicine and VA Pittsburgh Healthcare System, Pittsburgh, PA, United States; 2Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates; 3David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, United States; 4Harvard Medical School and Massachusetts General Hospital, Boston, MA, United States; 5Emory University, Atlanta, GA, United States; 6University of Cincinnati, Cincinnati, OH, United States; 7Weill Cornell Medical Center, New York, NY, United States

Impact of HCV Coinfection On T-Cell Dynamics in Long-Term HIVSuppressors Under CART

Olivia Zaegel 1, Sylvie Bregeon 1, Carla E. Cano 1, Véronique Oby- Raguët 1, Corinne Nicolino-Brune 1, Catherine Tamalet 1,2, Françoise Dignat-George 1, Isabelle Poizot-Martin 1,2
1Immuno-Hematological Clinical Unit, Aix Marseille University, APH, Sainte Marguerite Hospital, Marseille, France; 2Service d’Hematologie et de Biologie Vasculaire, Aix Marseille University, APH, Conception Hospital, Marseille, France; 3Fédération de Microbiologie Hospitalière, Aix Marseille University, APH, Timone Hospital, Marseille, France; 4URMITE CNRS-IRDUMR 6236, Marseille, France; 5INSERM U912 (SESSTIM), Marseille, France

HCV Viremia and the Risk of Acute Myocardial Infarction

Adeel A. Butt 1,2, Kara W. Chew 1, Kathleen Corey 1, Raymond T. Chung 1, Javed Butler 1, Kenneth E. Sherman 2, Matthew S. Freiberg 1, Sebhat Erqou 7
1University of Pittsburgh School of Medicine and VA Pittsburgh Healthcare System, Pittsburgh, PA, United States; 2Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates; 3David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, United States; 4Harvard Medical School and Massachusetts General Hospital, Boston, MA, United States; 5Emory University, Atlanta, GA, United States; 6University of Cincinnati, Cincinnati, OH, United States; 7Weill Cornell Medical Center, New York, NY, United States
**Incidence Rates and Risk Factors for Severe Bacterial Infections in HIV/HCV-Coinfected Patients**

Kathleen C. Rollet, John Gill, Curtis Cooper, Mark Huff, Joseph Cox, Bryan Conway, Neora Pick, Marie-Louise Vachon, Marina B. Klein

Division of Infectious Diseases and Chronic Viral Illness Service, McGill University Health Centre, Montreal, QC, Canada; Southern Alberta HIV Clinic, Calgary, AB, Canada; The Ottawa Hospital – General Campus, Ottawa, ON, Canada; BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada; The Ottawa Hospital – General Campus, Ottawa, ON, Canada; Montreal General Hospital, Montreal, QC, Canada; Vancouver Infectious Diseases Research and Care Centre, Vancouver, BC, Canada; Oak Tree Clinic, Vancouver, BC, Canada; Centre Hospitalier Universitaire de Quebec, Quebec, QC, Canada

**Association of HIV and HCV Coinfection With Cardiovascular Disease Outcomes Among US Veterans**

Sebah E. Eroqu, Arpan Mohanty, Adee A. Buttl

1Hospital Medicine, Weill Cornell Medical College, New York, NY, United States
2Yale School of Medicine, New Haven, CT, United States
3Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States

**HCV Accelerates Non-Liver Mortality in HIV-Infected Patients: A Nationwide Cohort Study**

Vincent Malelet, Sophie Thiebaut, Yvannet Yazdanpanah, Stanislas Poi, Michael Schwarzer


**Increased Hepatitis B Virus Coinfection Screening Following a Change in Zambian HIV Guidelines**

Kalo Musukuma, Arianna Zanolini, Lloyd Mulenga, Carolyn Bolton-Moore, Samuel Zuercher, Izuanki Sikazwe, Aggrey Mwambia, Gilles Wandelier, Benjamin H. Chi, Michael J. Vinkoor

1Centre for Infectious Disease Research in Zambia, Lusaka, Zambia; 2Institute of Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States; 3University Teaching Hospital, Lusaka, Zambia; 4Obstetrics and Gynecology, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States; 5Institute for Infectious Diseases, University of Bern, Bern, Switzerland; 6Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland

**Increased Hepatitis B Virus Coinfection Screening Following a Change in Zambian HIV Guidelines**

Kalo Musukuma, Arianna Zanolini, Lloyd Mulenga, Carolyn Bolton-Moore, Samuel Zuercher, Izuanki Sikazwe, Aggrey Mwambia, Gilles Wandelier, Benjamin H. Chi, Michael J. Vinkoor

1Centre for Infectious Disease Research in Zambia, Lusaka, Zambia; 2Institute of Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States; 3University Teaching Hospital, Lusaka, Zambia; 4Obstetrics and Gynecology, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States; 5Institute for Infectious Diseases, University of Bern, Bern, Switzerland; 6Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland

**Isolated Hepatitis B Core Antibody Is Associated With Advanced Hepatic Fibrosis**

Debika Bhattacharya, Chi-hong Tseng, Jan Tate, Vincent Lo, Cynthia Gibert, Joseph K. Lim, Maria Rodriguez-Barradas, David Rimland, Amy S. Justice, Matthew B. Goetz

1David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, United States; 2VA Pittsburgh Healthcare System, Pittsburgh, PA, United States; 3University of Pittsburgh School of Medicine, Pittsburgh, PA, United States; 4David Geffen School of Medicine at UCLA, Los Angeles, CA, United States; 5VA Pittsburgh Healthcare System, Pittsburgh, PA, United States; 6University of Pittsburgh School of Medicine, Pittsburgh, PA, United States; 7Montefiore Medical Center, Bronx, NY, United States; 8University of California San Francisco, San Francisco, CA, United States

**Isolated Hepatitis B Core Antibody and Hepatic Fibrosis in HIV/HCV-Coinfected Women**

Audrey L. French, Anna Hutton, Mary Young, Marek Nowicki, Michael Augenbraun, Kathryn Anastos, Marion Peters

1Division of Infectious Diseases, Stroger Hospital of Cook County, Chicago, IL, United States; 2VA Chicago Healthcare System, Chicago, IL, United States; 3VA Chicago Healthcare System, Chicago, IL, United States; 4VA Chicago Healthcare System, Chicago, IL, United States; 5VA Greater Los Angeles Healthcare System, Los Angeles, CA, United States; 6VA Greater Los Angeles Healthcare System, Los Angeles, CA, United States; 7David Geffen School of Medicine at UCLA, Los Angeles, CA, United States; 8University of California San Francisco, San Francisco, CA, United States

**Therapeutic Management and Evolution of Chronic Hepatitis B: Does HIV Coinfection Still Matter?**

Lionel Piroth, Stanislas Poi, Patrick Mailhes, Karine Lacombe, Amanda Lopes, Francois Borsa-Lebas, Dominique Salmon, Eric Rosenhall, Fabrice Carrat, Patrice Casaubon

1Infectious Diseases Department, CHU, and UMR 1347, University of Burgundy, Dijon, France; 2Institut Cochin, CNRS (UMR 8104), INSERM U-1016, Paris, France, France; 3Hospices Civils de Lyon, Hôpital de la Croix-Rousse, Service des Maladies Infectieuses et Tropicales, and INSERM U1052, Lyon, France; 4Infectious Diseases Department, CHU, and UMR-S707, University Pierre and Marie Curie, Paris, France; 5Université Paris Diderot and AP-HP, Service de Medicine Interne A, Hopital Lariboisière, Paris, France; 6Infectious Diseases, Hôpital Charles Nicolle, Rouen, France; 7Infectious Pathology Unit, Cochin Hospital, Paris Descartes University, Paris, France; 8Department of Internal Medicine, CHU and University of Nice Sophia Antipolis, Nice, France; 9UPMC Université Paris 06, UMR-S707, INSERM U-707, AP-HP, Public Health Department, Groupe Hospitalier Est Parisien, Paris, France; 10UPMC Université Paris 06, UMR 7211, INSERM, UMR_S 959, Department of Internal Medicine, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
697 Effectiveness of Taiwan Nationwide HBV Vaccination in Persons at Risk for HIV Infection
Hsin-Yun Sun1, Chia-Jui Yang2, Nan-Yao Lee3, Shiou-Haur Liang4, Chien-Chung Hung5
1National Taiwan University Hospital, Taipei, Taiwan, 2Far Eastern Memorial Hospital, New Taipei City, Taiwan, 3National Cheng Kung University Hospital, Tainan, Taiwan, 4E-Da Hospital, Kaohsiung, Taiwan

698 Hepatitis B Virus Mother-To-Child-Transmission Among HIV-Infected Pregnant Women in Kenya
Timothy D. Minniear1,2, Alex Morwabe3, Sonali Girde4, Fredrick Harrison5, Frank Angira6, Boaz Oyaro7, Lisa A. Mills8,9, Clement Zeh10, Philip J. Peters11
1CDC, Atlanta, GA, United States, 2St. Jude Children’s Research Hospital, Memphis, TN, United States, 3KEMRI/CDC Research and Public Health Collaboration, Kisumu, Kenya, 4ICF International, Atlanta, GA, United States, 5KEMRI/CDC Research and Public Health Collaboration, Kisumu, Kenya

699 Vaccine Escape Mutants and Suboptimal Hepatitis B Virus Response in HIV HBV Coinfected Patients
Anders Boyd1, Raoul Moh1, Paul Déry2, Mariama Issoufou3, Christine Daniel4, Xavier Anglaret1,2, Serge Enhö2, Pierre-Marie Girard3, Fabien Zoulim4, Karine Lacombe5
1Inserm UMR-S707, Paris, France, 2Programme PACC1, Abidjan, Côte D’Ivoire, 3Centre de Recherche sur le Cancer de Lyon, Equipes 15 et 16, INSERM, Unité 1052, CNRS, UMR 5296, Lyon, France, 4Department of Infectious and Tropical Diseases, Saint-Antoine Hospital, Paris, France

700 Long-Term Benefit of Tenofovir On Hepatitis Delta
Rocio Sierra-Enguita, Zulema Plaza, Eugenia Vispo, Pablo Barreiro, Pablo Labarga, José Vicente Fernández-Montero, Carmen De Mendoza, Vicente Soriano
Infectious Diseases, Hospital Carlos III, Madrid, Spain

Session P-N10 Poster Session
Thursday March 6, 2014, 2:30 PM—4:00 PM Exhibit Hall B

633 Chronic Hepatitis E Virus Infection Is Uncommon in HIV-Infected Patients
Antonio Rivero-Juárez1, Loreto Martínez-Dueñas1, Antonio Martínez-Peinado2, Angela Camacho3, Celia Cifuentes3, Ana Gordon3, Mario Firas4, Julian Torre-Cisneros5, Juan A. Pineda6, Antonio Rivero7
1Infectious Diseases, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Córdoba, Spain, 2Clinical Analysis, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Córdoba, Spain, 3Infectious Diseases, Hospital Universitario de Valme, Córdoba, Spain

634 High Frequency of HEV Seropositivity in HIV-Infected Patients in Southern Spain
Unit of Infectious Diseases and Microbiology, Hospital Universitario de Valme, Seville, Spain

Session P-O2 Poster Session
Tuesday March 4, 2014, 2:30 PM—4:00 PM Exhibit Hall B Cancer: Natural History and Epidemiology

704 Risk of Cancer Among HIV Patients Compared To the Background Population: Impact of Smoking and HIV
Marie Helleberg1, Jan Gerstoft2, Shoaib Afzal3, Gitte Kronborg4, Carsten S. Larsen1, Stig E. Bojesen5, Court Pedersen5, Börge G. Nordestgaard6, Niels Obel6
1Department of Infectious Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen Ø, Denmark, 2Department of Clinical Biochemistry, Copenhagen University Hospital, Herlev, Herlev, Denmark, 3Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, Hvidovre, Denmark, 4Department of Infectious Diseases, Aarhus University Hospital, Skejby, Aarhus, Denmark, 5Department of Infectious Diseases, Odense University Hospital, Odense, Denmark

705 Cancer Stage at Diagnosis in HIV-Infected Individuals and Transplant Recipients
Meredith S. Shiel1, Glenn Copeland2, Marc Goodman3, Charles F. Lynch4, Karen Pawlish1, Ruth M. Pfeiffer4, Jon J. Snyder5, Eric A. Engels6
1National Cancer Institute, Bethesda, MD, United States, 2Michigan Department of Community Health, Lansing, MI, United States, 3Cedars Sinai Hospital, West Hollywood, CA, United States, 4University of Iowa, Iowa City, IA, United States, 5New Jersey Department of Health, Trenton, NJ, United States, 6Scientific Registry of Transplant Recipients, Minneapolis, MN, United States

Yi-Ming A. Chen1, Marcelo Chen2, Ian Jen3, Matthew G. Law4, Kishor Bhattia5, Gerald B. Sharp6
1Center for Infectious Disease and Cancer Research (CICAR), KMU, Taiwan, Kaohsiung Medical University, Taiwan, Kaohsiung City, Taiwan, 2Department of Urology, Mackay Memorial Hospital, Taipei, Taiwan, 3Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan, 4Division of AIDS, National Institute of Health, National Yang-Ming University, Taipei, Taiwan, 5Kirby Institute, University of New South Wales, Sydney, Australia, Sydney, Australia, 6AIDS Malignancy Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA, Bethesda, MD, United States, 7Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA, Bethesda, MD, United States

707 Excess Burden of Cancer Among HIV-Infected Persons in the United States
Hilary A. Robbins1, Meredith S. Shiel1, Ruth M. Pfeiffer2, Jianmin Li3, H. Irene Hall4, Eric A. Engels1
1Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, United States, 2National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, United States

Session P-O4 Poster Session
Wednesday March 5, 2014, 2:30 PM—4:00 PM Exhibit Hall B Kaposi Sarcoma, PEL, and KSHV

708 The Effect of Protease Inhibitor Use on Kaposi Sarcoma Incidence in a CART-Experienced Cohort
Elizabeth Chiao1, Marc Kowalkowski1,2
1Baylor College of Medicine, Houston, TX, United States, 2University of North Carolina at Chapel Hill, Chapel Hill, NC, United States

703 Different Immunologic and Virologic Contexts for HIV-Associated Lymphoma in the CNICS Cohort
Satish Gopal1, Morita Patel1, Chad Achenbach2, Elizabeth Yanik3, Stephen Cole4, Sonia Napravnik5, Kristy Richards1, Joseph Eron5, for the CNICS Investigators
1University of North Carolina at Chapel Hill, Chapel Hill, NC, United States, 2Northwestern University, Chicago, IL, United States
710 Randomized Trial of Protease Inhibitor-Based Antiretroviral Therapy for Kaposi Sarcoma in Africa
Jeffrey Martin1, Miriam Laker-Oketta2,3, Victoria Walusansa4, Jackson Greim1, John Bennett1, Adrienne Mocellino4, Toby Maurer4, Peter Hunt1, Andrew Kambuugo5, Edward Mbidde4,4
1University of California San Diego, La Jolla, CA, United States, 2Mbarara University of Science and Technology, Mbarara, Uganda, 3Infectious Diseases Institute, Kampala, Uganda, 4Department of Medical Laboratory Sciences, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe

711 Kaposi Sarcoma in the Era of Combination Antiretroviral Therapy
Natascha Wyss, Matthias Egger, Julia Bohlius, Malignancy Working Group for COHEREx EuroCoord, Department of Social and Preventive Medicine, University of Bern, Bern, Switzerland

712 Vitamin D Insufficiency in AIDS-Associated Kaposi Sarcoma in Zimbabwe
Kristine M. Erlandson1, ivy Gudza2, Suzanne Fiorillo3, Buxton Ndemera3, Robert T. Schooley3, Lovemore Gwanzura4, Margaret Borok2, Thomas B. Campbell1
1University of Colorado Anschutz Medical Campus, Aurora, CO, United States, 2Department of Medicine, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe, 3Infectious Diseases, University of California San Diego, San Diego, CA, United States, 4Department of Medical Laboratory Sciences, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe

713 Patients From a Single Institution
Stephanie Guillet1, Laurence Gerard2,3, Veronique Meignin2, Felix Agbalika4, Wendy Cuccuini5, Lionel Galicier6, Eric Oksenhendler7
1Department of Health Sciences, Clinic of Infectious Diseases, San Paolo Hospital, Milan, Italy, 2Departments of Biomedical and Clinical Sciences, “San Paolo Hospital,” University of Milan, Milan, Italy, 3Titu Maiorescu University, Bucharest, Romania, 4Infectious Diseases Unit, University Hospital Virgen de las Nieves, Granada, Spain, 5Pathology Service, University Hospital Virgen de las Nieves, Granada, Spain, 6University of California San Diego, La Jolla, CA, United States, 7Gynaecology and Obstetrics, R.K. Kahn Hospital, Chatsworth, South Africa, 8Boston Children’s Hospital, Boston, MA, United States

714 Indoleamine 2,3-Dioxygenase (IDO) Activity as a Determinant of Kaposi Sarcoma in Africa
Helen Byakwaga1,2, Peter W. Hunt1, Miriam Laker-Oketta3,4, David V. Glidden3, Hong Nguyen3, Mwebesa Mwebesa4, Victoria Walusansa5, David R. Bangsberg6, Edward Mbidde7, Jeffrey N. Martin8
1University of California San Diego, La Jolla, CA, United States, 2Infectious Diseases Institute, Kampala, Uganda, 3Infectious Diseases Institute, Kampala, Uganda, 4Department of Medical Laboratory Sciences, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe, 5Infectious Diseases Institute, Kampala, Uganda, 6Harvard Medical School, Massachusetts General Hospital, Center for Global Health, Boston, MA, United States

715 Epidemiology and Dynamics of HPV Infection in Romanian Women Infected With HPV in Early Childhood
Sanjay R. Mehta1, Lumi Ene2, Cristina Voinea3, Claudia Stefanescu4, Diana Sima2, Dan Duculescu3,3
1Medicine, University of California San Diego, La Jolla, CA, United States, 2“Dr. Victor Babes” Hospital for Infectious and Tropical Diseases, Bucharest, Romania, 3Titu Maiorescu University, Bucharest, Romania

716 Baseline Data of a Phase 3 Trial of the Quadrivalent HPV Vaccine in HIV+ Males and Females: ACTG 5298
Ross Cranston1, Ming Yang1, Pawel Paczuski2, Michelle Cespedes3,1, Elizabeth Chiao1, Jennifer Webster-Cyriac1, Catherine Godfrey4,5, Timothy Wilkin6
1Department of Medicine, University of California San Diego, La Jolla, CA, United States, 2Health Sciences, Faculty of Medicine and Health Sciences, Harare, Zimbabwe, 3Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States, 4Department of Medicine, University of North Carolina at Chapel Hill, NC, United States, 5Weill Cornell Medical College, New York, NY, United States, 6Department of Dermatology, University of California at San Francisco, San Francisco, CA, United States

717 Cervical Abnormalities in HIV-Infected South African Women With High Screening and Referral Rates
Ingrid T. Katz1,2, Alexi A. Wright2,3, Tamaryn L. Crankshaw4, Janet Giddy5,6, Sean Mould7, Lisa M. Butler2,8
1Medicine, Brigham and Women’s Hospital, Boston, MA, United States, 2Harvard Medical School, Boston, MA, United States, 3Medicine, Harvard University, Cambridge, MA, United States, 4New York University School of Medicine, New York, NY, United States, 5Houston VA Medical Center, Houston, TX, United States, 6University of North Carolina at Chapel Hill, Chapel Hill, NC, United States, 7Department of Medicine, University of Cape Town, Cape Town, South Africa, 8Gynaecology and Obstetrics, R.K. Kahn Hospital, Chatsworth, South Africa, 9Boston Children’s Hospital, Boston, MA, United States

Session P-06 Poster Session
Thursday March 6, 2014, 2:30 PM–4:00 PM Exhibit Hall B
Anal Cancer and HPV

718 Prevalence of Anal Dysplasia in HIV-Infected Women From Johannesburg, South Africa
Bridgette Goeiemans1,2, Cynthia Finnhaber2,3, Pamela Michelow2,3, Avril Swarts4, Jennifer S. Smith4, Timothy Wilkin5
1University of Witwatersrand, Johannesburg, South Africa, 2Right to Care, Johannesburg, South Africa, 3National Health Laboratory Services, Johannesburg, South Africa, 4University of North Carolina, Chapel Hill, NC, United States, 5Weill Cornell Medical College, New York, NY, United States

719 Mucosal and Systemic Immune Responses in HIV/HPV Co/Infected Males
LAURA COM1, Camilla Tincati1, Giusi Maria Bellistrì1, Alessandro Pandolfo2, Javier Sanchez Martinez2, Veronica Rainone2, Marco Roveri2, Daria Trabattoni3, Antonella d’Arminio Monforte1, Giulia Marchetti1
1Department of Health Sciences, Clinic of Infectious Diseases, San Paolo Hospital, Milan, Italy, 2Departments of Biomedical and Clinical Sciences “L. Sacco” and of Physiotherapy and Transplantation, University of Milan, Milan, Italy, 3Department of Health Sciences, Surgery Chair, “San Paolo Hospital,” University of Milan, Milan, Italy

720 Natural History of HIV-Related Anal Dysplasia: A Multi-State Modeling Analysis
Woolivow W. Agmas1, Edward R. Cachay2, Christopher Jackson3, Wm. Christopher Mathews4
1Internal Medicine, University of California San Diego, La Jolla, CA, United States, 2Public Health, Medical Research Council Biostatistics Unit, Cambridge, United Kingdom

721 Antiretroviral Therapy as Protector Factor of Anal Dysplasia in HIV-Infected MSM
Carmen Hidalgo Tenorio1, Concepcion Gil Anguita1, Jessica Ramirez Taborda1, Juan Gabriel Martinez Cará1, Javier Esquivias2, Pablo Palma3, Mar Rivero1, Rosario Javier Martinez1, Miguel Angel Lopez Ruiz4, Juan Pasquau Llafu5
1Infectious Diseases Unit, University Hospital Virgen de las Nieves, Granada, Spain, 2Gastroenterology Service, University Hospital Virgen de las Nieves, Granada, Spain, 3Pathology Service, University Hospital Virgen de las Nieves, Granada, Spain, 4General Surgery Service, University Hospital Virgen de las Nieves, Granada, Spain
Session P-P1 Poster Session

Tuesday March 4, 2014, 2:30 pm–4:00 pm

Heart Failure, Cardiac Steatosis, and HIV

723 Elevated NT-proBNP Levels Predict Mortality in HIV-Infected Women
Matthew R. Gingo1, Kidane Ghebrehiwot2, Jong-Hyeon Jeong3, Yanxia Chu4, Quanwei Yang4, Lorrie Lucht1, David Hanna2, Jason Lazar3, Mark Gladwin4, Yingze Zhang4, Alison Morris4
1University of Pittsburgh, Pittsburgh, PA, United States; 2Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY, United States; 3SUNY Downstate Medical Center, Brooklyn, NY, United States; 4University of Pittsburgh, Pittsburgh, PA, United States

724 Cardiac Steatosis Increased in HIV: Related To Gender, Visceral Fat and ARV Exposure
Julia B. Purdy1, Chia-Ying Lii1, Sabrina Mangat1, Horacio Duarte2, Diana Thiera3, Nancyanne Schmidt3, Jamie Hur4, Christopher T. Sibley1, David A. Bluemke2, Colleen Hadigan1
1Critical Care Medicine, National Institutes of Health, Bethesda, MD, United States; 2Diagnostic Radiology Department, National Institutes of Health, Bethesda, MD, United States; 3National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States; 4University of Washington School of Medicine, Seattle, WA, United States; 5Vanderbilt University School of Medicine, Nashville, TN, United States; 6Stony Brook University School of Medicine, Stony Brook, NY, United States; 7Drew University College of Medicine, Philadelphia, PA, United States

725 ST2 and GDF-15 Are Associated With Structural Heart Disease and Mortality in HIV
Eric Secemsky1, Rebecca Scherzer1, Elaine Nitta1, Alan Wu1, David Lange1, Steven Deeks2, Jeffrey Martin2, James Snider3, Peter Ganz3, Priscilla Hsu1
1UCSF, San Francisco, CA, United States; 2University of California San Francisco, San Francisco, CA, United States

726 Depression and HIV Are Risk Factors for Incident Heart Failure Among Veterans
Jessica R. White1, Chung-Chou H. Chang2, Adesil A. Bult3, Hilary A. Tindle4, Maria C. Rodriguez Barradas1,4, David Riland1,2, David Leaf1,2, Matthew Buddoff1,2, Amy C. Justice2,12, Matthew S. Freiberg3
1University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, United States; 2University of Pittsburgh School of Medicine, Pittsburgh, PA, United States; 3Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, United States; 4University of Pittsburgh, Pittsburgh, PA, United States; 5University of Bern, Bern, Switzerland; 6Bern University Hospital, Bern, Switzerland; 7University Hospital St. Gallen, St. Gallen, Switzerland; 8University Hospital Geneva, Geneva, Switzerland; 9University Hospital Lausanne, Lausanne, Switzerland; 10Veterans Affairs Medical Center, Torrance, CA, United States; 11Johns Hopkins University, Baltimore, MD, United States; 12University of California San Francisco, San Francisco, CA, United States

Session P-P2 Poster Session

Tuesday March 4, 2014, 2:30 pm–4:00 pm

Immune Activation, Immunodeficiency, and CVD

727 Impact of Low CD4 Count and HIV Persistence On Endothelial Function in Patients With Low Plasma RNA
Amanda Schnell Heringer1, Hiroyu Hatano2, Peter W. Hunt3, Yunuer Wu4, Yifen Ma5, Rebecca Scherzer6, Jeffrey N. Martin7, Peter Ganz8, Steven G. Deeks3, Priscilla Y. Hsu1
1Division of Cardiology, San Francisco General Hospital, University of California San Francisco, San Francisco, CA, United States; 2Positive Health Program, University of California San Francisco, San Francisco, CA, United States; 3Division of Adolescent Medicine, University of California San Francisco, San Francisco, CA, United States; 4Veterans Administration Medical Center, University of California San Francisco, San Francisco, CA, United States; 5Vanderbilt University School of Medicine, Nashville, TN, United States; 6Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, United States

728 Carotid Dendritic Cells and Immune Activation in HIV-Infected Patients Without Coronary Calcium
Chris T. Longenecker1, Ying Jiang1, Sara Debanne1, Grace A. McComsey1,2
1Case Western Reserve University, Cleveland, OH, United States; 2University Hospitals Case Medical Center, Cleveland, OH, United States

729 Microvascular Disease in Controllers Is Mediated by HIV DNA and Immune Dysfunction
Hiroyo Hatano1, Yifen Ma2, Rebecca Scherzer3, Yunuer Wu4, Elaine Nitta5, Kara Harville6, Elizabeth Sinclair7, Michael P. Busch8,9, Steven G. Deeks1, Priscilla Y. Hsu1
1Medicine, University of California San Francisco, San Francisco, CA, United States; 2Pediatrics, University of California San Francisco, San Francisco, CA, United States; 3San Francisco Veterans Affairs Medical Center, San Francisco, CA, United States; 4Laboratory Medicine, University of California San Francisco, San Francisco, CA, United States; 5Blood Systems Research Institute, San Francisco, CA, United States

730 Monocyte But Not Cellular Activation Is Associated With Coronary Atherosclerosis in the MACS
Eric S. Daar1, Wendy S. Post2, Annie T. Darilay3, Peter W. Hunt4, Todd T. Brown4, Rebecca McKibben5, Beth Jamieson4, Mathew J. Budoff1, Mallory D. Witt1
1Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, United States; 2Johns Hopkins University, Baltimore, MD, United States; 3University of California San Francisco, San Francisco, CA, United States; 4David Geffen School of Medicine at UCLA, Los Angeles, CA, United States

Session P-P3 Poster Session

Wednesday March 5, 2014, 2:30 pm–4:00 pm

Alcohol, Smoking, and Atherosclerosis

731 The J-Curve in HIV: Better Cardiovascular-Disease-Free Survival With Moderate Alcohol Intake
Gilles Wandelier1,2, David Kraus3, Jan Fehr2, Anina Conen1, Alexander Calmy1, Christina Orasch1, Manuel Battegay2, Patrick Schmidt2, Enoi Bernasconi1, Hansjakob Furrer1
1Swiss HIV Cohort Study; 2University of Bern, Bern, Switzerland; 3Bermingham Medical School, Birmingham, United Kingdom

732 Soluble CD14 and D-Dimer Are Associated With Smoking and Heavy Alcohol Use in HIV-Infected Adults
Patricia A. Cioe1, Jason Baker2, John Hammer1, Erna M. Koci3, Nur Onen1, Pragati Patil1, Christopher W. Kahler1
1Center for Alcohol & Addiction Studies, Brown University, Providence, RI, United States; 2University of Minnesota Medical School, Minneapolis, MN, United States; 3Denver Infectious Disease Consultants, Denver, CO, United States; 4Department of Infectious Diseases, Brown University, Providence, RI, United States; 5School of Medicine, Washington University, St. Louis, MO, United States; 6Centers for Disease Control and Prevention, Atlanta, GA, United States; 7Behavioral & Social Sciences, Brown University, Providence, RI, United States

733 Antiviral Therapy and Smoking Associated With Coronary Vessel Thickening in HIV-Infected Youth
Aylin Ussal1, Khaled Z. Abd-Elmoniem2, Sarah Eshera2, Julia B. Purdy2, Rohan Hazra3, Colleen Hadigan4, Ahmed M. Gharib2
1Center for Applied Medical Research, St. Vincent’s Hospital, Darlinghurst, NSW, Australia; 2The Kirby Institute, Sydney, NSW, Australia

Poster Abstracts

Program and Agenda
Session P-P4 Poster Session  
Wednesday March 5, 2014, 2:30 PM–4:00 PM  
Exhibit Hall B  
Risk Factors and Incidence: MI and Stroke

### 734 HIV Infection and the Risk of Cardiovascular Disease in Women


School of Nursing, Yale University, New Haven, CT, United States  
University of Pittsburgh School of Medicine, Pittsburgh, PA, United States  
Vanderbilt University School of Medicine, Nashville, TN, United States  
VA Greater Los Angeles Healthcare System, Los Angeles, CA, United States  
David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, United States  
VA Medical Center, Washington, DC, United States  
George Washington University School of Medicine, Washington, DC, United States  
James J. Peters VA Medical Center, Bronx, NY, United States  
Mount Sinai School of Medicine, New York, NY, United States  
Yale University School of Medicine, New Haven, CT, United States  
University of Pittsburgh School of Medicine, Pittsburgh, PA, United States  
University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, United States

**Depression Predicts Incident Myocardial Infarction in HIV+ Veterans: Veterans Aging Cohort Study**

**Tasneem Khambhaty**, Jese C. Stewart, Samir K. Gupta, Chung-Chou H. Chang, Adedei A. Butts, Cynthia L. Gilbert, Hilary A. Tindle, Heidi Crane, Roger Bedimo, Matthew S. Freiberg, on behalf of the VACS project team  

Psychology, Indiana University-Purdue University Indianapolis (IUPUI), Indianapolis, IN, United States  
Infectious Diseases, Indiana University School of Medicine, Indianapolis, IN, United States  
University of Pittsburgh School of Medicine, Pittsburgh, PA, United States  
George Washington University School of Medicine, Washington, DC, United States  
University of Washington School of Medicine, Seattle, WA, United States  
University of North Carolina at Chapel Hill, NC, United States  
University of California, San Francisco, San Francisco, CA, United States

### 735 HIV Infection, Cardiovascular Risk Factor Profile, and Risk for Acute Myocardial Infarction

**Anne-Lise Paisable**, Joyce Chang, Kaku Armah, Matthew B. Goetz, Adedei A. Butts, Maria C. Rodriguez-Barradas, David Rimland, Sheldon T. Brown, Amy C. Justice, Matthew S. Freiberg, the VACS Project Team  

Internal Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States  
Biostatistics, University of Pittsburgh School of Public Health, Pittsburgh, PA, United States  
Epidemiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, United States  
Veterans Affairs Greater Los Angeles Health Care System and David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, United States  
University of Pittsburgh School of Medicine and VA Pittsburgh Healthcare System, Pittsburgh, PA, United States  
University of Washington, Seattle, WA, Seattle, WA, United States  
University of North Carolina, Chapel Hill, NC, United States  
University of California, San Francisco, San Francisco, CA, United States

### 736 No Difference in Incidence of Myocardial Infarction for HIV+ and HIV- Individuals in Recent Years


Kaiser Permanente Northern California, Hayward, CA, United States  
Kaiser Permanente Northern California, Oakland, CA, United States  
Kaiser Permanente Southern California, Pasadena, CA, United States  
Kaiser Permanente Mid-Atlantic States, Rockville, MD, United States  
Kaiser Permanente Southern California, Los Angeles, CA, United States

### 738 MACE Incidence Among HIV- and Non-HIV-Infected Patients in a Clinical Care Cohort

**Virginia A. Triant**, Susan Regan, Steven Grinspoon  
Massachusetts General Hospital, Boston, MA, United States

### 739 Lower CD4 Count and Higher Viral Load Are Associated With Increased Risk of Myocardial Infarction


University of Washington, Seattle, WA, United States  
University of Alabama at Birmingham, Birmingham, AL, United States  
University of California, San Diego, San Diego, CA, United States  
Johns Hopkins University, Baltimore, MD, United States  
University of North Carolina, Chapel Hill, NC, United States  
University of California, San Francisco, San Francisco, CA, United States

### 740 Long-Term Effects of Nitrite Inhalants On Cardiovascular and Renal Outcomes in the MACS Cohort

**Alex Holman, Anupriya Dutta, Dana Gabuzda**  
Dana-Farber Cancer Institute, Boston, MA, United States

### 741 HIV Infection and Immunodeficiency as Risk Factors for Ischemic Stroke


Kaiser Permanente Northern California, Oakland, CA, United States  
Kaiser Permanente Southern California, Pasadena, CA, United States  
University of California San Francisco, San Francisco, CA, United States  
Kaiser Permanente Mid-Atlantic States, Rockville, MD, United States  
Kaiser Permanente Northern California, Hayward, CA, United States  
Kaiser Permanente Southern California, Los Angeles, CA, United States

### Session P-P5 Poster Session  
Thursday March 6, 2014, 2:30 PM–4:00 PM  
Exhibit Hall B  
Antiretroviral Therapy, Lipids, and CVD

### 742 Antiretroviral Therapy Is Associated With Significant Changes in Plasma Lipidome

**Janine M. Treviyan**, Gerard Wong, Rebekah Puls, Kathy Petoumenos, Sean Emery, Natalie Mellott, Peter J. Mellick, Jennifer F. Hylt  
Infectious Diseases, Alfred Health, Melbourne, Australia  
Department of Infectious Diseases, Monash University, Melbourne, Australia  
Melbionics, Baker IDI Heart and Diabetes Institute, Melbourne, Australia  
The Kirby Institute, Sydney, Australia

### 743 Rosuvastatin Lowers Cystatin C in HIV-Infected Subjects On Antiretroviral Therapy: SATURN-HIV

**Chris T. Longenecker**, Corilynn O. Hileman, Norma J. Storer, Dani E. Labatto, Grace A. McComsey  
Case Western Reserve University, Cleveland, OH, United States  
University Hospitals Case Medical Center, Cleveland, OH, United States  
MetroHealth Medical Center, Cleveland, OH, United States

### 744 Abacavir Induces Leukocyte Accumulation Through the Interaction of ATP and P2X7 Receptors

**Carmen de Pablo**, Samuel Orden, Ofir Ruiz-Navarro, Maria Angeles Martinez-Cuesta, Juan V. Esplugues, Angeles Alvarez, Carmen de Pablo, Samuel Orden, Ofir Ruiz-Navarro, Maria Angeles Martinez-Cuesta, Juan V. Esplugues, Angeles Alvarez, Carmen de Pablo, Samuel Orden, Ofir Ruiz-Navarro, Maria Angeles Martinez-Cuesta, Juan V. Esplugues, Angeles Alvarez, Carmen de Pablo, Samuel Orden, Ofir Ruiz-Navarro, Maria Angeles Martinez-Cuesta, Juan V. Esplugues, Angeles Alvarez
745 LDL Particles and Lipoprotein-Phospholipase A2 in Naive HIV+ Patients Randomized To DRV/r vs ATV/r Maria Saumoy1, Jordi Ordóñez-Llano2, Esteban Martínez2, Elena Ferrer1, Gracia Mateo1, Esteban Ribera2, Eugenia Negroso2, Ifaki Perez2, Daniel Podzamczer1
1Hospital Universitari de Bellvitge, Hospital de Llobregat, Spain; 2Biochemistry Department, Biomolecular Research Institute IIB Sant Pau, Barcelona, Spain; 3Hospital Clinic, Barcelona, Spain; 4Hospital de Sant Pau, Barcelona, Spain; 5Hospital Universitari Vall d’Hebron, Barcelona, Spain; 6Fundación Lluita contra la Sida, Hospital Germans Trias i Pujol, Badalona, Spain

746 Darunavir or Atazanavir andRaltegravir Lipid Changes Are Unlinked To Ritonavir Exposure: ACTG 5257 Ighowherfa Ototokun1, Heather Ribaudo2, Lumine Na3, Grace McComsey2, Susan E. Cohn1, Catherine Godfrey4, Manish Sagar5, Frances Aweka6, Jeffrey LeNoo7, Judith Currier8
1Department of Medicine, Emory University School of Medicine, Atlanta, GA, United States; 2Harvard University, Boston, MA, United States; 3Case Western Reserve University, Cleveland, OH, United States; 4Northwestern University, Chicago, IL, United States; 5National Institute of Allergy and Infectious Diseases, Bethesda, MD, United States; 6University of California San Francisco, San Francisco, CA, United States; 7University of California Los Angeles, Los Angeles, CA, United States

751LB After 52 Weeks, Pitavastatin Is Superior To Pravastatin for LDL-C Lowering in Patients With HIV Craig A. Spoonteller1, Judith Abrey2, INTREPID Team 1Medical Affairs, Kowa Pharmaceuticals America, Inc., Montgomery, AL, United States; 2Chief, Division of Infectious Diseases, ICAHN School of Medicine at Mount Sinai, New York, NY, United States

752 Endothelial Progenitor Cells Increase in Older HIV-Infected Patients Receiving Telmisartan Jordan E. Lake, Theodoros Kelesidis, Diana H. Liao, Judith S. Currier, Otto O. Yang University of California Los Angeles, Los Angeles, CA, United States

Session P-Q1 Poster Session Tuesday March 4, 2014, 2:30 PM–4:00 PM Exhibit Hall D Biomarkers and Non-AIDS Events

753 Incidence of CD4/CD8 Ratio Normalization and Its Role in the Onset of Non-AIDS-Related Events Cristina Mussini1, Patrizia Lorenzini1, Alessandro Cozzi-Leprì3, Giuseppe Lapadula1, Giulia Marchetti1, Emanuela Nacosti1, Antonella Cingolani1, Miriam Lichtner2, Andrea Antinori1, Antonella d’Arminio Monforte1,2 for the ICONA Foundation Study Group 1University of Modena and Reggio Emilia, Modena, Italy; 2INMI L. Spallanzani, Rome, Italy; 3University College London, London, United Kingdom; 4San Gerardo Hospital, Monza, Italy; 5University of Milan, Milan, Italy; 6Catholic University, Rome, Italy; 7La Sapienza University Polo Pontino, Rome, Italy

754 Longitudinal Changes in Free Testosterone Among Older HIV-Infected and HIV-Uninfected Men Laurence Smaila1,2, Lisa P. Jacoboni1,2, Xiaohong Li3, Frank J. Palella1, Joseph B. Margolick4, Lawrence Kingsley5, Dorothy Wiley6, Gilles Pialoux1, Adrian Dube7, Todd T. Brown8
1Infectious Diseases, Tenon Hospital, Paris, France; 2Infectious Diseases, Northwestern University, Feinberg School of Medicine, Chicago, IL, United States; 3Epidemiology, Johns Hopkins University, Baltimore, MD, United States; 4Infectious Diseases, Johns Hopkins University, Baltimore, MD, United States; 5Infectious Diseases, University of Pittsburgh, Pittsburgh, PA, United States; 6School of Nursing, University of California, Los Angeles, CA, United States; 7Endocrinology, Diabetes, and Metabolism, Johns Hopkins University, Baltimore, MD, United States

755 Inflammatory Biomarkers in Chronic HIV Disease Predominantly Associate With Monocyte Activation Eleanor M. P. Wilson1, Amrit Singh2, Kathy Huipler Huisiekek3, Keith Henry-3, Ken Lichtenstein5, Pragna Patel1, John T. Brooks2, Irini Sereti1, Jason V. Baker5
1Lab of Immunoregulation, NIAID, NIH, Bethesda, MD, United States; 2University of Minnesota, Minneapolis, MN, United States; 3Hennepin County Medical Center, Minneapolis, MN, United States; 4National Jewish Health, Denver, CO, United States; 5CDC, Atlanta, GA, United States

756 Extrinsic Pathway Coagulation Factors Are Associated With Mortality During Treated HIV Disease Jason V. Baker, Kathleen Brummel-Ziedins2, Jacqueline Neuhaus1, James D. Neaton1, Russell P. Tracy, INSIGHT SMART and ESPRIT Study Groups 1Infectious Diseases, University of Minnesota, Minneapolis, MN, United States; 2Biochemistry, University of Vermont, Burlington, VT, United States; 3Biostatistics, University of Minnesota, Minneapolis, MN, United States

757 Correlates of Inflammatory Markers After One Year of Suppressive Antiretroviral Treatment (ART) Supriya Krishnan1, Ronald J. Bosch2, Benigno Rodriguez3, Peter W. Hunt4, Cara Willson5, Steven G. Deeks6, Michael M. Lederman7, Alan L. Landay8, Allan R. Tenorio9
1Harvard School of Public Health, Center for Biostatistics in AIDS Research, Boston, MA, United States; 2Division of Infectious Diseases and HIV Medicine, Case Western Reserve University School of Medicine, Cleveland, OH, United States; 3Positive Health Program, Department of Medicine, San Francisco General Hospital, University of California, San Francisco, CA, United States; 4Division of Infectious Diseases, University of Colorado Hospital, Denver, CO, United States

Program and Agenda

Poster Abstracts

750 Rosuvastatin Lowers Oxidative LDL in HIV-Infected Persons On Antiretroviral Therapy: SATURN-HIV Corrilyn O. Hileman1, Richard D. Semlar1, Randi Turner1, Danielle E. Labatto4, Norma J. Storer1, Grace A. McComsey1,4 1Case Western Reserve University School of Medicine, Cleveland, OH, United States; 2MetroHealth Medical Center, Cleveland, OH, United States; 3Wilmot Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, United States; 4University Hospitals Case Medical Center, Cleveland, OH, United States

Session P-P6 Poster Session Thursday March 6, 2014, 2:30 PM–4:00 PM Exhibit Hall B Statins and ARV Effects in HIV

751 Rosuvastatin Lowers Oxidative LDL in HIV-Infected Persons On Antiretroviral Therapy: SATURN-HIV Corrilyn O. Hileman1, Richard D. Semlar1, Randi Turner1, Danielle E. Labatto4, Norma J. Storer1, Grace A. McComsey1,4 1Case Western Reserve University School of Medicine, Cleveland, OH, United States; 2MetroHealth Medical Center, Cleveland, OH, United States; 3Wilmot Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, United States; 4University Hospitals Case Medical Center, Cleveland, OH, United States
758 Pro12Ala Polymorphism Is Associated With Metabolic Disturbance in HIV/HCV Coinfected Patients

Pilar García-Broncano 1, Juan Berenguer 2, 3, Amanda Fernández-Rodríguez 1, Daniel Pineda-Tenero 1, María A Jiménez-Sousa 1, Mónica García-Álvarez 4, Teresa Aïdámiz-Echevarria 5, Juan Carlos López 1, Dariea Micheloud 6, Salvador Resino 1, 2

1Unidad de Enfermedades Infecciosas/HIV, Hospital General Universitario “Gregorio Marañon,” Madrid, Spain; 2Instituto de Investigación Sanitaria Gregorio Marañón (IISGM), Madrid, Spain; 3Servicio de Medicina Interna, Hospital General Universitario “Gregorio Marañon,” Madrid, Spain; 4Unidad de Enfermedad Viral e Inmunidad, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Universitat Màjadahonda, Spain

Session P-Q2 Poster Session

Tuesday March 4, 2014, 2:30 PM – 4:00 PM Exhibit Hall D Diabetes and Insulin Resistance

767 Physical Function Impairment On Quality of Life Among Persons Aging With HIV Infection

Kristine M. Erlandson, Amanda A. Allhouse, Catherine M. Jankowski, Samantha MalWhinney, Wendy M. Kohrt, Thomas B. Campbell

University of Colorado Anschutz Medical Campus, Aurora, CO, United States

Session P-Q3 Poster Session

Tuesday March 4, 2014, 2:30 PM – 4:00 PM Exhibit Hall D Diabetes and Insulin Resistance

767 IL-6, hsCRP, and the Development of Type 2 Diabetes Among HIV Positive Patients Taking ART

Gclaude L. Bétiené A Dooko

School of Public Health, University of Minnesota, St Paul, MN, United States

770 Triglycerides/HDLO Ratio and Risk of Developing Diabetes Mellitus During Antiretroviral Therapy

Nicolò Squillace 1, Patrizia Lorenzini 1, Giuseppe Lapadula 1, Alessandro Cozzi-Lepri 2, Stefano Rusconi 2, Massimo Puoti 3, Antonella Castagna 3, Andrea Antinori 3, Andrea Gorî 4, Antonella d’Arminio Monforte 5, for the ICONA Foundation Study Group

1Infectious Diseases, Tenon Hospital, Paris, France; 2Infectious Diseases, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States; 3Epidemiology, Johns Hopkins University, Baltimore, MD, United States; 4Biochimie et Hormonologie, Tenon Hospital, Paris, France; 5UPMC Paris 6, UMR 939, Paris, France; 6University of Pittsburgh, Pittsburgh, PA, United States; 7Infectious Diseases, University of California Los Angeles, Los Angeles, CA, United States; 8Endocrinology and Metabolism, Johns Hopkins University, Baltimore, MD, United States

771 Measuring Physical Activity and its Impact On Insulin Resistance in MACS Men

Anne K. Monroe 1, Todd T. Brown 2, Christopher Cox 2, Dorothy Wiley 3, Douglas Kitch 2, Paul E. Sax 3, Eric S. Daar 4, Anne K. Monroe 1, Todd T. Brown 2, Christopher Cox 2, Dorothy Wiley 3, Douglas Kitch 2, Paul E. Sax 3, Eric S. Daar 4

1Medicine-HIV/AIDS, University of California San Francisco, San Francisco, CA, United States; 2Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States; 3Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, United States; 4UCLA School of Nursing, Los Angeles, CA, United States; 5Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States; 6Department of Infectious Diseases and Microbiology, School of Public Health, University of Pittsburgh, Pittsburgh, PA, United States; 7Medicine, Georgetown University School of Medicine, Washington, DC, United States

772 Impact of Randomized Antiretroviral Therapy (ART) Initiation On Glucose Metabolism: ACTG A5224s

Kristine M. Erlandson 1, Douglas Ritch 2, Paul E. Sax 3, Eric S. Daar 4, Camilin Tierny 5, Kathleen M. Melbourne 5, Belinda Hal 6, Grace A. McComsey 7

1Infectious Diseases, Tenon Hospital, Paris, France; 2Infectious Diseases, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States; 3Infectious Diseases, University of California Los Angeles, Los Angeles, CA, United States; 4Infectious Disease Unit, Niguarda Ca Granda Hospital, Milan, Italy; 5Infectious Diseases, University of Milan, Milan, Italy; 6Department of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy; 7Medicine, Johns Hopkins University, Baltimore, MD, United States
773 HIV Infection Increases Risk of Acute Exacerbations of COPD
Allison A. Lambert, Gregory D. Kirk, Jacquie Astemborski, Shruti H. Mehta, M. Bradley Drummond
Johns Hopkins University, Baltimore, MD, United States

774 Association of HIV Infection and Immune Activation With Decline in Lung Function
Kristina Crothers1, Carla V. Rodriguez2, Cherry Wongtrakool2, Guy Soo Hoo3, Joon Kim1, Sheldon T. Brown4, David Rimland5, Maria C. Rodriguez-Barradas6, Matthew B. Goetz2, Amy C. Justice6
1Department of Medicine, University of Washington, Seattle, WA, United States; 2Department of Medicine, Atlanta Veterans Affairs Medical Center and Emory University, Atlanta, GA, United States; 3Department of Medicine, West Los Angeles Veterans Affairs Medical Center and David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA, United States; 4Department of Medicine, James J. Peters Bronx Veterans Affairs Medical Center and and Icahn School of Medicine at Mount Sinai, New York, NY, United States; 5Department of Medicine, Michael E. DeBakey Veterans Affairs Medical Center and Baylor College of Medicine, Houston, TX, United States; 6Department of Medicine, Veterans Affairs Connecticut Healthcare System and Yale University, New Haven, CT, United States

775 HIV Infection and Related Biomarkers Are Independent Risk Factors for Radiographic Emphysema
Engi F. Attia1, Matthew B. Goetz2, Maria C. Rodriguez-Barradas2, David Rimland3, Sheldon T. Brown4, Joon Kim1, Cherry Wongtrakool1, Kathleen Akgun5, Kristina Crothers1
1Department of Medicine, University of Washington, Seattle, WA, United States; 2Department of Medicine, West Los Angeles Veterans Affairs Medical Center and David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA, United States; 3Department of Medicine, University of Alabama School of Medicine, Birmingham, AL, United States; 4Department of Medicine, Veterans Affairs Connecticut Healthcare System and Yale University, New Haven, CT, United States

776 Factors Associated With Chronic Obstructive Pulmonary Disease in a High Risk HIV-Infected Cohort
Alain Makinison1, Maurice Hayot2, Sabrina Eymard-Duvernay3, François Raffi4, Laurence Thiard4, Fabrice Bonnet5, Pierre Tattavin6, Sophie Abgrall7, Jacques Reyes8, Vincent Grace McComsey8, Carole Meynard1
1Clinical Investigation and Research Unit, Brighton and Sussex University Hospitals, Brighton, United Kingdom; 2Laboratoire d’Epidémiologie et de Santé Publique, Paris, France; 3AP-HP, Hôpital Saint-Antoine, Paris, France; 4Service de Maladies Infectieuses, AP-HP, Hôpital Saint-Antoine, Paris, France; 5Department of Infection and Immunity, Brighton and Sussex Medical School, Brighton, United Kingdom; 6Internal Medicine and Infectious and Tropical Diseases Department, University Hospital Bordeaux, INSERM U1046, University Hospital Bordeaux, Bordeaux, France; 7MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, United Kingdom; 8Department of Infection and Immunity, Brighton and Sussex Medical School, Brighton, United Kingdom; 9Centre National de la Recherche Scientifique, Infectiens et Tropiques, Hôpital Saint-Antoine, Paris, France

777 Minimal Change in Bone Density and No Association With HIV Factors Over 12 Months in HIV-Infected Men
Amanda Samarawickrama1, Sophie Jose2, Caroline Sabini3, Karen Walker-Bone2, Martin Fisher4, Yvonne Gillette5
1Clinical Investigation and Research Unit, Brighton and Sussex Medical School, Brighton, United Kingdom; 2Research Department of Infection and Population Health, University College London, London, United Kingdom; 3MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, United Kingdom; 4Department of Infection and Immunity, Brighton and Sussex Medical School, Brighton, United Kingdom; 5Department of HIV and Sexual Health, Brighton and Sussex University Hospitals, Brighton, United Kingdom

778 New Fracture Risk and FRAX 10-Year Probability of Fracture in HIV-Infected Adults
Linda A. Battalora1, Kate Buchacz2, Carl Armon3, Edgar T. Overton4, John Hammer1, Pragna Patel3, Joan Chmiel6, Kathy Wood1, John T. Brooks3, Benjamin Young2
1Colorado School of Mines, Golden, CO, United States; 2Centers for Disease Control and Prevention, Atlanta, GA, United States; 3Cerner Corporation, Vienna, VA, United States; 4University of Alabama School of Medicine, Birmingham, AL, United States; 5Denver Infectious Disease Consultants, Denver, CO, United States; 6Feinberg School of Medicine, Northwestern University, Chicago, IL, United States; 7International Association of Providers of AIDS Care, Washington, DC, United States

779LB Bone Density Changes After Antiretroviral Initiation With Protease Inhibitors or Raltegravir
Todd Brown1, Carlie Moser2, Judith Currier3, Heather Ribaud4, Jennifer Rothenberg1, Michael Dube5, Robert Murphy1, James Stein6, Grace McComsey7
1Johns Hopkins University, Baltimore, MD, United States; 2Harvard University, Boston, MA, United States; 3UCLA, Los Angeles, CA, United States; 4Fox Chase Cancer Center, Philadelphia, PA, United States; 5University of Southern California, Los Angeles, CA, United States; 6Northwestern University, Chicago, IL, United States; 7University of Wisconsin, Madison, WI, United States; 8Case Western Reserve University, Cleveland, OH, United States

780 Hand Osteoarthritis, a Joint Disorder Frequent and More Severe in HIV-1 Patients: METAFLIB-OA Study
Anne-Laurence Tomi1, Jeremy Sellami2, Karine Lacombe3, Manuela Sebire4, Caroline Rey-Jouvin5, Anne-Laurence Miquel1, Emmanuel Mahieu1, Francis Berenbaum1, Pierre-Marie Girard1, Jean-Luc Meynard1

781 Low Bone Mineral Density Is Associated With Increased Risk of Incident Fracture in HIV+ Adults
Linda A. Battalora1, Kate Buchacz2, Carl Armon3, Edgar T. Overton4, John Hammer1, Pragna Patel3, Joan S. Chmiel6, Tim Bush1, John T. Brooks3, Benjamin Young2
1Colorado School of Mines, Golden, CO, United States; 2Centers for Disease Control and Prevention, Atlanta, GA, United States; 3Cerner Corporation, Vienna, VA, United States; 4University of Alabama School of Medicine, Birmingham, AL, United States; 5Denver Infectious Disease Consultants, Denver, CO, United States; 6Feinberg School of Medicine, Northwestern University, Chicago, IL, United States; 7International Association of Providers of AIDS Care, Washington, DC, United States

782 A Randomized Open Label Study for Comparing Two Doses of Zoledronic Acid in HIV Infected Patients
Eugénia Negredo1, Anna Bonjoch2, Nuria Pérez-Alvarez3, Arelly Ornellas4, Jordi Pulgar1, Cristina Herrero1, Patricia Escumping1, Bonaventura Clotet1,2
Mechanism of Bone Disease in HIV and HCV: Impact of Tenofovir Exposure and Severity of Liver Disease

James Cутrell1, Naim M. Maalouf2, Song Zhang1, Henning Drechsler1, Ang Gaо2, Pablo Tebas1, Roger Bedimo1

Infectious Diseases, VA North Texas Health Care System, Dallas, TX, United States;1Center for Mineral Metabolism, University of Texas Southwestern Medical Center, Dallas, TX, United States;2Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, TX, United States;3Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, United States;4Infectious Diseases, University of Pennsylvania, Philadelphia, PA, United States

Low Bone Mineral Density (BMD) Among Ugandan HIV-Infected Patients On Failing First-Line ART

Antonella D. A. Monforte5, Stephane De Wit6, Matthew Law7, Ole Kirk1, Jens D. Lundgren1, on behalf of the D:A:D Study Group

1HIV-NAT, TRCARC, Bangkok, Thailand;2Faculty of Medicine, University of Valencia, Valencia, Spain;3Institute of Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States;4Institute of Social and Preventive Medicine, University of Copenhagen, Copenhagen, Denmark;5Division of Infectious Diseases and Department of Global Health, Copenhagen, Denmark;6Infection and Population Health, University College London, London, United Kingdom;7Division of Infectious Diseases and Department of Global Health, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands;8ICAP-Columbia University/Harlem Hospital, New York City, NY, United States;9Hospital San Paolo, University of Milan, Milan, Italy;10Infectious Diseases, CHU Saint-Pierre, Brussels, Belgium;11Kirby Institute, University of New South Wales, Sydney, Australia

Hepatic Fibrosis and Other Hepatic Complications

Monday, March 3, 2014, 2:30 pm – 4:00 pm

Abacavir and Didanosine Enhance Susceptibility To Acetaminophen-Induced Hepatotoxicity

Ana Blaz-Garcia1,2, Victor M. Víctor1,3, Alberto Martí-Rodrigo1,4, Lara Milán-Medina1,5, Nadeza Apostolova1,6, Juan V. Esplugues2,7,8,9

1Pharmacology, Faculty of Medicine, University of Valencia, Valencia, Spain;2FISABIO, Valencia, Spain;3CIBERehd, Valencia, Spain;4Unidad Predepartamental de Medicina, Universidad Jaime I, Castellón de la Plana, Spain

Liver Fibrosis Is Not Uncommon in HIV-Infected Patients Without Viral or Alcoholic Hepatitis

Anchalee Avihingsanon1,2, Saiyavit Jimtrirong1, Voraapat Sapsirisavat1,2, Tanakorn Apornpong1, Tawan Menghansising1, Stephen Kerr1,4, Gail V. Matthews1, Sharon R. Lewin1,5, Kiat Ruxrungtham1,4,6, and the HIV-NAT 006 study team.

1HIV-NAT, TRCARC, Bangkok, Thailand;2Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand;3Department of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand;4Kirby Institute, University of New South Wales, Sydney, Australia;5Infectious Diseases, Alfred Hospital and Monash University, Melbourne, Australia;6Centre for Biomedicine, Burnet Institute, Melbourne, Australia;7Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

Association Between Dideoxynucleoside Analogues (d-Drugs) and End-Stage Liver Disease (ESLD)

Lene Ryom1, Caroline A. Sabin2, Peter Reiss3, Michael Ross4, Olivier Moranne5, Philippe Marijnissen6, Marianna K. Baum7, Catherine Horsfield8, Patrick O’Donnell9, Catherine Horsfield4, Patrick O’Donnell9, Rachael Jones10, Caroline Sabin1, Frank A. Post2

1University College London, London, United Kingdom;2King’s College London, London, United Kingdom;3Imperial College London, London, United Kingdom

Microbial Translocation, Immune Activation, Apoptosis and Liver Fibrosis in the MASH Cohort

Mariana M. Baum1, Kenneth E. Sherman2, Sabrina S. Martinez2, Pedro Green3, Triffanie Stewart4, Christina Jacobs4, Sonya Sule5, Kimberly Dizor1, Adriana Campa2

1Stempef College of Public Health and Social Work, Florida International University, Miami, FL, United States;2Division of Digestive Disease, University of Cincinnati, Cincinnati, OH, United States;3College of Medicine, Florida International University, Miami, FL, United States

Cumulative Exposure To Ritonavir-Boosted Atazanavir Is Associated With Cholelithiasis

Takeshi Nishijma1, Hiroshige Gaiatani2, Takuro Shimbo2, Yohei Hamada2, Junko Tanuma1, Kunihisa Toukada1, Katsuyi Teruya1, Yoshihiko Kikuchi1, Shinichi Oka2

1AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan;2Center for AIDS Research, Kumamoto University, Kumamoto, Japan;3Department of Clinical Study and Informatics, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan

Prevalence of Liver Fibrosis Based On Non-Invasive Markers Among HIV-Infected Patients in Zambia

Michael J. Vinkoor1,2, Kalo Musukuma1, Gilles Wandelé1, Arianna Zanolini1,2, Aggrey Mweemba3, Carolyn Bolton-Moore4,5, Izukanji Sikazwe1, Benjamin H. Chi6, Lloyd Muelenga7,8

1Centre for Infectious Disease Research in Zambia, Lusaka, Zambia;2Institute of Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States;3Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland;4University Teaching Hospital, Lusaka, Zambia;5Obstetrics and Gynecology, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States

Significance of Alcohol Abuse Diagnosis vs Other Risk Factors for Advanced Liver Fibrosis by FIB-4

H. Nina Kim1, Heidi M. Crane2, Carla V. Rodriguez1, Stephen Van Rompaey3, W. ChristopherMatthews4, Michael Mugavero5, Kenneth H. Mayer6, Katherine Christopoulos7, Sonia Napravnik7, Mari M. Kitahata6,1

1University of Washington, Seattle, WA, United States;2University of California San Diego, La Jolla, CA, United States;3University of Alabama at Birmingham, Birmingham, AL, United States;4Fenway Health, Harvard University, Boston, MA, United States;5University of California San Francisco, San Francisco, CA, United States;6University of North Carolina at Chapel Hill, Chapel Hill, NC, United States

Predictors of Progression, Stabilisation, or Improvement of eGFR After Chronic Renal Impairment

Lene Ryom1, Amanda Mocroft2, Ole Kirk3, Peter Reiss4, Michael Ross5, Olivier Moranne6, Philippe Marijnissen7, Marianna K. Baum8,9, Catherine Horsfield4, Patrick O’Donnell9, Rachael Jones10, Caroline Sabin1, Frank A. Post2

1University College London, London, United Kingdom;2King’s College London, London, United Kingdom;3Imperial College London, London, United Kingdom;4Division of Infectious Diseases and Department of Global Health, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands;5Division of Neurology, Mount Sinai School of Medicine, New York City, NY, United States;6Infectiology and Public Health Departments, CHU de Nice, Nice, France;7Service de Médecine Interne et Maladies Infectieuses, Hôpital Saint-André, CHU de Bordeaux, Bordeaux, France;8Clinic for Infectious Diseases and Hospital Hygiene, Kantonsklinik Aarau, Aarau, Switzerland
Program and Agenda

Renal and Metabolic Safety of Initial HIV-1 Therapy in Resource-Limited Settings
Francine Touard Romo1, Laura M. Smeaton2, Thomas B. Campbell3, Cynthia Riviere4, Rosie Mngqibisa5, Khuanchai Supparatpinyo6, Johnstone Kurwenda7, Nagaligeswaran Kumaraosamy8, James G. Hakim9, Timothy Flanagan9

1The Minam Hospital, Providence, RI, United States; 2Harvard School of Public Health, Boston, MA, United States; 3University of Colorado Denver, Aurora, CO, United States; 4Les Centres GHSKIO, Port-au-Prince, Haiti; 5University of KwaZulu Natal, Durban, South Africa; 6Chiang Mai University, Chiang Mai, Thailand; 7College of Medicine, Baintyre, Malawi; 8FRG CARE Medical Centre, Chennai, India; 9University of Zimbabwe College of Health Sciences, Harare, Zimbabwe; 10Brown Medical School, Providence, RI, United States

Risk Factors for Atazanavir (ATV)-Associated Urolithiasis: A Case-Control Study
Barbara De Sousa1, Diane Ponscarme1, Nathanael Lapidus2, Michel Daudon1, Laurence Weiss3, Christophe Rioux4, Erwan Fourni5, Christine Kaltama6, Jean-Michel Molina7, Matthieu Lafauvie8

1Infectious Diseases Unit, Hôpital Saint Louis, Paris, France; 2Hôpital Saint Louis, Paris, France; 3Hôpital Tenon, Paris, France; 4Hôpital Européen Georges Pompidou, Paris, France; 5Hôpital Bichat, Paris, France; 6Hôpital Bicêtre, Paris, France; 7Hôpital Pitit, Paris, France

Single Nucleotide Polymorphisms in UGT1A1 Associated With Atazanavir-Related Nephrolithiasis
Takehi Nishijima, Kyoto Tsuchiya, Akanoe Jaya, Yohei Hamada, Junko Tanuma, Kunthisa Toukada, Katsuji Teruya, Yoshimi Kikuchi, Shinichi Oka, Horiyuki Gatanaga

AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan

Atazanavir and Tenofovir Attenuate the Benefit of Antiretroviral Therapy On Cystatin C: ACTG A5224
Chris T. Longenecker1,2, Douglas Fitch1, Paul Sax1,3, Eric Daras1,2, Camlin Tierney1, Grace A. McCormy1

1Case Western Reserve University School of Medicine, Cleveland, OH, United States; 2University Hospitals Case Medical Center, Cleveland, OH, United States; 3Harvard School of Public Health, Boston, MA, United States; 4Harvard Medical School, Boston, MA, United States; 5University of California Los Angeles, Los Angeles, CA, United States

A Chronic Kidney Disease Risk Score To Determine Tenofovir Safety Among HIV+ Male Veterans
Rebecca Scherer1, Monica Gandhi2, Michelle Estrella3, Phyllis Tien4, Steven Deeko1, Carl Grunfeld5, Carmen Peralta1, Michael Shlipak1

1University of California San Francisco, San Francisco, CA, United States; 2Johns Hopkins University, Baltimore, MD, United States

Genetic Variants of ABC2 and ABC10 Are Associated With TFV-Induced Proximal Tubular Dysfunction
Anchalee Aiwingsanong1,2, Baralee Punyawudho3, Kearsik Prathipromsira4, Yingyos Aiwingsanong5, Wirach Maek-a-nantawan6, Jiratchaya Sophonhan6, Sasitewit Ubohvan7, Stephen Kerr1,2, David Burger1, Kiat Ruxumphong1,2, and HIV-NAT 114 study team

1HIV-NAT, TRCARC, Bangkok, Thailand; 2Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; 3Faculty of Pharmaceutical Sciences, Bangkok, Thailand; 4Division of Nephrology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; 5Kirti Institute, University of New South Wales, Sydney, Australia; 6Radboud University Nijmegen Medical Center, Nijmegen, Netherlands; 7Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

End-Stage Kidney Disease and Kidney Transplantation in HIV-Positive Patients
Esther N. Gathogo1, Sophie Jose2, John Booth3, Stephen P. McAdoo4, Emil A. Kumar5, Michael Rayment5, Clifford Leen6, Deborah Williams4, Caroline Sabin7, Frank Post1

1Renal Sciences, King’s College London, London, United Kingdom; 2University College London, London, United Kingdom; 3Imperial College London, London, United Kingdom; 4Chelse and Westminster Hospital, London, United Kingdom; 5Western General Hospital, Edinburgh, United Kingdom; 6Brighton and Sussex University Hospitals, Brighton, United Kingdom

Session P-Q9 Poster Session
Thursday March 6, 2014, 2:30 PM–4:00 PM Exhibit Hall D

Obesity: ART and Animal Models
801 Maraviroc, a CCR5 Antagonist, Alters Gut Microbiota Composition in a Mouse Model of Obesity
Patricia Pérez-Mateu1, Laura Pérez-Martínez2, José R. Blanco3, Jose A. Otero4

1Infectious Diseases, CIBIR, Logroño, Spain; 2Infectious Diseases, Hospital San Pedro-CIBIR, Logroño, Spain

802 Low Pre-ART CD4+ T Cells, Female Sex, and Atazanavir Use Increase Obesity Risk After Starting ART
Benjamin Atkinson1, Supriya Krishnan2, Ann C. Collier3

1Harborview Medical Center, Seattle, WA, United States; 2Statistical and Data Analysis Center, Harvard School of Public Health, Boston, MA, United States; 3Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, Health Economics and Epidemiology Research Office, Johannesburg, South Africa; 4Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, Clinical HIV Research Unit, Johannesburg, South Africa

803 Obesity or Hypertension at ART Initiation and Outcomes Amongst HIV Patients in South Africa
Alana T. Brennan1,2, Matthew P. Fox1,3, Mhaini Maskwe1, Ian Sanne1, Prudence Ive1, Julia Rohr1,2, Lawrence Long1, Sydney Rosen1,2

1Center for Global Health & Development, Boston University, Boston, MA, United States; 2Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, Health Economics and Epidemiology Research Office, Johannesburg, South Africa; 3School of Clinical Medicine, Faculty of Health Sciences, Clinical HIV Research Unit, Johannesburg, South Africa

Session P-Q9 Poster Session
Thursday March 6, 2014, 2:30 PM–4:00 PM Exhibit Hall D

Genetic Factors and ART Outcomes
804 Specific Binding Characteristics of HLA Alleles Associate With Nevirapine Hypersensitivity
Rebecca Pawlos1, Craig Rice2, Elizabeth McKinnon3, David Ostrov4, Bjorn Peters5, Jing Yuan6, Silvana Gaudieri7,8, David Haas4, Simon Mallia9, Elizabeth J. Phillips9

1Institute for Immunology and Infectious Diseases, Murdoch, Australia; 2University of Florida College of Medicine, Gainesville, FL, United States; 3La Jolla Institute for Allergy and Immunology, La Jolla, CA, United States; 4Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, United States; 5University of Western Australia, Crawley, Australia; 6Vanderbilt University Medical Center, Nashville, TN, United States

805 Large-Scale Gene-Centric Exploration of Risk for NRTI/NNRTI-Associated Toxicities in Botswana
C. William Wester1,2, Sophie Limou1, Hermann Bussmann3, Vladimir Novitsky1,2, Sighulile Moyo4, Max Essex1,4, Richard G. Martin1, Cheryl A. Winkler3

1Vanderbilt Institute for Global Health (VIGH), Vanderbilt University, Nashville, TN, United States; 2Vanderbilt University School of Medicine, Division of Infectious Diseases, Nashville, TN, United States; 3Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, MA, United States; 4Center for Cancer Research, Basic Science Program, Frederick National Laboratory, Leidos BioMedical Research for the National Cancer Institute, Frederick, MD, United States; 5Botswana-Harvard School of Public Health AIDS Initiative Partnership for HIV Research and Education (BHP), Gaborone, Botswana
Session P-Q10 Poster Session

**Suicide Rates Decrease Among HAART Initiators From 1996 To 2012 in British Columbia, Canada**

Silvia Guillen1,2, Erin Ding3, Jasmine Gurni4, Julia Zhu5, Verena Strehlau6,7, Julio S. G. Montaner6,7, Robert S. Hoogii8

1BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada
2University of British Columbia, Faculty of Medicine, Vancouver, BC, Canada
3University of British Columbia, Department of Psychiatry, Vancouver, BC, Canada
4Simon Fraser University, Faculty of Health Sciences, Burnaby, BC, Canada

**Disproportionality Analysis of Antiretrovirals With Suicidality Using FDA AERS Data**

Andrew Napoli1, John Columbis2, Jennifer Wood3, Amit Soitkar2, Daniel Seekins1

1Bristol-Myers Squibb, Plainsboro, NJ, United States
2Bristol-Myers Squibb, Hopewell, NJ, United States

**High Clonality of M. tuberculosis Strains Among MDR-TB Patients in Gauteng, South Africa**

Dorothy A. Fallows1, Nicole Kusnierz1, Amanda Axcell1, Lynsey Stewart-Isherwood1, Pamela Denis1, Francesca Conradi2, Gerrit Coetzee1, Hendrik Koornhof1, Nazir Ismail1, Gillia Kaplan1,2

1PHRI, NJMS-Rutgers University, Newark, NJ, United States
2Centre for Tuberculosis, Johannesburg, South Africa
3Department of Clinical Medicine, University of the Witwatersrand, Johannesburg, South Africa

**Identifying Location of Recent TB Transmission in Rural Uganda: A Multidisciplinary Approach**

Gabriel Chamie1, Bonnie Wandera2, Carina Marquez1, Midori Kato-Maeda1, Moses R. Kamya3, Diane V. Havlir4, Edwin D. Charlebois5,6

1Division of Global HIV/AIDS, Centers for Disease Control and Prevention, Atlanta, GA, United States
2Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, GA, United States
3Division of Global HIV/AIDS, Centers for Disease Control and Prevention, Atlanta, GA, United States
4Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, GA, United States
5Division of Global HIV/AIDS, Centers for Disease Control and Prevention, Atlanta, GA, United States
6Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, GA, United States

**Timing of TB Episodes After the End of Isoniazid Preventive Therapy: Reinfection or Reactivation?**

Sabine Hermans1, Alison Grant1, Violet Chithota1, James Lewis1, Gavin Churchyard1, Katherine Fielding1

1Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom
2Clinical Research, London School of Hygiene and Tropical Medicine, London, United Kingdom
3Aurum Institute for Health Research, Johannesburg, South Africa

**HIV and Tuberculosis in Kenya, 2012-2013: Results From a National Survey**

Agneta Mbithi1, Anthony Gichangi2, Herman Wyenga3, John Williamson1, Tom Ololochi1, Catherine Robinson1, Timothy Kellogg1, Andrea A. Kim1, William Maina1, Kevin M. De Cock1

1National AIDS and STI Control Programme, Ministry of Health, Nairobi, Kenya
2Division of Global HIV/AIDS-Kenya, US Centers for Disease Control and Prevention, Nairobi, Kenya
3Division of Leprosy, Tuberculosis and Lung Diseases, Ministry of Health, Nairobi, Kenya
4Global Health Sciences, University of California San Francisco, San Francisco, CA, United States

**Screening for Tuberculosis in HIV-Infected Nigerian Children With a Urinary Antigen Assay**

Holly E. Rawizza1,2, Stephen Oguche3, Godwin Imade4, Oche Agbaji4, David Olaleye2, Georgina Odabako5, Kike Osinusi1, Isaac Adewole1,6, Prosper Okonkwo1, Phyllis Kanki7,8

1Infectious Disease, Brigham & Women's Hospital, Boston, MA, United States
2Harvard School of Public Health, Boston, MA, United States
3Infectious Disease, Joe University Teaching Hospital, Jos, Nigeria
4Joe University Teaching Hospital, Jos, Nigeria
5University College Hospital in Ibadan, Ibadan, Nigeria
6AIDS Prevention Initiative Nigeria, Abuja, Nigeria

**TB Screening and Diagnosis**

**Massive Diagnostic Yield of HIV-Associated Tuberculosis Using Rapid Urine Assays in South Africa**

Stephen D. Lawn1, Andrew Kerkhoff2, Rosie Burton1, Charlotte Schutz2, Gavin van Wyk1, Monica Vogt1, Pearl Paliha1, Mark Nicol1, Graeme Meintjes1

1Department of Clinical Research, London School of Hygiene & Tropical Medicine, London, United Kingdom
2University of Cape Town, Cape Town, South Africa
3Department of Medicine, University of Cape Town, Cape Town, South Africa
4Department of Clinical Research, University of Cape Town, Cape Town, South Africa
5Division of Medical Microbiology, University of Cape Town, Cape Town, South Africa
6Division of Medical Microbiology, University of Cape Town, Cape Town, South Africa

**Symptom-Based Screening for Tuberculosis Among Pregnant Women Living With HIV in Kenya**

Surbhi Modi1, Joseph S. Cavanaugh2, Ray W. Shiraishi3, Barbara Burmen1, Heather Alexander1, Kimberly McCarthy1, Hellen Mutua2, Kevin P. Cain3

1Division of Global HIV/AIDS, Centers for Disease Control and Prevention, Atlanta, GA, United States
2Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, GA, United States
3Division of Global HIV/AIDS, Centers for Disease Control and Prevention, Atlanta, GA, United States

**Highly Multiplexed Detection of Antibodies in Whole Blood During Tuberculosis Infection**

Charles Greff1, Greg Husia2, Christen Gray2, David Dank1, Pamela Nabeta3, Mark Perkins4, Michael Lochhead5

1MBio Diagnostics, Inc, Boulder, CO, United States
2FIND, Geneva, Switzerland
3Carnegie Mellon University, Pittsburgh, PA, United States

**Performance of the World Health Organization Algorithm for Tuberculosis Screening in Kenya**

Surbhi Modi1, Joseph S. Cavanaugh2, Ray W. Shiraishi3, Barbara Burmen1, Heather Alexander1, Kimberly McCarthy1, Hellen Mutua2, Kevin P. Cain3

1Division of Global HIV/AIDS, Centers for Disease Control and Prevention, Atlanta, GA, United States
2Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, GA, United States
3Division of Global HIV/AIDS, Centers for Disease Control and Prevention, Atlanta, GA, United States

**Diagnosing Extra Pulmonary Tuberculosis Using Xpert MTB/RIF: A Laboratory Algorithm**

Lesley E. Scott1, Natalie Beylis1, Mark Nicol2, Tintswalo Nkuna1, Prosper Oyonkwo1, Phyllis Kanki7,8

1Molecular Medicine and Haematology, University of the Witwatersrand, Johannesburg, South Africa
2Division of Clinical Microbiology and Infectious Diseases, University of the Witwatersrand, Johannesburg, South Africa
3Division of Medical Microbiology, Clinical Laboratory Sciences and Institute for Infectious Disease, University of Cape Town, Cape Town, South Africa
Session P-R3 Poster Session
Wednesday March 5, 2014, 2:30 PM–4:00 PM Exhibit Hall D
Latent TB Screening and Treatment

816 Rifapentine Safety and PK With Novel Dosing Strategies To Increase Drug Exposures for TB: ACTG A5311
Kelly E. Dooley1, Rada Savic2, Jeong-Gun Park3, Yoninah Cramer4, Richard Halber1, Jennifer Janik1, Mark A. Marzinke1, Marc Weiner1, Susan Dorman1, David W. Haas3, and the A5311 Study Team
1Johns Hopkins University School of Medicine, Baltimore, MD, United States; 2University of California, San Francisco, CA, United States; 3Statistical and Data Analysis Center, Harvard School of Public Health, Boston, MA, United States; 4Division of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, MD, United States; 5Frontier Science Foundation, Amhcest, NY, United States; 6Veterans Administration Medical Center, San Antonio, TX, United States; 7Vanderbilt University School of Medicine, Nashville, TN, United States

817 Three Months of Weekly Rifapentine + INH for M. tuberculosis Infection in HIV-Infected Persons
Timothy Sterling1, Connie Benson1, Nigel Scott2, Jose Miro4, Guilherme Calvet3, Richard Chaissoun4, Alberto La Rosa5, Rosa Infante1, Michael Chen1, Ella Villarino1, TBC/ACTG
1Medicine/Infectious Diseases, Vanderbilt University, Nashville, TN, United States; 2University of California at San Diego, San Diego, CA, United States; 3Centers for Disease Control and Prevention, Atlanta, GA, United States; 4Barcelona Department of Health, Barcelona, Spain; 5Instituto de Pesquisa Clinica Evandro Chagas, Rio de Janeiro, Brazil; 6The Johns Hopkins University, Baltimore, MD, United States; 7Impacta, Lima, Peru

818 Effect of HIV On Latent TB Screening of Pregnant Women in Pune, India
Yuji S. Mathad1, Ramesh Bhosale1, Savita Kanade1, Prasad Deshpande1, Vandana Kulkarni1, Neetal Nevekar2, Vidya Mave3, Nishi Suryavanshi1, Nikhil Gupte1, Amita Gupta1, Weil Cornell Medical College, New York, NY, United States; 2Byramjee Jeejeebhoy Government Medical College-Sassoon General Hospital, Pune, India; 3Johns Hopkins University-Byrarnjee Jeejeehoby Government Medical College Clinical Trials Unit, Pune, India; 4Johns Hopkins University School of Medicine, Baltimore, MD, United States; 5Impacta, Lima, Peru

Session P-R4 Poster Session
Wednesday March 5, 2014, 2:30 PM–4:00 PM Exhibit Hall D
Inflammatory and Immune Activation Markers in TB

819 Baseline Inflammatory and Immune Activation Markers Predictive of TB After ART Initiation
Mark Tenforde1, Nikhil Gupte1, David Dowdy2, David Asmuth3, Ashwin Balasubramanian4, Richard Pollard5, James Hakim5, Richard Semba5, Thomas Campbell6, Amita Gupta1, for the ACTG A5175 (PEARLS) and NWCS 319 Study Group
1Medicine, Johns Hopkins University, Baltimore, MD, United States; 2Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States; 3University of California Davis, Medical Center, Sacramento, CA, United States; 4University of Zimbabwe College of Health Sciences, Harare, Zimbabwe; 5Johns Hopkins University, Baltimore, MD, United States; 6University of Colorado Denver, Aurora, CO, United States

820 MAIT Cells Are Highly Enriched in the Bronchoalveolar Lavage Fluid of Patients With TB
Emily B. Wong1,2, Zuri Sullivan1, Marielle C. Gold3,4, Umesh G. Laloo5, Ansh Ambarchi6, Printa Bajnath7, Leon Naidoo7, Thumbi Ndung8,9, William R. Bishop10, David M. Lewis11,12
1KwaZulu Natal Research Institute for Tuberculosis and HIV, Durban, South Africa; 2Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, United States; 3Division of Pulmonary and Critical Care Medicine, Oregon Health & Science University, Portland, OR, United States; 4Portland Veterans Administration Medical Center, Portland, OR, United States; 5Department Pulmonary and Critical Care, Nelson R. Mandela School of Medicine, Durban, South Africa; 6Department of Pulmonary and Critical Care, Nelson R. Mandela School of Medicine, Durban, South Africa; 7HIV Pathogenesis Programme, University of KwaZulu Natal, South Africa; 8Division of Infectious Diseases, Johns Hopkins School of Medicine, Baltimore, MD, United States

821 Vitamin D and TMEM16J Host Variants Associated With TB or Death in HIV-Infected and -Exposed Infants
Amrita Gupta1, Jennifer Jubilier1, Brett Zeldow3, Grace Montepiedra1, Barbara Detrick1, Aiy Violor1, Shabir A. Madhi4, Charles Mitchell5, Stephen A. Spector1, for the IMPAACT NWCS113 and P1041 Study Team
1Medicine, Johns Hopkins University, Baltimore, MD, United States; 2Pediatrics, Maine Medical Center/Tufts University, Portland, ME, United States; 3Harvard School of Public Health, Boston, MA, United States; 4Pathology, Johns Hopkins University, Baltimore, MD, United States; 5PHRU, University of the Witwatersrand, Johannesburg, South Africa; 6University of the Witwatersrand, MRC: Respiratory and Meningeal Pathogens Research Unit, Johannesburg, South Africa; 7University of Miami Miller School of Medicine, Miami, FL, United States; 8Medicine, University of California San Diego, La Jolla, CA, United States

822 Latent and Active TB Infection Increase Harmful Immune Activation in Those Co-Infected With HIV
Zuri A. Sullivan1, Emily B. Wong1, Thumbi Ndung8,9, Victoria O. Kasprowicz1, William R. Bishop10
1KwaZulu Natal Research Institute for Tuberculosis and HIV, Durban, South Africa; 2School of Medicine, Johns Hopkins University, Baltimore, MD, United States

823 Ex Vivo Fitness of MTB Correlates With Lysozyme Sensitivity in the East-African Indian lineage
Claire Pardieu1, Nicola Casali1, Simon Clark2, Ann Rawkins2, Richard Hooper1, Preya Vejli1, Ximenia Gonzalez3, Jane D. Reynot1, Francis A. Drobniewski1
1Clinical TB and HIV Group, Queen Mary University of London, London, United Kingdom; 2TB Research Group, Public Health England, Salisbury, United Kingdom; 3Centre for Primary Care and Public Health, Barts and The London School of Medicine and Dentistry, London, United Kingdom; 4National Mycobacterium Reference Laboratory, Public Health England, London, United Kingdom; 5Centre for Immunology and Infectious Disease, Barts and The London School of Medicine and Dentistry, London, United Kingdom

824 Polynufunctionality of TB-Specific CD4+ T-Cells in HIV-TB Co-Infection in Latent and Pulmonary Tuberculosis
Puja Van Epps1, Sankar Sridaran1, Hitin Aung2, Michael R. Betts3, Zahra Toosi1, David H. Canaday1,2
1Department of Medicine, Division of Infectious Diseases and HIV Medicine, Case Western Reserve University, Cleveland, OH, United States; 2Genetic Research Education & Clinical Center (GRECC), Louis Stokes Cleveland VA Medical Center, Cleveland, OH, United States; 3Department of Microbiology, University of Pennsylvania, Philadelphia, PA, United States

Program and Agenda
827  Depleted DHEA-S Reserves Are Associated With Early Mortality After ART Initiation in HIV/TB  Shrutii Ravi Mohan1, Neo Tamhilar, Andrew P. Steenhoff2,3, Rona Lettoghie2, Kebatshabile Nyanaya2, Tumelo Rantleru2, Michael Adu4, Drew Weissman4, Gregory P. Bisson4,4 1Department of Medicine, Division of Infectious Diseases, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States; 2Botswana-UF Partnership, Gaborone, Botswana; 3Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States; 4Infectious Diseases, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States

828  Impacts of National ART Initiation Policy Change On Integrated TB HIV Practice in Zomba, Malawi  Kevin D. Bezansoni1, Adrienne K. Chan1, Monique van Lettow2, Jean Bourgeois3, Edson Mwinjwa4, Harry Mbewe4, Martin Kachingwe5, Donald Cole6, Sumeet Soothi1 1Dignitas International, Toronto, ON, Canada; 2Dignitas International, Zomba, Malawi; 3Zomba Central Hospital, Zomba, Malawi; 4Dalla Lana School of Public Health, Toronto, ON, Canada

829  Does Long-Term ART Reduce TB Rates To Background Population Levels? Data From a National HIV Cohort  Rishi K. Gupta1,2, Marc Lipman3, Alison Brown2, Brian Rice1, Anton Pozniak4, Dominik Zemner5, Lucy Thomas6, Ibrahim Abubakar7,8, Valerie Delpech9 1University College London, London, United Kingdom; 2Public Health England, London, United Kingdom; 3Chelsea and Westminster NHS Foundation Trust Hospital, London, United Kingdom

830  Development of Tuberculosis in HIV-Infected Patients Receiving Successful TARGA  Esteban Echeverria1, Sergio Serrano Villar1, Tala Sainz1, Ana Moreno1, Jose Luis Casado2, Fernando Ondracek1, Maria Jesus Perez Elias1, Enrique Navas2, Manuel Rodriguez Zapata1, Santiago Moreno1 1Hospital Universitario Guadalajara, Guadalajara, Spain; 2Hospital Universitario Ramón y Cajal, Madrid, Spain

831  Timeliness of ART Initiation Among HIV-Infected Patients With TB in Sub-Saharan Africa  Suzue Saito1, Wafa El-Sadr2,3,4,5, Yael Hirsch-Moverman1, Faiz A. Khan1, Veronica Michaud6, Zulima de Silva7, Batya Elul1, Andrea Howard2 1ICAP, Columbia University, New York, NY, United States; 2Department of Epidemiology, Columbia University, New York, New York, United States

832  Antiretroviral Therapy Initiation and Tuberculosis (TB) Risk in the United States (US) and Canada  April Pettit1, Adell Mendes2, Sonia Napravnik3, Aimee Freeman3, Bryan Shepherd4, David Douda5, Anita Rachlis6, Richard Moore7, Timothy Sterling8, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) 1Vanderbilt University, Nashville, TN, United States; 2Johns Hopkins University, Baltimore, MD, United States; 3University of North Carolina, Chapel Hill, NC, United States; 4Sunnybrook Health Sciences Center, Toronto, ON, Canada

Session P-R6 Poster Session
Thursday March 6, 2014, 2:30 PM–4:00 PM  Exhibit Hall D

833  Prevalence of Cryptococcal Antigen Positivity Among AIDS Patients, United States From 1986-2012  Jennie L. McNeney1, Sean Bauman2, Brandon Neary3, Roger Detels4, Audrey French1, Joseph Margolick1, Jeffrey D. Klausner4 1Epidemiology, University of California, Los Angeles, Los Angeles, CA, United States; 2Inmunno-Mycoligies, Inc., Norman, OK, United States; 3Inmunno-Mycoligies, Inc., Norman, OK, USA; 4Infectious Diseases, John H. Stroger, Jr. Hospital, Chicago, IL, United States

834  High Prevalence of Undiagnosed Cryptococcus at HIV Diagnosis Across the CD4 Spectrum in Durban  Paul K. Brain1, Julia M. Losina2, Sharon M. Coleman2, Janey Giddy1, Douglas Ross1, Jeffrey Katz3, Rochelle P. Walensky1, Kenneth A. Freedberg1, Ingrid V. Bassett2 1Massachusetts General Hospital; Harvard Medical School, Boston, MA, United States; 2Stony Brook School of Medicine, Stony Brook, NY, United States; 3Boston University School of Public Health, Boston, MA, United States; 4McCord Hospital, Durban, South Africa; 5St. Mary’s Hospital, Durban, South Africa; 6Barghoo and Menahem’s Hospital, Harvard Medical School, Boston, MA, United States

835  Monocyte Dysfunction Is Associated With 14-Day Mortality in Cryptococcal Meninigits  James Scriven1, Lisa Graham1, Charlotte Schutz1, Robert Wilkinson1, Britta Urban1, Graeme Meintjes6, David Lalloo1 1Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town, South Africa; 2Liverpool School of Tropical Medicine, Liverpool, United Kingdom

836  Serum Biomarkers Following Induction Therapy for Cryptococcal Meningitis Predict Survival  Joshua Rhine1, James Scriven1, Kathy Huppler Hullsiek4, Maximillian von Hohengberg2, David B. Maya3, Conrad Muzoora4, Graeme Meintjes6, David R. Boulware2 1University of Minnesota, Minneapolis, Minnesota, United States; 2Infectious Disease Institute, Kampala, Uganda; 3Liverpool School of Tropical Medicine, Cape Town, South Africa; 4University of Minnesota, Minneapolis, MN, United States; 5Infectious Disease Institute, Kampala, Uganda; 6Diaspora University of Science and Technology, Mbagra, Uganda; 7University of Cape Town, Cape Town, South Africa

837  Cryptococcal Antigenemia in Severely Immunocompromised HIV Patients in Rural Tanzania  Matthias C. Müller1,2, Alex J. Mkatamatu2, Avinna Kimera1, Hansjakob Furrer1, Manuel Battegay2, Yael Hirsch-Moverman1, Faiz A. Khan1, Christoph Hatz1, David R. Boulware2, Tracy R. Glass1, Emilio Letang1 1Swiss Tropical and Public Health Institute (Swiss TPH), Basel, Switzerland; 2Ifakara Health Institute (IHI), Ifakara, Morogoro, Tanzania, United Republic of; 3Division of Infectious Diseases, University Hospital Bern, Bern, Switzerland; 4Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland; 5Division of Infectious Diseases & International Medicine, Department of Medicine, University of Minnesota, Minneapolis, MN, United States

Session P-R7 Poster Session
Thursday March 6, 2014, 2:30 PM–4:00 PM  Exhibit Hall D

838  HSV-2 Serostatus Is Not Associated With Inflammatory or Metabolic Markers in ART-Treated HIV  Darrell Tan1, Janet Raboud2, Leah Szadkowski3, Tae Joon You4, Brett Shannon1, Rupert Kauf5, W. Conrad Lies6, Sharon Walmsley6 1St. Michael’s Hospital, Toronto, ON, Canada; 2Toronto General Research Institute, Toronto, ON, Canada; 3University Health Network, Toronto, ON, Canada; 4University of Toronto, Toronto, ON, Canada; 5University of Washington, Seattle, WA, United States

839  High Prevalence of Undiagnosed Cryptococcus at HIV Diagnosis Across the CD4 Spectrum in Durban  Paul K. Brain1, Julia M. Losina2, Sharon M. Coleman2, Janey Giddy1, Douglas Ross1, Jeffrey Katz3, Rochelle P. Walensky1, Kenneth A. Freedberg1, Ingrid V. Bassett2 1Massachusetts General Hospital; Harvard Medical School, Boston, MA, United States; 2Stony Brook School of Medicine, Stony Brook, NY, United States; 3Boston University School of Public Health, Boston, MA, United States; 4McCord Hospital, Durban, South Africa; 5St. Mary’s Hospital, Durban, South Africa; 6Barghoo and Menahem’s Hospital, Harvard Medical School, Boston, MA, United States

840  Latent, Acute, or Neuro-Syphilis Does Not Increase HIV-1 Replication in Central Nervous System  Maximilian Donath1, Timo Wolf2, Annette Haber3, Markus Bickel2, Sari Gölö1, Annemarie Berger1, Dimitria Boni1, Claudia Brandt1, Christoph Stephani1 1Goethe University Hospital, Frankfurt, Germany; 2Infectious Diseases, Goethe University Hospital, Frankfurt, Germany; 3Medical Virology Institute, Goethe University Hospital, Frankfurt, Germany; 4Biomeathemastics, Goethe University Hospital, Frankfurt, Germany; 5Medical Microbiology Institute, Goethe University Hospital, Frankfurt, Germany

841  Early Impact of cART On the Risk of Herpes Zoster: Results From the FHDH-ANRS CO4  Sophie Grabin1,2, Pierre Tattavín1, Hana Selinger-Leneman1, Arnaud de la Blanchardière1, Christian Rabaud1, David Rey1, Vincent Daneluzzi2, Samuel Ferret1, Dominique Costagliola1, Odile Launay1 1Goethe University Hospital, Frankfurt, Germany; 2Infectious Diseases, Goethe University Hospital, Frankfurt, Germany; 3Medical Virology Institute, Goethe University Hospital, Frankfurt, Germany; 4Biomeathemastics, Goethe University Hospital, Frankfurt, Germany; 5Medical Microbiology Institute, Goethe University Hospital, Frankfurt, Germany
Session P-S1 Poster Session
Tuesday March 4, 2014, 2:30 pm–4:00 pm

Reproductive Hormones in Women: Impact On Risk and Barrier Dysfunction

844 Depot-Medroxyprogesterone Acetate Does Not Increase Genital SHIV Shedding in Macaques
Jessica Radzio,1 Kristztina Hanley,2 Debra Hanson,3 James Mitchell,4 Leecresia Jenkins5, Shanan Ellis1, Frank Deyounks1, Walid Heneine1, U943, Nancy, France,6 CHU Strasbourg, Strasbourg, France,7 Hôpital Voïce Study (MTN-003)

845 Incidence of AIDS-Defining Opportunistic Illnesses (ADOIs) Among Patients in North America
Kate A. Buchacz,1 Bryan Lau,2 Yuezhao Jing,3 Stephen J. Gange2, John T. Brooks1
1 Centers for Disease Control and Prevention, Atlanta, GA, United States; 2 Johns Hopkins University, Baltimore, MD, United States

846 Hormonal Contraceptives Increase Innate Immunological Effector Molecules in Cervicovaginal Secretions
Brandon L. Guthrie,1 Robert Y. Choi,1 Alison C. Roxby2, Rose Bosire3, Barbara Lohman-Payne4, Taha Hird,5 Carey Fanjuhar1, Kristina Broliden4
1 Department of Global Health, University of Washington, Seattle, WA, United States; 2 Department of Medicine, University of Washington, Seattle, WA, United States; 3 Center for Public Health Research, Kenya Medical Research Institute, Nairobi, Kenya; 4 Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden

847 Injectable Contraception and HIV Acquisition in the VOICE Study (MTN-003)
Lisa M. Noguchi1,2, Barbra Richardson1, Z. Mike Chirenje3,4, Thesla Palanee5,6,7, Pearl Selepe1,2,3, J. Gerardo Garcia-Lerma1
1 Makerere University - Johns Hopkins University Research Collaboration, Kampala, Uganda; 2 Johns Hopkins University, Baltimore, MD, United States; 3 Anova Health Institute, Johannesburg, South Africa; 4 Department of Infectious Diseases and Molecular Medicine, Cape Town, South Africa; 5 Centre for HIV and STIs, Johannesburg, South Africa; 6 University of Columbia, New York City, NY, United States

Program and Agenda

Thursday March 6, 2014, 2:30 pm–4:00 pm

Session P-S2 Poster Session

HIV in Women: Pregnancy, Progression, Pap, and Bones

848 Rapid Disease Progression in HIV-1 Subtype C Infected South African Women
Nigel J. Garrett1, Lise Werner2, Koleka Mlisana1,2, Lyfe McKinnon3, Francois van Loggerenberg1,2, Thumi Ndungu1, Olive Gray4, Lynn Morris4, Carolyn Williams4, Salim Abdool Karim1,2
1 CAPRISA, Durban, South Africa; 2 Department of Medical Microbiology, University of KwaZulu-Natal, South Africa; 3 The Global Health Network, University of Oxford, United Kingdom; 4 HIV Pathogenesis Programme, Durban, South Africa; 5 Institute of Infectious Diseases and Molecular Medicine, Cape Town, South Africa; 6 Centre for HIV and STIs, Johannesburg, South Africa; 7 University of Columbia, New York City, NY, United States

849 Pregnancy Intentions Among HIV-Infected Women Seeking Antenatal Care in Cape Town, South Africa
Tammy Phillips1,2, Allison Zerbe1,3, James McIntyre1,4, Greg Petro5, Elaine Abrams1,2, Landon Myer1
1 Division of Epidemiology & Biostatistics, University of Cape Town, Cape Town, South Africa; 2 ICAP, Columbia University, New York, NY, United States; 3 Anova Health Institute, Johannesburg, South Africa; 4 Division of Obstetrics & Gynaecology, University of Cape Town, Cape Town, South Africa

850 Effect of Antiretroviral Regimens On Bone Mineral Density Of HIV-Infected Lactating Ugandan Women
Carolyn Oyang-O-Makumbi1, Mike Mburu1, Prissy Ethel Namuli1, Jane Ssebagalla1, Joyce Matovu Namale1, Mary Glenn Fowler1,2
1 Makerere University - Johns Hopkins University Research Collaboration, Kampala, Uganda; 2 Johns Hopkins University, Baltimore, MD, United States

851 Visual Inspection With Acetic Acid Is Good for Follow-Up After Cryotherapy in HIV-Infected Women
Eikanan O. Omenga1, Peter M. Iszura2, Tao Liu2, Hillary Mabeya3, Astrid Christofferisen-Deb1, Sierra Washington1, Susan Cu-Uvin1,2
1 Reproductive Health, Moi University School of Medicine, Eldoret, Kenya; 2 Biostatistics, Brown University/ The Miriam Hospital, Providence, RI, United States; 3 Obstetrics and Gynaecology, University of Toronto, ON, Canada; 4 Toronto, ON, Canada; 5 Obstetrics and Gynaecology, Albert Einstein College of Medicine, Bronx, NY, United States; 6 Obstetrics and Gynaecology, Brown University/ The Miriam Hospital, Providence, RI, United States

Session P-S3 Poster Session

Immune Mediators and Immune Activation in Women

852 HIV Inhibition and Variation in Anti-Microbial Peptides Associated With Intercourse
J. D. Fortenberry1, Mary A. M. Rogers2, Krystle Fordyce3, Steven R. King1, David M. Aronoff1,3, Sari M. Van Anders4
1 Pediatrics, Indiana University School of Medicine, Indianapolis, IN, United States; 2 University of Michigan, Ann Arbor, MI, United States; 3 Vanderbilt University, Nashville, TN, United States

853 Sex-Related Inflammatory Marker Changes Pre- and Post-ART Initiation
Jyoti S. Mathad1,2, Nikhil Gupta1,3, Ashwin Balagopal1,3, David Asmuth1, James Hakim1, Nagalingeswaran Kumarasamy1, Thomas Campbell2,6,7, Judith S. Currier1,2, Susan E. Cohn1, Amita Gupta1, for the NWCS319 and ACTG S175 PEARLS Study Teams
1 Weill Cornell Medical College, New York, NY, United States; 2 Johns Hopkins University School of Medicine, Baltimore, MD, United States; 3 University of California Davis Medical Center, Sacramento, CA, United States; 4 University of California Davis Medical Center, Sacramento, CA, United States; 5 Institute of Infectious Diseases and Molecular Medicine, Cape Town, South Africa; 6 Department of Internal Medicine, University of California Los Angeles, Los Angeles, CA, United States; 7 Northwestern University Feinberg School of Medicine, Chicago, IL, United States
854  Influence of RAL vs Boosted ATZ-based Regimens On Cervical Immune Reconstitution and Activation
Amie L. Meditz1, Claire Palmer2, Julie Predhomme3, Kristina Sears1, Becky Kerr1, Patricia Caraway4, Edward M. Gardner4, Samantha MaWhinney5, Peter L. Anderson6
1Medicine, University of Colorado, Aurora, CO, United States; 2Biostatistics, University of Colorado, Aurora, CO, United States; 3Pharmacy, University of Colorado, Aurora, CO, United States; 4Denver Health Medical Center, Denver, CO, United States

**Session P-S4 Poster Session**
**Thursday March 6, 2014, 2:30 PM–4:00 PM Exhibit Hall D**

**Immune Response To Vaccination in HIV+ Women**
Warszawski 1,11, and the ANRS French Perinatal Cohort (ANRS CO1/Paris, France,11AP-HP Hôpital Bicêtre, Paris, France,8Hôpital de la Croix Rousse, Lyon, France,9AP-HP Medicine, University of Wisconsin, Madison, WI, United States,1,2Université Paris Diderot - Paris 7, Paris, France,3AP-HP Hôpital Robert Debré, Paris, France,4AP-HP Hôpital Trousseau, Paris, France,5AP-HP Hôpital Louis Mourier, Colombes, France,6AP-HP Hôpitaux Universitaires Paris-Sud, Clamart, France,7University of Maryland, Baltimore, MD, United States,8Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, United States,9Obstetrics, Gynecology & Reproductive Science, Icahn School of Medicine at Mount Sinai, New York, NY, United States,10Columbia University, Mailman School of Public Health, New York, NY, United States,11Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, United States,12Obstetrics, Gynecology & Reproductive Science, Icahn School of Medicine at Mount Sinai, New York, NY, United States

855  B and T Cell Immune Responses To pH1N1 Monovalent Vaccine in HIV+ Pregnant Women in IMPACT P 1086
Joel Palefsky1, Selvaramuthu Poongulali2, Shelly Lensing3, Jeannette Lee4, Maria Da Costa5, Arumugam Murugesan6, Syed Iqbal7, Nagalingeswaran Kumarasamy8
1University of California San Francisco, San Francisco, CA, United States; 2Rochester University School of Medicine, Rochester, NY, United States; 3University of Arkansas for Medical Sciences, Little Rock, AR, United States

856  CLINICAL Outcomes of HIV-Exposed Uninfected Infants
Terrence Fenton1, Teresa Dominguez1, Anthony Bloom2, Mark Abzug4, Theodore Ruel1, Abel Kakuru2, Moses R. Kamya4, Petronella Muresan2, Kelly Richardson1, Selvamuthu Poongulali1, Shelly Lensing3, Jennifer Jao2, Deborah Kacanek2, Rohan Hazra3, William Borkowsky4, Russell Van Dyke5, Kenneth Rich6, Jennifer S. Read7, Emma Ngoma1, Jaffer Okiring2, Gabriel Chamie1, Jane Achan2,3, Theodore Ruel1, Cenk Yildirim2, Marilyn Crain3, Rohan Hazra4, Joel Palefsky1, Brian Kirmse5, Roberto Posada6, Elaine J. Abrams7, Nancy Hutton8, Rhoda S. Kamya9, Taylor G. Sandison5, Jordan W. Tappero6, Deborah Kacanek2, Rohan Hazra3, William Borkowsky4, Russell Van Dyke5, Marshall Summar1
867 Maternal HIV Envelope V3-Specific IgG Responses Are a Correlate of Risk of Perinatal Transmission
Sallie P. Perner,1,2 Youyi Fong,3 Genevieve Fouda,4 Nathan A. Vannadig5,6,7, Pete Gilbert5,6, Guido Ferrari,8 Murit Alam,9 Georgia D. Tomaras,9 Thomas N. Denny6, Barton F. Haynes6, Women and Infant Transmission Study Group
1Human Vaccine Institute, Duke University Medical Center, Durham, NC, United States; 2Fred Hutchinson Cancer Research Center, Seattle, WA, United States

871 Ontogeny of HIV-Targeted CD4+ T Cells During Exclusive and Non-Exclusive Breastfeeding
Elizabeth J. McFarland,1,2 Tina Powell,2,3 Welming Zhang,2,3 Carolyne Onyango-Makumbi2,3,4 Kelsey Melander,5 Prossy Naluynya6, Samuel Okurut7, Michael A. Eller2,8,9, Mary Glen Fowler7,10,11, Edward N. Janoff2,12 Pediatric Infectious Diseases, University of Colorado School of Medicine, Aurora, CO, United States; 2Biostatistics and Informatics, Colorado School of Public Health, Aurora, CO, United States; 3MU-JUH Care LTD, Makerere University, Kampala, Uganda; 4Johns Hopkins University School of Medicine, Baltimore, MD, United States; 5Skags School of Pharmacy and Pharmaceutical Sciences, University of Colorado AMIC, Aurora, CO, United States; 6Mulago Hospital Complex, Makerere University Walter Reed Project, Kampala, Uganda; 7Mulago Hospital Complex, Makerere University Walter Reed Project, Kampala, Uganda; 8US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, United States; 9Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, United States;10Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, United States; 11Johns Hopkins University Research Collaboration, Makerere University, Kampala, Uganda; 12Mucosal and Vaccine Research Colorado (MAVRC), Division of Infectious Diseases, University of Colorado School of Medicine, Aurora, CO, United States

872 Infant Variants Require More CD4+ for Entry Than Maternal Variants Regardless of Transmission Route
Kyle J. Nakamura1, Edwin R. Sobrera1, Wicken Khatchadourian1, Moses Sinka1,2,稠hippe Kankasa2,3, Donald M. Thea1,4, James I. Mullins1, Louise Kuhn1, Grace M. Airdorvandi1
1Infectious Diseases, Children's Hospital Los Angeles, Los Angeles, CA, United States; 2Catholic Medical Missions Board, Lusaka, Zambia; 3University Teaching Hospital, Lusaka, Zambia; 4Boston University School of Public Health, Boston, MA, United States; 5Department of Microbiology, University of Washington, Seattle, WA, United States; 6Epidemiology, Columbia University, New York, NY, United States

873 HIV Viral Load and CD4 Cell Count in Untreated Pregnant Women Entering Care in Cape Town, South Africa
Landon Myer1, Tamsin Phillips2, Marvin Hsiao3, Allison Zerbe4, James McIntyre5, Linda-Gail Bekker6, Elaine Abrams7
1Division of Epidemiology & Biostatistics, University of Cape Town, Cape Town, South Africa; 2Division of Virology, University of Cape Town, Cape Town, South Africa; 3ICAP, Columbia University, New York, NY, United States; 4Anova Health Institute. Johannesburg, South Africa; 5Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa

874 Detectable Viraemia Among Pregnant Women On Antiretroviral Therapy Initiating Antenatal Care
Landon Myer1, Tamsin Phillips2, Allison Zerbe2, Marvin Hsiao3, James McIntyre5, Elaine Abrams7
1Division of Epidemiology & Biostatistics, University of Cape Town, Cape Town, South Africa; 2Division of Virology, University of Cape Town, Cape Town, South Africa; 3ICAP, Columbia University, New York, NY, United States; 4Anova Health Institute. Johannesburg, South Africa; 5Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa
875 Steady Decline: Temporal Changes in Substance Use by HIV-Positive Pregnant Women in the US
KathyRough1, KatherineTassiopoulos1, DeborahKacanek1, RaymondGriner1, RamYogev2, KennethC. Richi3, GeorgeR. Seagel4, for the PediatricHIV/AIDS C Hosp Study
1Department of Epidemiology, Harvard School of Public Health, Boston, MA, United States; 2Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, MA, United States; 3Department of Epidemiology, Biostatistics, and Occupational Health, McGill University School of Medicine, Montreal, QC, Canada; 4Ann & Robert H. Lurie Children’s Hospital, Chicago, IL, United States; 5University of Illinois at Chicago, Chicago, IL, United States

Session P-T6 Poster Session

Wednesday March 5, 2014, 2:30 PM–4:00 PM Exhibit Hall D

Early Infant HIV Diagnosis

876 Modeling the Performance and Cost of Early Infant HIV Diagnosis at Birth
Intraj C. Collins1, Martina Penazzato1, Dick Chamila1, AnisaGhadrshenas1, Teri Roberts2, Jennifer Cotri3, Nicole Ngo-Giang-Huong4, NathanShaffer5, Lisa J. Nelson5
1Department of ClinicalVirology and Epidemiology, University of Western Cape, Cape Town, South Africa; 2Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, MA, United States; 3Department of Epidemiology, Biostatistics, and Occupational Health, McGill University School of Medicine, Montreal, QC, Canada; 4Clinical Trials Unit, Children’s Hospital, Chicago, IL, United States; 5University of Illinois at Chicago, Chicago, IL, United States

877 Access To Early Infant Diagnosis and Antiretroviral Therapy in Abidjan, Côte d’Ivoire, 2011-2013
DivineAvit1, MadeleineFouquet-Amorin2, ClarisseAmani-Bosse3, JeanneEliau-Kouakou4, VéroniqueMéa-Assandé5, EdmondAka5, IrmaAho6, Didier K. Ekué7, MargueriteTimbé-Konan8, ValérianeLery9, for the MONOD ANRS 12206 Study Group
1Programme Pacci, Site ANRS, Projets Monod, Abidjan, Côte d’Ivoire; 2Service de Pédiatrie, Centre Hospitalier Universitaire (CHU) Cocody, Abidjan, Côte d’Ivoire; 3FSU Abobo-Avocatier, Programme Pacci; 4Site ANRS, Projets Monod, Abidjan, Côte d’Ivoire; 5Centre de Prise en Charge, de Recherche et de Formation (CaReF), Site Aconda-vo, Yopougon, Abidjan, Côte d’Ivoire; 6National Program of HIV Care, Abidjan, Côte d’Ivoire; 7Programme Pacci, Site ANRS, Abidjan, Côte d’Ivoire; 8Service de Pédiatrie, Centre Hospitalier Universitaire (CHU) Yopougon, Abidjan, Côte d’Ivoire; 9Inserm U897, Bordeaux, France; 10Bordeaux University, Bordeaux, France

Session P-T7 Poster Session

Thursday March 6, 2014, 2:30 PM–4:00 PM Exhibit Hall D

Risk Factors for MTCT

878 Impact of Maternal Incident HIV Infection On Early HIV Vertical Transmission, South Africa in 2011
Thu-Ha Dinh1, Kevin Delaney1, Debra Johnson2, Selam Woldesenbet3, Yogan Pillay3, Ameena Goga4
1Centers for Disease Control and Prevention, Atlanta, GA, United States; 2School of Public Health, University of the Western Cape, Cape Town, South Africa; 3South Africa Medical Research Council, Cape Town, South Africa; 4National Department of Health, Pretoria, South Africa; 5South Africa Medical Research Council, Pretoria, South Africa

879 Syphilis in HIV-Infected Mothers and Infants: Results From the NICHD/HPTN 040 Study
NavaYeganah1, HeatherWatts1, MargaretCamurca2, EsauJoao1, JoseHenriquePletto1, GlendaGray2, GerhardTheron2, ValdileaG. Veloso3, Lynne M. Mofenson4, KarinNielsen-Saines5, NICHD HPTN 040 P104 Study Team
1Department of Pediatrics, David Geffen School of Medicine, Los Angeles, CA, United States; 2Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, United States; 3Westat, Rockville, MD, United States; 4Hospital Federal dos Servidores do Estado, Rio De Janeiro, Brazil; 5Hospital Geral de Nova Iguacu, Nova Iguacu and Laboratory de AIDS e Imunologia Molecular, Instituto Oswaldo Cruz, Rio de Janeiro, Brazil; 6Penentral HIV Research Unit, Johannesburg, South Africa; 7Stellenbosch University, Cape Town, South Africa; 8Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil

880 Antiretroviral Adherence Associated With Reduced Breastmilk HIV-1 Transmission: The BAN Study
Nicole L. Davis1, William C. Miller2, Michael G. Hudgens3, Charles S. Chasela4, Dorothy S. Sicahi5, Dumbani Kayira6, Athena P. Kourtis7, Sascha R. Ellington8, Denise J. Jamieson4, Charles M. van der Horst9
1Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States; 2Epidemiology, Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States; 3Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States; 4Department of Obstetrics and Gynecology, Center for Disease Control and Prevention, Atlanta, GA, United States; 5Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States

881 Cytomegalovirus and Possibly Epstein-Barr Virus in Breast Milk May Facilitate HIV-1 Transmission
JohannesVlijmen1, ÉdouardTualler1, NicolasNagel2, SinaDanavi3, MariannePeries4, ChristophePeyronnet5, VincentFoulongne6, RuthBland7, NigelRollins8, Marie-LouiseNewell9, PhilippeVan de Perre10
1Africa Centre for Health and Population Studies, University of KwaZulu-Natal, Durban, South Africa; 2CHRU de Montpellier, Département de Bactériologie-Virologie, Montpellier 1, Montpellier, France; 3Department of Paediatrics & Child Health, University of KwaZulu-Natal, Durban, South Africa

Session P-T8 Poster Session

Thursday March 6, 2014, 2:30 PM–4:00 PM Exhibit Hall D

PMTCT Approaches: Implementation and Outcome

882 Programmatic Implementation of WHO Option B in Botswana Associated With Increased Projected MTCT
ScottDryden-Peterson1, SajiniSouda1, RebeccaZash2, JenniferChen1, ChipPoletto1, EldahN. Dintwa3, RelefetseitsweLesebonyane4, MompattiMimalane5, ShahinLockman6, RogerL. Shapiro7, 1Department of Medicine, Brigham & Women’s Hospital, Boston, MA, United States; 2Botswana Harvard AIDS Institute, Gaborone, Botswana; 3University of Botswana, Gaborone, Botswana; 4Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, United States; 5Department of Medicine, Massachusetts General Hospital, Boston, MA, United States; 6Ministry of Health, Gaborone, Botswana

883 Impact of Option B+ On Uptake, Retention, and Transmission: A Pre/Post Study in Lilongwe, Malawi
MariaH. Kim1,2, SaeedAhmed1,2, PeterN. Kazembe1, MinaC. Hosseinipour3,4, ThomasP. Giordano5, ElizabethY. Chiao5, XiaoyingYu1, DeborahNanturu1, MaryE. Paul1, ElaineJ. Abrams7
1Baylor College of Medicine, Texas Children’s Hospital, Houston, TX, United States; 2Baylor College of Medicine–Abbott Fund Children’s Clinical Center of Excellence, Lilongwe, Malawi; 3UNC Project, Lilongwe, Malawi; 4University of North Carolina School of Medicine, Chapel Hill, NC, United States; 5Department of Medicine, Baylor College of Medicine, Houston, TX, United States; 6Department of Pediatrics, Epidemiology Center, Baylor College of Medicine, Houston, TX, United States; 7ICAP, Mailman School of Public Health, Columbia University, New York, NY, United States

884 Home, Antenatal Clinic or VCT: Preferences of Pregnant Women and Their Partners for Male HIV Testing
AlfredOsoti1,2, GraceJohn-Stewart3, JamesKairie4, JohnKinuthia5, BarbraRichardson6, DaisyKrakowiak7, CareyFarquhar8
1Epidemiology, University of Washington, Seattle, WA, United States; 2Obstetrics and Gynecology, University of Nairobi, Nairobi, Kenya; 3Epidemiology, Pediatrics, Medicine, Global Health, University of Washington, Seattle, WA, United States; 4Obstetrics and Gynecology, University of Nairobi, Nairobi, Kenya; 5Research, Kenyatta National Hospital, Nairobi, Kenya; 6Epidemiology, Medicine, Global Health, University of Washington, Seattle, WA, United States

Poster Abstracts
85 Early Infection Among Ugandan HIV-Exposed Infants Whose Mothers Received Option B+ vs Option A
Julie N. Murphy1, Zikulah Namukwaya4, Adeodata Kekitiinwa1,3, Albert Maganda2, Rachael Ayang1, Ayoub Kakande1, Joyce Matovu1, Josaphat Byamugisha1, Godfrey Eshri1, Mary G. Fowler1,8,9
1PMCTT, Makerere University-Johns Hopkins Research Collaboration (MU-JHU), Kampala, Uganda, 2Baylor College of Medicine Children's Foundation-Uganda, Kampala, Uganda, 3Pediatrics and Child Health, Makerere University College of Health Sciences, Kampala, Uganda, 4Obstetrics and Gynecology, Makerere University College of Health Sciences, Kampala, Uganda, 5PMCTT, Ministry of Health, Kampala, Uganda, 6Johns Hopkins University School of Medicine, Baltimore, MD, United States

868 Poster Abstracts
886 Breast-Feeding ART Pharmacokinetics During Pregnancy and Postpartum
Kathryn Stinson1, Debbie van Zyl1, Hengiwe Mdabe1, Jean-Pierre Zetiele1, Christopher J. Colvin1, Leigh F. Johnson1, David Coetzee1, Helen Schneider1
1Centre for Infectious Disease Epidemiology & Research, University of Cape Town, Observatory, South Africa, 2Community Media Trust, Cape Town, South Africa, 3University of the Western Cape, Cape Town, South Africa

886 Lay Health Worker Support To Strengthen PMCTT: A Randomised Controlled Trial in South Africa
Julien Potier1, Roland Tubiana5, Sophie Matheron6, Roland Landman6,1,1,2, Marco Siccardi1, Ogechi Okafor3, Oluseye Bolaji1, Saye Kno1, Andrew Owen2
1Department of Pharmacy, Radboud University Medical Center, Nijmegen, Netherlands, 2Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 3National Institute of Infectious Diseases “L. Spallanzani”, Rome, Italy, 4Chelsea & Westminster Hospital, London, United Kingdom, 5Charité Universitätsmedizin, Berlin, Germany, 6Funderklinik Innenstadt, Klinikum der Universität München, Munich, Germany, 7Fondation Universitaire de la Sida, Foundation Hospital Universitari Germans Trias i Pujol, Badalona, Spain

8868 Poster Abstracts
895 Intensive Etravirine PK and HIV-1 Viral Load in Breast Milk and Plasma in HIV+ Women Receiving HAART
LaShonda Y. Spencer1, Suyu Liu2, Chia-Hao Wang3, Michael Neely1, Stan Louise1, Andrea Kovacs1
1Pediatric Infectious Diseases, Keck School of Medicine at University of Southern California, Los Angeles, CA, United States, 2University of Southern California School of Pharmacy, Los Angeles, CA, United States

889 ART Pharmacokinetics During Pregnancy and Breast-Feeding
Adeniyi Olagunju1,2,3, Marco Saccardi4, Ogechi Okaro5, Oluseye Bolaji1, Saye Knoo1, Andrew Owen2
1University of Liverpool, Liverpool, United Kingdom, 2Obafemi Awolowo University, Ile-Ife, Nigeria, 3Bishop Murray Medical Centre, Makurdi, Nigeria

889 Safety, Efficacy, and PK of Atazanavir/Ritonavir (300/100 mg QD) in HIV+ Pregnant Women Cohort
Minh P. Le1, Charlotte Charpentier1, Cathia Soulie1, Houria Ichou1, Julien Pottier1, Roland Tubiana1, Sophie Matheron1, Roland Landman1, Laurent Mandelbrot1, Gilles Peytavin1

890 A Comparison of the Pharmacokinetics of Raltegravir During Pregnancy and Postpartum
Maren Bongartz1, Angela Colbers1, Carmen Hidalgo-Tenorio2, Katharina Weizsäcker3, José Moltó4, David Hawkins5, Marchina van der Ende1, Andrea Gingelmaier1, Graham Taylor6, David Burger10
1Department of Pharmacy, Radboud University Medical Center, Nijmegen, Netherlands, 2Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 3National Institute of Infectious Diseases “L. Spallanzani”, Rome, Italy, 4Chelsea & Westminster Hospital, London, United Kingdom, 5Erasmus Medical Center, Rotterdam, Netherlands, 6Fondation Universitaire de la Sida, Foundation Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 7Funderklinik Innenstadt, Klinikum der Universität München, Munich, Germany, 8Mater and Rotunda Hospitals, Dublin, Ireland, 9Imperial College Healthcare NHS Trust, London, United Kingdom, 10Department of Pharmacy, Radboud University Medical Center, Nijmegen, Netherlands

Session P-T9 Poster Session
Thursday March 6, 2014, 2:30 PM–4:00 PM Exhibit Hall D

890 Effective Exposure To Atazanavir During Pregnancy, Regardless of Tenofuvir Use
Angela Colbers1, David Hawkins2, Carmen Hidalgo-Tenorio3, Marchina van der Ende1, Kalmira Kabeby4, Andrea Gingelmaier4, Katharina Weizsäcker4, John Lambert5, Jürgen Rockstroh6, David Burger7,10
1Department of Pharmacy, Radboud University Medical Center, Nijmegen, Netherlands, 2Chelsea & Westminster Hospital, London, United Kingdom, 3Hospital Universitario Virgen de las Nieves, Granada, Spain, 4Erasmus Medical Center, Rotterdam, Netherlands, 5Saint-Pierre University Hospital, Brussels, Belgium, 6Fondation Universitaire de la Sida, Foundation Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 7Funderklinik Innenstadt, Klinikum der Universität München, Munich, Germany, 8Mater and Rotunda Hospitals, Dublin, Ireland, 9Imperial College Healthcare NHS Trust, London, United Kingdom

889 Pharmacogenetics of Efavirenz Excretion Into Human Breast Milk and Transfer To Breastfed Infants
Musiime4, Tawanda Mhute5, Sabrina Kitaka1, Oscar Senfuma4, Joern Paulsen6, Cameron Murray7,8,9
1Centre for Infectious Disease Epidemiology & Research, University of Cape Town, Observatory, South Africa, 2Community Media Trust, Cape Town, South Africa, 3University of the Western Cape, Cape Town, South Africa

Session P-U1 Poster Session
Tuesday March 4, 2014, 2:30 PM–4:00 PM Exhibit Hall D

893 P1073: Immune Reconstitution Inflammatory Syndrome - Wide Spectrum and Severity in Children Mark F. Cotton1, Hilda Mujura2,3,4,3, Anna Boya2,4, Boniface Njau4, Avy Viasiri4, Vielya Mave4, Charles Mitchell1, James Oleske1, Bonnie Zimmer1, Savita Patwa21,2
1Pediatrics & Child Health, Stellenbosch University, Tygerberg, South Africa, 2Pediatrics & Child Health, UZ College of Health Sciences, Harare, Zimbabwe, 3Pediatrics & Child Health, University of Natal, Durban, South Africa, 4Pediatric Research Unit, Perinatal HIV Research Unit, Pretoria, South Africa, 5BJ Medical College, Pune, India, 6Pediatric Immunology, University of Miami, Miami, FL, United States, 7Pediatrics & Child Health, New Jersey Medical School, Newark, NJ, United States, 8Frontier Science & Technology Research Foundation, Aamherst, NY, United States, 9Pediatrics & Child Health, University of Miami Miller School of Medicine, Miami, FL, United States

894 sdNVP Exposure and ART Response in Children <3 Years Initiating ART in the ARRIVAL Trial
Philippa Musoke1, Victor Musumile2, Kuzum Nathoo3, Patricia Nahinya-Ntege4, Alexander J. Szubert5, Kuda Muchena1,2, Mark F. Cotton1, Hilda Mujura2,3,4,3, Anna Boya2,4, Boniface Njau4, Avy Viasiri4, Vielya Mave4, Charles Mitchell1, James Oleske1, Bonnie Zimmer1, Savita Patwa21,2
1Department of Pharmacy, Radboud University Medical Center, Nijmegen, Netherlands, 2Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 3National Institute of Infectious Diseases “L. Spallanzani”, Rome, Italy, 4Chelsea & Westminster Hospital, London, United Kingdom, 5University Hospital Van Gogh, Amsterdam, Netherlands, 6Fondation Universitaire de la Sida, Foundation Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 7Hospital Universitario Virgen de las Nieves, Granada, Spain, 8Mater and Rotunda Hospitals, Dublin, Ireland, 9Imperial College Healthcare NHS Trust, London, United Kingdom

895 Virolologic Response To Efavirenz vs Nevirapine-Containing ART in the ARRIVAL Trial
Adedotun A. Kekitiinwa1, Moira Spyer2, Richard Katuramu3, Victor Musumile1, Tawanda Mhute1, Sabrina Kitaka1, Oscar Sentumula1, Marshall Munjoma1, Ann Sarah Walker5, Diana M. Gibb1, and the ARRIVAL Trial Team
1Baylor-Uganda, Kampala, Uganda, 2Joint Clinical Research Center, Kampala, Uganda, 3University of Zimbabwe, Harare, Zimbabwe, 4MRC/UWRI Uganda Research Unit on AIDS, Entebbe, Uganda, 5MRC Clinical Trials Unit, London, United Kingdom, 6Climatmo Institute for Maternal Child Health Research, Harare, Zimbabwe
901 Safety, Pharmacokinetics and Efficacy of Dolutegravir in Treatment-Experienced HIV+ Children
Rolando M. Viani1, Carmelita Alverno1, Terry Fenlon1, Edward Acosta2, Rohan Hazra2, Ellen O’Gara3, Barbara Heckman4, Debra Steimers2, Sherene Min5, Andrew Wiznia1
1University of California San Diego, La Jolla, CA, United States; 2Harvard School of Public Health, Boston, MA, United States; 3University of Alabama at Birmingham, Birmingham, AL, United States; 4NIH, Bethesda, MD, United States; 5University of Birmingham, Birmingham, United Kingdom; 6United States; 7GlaxoSmithKline, Research Triangle Park, NC, United States; 8Jaciobi Medical Center, Bronx, NY, United States

902 Bioequivalence of Two Pediatric Formulations vs Adult Tablet Formulation of Efavirenz
Joseph M. Custodio1, Xiang Yin2, Hiba Graham3, Mischa Hepner4, Lauren Wiser5, Erin Quirk6, Brian P. Kearney6, Sinivisan Ramanathan1
1Clinical Pharmacology, Gilead Sciences, Foster City, CA, United States; 2Biometrics, Gilead Sciences, Foster City, CA, United States; 3Clinical Research, Gilead Sciences, Foster City, CA, United States; 4Clinical Operations, Gilead Sciences, Foster City, CA, United States; 5Formulations Process Development, Gilead Sciences, Foster City, CA, United States

903 CYP2B6 Polymorphisms Challenge Generalized FDA Efavirenz Dosing Guidelines in Children < 3 Yrs
Carolyn Bolton Moore1, Edmund Capparel1, Pearson Samson2, Mutsa Bwakura-Gandarembiz3, Patrick Jean-Philippe4, Carol Worrell5, Barbara Heckman6, Lynette Purdue6, Stephen A. Specter7, Ellen G. Chadwick8, IMPACT P10170 team
1University of North Carolina Chapel Hill, Centre for Infectious Disease Research in Zambia, Lusaka, Zambia; 2University of California San Diego, San Diego, CA, United States; 3Harvard School of Public Health, Boston, MA, United States; 4University of Zimbabwe, Harare, Zimbabwe; 5Henry Jackson Foundation Foundation, NIAID, Bethesda, MD, United States; 6Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, United States; 7Frontier Science and Technology Research Foundation, Amherst, NY, United States; 8Northeastern University’s Feinberg School of Medicine, Chicago, IL, United States

904 High Nevirapine and Low Lopinavir/Efavirenz Exposures in Resource-Poor Ugandan Children
Imke H. Bartelink1, Rada M. Savic2, Grant Dorsey3, Henriette J. Scherpert1, Edmund Capparel4, Jane Achian5, Albert Plenty6, Moses Kamya7, Diane Havir8, Francesca T. Aweka1
1Bioengineering and Therapeutics Sciences, University of California San Francisco, San Francisco, CA, United States; 2Pediatrics, University of California San Francisco, San Francisco, CA, United States; 3Pediatrics, University of California San Diego, La Jolla, CA, United States; 4Medicine, The Makerere University, Kampala, Uganda; 5Center for AIDS Prevention Studies, University of California San Francisco, San Francisco, CA, United States; 6Clinical Pharmacy, University of California San Francisco, San Francisco, CA, United States

905 Bone and Renal Safety at 96 Weeks of TDF-Containing Regimens in HIV-Infected Thai Children
Wasana Prasitsuksai1, Thanyawee Puthananakul2, Tanakorn Apornpatana1, Sirawan Keadpuda3, Tornak Burunputrabhat3, Thongsai Chumjaroen1, Narukjaporn Thammajaruk2, Thidarat Jupimai1, Stephen J. Kerr3,4, Jintanat Ananworanich1,2,4
1HIV-NAT, TRARC, Bangkok, Thailand; 2Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; 3The Kirby Institute, University of New South Wales, Sydney, Australia; 4HIV-NAT, SEARCH, TRARC, Bangkok, Thailand

906LB Safety and Efficacy of Dolutegravir in HIV Treatment-Experienced Adolescents: 48-Week Results
Rolando M. Viani1, Carmelita Alverno1, Terry Fenlon2, Edward Acosta2, Rohan Hazra2, Ellen O’Gara2, Barbara Heckman2, Debra Mcarty-Steimers3, Sherene Min2, Andrew Wiznia2
1University of California San Diego, La Jolla, CA, United States; 2Harvard School of Public Health, Boston, MA, United States; 3University of Alabama, Birmingham, Birmingham, AL, United States; 4Eunice
907 Simulation and Exposure-Based Assessment of Pediatric Lopinavir Fixed-Dose Combination Product  
Salk Unier1, Naim Bouazza1, Franzo Frissac2, Floris Fauchet2, David Burgess1, Jean-Pierre Kiechel1, Edmund Capparelli3, Jean-Marc Tréluyer4, Marc Lallemant5  
1Cochin Hospital, Paris, France; 2Radboud University, Nijmegen, Netherlands; 3For Drug Needs Investigated Initiative, Geneva, Switzerland; 4University of California San Diego, La Jolla, CA, United States

908 Bioequivalence of Two Pediatric Formulations vs Adult Tablet Formulation of Cobicistat  
Joseph M. Custodio1, Xiang Yin1, Hiba Graham2, Mischa Nepher2, Joanna Kozlara2, Erin Quirk3, Brian P. Kearney4, Srinivasan Ramanathan5  
1Clinical Pharmacology, Gilead Sciences, Foster City, CA, United States; 2Biometrics, Gilead Sciences, Foster City, CA, United States; 3Clinical Research, Gilead Sciences, Foster City, CA, United States; 4Formulations Process Development, Gilead Sciences, Foster City, CA, United States

909 Pharmacokinetics, Efficacy, and Safety of an Integrase Inhibitor STR in HIV-Infected Adolescents  
Aditya Gaur1, Jan Fourie2, Kulkanya Chokephaibulkit3, Linda-Gail Bekker1, Xiang Yin1, Joseph M. Custodio1, Sean R. Bennett1, Andrew Cheng1, Erin Quirk3  
1St Jude’s Children’s Research Hospital, Memphis, TN, United States; 2MPafi Medical Centre, Dundee, South Africa; 3Queen Siriraj Hospital, Bangkok, Thailand; 4Desmond Tutu HIV Centre, Cape Town, South Africa; 5Gilead Sciences, Inc, Foster City, CA, United States

910 Complex Pattern of Inflammatory Biomarkers After ART Initiation in HIV-Infected African Children  
Nigel Klein1, Chipo Berejena2, Godfrey Pimundu3, Andrew Wiznia4, Rohan Hazra5, Russell Van Dyke5  
1Pediatrics and Pharmacology, David Geffen School of Medicine, UCLA AIDS Institute, Los Angeles, CA, United States; 2Mango Medical Centre, Dundee, South Africa; 3Queen Siritaj Hospital, Bangkok, Thailand; 4University of Colorado/Children’s Hospital Colorado, Aurora, CO, United States; 5Rutgers University, Newark, NJ, United States; 6Albert Einstein School of Medicine, Bronx, NY, United States; 7NICHD, Bethesda, MD, United States; 8Tulane University Health Sciences Center, New Orleans, LA, United States

911 Incomplete Immune Reconstitution in HIV-1-Infected Children With Virological Suppression  
Paul Krogsdal1, Kunjal Patel1, Brad Kacarulis2, Mark Abzug3, James Oleske4, George Seage5, Andrew Wiznia5, Rohan Hazra6, Russell Van Dyke5  
1Pediatric HIV/AIDS Cohort Study and NISD Investigators; 2Pediatrics and Pharmacology, David Geffen School of Medicine, UCLA AIDS Institute, Los Angeles, CA, United States; 3Harvard School of Public Health, Boston, MA, United States; 4University of Colorado/Children’s Hospital Colorado, Aurora, CO, United States; 5Rutgers University, Newark, NJ, United States; 6Albert Einstein School of Medicine, Bronx, NY, United States; 7NICHD, Bethesda, MD, United States; 8Tulane University Health Sciences Center, New Orleans, LA, United States

912 Perturbation of Regulatory T Cell Subsets in HIV Infected Children  
Alka Khatian1, Musa Mwanzuka2, Fatma Marshed2, Adam Kravitz2, Tina Imen1, Swate Said1, Aabid Ahmed3, William Borkowsky4, Derya Unutmaz5  
1Pediatrics, Division of Infectious Diseases and Immunology, New York University School of Medicine, New York, NY, United States; 2Boum Hospital, Mombasa, Kenya; 3Microbiology, New York University School of Medicine, New York, NY, United States; 4Microbiology, Pathology, Medicine, New York University School of Medicine, New York, NY, United States; 5Rutgers University, Newark, NJ, United States

913 CD127 Expression On Naive T-Cells and HIV Replication in Youths Infected in the Perinatal Period  
Daniel Scott-Algara1, Jérôme Le Chenadec2, Josiane Warszawi3, Thomas Montagne3, Jean-Paul Viard3, Catherine Dollfus4, Véronique Avettand-Fenoel5, Christine Rouzioux1, Stéphane Blanche6, Florence Buseyne7  
1Virology, Institut Pasteur, Paris, France; 2CESP INSERM U1018, Le Kremlin-Bicêtre, France; 3AP-HP, Paris, France; 4EA3620, Université Paris Descartes, Paris, France

Session P-U5 Poster Session  
Wednesday March 5, 2014, 2:30 pm – 4:00 pm  Exhibit Hall D

Compliances of HIV and ART in Children and Adolescents  
916 Pediatric HIV Infection and Dental Caries in the Era of Antiretroviral Therapy in West Africa  
Noella Rajonson1, David G. Meless2, Boubacar Ba3, Malick Faye4, Jean-Serge Diby5, Serge N’Zoré6, Sébastien Datté7, François Dabis8, Shiboski Caroline9, Elise Arrivé1  
1SPED, Université Bordeaux Ségalen, Bordeaux, France; 2Rutgers University, Newark, NJ, United States; 3Biochemistry, Black Lion Hospital, Addis Ababa, Ethiopia; 4Pediatrics, Black Lion Hospital, Addis Ababa, Ethiopia; 5Department of Orofacial Sciences, University of California San Francisco, San Francisco, CA, United States

917 Preclinical Atherosclerosis in Eastern Africa: Results From a Pediatric Ethiopian Cohort  
Julia C. Rosebush1, Rahul L. Gleason2, Alexander Cauik2, Daniel Seifu3, Allison Eckard1, Workbeabea Taye4  
1Pediatric Infectious Diseases, Emory University, Atlanta, GA, United States; 2Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA, United States; 3Biochemistry, Black Lion Hospital, Addis Ababa, Ethiopia; 4Pediatrics, Black Lion Hospital, Addis Ababa, Ethiopia

918 Insulin Resistance in HIV-Infected Youth Is Associated With Decreased Mitochondrial Respiration  
Jody K. Takemoto1, JiJia Wang1, Denise L. Jacobson2, Tracie L. Miller1, Mitchell E. GEffner3, Russell B. Van Dyke5, Daniel E. Libutti1, Patricia Graham1, Mariana Gerschenson1  
1Pediatric HIV/AIDS Cohort Study; 2Pediatrics and Pharmacology, David Geffen School of Medicine, UCLA AIDS Institute, Los Angeles, CA, United States; 3Cell and Molecular Biology, University of Hawaii, Honolulu, HI, United States; 4Harvard School of Public Health, Boston, MA, United States; 5University of Colorado/Children’s Hospital Colorado, Aurora, CO, United States; 6Children’s Hospital Los Angeles, Los Angeles, CA, United States; 7Tulane University Health Sciences Center, New Orleans, LA, United States
922 Routine Antibody Tests Have No Place in Determining HIV Status After Early ART: Evidence From CHER
Helen Payne1,2, Nonhlanhla Mkhize1, Lynn Morris1, Kenneth Otombe2, Ravindre Panchiar1, Avy Violari1, Nigel Klein2, Abdel G. Babiker2, Mark F. Cotton1, Diana M. Gibb1, Infectious Diseases and Global Health, London, United Kingdom; Children’s Infectious Diseases Clinical Research Unit, Faculty of Medicine and Health Sciences, University of Pretoria, South Africa; Centre for HIV and STIs, National Institute for Communicable Diseases, Johannesburg, South Africa; Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa; Clinical Trials Unit, Medical Research Council, London, United Kingdom

923 Different Profiles of HIV in Early Treated HIV-Infected Children Seronegative by ELISA in Cameroon
Mathurin C. Tejokempt1, Amfumon Kfutw2, Francis Atiba 3, Ndongo1, Suzie Teteang Ndiang1, Ida Calixte Penda4,5,6, William Mbanzon2, Felicite Owona1, Josiane Warszawski2,11, Christine Rouzioux2,11,12,13,14, Albert Fay1,2
1Service d’Épidémiologie et de Santé Publique, Centre Pasteur du Cameroun, Membre du Réseau International des Instituts Pasteur, Yaoundé, Cameroon; 2Service de Virologie, Centre Pasteur du Cameroun, Membre du Réseau International des Instituts Pasteur, Yaoundé, Cameroon; 3Unité de Jour, Centre Mère et Enfant, Fondation Chantal Biya, Yaoundé, Cameroon; 4Service de Pédiatrie, Centre Hospitalier d’Essou, Yaoundé, Cameroon; 5Hôpital de Jour, Hôpital Laquentine de Douala, Douala, Cameroon; 6Université de Douala, Faculté de Médecine et des Sciences Pharmaceutiques, Douala, Cameroon; 7EPF, Equipe 4 (VH et IST), INSERM U1018 (CESP), Le Kremlin Bicêtre, France; 8Université de Paris Sud 11, Paris, France; 9Laboratoire de Virologie, Assistance Publique des Hôpitaux de Paris, Hôpital Necker, Paris, France; 10Université Paris Descartes, EA 3620, Paris, France; 11Pédiatrie Générale, Assistance Publique des Hôpitaux de Paris, Hôpital Robert Debré, Paris, France; 12Université Paris 7 Denis Diderot, Paris Sorbonne Cité, Paris, France

924 Greater Virologic Control in Infants Initiated On ART Before 6 Months of Age
Stephanie Shiu1, Ashraf Coovadia2, Karl-Gunter Technau3, Renate Strehlau4, Leigh Martin5, Francoise Pinillos1, Elaine J. Abrams1, Louise Kuhn1
1Columbia University, New York, NY, United States; 2University of the Witwatersrand, Johannesburg, South Africa

925 Early Viral Suppression Improves Neurocognitive Outcomes in HIV-Infected Children
Claudia S. Crowell1, Yanling Huo1, Katherine Tassiopoulos2, Kathleen M. Maleke3, Ram Yoge4, Rohan Hazra5, Richard M. Rutstein6, Sharan I. Nicholls7, Renee A. Smith1, William J. Muller1, for the IMPAACT 219C Study Team and the PediatricHIV/AIDS Cohort Study
1Pediatrics, University of Washington, Seattle, WA, United States; 2Epidemiology, Harvard School of Public Health, Boston, MA, United States; 3Northwestern University Feinberg School of Medicine, Chicago, IL, United States; 4National Institute of Child Health and Human Development, Bethesda, MD, United States; 5Children’s Hospital of Philadelphia, Philadelphia, PA, United States; 6University of California San Diego, La Jolla, CA, United States; 7University of Illinois at Chicago, Chicago, IL, United States

926 Early Cytomegalovirus Viraemia and Clinical Outcomes of HIV-Infected Children in the Early ART Era
Nei-yuan Hsiao1, Kenneth Otombe2, Landon Myer3, Avy Violari4, Diana Gibb5, Ravindre Panchiar1, Abdel Babiker5, Patrick Jean-Phillipe6, Mark Fredric Cotton7
1Clinical Laboratory Sciences, University of Cape Town, Cape Town, South Africa; 2Perinatal HIV Research Unit, Johannesburg, South Africa; 3Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa; 4Medical Research Council UK, London, United Kingdom; 5National Institute of Allergy and Infectious Diseases, Bethesda, MD, United States; 6Paediatrics and Child Health, Stellenbosch University, Cape Town, South Africa
Parental Absence From Clinic Predicts Virologic Failure in Adolescents in Botswana
Elizabeth Lowenthal1,2, Taferei Marukutira3, Ontibile Tshume3, Jennifer Chapman, Tebo Dipotso3, Omphile Lepodisi3, Kebleless Mokete1, Jean Nachega1,2, Gabriel Anabwani3, Robert Gross6,7, Charles Farmer1, William R. Spreen2, Yun Lan Yueh2, Agegnehu Chasity D. Andrews, Nigel J. Garrett1, Hiroshi Mohri1, William Spreen2, Zhi Hong2, David Ho4, Martin Markowitz3, Aaron Diamond AIDS Research Center, an affiliate of The Rockefeller University, New York, NY, United States,4GlaxoSmithKline, Research Triangle Park, NC, United States,5Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, PA, United States,6Departments of Pediatrics & Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD, United States,7Department of Medicine, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States,8Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, United States,1DHAP, CDC, Atlanta, GA, United States,2Total Solutions, Atlanta, GA, United States,3Tulane University School of Medicine, New Orleans, LA, United States,4Department of Mechanical Engineering and Mechanics, Drexel University, Philadelphia, PA, United States,5Department of Epidemiology and Biostatistics, Emory University, Atlanta, GA, United States,6Departments of Pediatrics and Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States,7Duke University Medical Center, Durham, NC, United States,8Westat, Rockville, MD, United States,1University of Alabama at Birmingham, Birmingham, AL, United States,2Johns Hopkins University School of Medicine, Baltimore, MD, United States,3University of Florida College of Medicine, Gainesville, FL, United States,4Department of Infectious Diseases, New York University School of Medicine, New York, NY, United States,5Department of Medicine, Division of Infectious Diseases, Thomas Jefferson University, Philadelphia, PA, United States

Factors Associated With Successful Retention Among Non-Perinatally HIV-Infected Youth
Charles Farmer1, Baligh Yehia1, Richard Rutstein1, Stephen Berry4, Kelly Gebo1, Allison Agwu1, for the HIV Research Network, 1Johns Hopkins University School of Medicine, Baltimore, MD, United States,2Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States,3University of Florida College of Medicine, Gainesville, FL, United States,4Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, PA, United States,5Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States,6Departments of Pediatrics and Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD, United States

Factors Associated With Successful Retention Among Non-Perinatally HIV-Infected Youth
Charles Farmer1, Baligh Yehia1, Richard Rutstein1, Stephen Berry4, Kelly Gebo1, Allison Agwu1, for the HIV Research Network, 1Johns Hopkins University School of Medicine, Baltimore, MD, United States,2Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States,3University of Florida College of Medicine, Gainesville, FL, United States,4Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, PA, United States,5Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States,6Departments of Pediatrics and Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD, United States

Factors Associated With Successful Retention Among Non-Perinatally HIV-Infected Youth
Charles Farmer1, Baligh Yehia1, Richard Rutstein1, Stephen Berry4, Kelly Gebo1, Allison Agwu1, for the HIV Research Network, 1Johns Hopkins University School of Medicine, Baltimore, MD, United States,2Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States,3University of Florida College of Medicine, Gainesville, FL, United States,4Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, PA, United States,5Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States,6Departments of Pediatrics and Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD, United States

Factors Associated With Successful Retention Among Non-Perinatally HIV-Infected Youth
Charles Farmer1, Baligh Yehia1, Richard Rutstein1, Stephen Berry4, Kelly Gebo1, Allison Agwu1, for the HIV Research Network, 1Johns Hopkins University School of Medicine, Baltimore, MD, United States,2Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States,3University of Florida College of Medicine, Gainesville, FL, United States,4Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, PA, United States,5Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States,6Departments of Pediatrics and Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD, United States

Factors Associated With Successful Retention Among Non-Perinatally HIV-Infected Youth
Charles Farmer1, Baligh Yehia1, Richard Rutstein1, Stephen Berry4, Kelly Gebo1, Allison Agwu1, for the HIV Research Network, 1Johns Hopkins University School of Medicine, Baltimore, MD, United States,2Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States,3University of Florida College of Medicine, Gainesville, FL, United States,4Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, PA, United States,5Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States,6Departments of Pediatrics and Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD, United States

Factors Associated With Successful Retention Among Non-Perinatally HIV-Infected Youth
Charles Farmer1, Baligh Yehia1, Richard Rutstein1, Stephen Berry4, Kelly Gebo1, Allison Agwu1, for the HIV Research Network, 1Johns Hopkins University School of Medicine, Baltimore, MD, United States,2Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States,3University of Florida College of Medicine, Gainesville, FL, United States,4Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, PA, United States,5Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States,6Departments of Pediatrics and Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD, United States

Factors Associated With Successful Retention Among Non-Perinatally HIV-Infected Youth
Charles Farmer1, Baligh Yehia1, Richard Rutstein1, Stephen Berry4, Kelly Gebo1, Allison Agwu1, for the HIV Research Network, 1Johns Hopkins University School of Medicine, Baltimore, MD, United States,2Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States,3University of Florida College of Medicine, Gainesville, FL, United States,4Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, PA, United States,5Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States,6Departments of Pediatrics and Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD, United States

Factors Associated With Successful Retention Among Non-Perinatally HIV-Infected Youth
Charles Farmer1, Baligh Yehia1, Richard Rutstein1, Stephen Berry4, Kelly Gebo1, Allison Agwu1, for the HIV Research Network, 1Johns Hopkins University School of Medicine, Baltimore, MD, United States,2Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States,3University of Florida College of Medicine, Gainesville, FL, United States,4Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, PA, United States,5Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States,6Departments of Pediatrics and Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD, United States

Factors Associated With Successful Retention Among Non-Perinatally HIV-Infected Youth
Charles Farmer1, Baligh Yehia1, Richard Rutstein1, Stephen Berry4, Kelly Gebo1, Allison Agwu1, for the HIV Research Network, 1Johns Hopkins University School of Medicine, Baltimore, MD, United States,2Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States,3University of Florida College of Medicine, Gainesville, FL, United States,4Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, PA, United States,5Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States,6Departments of Pediatrics and Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD, United States

Factors Associated With Successful Retention Among Non-Perinatally HIV-Infected Youth
Charles Farmer1, Baligh Yehia1, Richard Rutstein1, Stephen Berry4, Kelly Gebo1, Allison Agwu1, for the HIV Research Network, 1Johns Hopkins University School of Medicine, Baltimore, MD, United States,2Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States,3University of Florida College of Medicine, Gainesville, FL, United States,4Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, PA, United States,5Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States,6Departments of Pediatrics and Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD, United States
Session P-V3 Poster Session
Wednesday March 5, 2014, 2:30 PM–4:00 PM Exhibit Hall D
Identifying and Reducing HIV Risk

943 Controlled Trial of an Internet-Based Risk Reduction Intervention in HIV+ Men Who Have Sex With Men
Joel Milam1, Sonja Jain1, Eric Daar2, Michael Dubé1, Edward Seetfreid3, Eric Ellorin1, Gustavo A. Jimenez-Maggiora4, Sheldon R. Morris1, Richard H. Haubrich5
1University of Southern California Keck School of Medicine, Los Angeles, CA, United States; 2UC, San Diego, San Diego, CA, United States; 3Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, United States

944 Changes in the Contribution (PAR%) of STIs To HIV Acquisition Among Kenyan FSWs From 1993 To 2012
Ennet Masese1, Jared M. Baeten2, Barbra A. Richardson3, Susan M. Graham4, Elizabeth Bukusi5, Juma Shafi6, Walter Jakob7, James Kiarie1, R. Scott McClelland8
1University of Washington, Seattle, WA, United States; 2KEMRI, Nairobi, Kenya; 3University of Nairobi, Nairobi, Kenya

945 Intervention To Reduce HIV/STI Among High-Risk Patients in China: Cluster Randomized Trial
Don Orapio1, Debin Wang2, Mei-Fen Yang3, Kathleen Blaney4, Jing Cheng5, Hong Gai6, Hongbo Zhang7, Gregory Szekeres8, Jerome Galea9, Thomas Coates10
1School of Public Health, Brown University, Providence, RI, United States; 2Artz Medical University, Hefei, China; 3University of California Los Angeles, Los Angeles, CA, United States

946 Validation of the Refined Denver HIV Risk Score Using a National HIV Testing Cohort
Jason Haukoos1, Emily Hopkins2, Meggan Buccosi3, Michael Lyons4, Richard Rothman5, Douglas White6, Ali Al-Tayyib7, Lucy Bradley-Springer8, Allison Sabel9, Mark Thrun10
1Emergency Medicine, Denver Health Medical Center, Denver, CO, United States; 2Emergency Medicine, University of Cincinnati, Cincinnati, OH, United States; 3Emergency Medicine, Johns Hopkins University, Baltimore, MD, United States; 4Emergency Medicine, Highland Hospital, Oakland, CA, United States; 5Denver Public Health, Denver, CO, United States; 6University of Colorado School of Nursing, Aurora, CO, United States; 7Denver Health Medical Center, Denver, CO, United States

Session P-V4 Poster Session
Wednesday March 5, 2014, 2:30 PM–4:00 PM Exhibit Hall D

947 Cost Effectiveness of Antiretrovirals in HIV Control in Rural Zambia: A Stochastic League Approach
Brooke E. Nichols1, Rob Baltussen2, Janneke H. van Dijk3, Phil E. Thuma4, Jan L. Nouwen5, Charles A. B. Boucher6, David A. M. C. van de Vijver7
1Virotech, Erasmus Medical Center, Rotterdam, Netherlands; 2Primary and Community Care, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands; 3Macha Mission Hospital and Macha Research Trust, Macha, Zambia; 4Medical Microbiology and Infectious Diseases, Erasmus Medical Center, Rotterdam, Netherlands

948 Darunavir(DRV)/r-Based PEP Versus Standard of Care (SOC) - the Randomized PEPPDar Study
Gerd Fäktinen1, Norma Jung1, Heiko Jessen2, Albrecht Stoehr3, Keikawus Arasteh4, Johannes Bogner5, Christoph Stephan6, Christoph D. Spinnler7, Olaf Degen8, Britta Ranneberger9
1Med. Einrichtungen der Universität Köln, Cologne, Germany; 2Klinik I für Innere Medizin, Med. Einrichtungen der Universität Köln, Cologne, Germany; 3Praxis Jessen, Berlin, Germany; 4Zentrum Infektiologie, ifi-institut für interdisziplinäre Medizin, Hamburg, Germany; 5Innere Medizin, Infektologie und Gastroenterologie, Vivantes Auguste-Viktoria-Klinikum, Berlin, Germany; 6Medizinische Poliklinik, Ludwigs-Maximilians-Universität, München, Germany; 7Zentrum der Innere Medizin, Klinikum der Johann Wolfgang Goethe-Universität, Frankfurt, Germany; 8Medizinische Poliklinik und Klinikum rechts der Isar, München, Germany; 9Bereich Infektiologie, Universitätsklinikum Eppendorf, Hamburg, Germany

949 High Initiation of PrEP and ART in a Demonstration Project Among African HIV-Discordant Couples
Renee Heffron1, Connie Celum2, Nelly Mugo3, Elka Katabira4, Elizabeth Bukusi5, Elida Turmusweyi6, Jessica Haberer7, Jared Baeten8, for the Partners Demonstration Project Team
1University of Washington, Seattle, WA, United States; 2Kenya Medical Research Institute, Nairobi, Kenya; 3Makere University, Kampala, Uganda; 4Integrated Community Based Initiatives (ICBII), Bushenyi, Uganda; 5Massachusetts General Hospital, Boston, MA, United States; 6Harvard University, Boston, MA, United States

950 PrEP Is Efficacious for HIV Prevention Among Women Using DMPA for Contraception
Renee Heffron1, Nelly Mugo2, Edwin Were3, James Kiarie4,5, Elizabeth Bukusi6, Andrew Mujuigira7, Deborah Donnelly8, Allan Ronald1, Connie Celum2, Jared Baeten9, for the Partners PrEP Study Team
1University of Washington, Seattle, WA, United States; 2Kenya Medical Research Institute, Nairobi, Kenya; 3UI University, Eldoret, Kenya; 4Kenyatta National Hospital, Nairobi, Kenya; 5University of Nairobi, Nairobi, Kenya; 6Fred Hutchinson Cancer Research Center, Seattle, WA, United States; 7University of Manitoba, Winnipeg, MB, Canada

951 PrEP Interest, Uptake, and Adherence Among Young Men Who Have Sex With Men (YMSM) in the United States
Sybil Hosek1, Jaime Martinez2, Kristine Santos3, Megha Mehrotra4, Christopher Balhazar5, Pedro Serrano6, Kelly Bojan7, Robert Grant8, The Adolescent Medicine Trials Network for HIV/AIDS Interventions
1Psychiatry, Stroger Hospital of Cook County, Chicago, IL, United States; 2Stroger Hospital of Cook County, Chicago, IL, United States; 3Ruth M. Rothstein CORE Center, Chicago, IL, United States; 4Gladdstone Institutes, San Francisco, CA, United States

952 Early Adopters: Correlates of Chemoprophylaxis Use in an Online Sample of US Men Who Have Sex With Men
Kenneth H. Mayer1,2, Cate Oldenberg3,4,5, David Novak6, Douglas Krakover7,8,9, Matthew Mimiaga10,11,12
1The Fenway Institute, Fenway Health/Harvard Medical School, Boston, MA, United States; 2Medicine, Beth Israel Deaconess Medical Center, Boston, MA, United States; 3Epidemiology, Harvard School of Public Health, Boston, MA, United States; 4Online Buddies, Cambridge, MA, United States

953 Measuring Intermittent and Daily PrEP Adherence by Hair Levels, Self-Report and MEMS Caps Openings
Sanjiv M. Baxi1, Albert Liu2, Peter Bacchetti3, Gaudensia Mutua4, Eduard Joachim Sanders5, Freddie M. Kibengo6, Jessica E. Haberer7, James Rooney7, Frances Friddy8, Monica Gandhi9,10
1Infectious Diseases, University of California San Francisco, San Francisco, CA, United States; 2San Francisco Department of Public Health, San Francisco, CA, United States; 3Epidemiology & Biostatistics, University of California San Francisco, San Francisco, CA, United States; 4Kenya AIDS Vaccine Initiative, Nairobi, Kenya; 5Centre for Geographic Medicine Research Coast, Kilifi, Kenya; 6Medical Research Council (MRC)/Uganda Virus Research Institute (UVRI), Entebbe, Uganda; 7Infectious Diseases, Center for Global Health, Boston, MA, United States; 8Gilead Sciences, Foster City, CA, United States; 9International AIDS Vaccine Initiative, New York, NY, United States

954 Implementation of PrEP in STD Clinics: High Uptake and Drug Detection Among MSM in the Demonstration Project
Stephanie E. Cohen1, Eric Vittinghoff2, Peter Anderson3, Susanne Dobiecki-Lewi3, Oliver Bacon4, Wairimu Chege5,6, Eric Vittinghoff7, Peter Bacchetti8, Gaudensia Mutua9, Albert Liu10
1Disease Prevention and Control, San Francisco Department of Public Health, San Francisco, CA, United States; 2Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, United States; 3University of Colorado at Denver, Denver, CO, United States; 4Department of Epidemiology; University of Miami, Miami, FL, United States; 5Prevention Sciences Program, National Institutes of Health, Bethesda, MD, United States; 6Whitman-Walker Health, Washington, DC, DC, United States; 7Bridge HIV, San Francisco Department of Public Health, San Francisco, CA, United States
Program and Agenda

955 High Medication Adherence Among HIV-1 Uninfected Women Experiencing Pregnancy in a PrEP Trial
Lynn T. Matthias1, Renee Heffron2, Nelly P. Mugo3, Craig R. Cohen4, Craig R. Hendrix5, Connie Celum6,2, David R. Bangsberg7, Jared M. Baeten3,7, for the PrEP Study Team
1Division of Infectious Disease & Center for Global Health, Massachusetts General Hospital, Boston, MA, United States; 2Division of Infectious Disease, Beth Israel Deaconess Medical Center, Boston, MA, United States; 3Department of Global Health, University of Washington, Seattle, WA, United States; 4Department of Obstetrics and Gynecology, Kenyatta National Hospital, Nairobi, Kenya; 5Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco, San Francisco, CA, United States; 6Department of Medicine, Johns Hopkins University, Baltimore, MD, United States; 7Department of Medicine, Johns Hopkins University, Baltimore, MD, United States; 8Department of Epidemiology, University of Washington, Seattle, WA, United States

956 Willingness To Use Pre-Exposure Prophylaxis Among Community-Recruited Injection Drug Users
Irene Kuo1, Gregory L. Phillips2, Mariva Maggs3, Janevieve Opekou4, Anthony L. Rawls5, James Petersen6, Michael Kharfen7, Alan E. Greenberg8
1George Washington University School of Public Health and Health Services, Washington, DC, United States; 2Department of Epidemiology and Biostatistics, George Washington University School of Public Health and Health Services, Washington, DC, United States; 3HIV/AIDS, Hepatitis, STD and TB Administration, District of Columbia Department of Health, Washington, DC, United States

957 PrEP Does Not Diminish the Pregnancy Prevention Effectiveness of Hormonal Contraception
Pamela M. Murnane1, Renee A. Heffron2, Connie Celum5, Elizabeth Bukusi7, Deborah Donnelly3, James Kiwire4, Nelly Mugo5, Allan Ronald6, Edwin Were7, Jared Baeten1
1University of Washington, Seattle, WA, United States; 2University of Nairobi, Nairobi, Kenya; 3University of Manitoba, Winnipeg, MB, Canada; 4Moi University, Eldoret, Kenya

958 Uptake of Treatment as Prevention and Continuum of Care Among Men Who Have Sex With Men in Nigeria
Christopher Akolo1,2,3, Stefano Barili4, Julie Ake5, Sara Kennedy5, Benjamin Emmanuel1, Ifeanyi Grazyulike7, Marc Boulay8, Babajide Keshinro1, William Blattner5, Manhattan Charurat1
1Institute of Human Virology - University of Maryland School of Medicine, Baltimore, MD, United States; 2Institute of Human Virology - Nigeria, Abuja, Nigeria; 3JHSPH, Epidemiology, Baltimore, MD, United States; 4U.S Military HIV Research Program, Silver Spring, MD, United States; 5International Centre for Advocacy on Rights to Health, Abuja, Nigeria; 6JHSPH, Health, Behavior, and Society, Baltimore, MD, United States

959L FEM-PrEP: Participant Explanations for Non-Adherence
Amy Cornell1, Brian Perry2, Kawango Agot3, Khatija Ahmed4, Kevin McKenna1, Fukulifule Malamatsho5, Jacob Odhiambo6, Joseph Skhosana7, Lut Van Damme8, FEM-PrEP study team
1Social and Behavioral Health Sciences, FH 360, Durham, NC, United States; 2Impact Research and Development Organization, Kisumu, Kenya; 3Setshaba Research Centre, Pretoria, South Africa; 4The Bill & Melinda Gates Foundation, Seattle, WA, United States

960 Prevention of HIV Transmission With Post-Exposure Prophylaxis After Infected-Blood Transfusion
Sam H. Al Hajjar1, Husn H. Frayha2, Mohammad Al Hazmi2, Reem Batawi1, Kenneth McIntosh1, Paul E. Sae1, Emily Hanushek2, Daniel R. Kourtzkes3, Jonathan Z. Li4, Timothy J. Henrich5
1King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia; 2King Fahad Central Hospital, Jazan, Saudi Arabia; 3Boston Children’s Hospital, Harvard Medical School, Cambridge, MA, United States; 4Bingham and Women’s Hospital, Harvard Medical School, Boston, MA, United States; 5Bingham and Women’s Hospital, Harvard Medical School, Cambridge, MA, United States

961 Contingency Management Facilitates PEP Completion Among Stimulant-Using MSM
Raphael J. Landovitz1, Jesse B. Fletcher2, Steve Shoptaw3, Cathy J. Reback2
1Center for Clinical AIDS Research & Education, University of California, Los Angeles, Los Angeles, CA, United States; 2Friends Community Center, Friends Research Institute, Los Angeles, CA, United States; 3Family Medicine, University of California, Los Angeles, Los Angeles, CA, United States

Session P-V5 Poster Session
Wednesday March 5, 2014, 2:30 pm – 4:00 pm  Exhibit Hall D

962 Male Circumcision: Association With HIV Prevalence, Knowledge, and Attitudes Among Women
Bertran Auvert1,2, Pascale Lissouba3, Dirk Taljaard4, Giles Petyatvin5, Beverley Singh6, Adrian Puren7
1University of Versailles, Villejuif, France; 2INSERM, Villejuif, France; 3CHAPS, Johannesburg, South Africa; 4APHP, Paris, France; 5NHLS-NICO, Johannesburg, South Africa; 6NHLS-NICO, Johannesburg, South Africa

963 Lower Odds of HIV Among Circumcised MSM in China and Interaction With Anal Sexual Role
Han-Zhu Qian1, Yuhua Rui2, Yu Liu7, Douglas F. Milian1, Hans M. L. Spiegel1, Lu Yin1, Yiming Shao1, Zhen H. Vermund8
1Vanderbilt University, Nashville, TN, United States; 2Chinese Center for Disease Control and Prevention, Beijing, China; 3IUF-DAIDS, Bethesda, MD, United States

964 Client Experiences of Odor Associated With PrEP™ Device Male Circumcision in Botswana
Adam Musigne1, Tigistu A. Asheng2, Lesego Busang3, Kenanoo Motsholow3, Alex Chipara4, Galina Stolarsky1, Frank Mwangem3, Conrad Ntsumpe1
1Jhpiego, Gaborone, Botswana; 2University of North Carolina, North Carolina, USA; 3Africa Comprehensive HIV/AIDS Partnerships (ACHAP), Gaborone, Botswana; 4Ministry of Health, Gaborone, Botswana; 5Ministry of Health of Botswana, Gaborone, Botswana

965 Penile Cytokines Correlate With HIV Target Cells and Decrease After Circumcision in Rakai, Uganda
Jessica L. Prodder1, Brett Shannon1, Kannmoss Shihabi2, Xiangrong Kong1, Cindy M. Liu1, Lance Price1,2, Godfrey Kigozi2, David Serwadda3, Ronald H. Gray4, Rupert Kauf1
1Department of Medicine, University of Toronto, Toronto, ON, Canada; 2Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States; 3African Comprehensive HIV/AIDS Partnerships (ACHAP), Gaborone, Botswana; 4Ministry of Health, Gaborone, Botswana; 5Ministry of Health of Botswana, Gaborone, Botswana

966 HIV Shedding From Male Circumcision Wounds in Rakai, Uganda
Aaron A. R. Tobian1, Jordyn G. Manucci2, Godfrey Kigozi2, Mary K. Grabowski3, David Serwadda4, Ronald H. Gray2, Fred Nalugoda1, Anthony Ndyabanob, Thomas C. Quinn5, Maria J. Wawer4,5
1Johns Hopkins University, Baltimore, MD, United States; 2National Institutes of Health, Bethesda, MD, United States

967 HIV Transmission With Post-Exposure Prophylaxis After Male Circumcision Wounds in Rakai, Uganda
Aaron A. R. Tobian1, Jordyn G. Manucci2, Godfrey Kigozi2, Mary K. Grabowski3, David Serwadda4, Ronald H. Gray2, Fred Nalugoda1, Anthony Ndyabanob, Thomas C. Quinn5, Maria J. Wawer4,5
1Johns Hopkins University, Baltimore, MD, United States; 2National Institutes of Health, Bethesda, MD, United States

Session P-W1 Poster Session
Tuesday March 4, 2014, 2:30 pm – 4:00 pm  Exhibit Hall D

968 Finding Unawares: High Levels of Undiagnosed HIV Infection Among Mosow Men Who Have Sex With Men
Andrea L. Wirtz1,2,3, Farla E. Zelaya4, Noya Galai4, Alena Peryshkina5, Vladimir Moguilnyi1, Petr Dzhigun4, Irina Kostetskaya5, Carl Latkin6
1Emergency Medicine, Johns Hopkins Medical Institute, Baltimore, MD, United States; 2Epidemiology, Johns Hopkins School of Public Health, Baltimore, MD, United States; 3Epidemiology, Johns Hopkins School of Public Health, Baltimore, MD, United States; 4AIDS Infoshare, Moscow, Russian Federation; 5National Institutes of Health, Bethesda, MD, United States

969 Cascade of Care and Testing
Laura A. Cooley, Alexandra M. Oster, Cyprian Wejnert, Binh C. Le, Charles E. Rose, Gabriela Paz-Bailey
Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, GA, United States

969 Feasibility of HIV Self-Test Vouchers To Raise Community-Level Serostatus Awareness, Los Angeles
Robert Marin1, Sean Young2, Greg Wilson2, Jeffrey P. Rodriguez2, Joe Montes3, Jose Ortiz4, Rhea Mathew5, Zoe Blick6, Jeffrey D. Klauser7
1David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, United States;2Reach LA, Los Angeles, CA, United States;3LA Gay & Lesbian Center, Los Angeles, CA, United States;4Bienestar, Los Angeles, CA, United States;5University of California Los Angeles, Los Angeles, CA, United States;6Brentwood School, Los Angeles, CA, United States

970 Availability, Accessibility, Price of Rapid HIV Self-Tests, New York City Pharmacies, Summer 2013
Julie E. Myers1, Olivia El-Sadir Davies2, Elliott R. Weinstein4, Molly Perlman3, Amy L. Edelstein2, Blayne H. Cutler1, Julia A. Schillinger5,6
1Division of Medicine, Division of Infectious Diseases, Columbia University Medical Center, New York, NY, United States;2Health Research Training Program, New York City Department of Health and Mental Hygiene, Queens, NY, United States;3Department of Medicine, Columbia University, New York, NY, United States;4Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States

971 Acceptability & Affordability of Self HIV Testing in an Urban Neighborhood With 3% Seroprevalence
Amy Nunn1, Philip Chan1, Caitlin Towey1, Joanna Pecot2, Sophie Feller3, Stacy Troock3
1Division of Infectious Diseases, Warren Alpert Medical School of Brown University, Providence, RI, United States;2Jefferson Medical College, Philadelphia, PA, United States;3Drexel University College of Medicine, Philadelphia, PA, United States

972 Getting To Zero: HIV Testing and Counselling in Kenya - Results From a Population-Based Survey
Anne Nganga1, Wanjiru Waruiru1, Carol Ngar2, Victor Ssempijja3, Patricia oluoch1, Inviolata Njoroge4, Thomas Gachuku4, William Maina1, Rex Mpyazanjie1, Andrea A. Kim3

973 Counselor Based Versus Integrated Routine HIV Screening in a Urban Emergency Department
Georgina Osorio1, Anca Giurgiulescu1, Zacharia Hennessey1, Andrea Wood3, Daniel Egan3, Dan Wiener2, Rita Rupama Pali1, Victoria Sharp1
1Medicine, Spencer Cox Center for Health, St. Luke’s-Roosevelt Hospital Center, New York, NY, United States;2Emergency Medicine, St. Luke’s-Roosevelt Hospital Center, New York, NY, United States;3Emergency Department, New York University School of Medicine, New York, NY, United States

974 Low Feasibility Rate of Self Testing With a Finger-Stick Whole Blood Test
Guillaume Gras1, Pascal Le Bret2, Jean Francois Dalloux2, Gwenaël Le Moal1, Aurelia Raulot1, Gaelle Fajole2, Penelope Hodges1, Claire Poirier1, Frédéric Bastides1, Louis Bernard1
1Infectious Diseases, CHU Bretonneau, Tours, France;2Infectious Diseases, Ressay VHI 37, Tours, France;3Infectious Diseases, CHU, Poitiers, France;4Pharmacie, CHU Bretonneau, Tours, France;5COREVIH, CHU Bretonneau, Tours, France

975 Estimating the Size of the Undiagnosed HIV Population in the Netherlands by Disease Stage
Ard van Sighem1, Fumiyo Nakagawa2, Daniela Bezemor3, Daniela De Angelis1, Eline De Coeuf1, Matthias Egger4, Frank de Wolf5, Christophe Fraser1, Andrew Phillips2
1Stichting HIV Monitoring, Amsterdam, Netherlands;2University College London, London, United Kingdom;3MRC Biostatistics Unit, Cambridge, United Kingdom;4National Institute for Public Health and the Environment, Bilthoven, Netherlands;5University of Bern, Bern, Switzerland;6Imperial College School of Medicine, London, United Kingdom

Christine E. Ross, Guoyu Tao, Karen W. Hoover
DSTDP, CDC, Atlanta, GA, United States

977 Measuring Late HIV Diagnosis Among Men Who Have Sex With Men: AIDS Diagnosis vs. Testing Frequency
David A. Katz2, Julia C. Dombrowski1, Amy Bennett4, Susan Buskin2, Christina Thibault3, Matthew R. Golden1
1University of Washington, Seattle, WA, United States;2Public Health - Seattle & King County, Seattle, WA, United States

Session P-W2 Poster Session
Tuesday March 4, 2014, 2:30 pm-4:00 pm Exhibit Hall D
Cascade of Care, Linkage, and Retention

978 Using HIV Surveillance Registry Data To Re-Link Patients To Care: The RSVP Project in San Francisco
Kate A. Buchacz1, Miao-Jung Chen1, Maree Kay Parisi3, Maya Yoshida2, Erin Antunez2, Viva Delgado2, Nicholas J. Moss1, Susan Scher1
1Centers for Disease Control and Prevention, Atlanta, GA, United States;2San Francisco Department of Public Health, San Francisco, CA, United States;3Alameda County Public Health Department, Oakland, CA, United States

979 Disentangling Roles of Internalized Stigma and Depression in Women’s Linkage To Care
Kristi L. Stringer1, Bulent Turan2, Marianich Onono3, Elizabeth A. Bukusi1, Craig C. Cohent, Janet M. Turan2
1Medical Sociology, University of Alabama at Birmingham, Birmingham, AL, United States;2Psychology, University of Alabama at Birmingham, Birmingham, AL, United States;3Kenya Medical Research Institute, Nairobi, Kenya;4Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco, San Francisco, CA, United States;5Medical Health Care Organization and Policy, University of Alabama at Birmingham, Birmingham, AL, United States

980 Longitudinal Treatment Outcomes in HIV-Infected Prisoners and Influence of Re-Incarceration
Jaimie P. Meyer1,2, Javier Cepeda, Johnny Wu3, Robert L. Trestman4, Frederick L. Altice1,2, Sandra A. Springer1
1Medicine, Yale University School of Medicine, New Haven, CT, United States;2Psychology, Yale University School of Public Health, New Haven, CT, United States;3Epidemiology of Microbial Diseases, Yale University School of Public Health, New Haven, CT, United States;4University of Connecticut Correctional Managed Healthcare, Farmington, CT, United States

981 Imprisonment Among a Large US Clinical Cohort of HIV-Positive Outpatients
David L. Rosen1, Carol E. Golin2, Catherine A. Grodensky3, Samuel Stinnette1, Becky L. White4, Sonia Napravnik1, David A. Wohl4
1Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States;2Medicine and Health Behavior, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States;3Center for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States;4Division of Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States
982 A Surveillance-Based Risk-Score Tool to Prioritize Cases for HIV Care Re-Linkage Efforts
Julia C. Dombrowski1,2, James P. Hughes3, Amanda D. Castel4, Kathleen A. Brady5,6, Susan Buakinskij, Amy Bennett5, Matthew R. Golden1,2
1University of Washington, Seattle, WA, United States;2Public Health - Seattle & King County, Seattle, WA, United States;3Georgetown University, Washington, DC, United States;4Philadelphia Department of Public Health, Philadelphia, PA, United States;5University of Pennsylvania, Philadelphia, PA, United States

983 Beyond Core Indicators of Retention in HIV Care: Added Prognostic Value of Missed Clinical Visits
Michael J. Mugavero1, Andrew O. Westfall2, Elvin Geng3, Stephen R. Cole4, Heidi M. Crane5, Mari M. Kitahata6, W. Christopher Mathews7, Sonia Napravnik8, James L. Raper6, CFAR Network of Integrated Clinical Systems (CNICS)
1Medicine, University of Alabama at Birmingham, Birmingham, AL, United States;2Medicine, University of California San Francisco, San Francisco, CA, United States;3Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States;4Medicine, University of Washington, Seattle, WA, United States;5Medicine, University of California San Diego, La Jolla, CA, United States;6Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States

984 National ART Monitoring System Enables Robust Transfer-Adjustment Retention Analyses in Namibia
Anna Jonas1, Andrew Maher2, Ray W. Shiraishi3, Michael de Klerk4, Francina Kaindjee-Tjituka5,6,7,8, Shadrack Mutadi5,7,8, Sadhna V. Patel1, Anne-Marie Nitschke3, Alexinaah Muatlholomola2, David W. Lowrance4,1
1Directorate of Special Programmes, Ministry of Health and Social Services, Windhoek, Namibia, 2Division of Global HIV/AIDS, US Centers for Disease Control and Prevention, Windhoek, Namibia, 3Division of Global HIV/AIDS, US Centers for Disease Control and Prevention, Atlanta, GA, United States

985 Migration After HIV Diagnosis, United States
Lorena Espinoza1,2, H. Irene Hall1, Aruna Surendara Babu1, Tian Tang1, Mi Chen2
1Division of HIV/AIDS Prevention, CDC, Atlanta, GA, United States

986 Early Linkage To HIV Care and Antiretroviral Therapy Use Among MSM — 20 US Cities, 2008 and 2011
Brooke Hoots, Teresa Finlayson, Cyprian Wegner, Gabriela Paz-Bailley for the NHBS Study Group
CDC, Atlanta, GA, United States

987 The Impact of Opioid Substitution Treatment On Highly Active Antiretroviral Treatment Adherence
Bohdan Nosyky5, Jeong Min9, Viviane Lima10, Guillaume Colley1, Benita Yip1, Evan Wood1, Julio Montaner6,7,8,9
1BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada

988 Correlation Between Community Variables and HIV Linkage To Care and Viral Suppression, Atlanta, GA
Neela D. Goswami1,2, Sharoda Dasgupta3, Patrick Sullivan2, Elvin Geng1,6, Travis Sanchez2
1Department of Epidemiology, Emory University School of Medicine, Atlanta, GA, United States;2Department of Global Health, Emory University School of Medicine, Atlanta, GA, United States;3Laboratory of Infectious Disease Prevention, New York Blood Center, New York, NY, United States;4Department of Infectious Diseases, Columbia University Medical Center, New York, NY, United States;5University of Pittsburgh, Pittsburgh, PA, United States;6Laboratory of Social and Behavioral Sciences, New York Blood Center, New York, NY, United States;7Rutgers University, Rutgers, NJ, United States;8Department of Epidemiology, Columbia University Mailman School of Public Health, New York, NY, United States;9University of New York, New York, NY, United States

989 Viral Suppression Among Foreign-Born HIV-Infected Persons in the United States
Tanya R. Myers1,2, Jacek Skartinski3
1CDC, Atlanta, GA, United States;2LSTHM, London, United Kingdom

990 Mapping Community Viral Load and Transmission Potential Prevalence of HIV Among MSM in New York City
Hong Van Tieu1,2, Vijay Nandi3, James E. Egan3, Victoria Frye4, Donald R. Hoover5,6, Eduardo Baez7, Debbie Lucy8, Magdalena Cerda9, Danielle C. Ompad10, Beryl A. Koblin11
1Laboratory of Infectious Disease Prevention, New York Blood Center, New York, NY, United States;2Division of Infectious Diseases, Columbia University Medical Center, New York, NY, United States;3University of Pittsburgh, Pittsburgh, PA, United States;4Laboratory of Social and Behavioral Sciences, New York Blood Center, New York, NY, United States;5Rutgers University, Rutgers, NJ, United States;6Department of Epidemiology, Columbia University Mailman School of Public Health, New York, NY, United States;7University of New York, New York, NY, United States;8U943, INSERM, Paris, France;9University of Bordeaux, Bordeaux, France;10UMR S943, UPMC Paris Univ 06, Paris, France;11U943, INSERM, Paris, France

991 HIV Care and Viral Suppression Among Persons Living With HIV/AIDS, New York City 2006-2010
Lucia V. Torian1, Ong Xia1, Elven W. Wiewel2
1HIV Epidemiology Program, New York City Department of Health, Long Island City, NY, United States

992A Low Incidence and High Population Viral Suppression in Malawi: The Chiradzulu HIV Incidence Study
David Maman1, Sophie Masson2, Benson Chilima3, Charles Masiku4, Elizabeth Szumilin5, Ahtijo Ayuba6, Benjamin Richene7, Etard Jean-Francois8
1Clinical research Department, Epicentre, Paris, France;2Community Health Science Unit, Ministry of Health, Lilongwe, Malawi;3Medecins sans Frontières, Lilongwe, Malawi;4Medecins sans Frontières, Paris, France;5UMI 233, Institut de Recherche pour le developpement, Montpellier, France;6Biostatistic Unit, Hospices Civils de Lyon, Lyon, France;7UMI 233, Institut de Recherche pour le Developpement, Montpellier, France

993 Disparities in Viral Suppression Among a Large Cohort of HIV-Infected Persons in Washington, DC
Amanda D. Castel, Alan E. Greenberg, Heather Young, Mariah M. Kalmijn, DC Cohort Executive Committee

994 Community Viral Load and HIV Incidence: A Multi-City Study of High-Risk Populations in India
Sunil S. Solomon1,2, Shrutl H. Mehta1, Aylur K. Srikrisnan1,3, Oliver Laeyendecker4,5, Shannumgar Saravan4, Allison McFai1, Pachamathur Balakrishnan1, Sunil Solomon1,2, David D. Celentano5, Gregory M. Lucas1
1Johns Hopkins University, Baltimore, MD, United States;2York Gaitonde Centre for AIDS Research and Education, Chennai, India;3National Institute of Allergy and Infectious Diseases, Bethesda, MD, United States

995 Declines in Community Viral Load in the Context of Population Prevention Strategies in the Bronx
David B. Hanna1,2, Andrew O. Westfall2,3,4,5, Barry S. Zingman3,6,7, Robert S. Bell3,8, Donna C. Futterman9, Howard D. Strickler9, Kathryn Anastos2
1Albert Einstein College of Medicine, Bronx, NY, United States;2Montefiore Medical Center, Bronx, NY, United States

Session P-W4 Poster Session
Tuesday March 4, 2014, 2:30 pm–4:00 pm Exhibit Hall D

Poster Abstracts

Session P-W3 Poster Session
Tuesday March 4, 2014, 2:30 pm–4:00 pm Exhibit Hall D

Cascade of Care, Community Viral Load, and Viral Suppression

996 New Epidemiological Indicator To Estimate the Gap Between WHO Eligibility ART Criteria and Reality
Jacques D. A. Ndawinz1,2, Xavier Anglaret3,4, Eric Delaporte5,6, Sinata Kouila-Shiira7, Delphine Gabillard8,9,10, Dominique Costagliola11, Virginie Supervie12
1Sotthis, Paris, France;2Centre 897, INSERM, Bordeaux, France;3Isped, University of Bordeaux, Bordeaux, France;4UMR 145, University of Montpellier 01, Montpellier, France;5IRD, Montpellier, France;6Central Hospital, Yaoundé, Cameroon;7UMR S943, UPMC Paris Univ 06, Paris, France;8U943, INSERM, Paris, France

Nikoloz Chkhartishvili1,2, Otar Chokoshvili1, Lali Sharvardze2,3, Jack A. DeHovitz1, Carlos del Rio1,2, Tengiz Tsertsvadze1
1Infectious Diseases, AIDS and Clinical Immunology Research Center, Tbilisi, Georgia;2Faculty of Medicine, Tbilisi State University, Tbilisi, Georgia;3State University of New York Downstate Medical Center, Brooklyn, NY, United States;4Emory University, Atlanta, GA, United States;5Tbilisi State University, Tbilisi, Georgia
Session P-W5 Poster Session

Acute Infection

1001 Atypical Clinical Presentations Occur in One Third of 293 Patients With a Primary HIV-1 Infection
Dominique L. Braun, Roger Koupas, Belinda Balmer, Christina Grube, Rainer Weber, Huldrych Günthard
Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Zurich, Switzerland

1002 Evaluating New Definitions of Acute and Early HIV Infection From HIV Surveillance Data
Susan E. Buskin1, Neway G. Fida1, Amy B. Bennett1, Matthew R. Golden1, Joanne D. Stekler1
1Prevention Division, Public Health - Seattle & King County, Seattle, WA, United States; 2Department of Medicine, University of Washington, Seattle, WA, United States; 3Division of Allergy & Infectious Diseases, University of Washington, Seattle, WA, United States

1003 Association Between Number of Acute Retroviral Symptoms and Extended High Viremia by HIV-1 Subtype
Kimberly A. Powers1, Matthew A. Price2, Etienne Karita3, Anatoli Kimogo3, Veronica Franco4, Ronald H. Gray3,5, Thomas C. Quinn1,4, Susan E. Buskin1,2, Neway G. Fida1, Amy B. Bennett1, Matthew R. Golden1,3
1Prevention Division, Public Health - Seattle & King County, Seattle, WA, United States; 2Department of Medicine, University of Washington, Seattle, WA, United States; 3Department of Epidemiology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States; 4Department of Epidemiology, University of California Los Angeles, Los Angeles, CA, United States; 5Blood Systems Research Institute, San Francisco, CA, United States

1004 Targeted Screening of Young Adults for Acute HIV-1 Infection at Care Seeking in Kenya
Eduard J. Sanders1, Peter Mugo1, Henrieke A. B. Prins2, Elizabeth Wahome1, Alexander Thiongo1, Grace Mwasigadi3, Elizabeth M. Van der Elst1, Anisa Omar1, Adrian D. Smith1, Susan M. Graham1,5
1Clinical Sciences, KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya; 2University of California San Francisco, San Francisco, CA, United States; 3Kenya AIDS Vaccine Initiative, Nairobi, Kenya; 4Kenya Medical Research Institute, Kilifi, Kenya; 5University of Oxford, Oxford, United Kingdom

Session P-W6 Poster Session

Disease Progression/Mortality

1009 Increasing Viral Suppression and Declining HIV/AIDS Mortality in the Era of Expanded Treatment
Susan E. Buskin1, Amy B. Bennett2, Julia C. Dombrowski1,3, Matthew R. Golden1,3
1Prevention Division, Public Health - Seattle & King County, Seattle, WA, United States; 2Department of Epidemiology, University of Washington, Seattle, WA, United States; 3Department of Medicine, University of Washington, Seattle, WA, United States

1010 BMI and CD4+ T-Cell Recovery at 12 Months Among Adults Initiating ART in the United States and Canada
John R. Koethe1, Cathy Jenkins2, Bryan Lau3, Bryan E. Shepherd4, Michael J. Silverberg5, Aaron J. Blashill6, Aranka Anema6, Amanda Willing7, Samuel E. Stinnette8, Timothy R. Sterling9, North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD)1
1Infectious Diseases, Vanderbilt University, Nashville, TN, United States; 2Biostatistics, Vanderbilt University, Nashville, TN, United States; 3Infectious Diseases, Johns Hopkins University, Baltimore, MD, United States

Page 101 of 101
CROI 2014
1011 Impact of Smoking On Life Expectancy Among HIV-Infected Individuals: The ART Cohort Collaboration Marie Helleberg1, Margaret T. May2, Jonathan A. C. Sterne3, Niels Obel4, for the ART-CC
1Department of Infectious Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, 2School of Social and Community Medicine, University of Bristol, Bristol, United Kingdom

1012 Standardized Mortality Ratios Among Drug Users in Amsterdam Differ by HCV and HIV Infection Status Daniela K. van Santen1, Jannie J. van der Helm1, Bart P. X. Grady2, Anneke S. de Vos3, Mirjam E. E. Kretzschmar4, Ineke G. Stolte1, Maria Prins1,2
1Research, Public Health Service of Amsterdam, Amsterdam, Netherlands, 2Center for Infection and Immunology Amsterdam (CINIMA), Academic Medical Center (AMC), Amsterdam, Netherlands, 3University Medical Center Utrecht, Utrecht, Netherlands, 4Center for Infectious Disease Control, National Institute of Public Health and the Environment, Bilthoven, Netherlands

1013 Prognostic Value of the VACS Index for Mortality in British Columbia, Canada
Angela Cescioni1, Mark Hull1, Wendy Zhang2, Thomas Roston3, Susan Shurgold4, Guillaume Colley5, Viviane D. Lima6, P. Richard Harrigan7, Julio S. G. Montaner1, Robert S. Hogg1, 1,2,8
1BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada, 3University of British Columbia, Vancouver, BC, Canada, 4Simon Fraser University, Burnaby, BC, Canada

1014 Impact of Low-Level Viremia On Clinical and Virological Outcomes in Treated HIV Infected Patients Marie-Anne Vandenhende1, Suzanne Ingle1, Margaret May2, Matthias Cavassini3, Amanda Mocroft4, Peter Reiss5, Janet Tate6, Heidi Crane1, Jonathan Sterne7, Geneviève Chêne8, on behalf of the Antiretroviral Therapy Cohort Collaboration (ART-CC)
1Epidémiologie-Biostatistique, Université Bordeaux, Centre INSERM U897, ISPED, Bordeaux, France, 2School of Social and Community Medicine, University of Bristol, Bristol, United Kingdom, 3Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland, 4Research Department of Infection and Population Health, UCL Medical School, London, United Kingdom, 5Academic Medical Center, Amsterdam Institute of Global Health and Development, Amsterdam, Netherlands, 6Yale University School of Medicine, VA Connecticut Healthcare System, New Haven, CT, United States, 7Center for AIDS Research; University of Washington, Seattle, WA, United States

1015 Increase in HIV Plasma Viral Load Set-Point Among UK MSM
Victoria Parsons1,2, Andrew Phillips1, Richard Gilson2, Sarah Fidler3, Martin Fisher4, Anne Johnson5, David Hawkins6, Ken McLean7, Margaret Johnson1, Khohlou Portel1, for the UK Register of HIV Serocounters
1MRC Clinical Trials Unit at UCL, London, United Kingdom, 2University College London, London, United Kingdom, 3Imperial College London, London, United Kingdom, 4Brighton & Sussex Medical School, Brighton, United Kingdom, 5Chelsea & Westminster NHS Foundation Trust, London, United Kingdom, 6West London Centre for Sexual Health, London, United Kingdom, 7Royal Free London NHS Foundation Trust, London, United Kingdom

1016 HIV, Non-Communicable Chronic Diseases and Associated Factors in Tanzania and Uganda
Saidi H. Kapiga1,2,3, Kathy Basile1,4, Samuel Biraro1, Bazli Baltazar4, Fiona Ewing5, Hashim Ramadhani6, Robert Peck7, Richard Hayes8, Paula Munderi9, Heiner Grosskurth10
1Infectious Disease Epidemiology, London School of Public Health, Mwanza, Tanzania, 2United Republic of Tanzania, 3Infectious Disease Epidemiology, London School of Public Health, Mwanza, United Kingdom, 4MRC/UWRI Uganda Research Unit on AIDS, Entebbe, Uganda, 5Mwanza Intervention Trials Unit, Mwanza, Tanzania, 6United Republic of Tanzania, 7Infectious Disease Epidemiology, London School of Public Health, London, United Kingdom

1017 Female Partner Bacterial Vaginosis and the Penis Microbiota: Rakai, Uganda
Cindy Liu1, Bruce Hungate2, Aaron Tobian3, Jacques Rawel4, Jessica Podger5, David Serwadda6, Fred Kalugoda7, Maria Wawer8, Ronald Gray9, Lance Price10
1Department of Pathology, Johns Hopkins School of Medicine, Baltimore, MD, United States, 2Department of Biological Sciences, Northern Arizona University, Flagstaff, AZ, United States, 3Institute for Genome Sciences, Baltimore, MD, United States, 4Department of Medicine, University of Toronto, Toronto, ON, Canada, 5Rakai Health Sciences Program, Entebbe, Uganda, 6Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States, 7Translational Genomics Research Institute, Flagstaff, AZ, United States

1018 Low Viral Suppression and High HIV Diagnosis Rate Among MSM With Syphilis - Baltimore, Maryland
Laura A. Cooley1,2,3, Marcia L. Pear3, Colin Flym4, David S. Blythre5, Christine Ross6, Geoffrey Hart-Cooper7, James Morgar7, Alexandra M. Oster8
1Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, GA, United States, 2Maryland Department of Health and Mental Hygiene, Baltimore, MD, United States, 3Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, GA, United States, 4Baltimore County Department of Health and Human Services, Baltimore, MD, United States

1019 Trends in Comorbid Conditions Mentioned With HIV Disease On Death Certificates, US, 2000-2010
Kpandja Djawe1, Kate Buchacz2, Charles E. Rose3, John T. Brooks4
1Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Epidemiology Branch, Atlanta, GA, United States

1020 The Association Between HPV and HIV Shedding in Vaginal and Anorectal Specimens
Julia Hood1, Geoffroy Gottlieb2, Papa Saif Sow3, Macourma Toure2, Qinghua Feng2, Nancy Kiviat2, Stephen Hawes3
1Epidemiology, University of Washington, Seattle, WA, United States, 2Medicine, University of Washington, Seattle, WA, United States, 3University of Washington School of Medicine, WA, United States, 4Department of Epidemiology, University of Dakar, Senegal, 5Pathology, University of Washington, Seattle, WA, United States, 6Epidemiology, Global Health, University of Washington, Seattle, WA, United States

1021 Incidence of Sexually Transmitted Diseases Among Persons With HIV, New York City, 2000-2010
Sarah L. Braune1, Preeti Pathela2, Laura Kersanske3, Colin Shepard4
1Bureau of HIV/AIDS Prevention and Control, New York City Department of Health and Mental Hygiene, Queens, NY, United States, 2Bureau of STD Control, New York City Department of Health and Mental Hygiene, Queens, NY, United States

1022 Increasing Rates of STI Are Linked To Reduced Condom Use in Patients With Primary HIV-1 Infection
Dominique L. Braun, Roger Kouyou, Raffael Ghenz, Christina Grube, Rainer Weber, Huldrych Günthard
Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland

1023 Does Substance Use Compromise Depression Treatment? A Randomized Trial of Homeless HIV+ Persons
David J. Grebliott1,2, Gwendolyn P. Hammer3, James W. Dilley4, Dan H. Karasic5, James L. Sorensen6, David R. Bangsberg7,8, Alexander C. Tsai9
1Department of Epidemiology, Harvard School of Public Health, Boston, MA, United States, 2Department of Psychiatry, Massachusetts General Hospital, Boston, MA, United States, 3Department of Communicable poster abstracts.
George Githuku1, Wolfgang Hladik2, Samuel Mwalili1, Davies Kimanga1, Mamo Umuro1, Mercy Mutui2, Joshua Gitonga3, William Maina4, Andrea A. Kim5
1National AIDS and STI Control Programme, Ministry of Health, Nairobi, Kenya; 2Division of Global HIV/AIDS, US Centers for Disease Control and Prevention, Atlanta, GA, United States; 3Division of Global HIV/AIDS, Kenya; 4Centers for Disease Control and Prevention, Nairobi, Kenya; 5National Public Health Laboratory Services, Ministry of Health, Nairobi, Kenya

1025 HIV Incidence in Rural Western Kenya Using Longitudinal Analysis From Home-Based HIV Testing
Lisa A. Mills1,2, George Ollion2, Maanae Amolohi3, Daniel Kwaro3, Victor Sempijja3, Fredrick Ondongo3, Fredrick Otieno3, Maqinis Sewer4, John Williamson5, Kayla Laserson2
1Centers for Disease Control and Prevention, Kisumu, Kenya; 2Kenya Medical Research Institute/Centers for Disease Control and Prevention Research and Public Health Collaboration, Kisumu, Kenya

1026 Temporal Trends in HIV-1 Incidence and Risk Behaviors Among MSM, Bangkok, Thailand, 2006-2013
Timothy H. Holtz1,2, Philip A. Mock1, Warune Thienkrua3, Wannee Kimanga4, William Maina5, Anupong Chitwarakorn6, Marcel E. Curnin7,8
1HIV/AIDS Research Program, Thailand MOPH - US CDC Collaboration, Nonthaburi, Thailand; 2Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, GA, United States; 3Department of Disease Control, Thailand MOPH, Nonthaburi, Thailand

1027 The Potential Impact of Targeting Prevention Strategies To HIV-Discordant Households
Ruth Emerson1, Deborah Donnell2, George Bicego2, Khanya Mabuzza2, Stephane Hellelenger3, Jessica Justman3
1Statistical Center for HIV/AIDS Research & Prevention, Fred Hutchinson Cancer Research Center, Seattle, WA, United States; 2Centers for Disease Control and Prevention, Atlanta, GA, United States; 3National Emergency Response Council on HIV and AIDS, Kingdom of Swaziland, Manzini, Swaziland; 4Department of Population and Family Health, Mailman School of Public Health, Columbia University, New York, NY, United States; 5CAP-Columbia, Mailman School of Public Health, Columbia University, New York, NY, United States

1028 The Effect of Sexually Transmitted Infections On HIV Incidence Among MSM in Atlanta, GA
Colleen F. Kelley1, Adam S. Vaughan2, Nicole Luisi2, Travis Sanchez3, Paula Frew4, Carlos del Rio1, Patrick S. Sullivan5, El S. Rosenberg5, Center for AIDS Research, Emory University, Atlanta, GA, United States

1029 Factors Associated With HIV Discordance Among Couples in Kenya: Results From a Population Survey
Wanjiru Warurua1, Agnete Mbitibi2, Anthony Waruru2, Jennifer Galbraith3, Timothy A. Kellogg4, Scott Epperson4, Anne Ng’ang’a5, Sophie Mwanyumba5, Lucy Kimondo6, Andrea A. Kim7
1University of California, San Francisco, Nairobi, Kenya; 2National AIDS and STI Control Programme, Nairobi, Kenya; 3Centers for Disease Control and Prevention, Nairobi, Kenya; 4Centers for Disease Control and Prevention, Atlanta, GA, United States; 5National Public Health Laboratory Services, Nairobi, Kenya; 6Ragon Institute of MGH, MIT, and Harvard, Boston, MA, United States; 7Department of Psychiatry, University of California San Francisco, San Francisco, CA, United States; 8Department of Medicine and MGH Center for Global Health, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States

Session P-W9 Poster Session
Thursday March 6, 2014, 2:30 PM-4:00 PM Exhibit Hall D
Transmission/Risk Factors

1030 Partners of Individuals With Acute HIV Infection Have a High Frequency of Known HIV Infection
Philip J. Peters1, Emily Westheimer2, Stephanie Cohen3, Charles E. Rose4, Cynthia L. Gay4, Charles Fann3, Steve Beagle5,6, Kate Washburn7, Tonya L. Jackson2,3, Lisa B. Hightow-Weidman7,8
1Centers for Disease Control and Prevention, Atlanta, GA, United States; 2New York City Department of Health & Mental Hygiene, New York City, NY, United States; 3San Francisco Department of Public Health, San Francisco, CA, United States; 4University of North Carolina at Chapel Hill, Chapel Hill, NC, United States; 5National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States; 6ICF International, Atlanta, GA, United States

1031 Baseline Predictors of HIV-1 Acquisition Among Women Participating in MTN-003 (VOICE)
Gonasadagare Nair1, Jennifer E. Bakuus2,3, Jeanne M. Marrazzini4, Gita Ramjee5, Thesla Patane6, Banangi Micheze7, Clemensia Nakabilita8, Marthiniette Talalid9, Kailazaidz Gomez10, Zvavahera M. Chirenje11, 12CAPRISA/ODRM11, Nelson R Mandela School of Medicine, Durban, South Africa; 2Fried Hutchinson Cancer Research Center, Seattle, WA, United States; 3University of Washington, Seattle, WA, United States; 4South African Medical Research Council, Durban, South Africa; 5University of Witwatersrand, Johannesburg, South Africa; 6Chris Han Baragwanath Hospital, Johannesburg, South Africa; 7Makerere University, Kampala, Uganda; 8The Aurum Institute, Klerksdorp, South Africa; 9FH1360, Durnam, NC, United States; 10UZ-GCDF, Harare, Zimbabwe

1032 Measuring Purposefully Adopted Serodiscordant Behaviors vs Reported Sexual Behaviors Among MSM
Christine M. Kheswopour1,2, Julia C. Dombrowski1,2, James P. Hughes3, Lisa E. Manhart4, Jane M. Simon5, Matthew R. Goldens6,7,8
1Epidemiology, University of Washington, Seattle, WA, United States; 2Medicine, University of Washington, Seattle, WA, United States; 3Public Health – Seattle & King County, Seattle, WA, United States; 4Biostatistics, University of Washington, Seattle, WA, United States; 5Psychology, University of Washington, Seattle, WA, United States

1033 Prevalence and Predictors of HIV Disclosure Among Adults Receiving Care in the United States
Christine L. Mattson1,2, Mark S. Freedman1,3, Linda Beer1,4, Patrick Sullivan1, Jacek Skarbinski5
1Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, GA, United States; 2Emory University, Atlanta, GA, United States

Andrew J. Mitsch1,2, H. I. Hall3, Amy L. Lansky4, Aruna Surendera-Babu5
1National Center for HIV, STD, Tuberculosis, and Viral Hepatitis Prevention, Centers for Disease Control and Prevention, Atlanta, GA, United States; 2Macro International, Inc., Atlanta, GA, United States

1035 An Emerging HIV Epidemic Among Injection Drug User Networks During Austerity in Athens, Greece
Ashley Taing1, John Schneider2, Vana Sypsa3, Georgios Nikolopoulos4, Dimitrios Paraskev11, Samuel Friedman5, Angelos Hatazaki6
1University of Chicago, Chicago, IL, United States; 2Department of Medicine, University of Chicago, Chicago, IL, United States; 3National Retròvirus Reference Center, Athens, Greece; 4Hellenic Center for Disease Control and Prevention, Athens, Greece; 5National Development and Research Institutes, New York, NY, United States

1036 High HIV Prevalence Among Injection Drug Users in India: Women Bear a Disproportionate Burden
Gregory M. Lucas1, Suniti S. Solomon2,4, Aiyur K. Srikishnani3, Syed H. Iqbal3, Olivier Laeyendecker1, Allison McFall1,2, Muniratnam S. Kumar2,3, David D. Celentano1, Suniti Solomon4, Shruti L. Mehta5
1Johns Hopkins University School of Medicine, Baltimore, MD, United States; 2YR Gaitonde Centre for AIDS Research and Education, Chennai, India; 3National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States; 4ICF International, Atlanta, GA, United States; 5Johns Hopkins University School of Medicine, Baltimore, MD, United States
1037 HIV Prevalence Among Women Who Inject Drugs and Exchange Sex for Money or Drugs: 20 US Cities, 2009
Lina M. C. Merland, Kristen L. Hess, Dita Broz, Birn C. Le, Cattapan Sionean, Charles E. Rose, Gabriela Paz-Bailey, for the NHBS Group Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, GA, United States

1038 Erectile Dysfunction Medication Use Associated With Unprotected Intercourse in HIV-Infected MSM
Xia Lin, Christine L. Mattson, Mark S. Freedman, Jacek Skarbinski, Centers for Disease Control and Prevention, Atlanta, GA, United States

1039 A Novel Analytical Approach Confirms Stabilization of HIV Epidemic in Pregnant Women in Namibia
Anna Jonas, Steven Gutreuter, Sadhna V. Patel, Andrew Maher, Michael de Klerk, Tuli Nakanyala, Francina Kaindee-Tjifuka, Elia Shihepo, David W. Lowrance
1Ministry of Health and Social Services, Windhoek, Namibia, 2US Centers for Disease Control and Prevention, Atlanta, GA, United States

1040 Viral Load Strategy: Impact On Risk Behavior and Serocommunication of MSM in Specialized Care
Elisabeth Kuhn, Anja Potthoff, Henrike Dirks, René Borgmann, Michael Wolter, Stefan Esser, Norbert Scherberbaum, Norbert H. Brockmeyer
1Clinic for Dermatology, Venerology and Allergology of the Ruhr-Universität Bochum, Bochum, Germany, 2Competence Network HIV/AIDS, Bochum/Essen, Germany, 3Department of Psychiatry and Psychotherapy, LVR-Klinikum Essen, Hospital of the University of Duisburg-Essen, Essen, Germany, 4Department of Dermatology and Venerology, University Hospital Duisburg-Essen, Essen, Germany

1041 Transmission Rates and Not Sexual Contact Patterns Drive HIV Epidemic Intensity in Africa
Steve E. Bellan, Jonathan Dushoff, David Champredon, Alison P. Galvani, Lauren A. Meyers
1Center for Computational Biology and Bioinformatics, University of Texas at Austin, Austin, TX, United States, 2Biology, McMaster University, Hamilton, ON, Canada, 3Department of Mathematics and Statistics, McMaster University, Hamilton, ON, Canada, 4School of Medicine, Yale University, New Haven, CT, United States, 5Integrative Biology, University of Texas at Austin, Austin, TX, United States

1042 Community-Based Integrated Family Planning and HIV Testing and Counseling Services in Uganda
Aurelie Bruné, Patricia Wamala-Muchumi, Jane Harriet Namwebya, Tricia Petruney, Vincent J. Wong, Benson Tumwesigye, Sarah Mercier, Victor Draman Afayo, Angela Akol
1FHI 360, Washington, DC, United States, 2Clinton Health Access Initiative, Kampala, Uganda, 3FHI 360, Kampala, Uganda, 4FHI 360, Durham, NC, United States, 5Office of HIV/AIDS, USAID, 1200 Pennsylvania Ave, DC, United States, 6National HTC Coordinator, Ugandan Ministry of Health, Kampala, Uganda

1043 HTC Campaign in Households Reached the Majority of Women But Only 50% of Men in Botswana Community
Vlad Novitsky,1 Hermann Bussmann,2 Sirkhulle Moyo,3 Erik van Widenfelt,4 Mompali Mmalane,5 Kudzanai Kristians,6 Hlengiwe Ltse,7 Joseph Makهمa,8 Shahin Lockman,9 Victor DeGruttol,1 Max Essex
1Infectious Diseases & Child Health Initiative, University of the Witwatersrand, Johannesburg, South Africa, 2Meheddi, Alexandria, 3Lilongwe University, Malawi, 4Tumaini University, Tanzania, 5University of Zimbabwe, Harare, Zimbabwe, 6University of Zimbabwe, Harare, Zimbabwe, 7Linden University, Kenya, 8800 University of California, San Francisco, CA, United States, 9Institute of Tropical Medicine and AIDS, Kinshasa, Democratic Republic of Congo

1044 Implementation of Routine, Opt-Out HIV Testing Does Not Increase Loss To Follow-up
Kate Clouse, Colleen Hannahian, Jean Bassett, Nandipha Gqangule, Lindi Matjeka, Sandra Mekonyane, Ian Sanne, Annelines Van Rie
1Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States, 2WitsKgosi Health and Wellness Centre, Johannesburg, South Africa, 3Right to Care, Johannesburg, South Africa

1045 Assessment of the Potential Cost-Effectiveness of HIV Self-Testing in Resource Limited Settings
Valentina Cambiano, Debbie Ford, Tavrov Magubu, Sue Napierala, Mavedzenge, Alec Miners, Owen Mugurungi, Fumiyu Nakagawa, Paul Revill, Andrew Phillips
1UCL, London, United Kingdom, 2Medical Research Council Clinical Trials Unit, London, United Kingdom, 3University of Zimbabwe Clinical Research Centre, Harare, Zimbabwe, 4RTI International, San Francisco, CA, United States, 5London School of Hygiene and Tropical Medicine, London, United Kingdom, 6Ministry of Health and Child Welfare, Zimbabwe, Harare, Zimbabwe, 7University of York, York, United Kingdom

Session P-X2 Poster Session
Tuesday March 4, 2014, 2:30 pm–4:00 pm
Exhibit Hall D
HIV Treatment and Care

1046 Treatment Outcomes Before and After the Decentralization of ART in an Urban Setting in Mozambique
Jan Walter,1 Marie-Luce Tombo,2 Celeste Gracia Edwards,1 Johnny Lunaj,1 Annick Antierens,2 Lucas Moffno2,3
1Médecins sans Frontières, Maputo, Mozambique, 2Médecins sans Frontières, Geneva, Switzerland

1047 CD4 Count at ART Initiation and Economic Restoration in Rural Uganda
Alheendar Venkataramani, Harsha Thirunurthy,1 Jessica Haberer,1 Yap Boum, Mark Siedner, Annet Kembabazi2, Peter Hunt,2 Jeffrey Martin,2 David Bangsbang,2,3 Alexander Tsi2,3
1Department of Medicine and Center for Global Health, Massachusetts General Hospital, Boston, MA, United States, 2Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States, 3Epicentre, MSF, Mbarara, Uganda, 4Department of Medicine, Massachusetts General Hospital, Boston, MA, United States, 5Mbarara University of Science and Technology, Mbarara, Uganda, 6University of California San Francisco, San Francisco, CA, United States, 7Massachusetts General Hospital, Boston, MA, United States, 8Department of Psychiatry and Center for Global Health, Massachusetts General Hospital, Boston, MA, United States

1048 48-Week Outcomes in Adults Starting ART at CD4>350 Using Streamlined Care in Rural Uganda
Vivek Jain,1 Dathan M. Byonamuye,2 Gideon Amarynry,2 Douglas Black,1 James Rooney,1 Gabriel Chandler1,6 Eva C. Geng,1 Edwin D. Charlebois,1 Moses R. Kamya,1 Diane V. Havlin1,6
1HIV/AIDS Division, University of California, San Francisco, San Francisco, CA, United States, 2Makerere University College of Health Sciences, Kampala, Uganda, 3Glaxo Sciences, Inc., Foster City, CA, United States

1049 Second-Line Failure and Protease Inhibitor Resistance in a Clinic in Johannesburg, South Africa
Rebecca H. Berhane,1 Denise Evans2, Prudence Ike,1 David Spencer,1 Cindy Firmhaber,1 Ian Sanne1, Matthew P. Fox2
1TB Focal Point, Right to Care, Johannesburg, South Africa, 2Health Economics and Epidemiology Research Office, University of the Witwatersrand, Johannesburg, South Africa, 3Clinical HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa, 4Helen Joseph Hospital, University of the Witwatersrand, Johannesburg, South Africa, 5Center for Global Health and Development Department of Epidemiology, Boston University, Boston, MA, United States

1050 A 5-Year Comparison of Viral Load and CD4 Cell Count Monitoring for ART Patients in Rural Uganda
Jonathan Wangsi,1 Paul Ekwaru,2 Stephen Okoboi,1 James Campbell,1 Rachel King,1 Aggrey Egessa,1 Celestine Bakanda,2 Emmy Muramuzi,3 Frank Kaharuza,2 Sam Malamba,1 David M. Moore4,5
1The AIDS Support Organisation, Kampala, Uganda, 2University of Alberta, Edmonton, AB, Canada, 3University of Maryland, Baltimore, MD, United States, 4University of California San Francisco, San Francisco, CA, United States, 5Makerere University School of Public Health, Kampala, Uganda
1051 Success of Transfer of HIV Care From a PEPFAR Site To Community-Based Clinics in Southern Africa
Christie Cloete1, Susan Regan1,3, Janet Giddy1, Tessa Govender1, Melanie R. Gaynes1, Kenneth A. Freedberg2, Jeffrey N. Katz1,2, Rochelle P. Walensky1,2, Elena Losina4, Ingrid V. Bassett3,4,5,6
1McCord Hospital, Durban, South Africa; 2Massachusetts General Hospital, Department of General Medicine, Boston, MA, United States; 3Massachusetts General Hospital, Medical Practice Evaluation Center, Boston, MA, United States; 4Brigham and Women’s Hospital, Department of Orthopedic Surgery, Boston, MA, United States; 5Brigham and Women’s Hospital, Division of Rheumatology, Boston, MA, United States; 6Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, United States; 7Boston University School of Public Health, Departments of Biostatistics and Epidemiology, Boston, MA, United States; 8Division of Infectious Disease, Massachusetts General Hospital, Boston, MA, United States

1052 The Feasibility and Economic Impact of Time-Designated Appointment System in a Busy HIV Care Clinic
Zachary A. Kwenya1, Betty Njoro2, Patrick Oyaro3, Craig R. Cohen4, Elizabeth A. Bukusi5
1Center for Microbiology Research, Kenya Medical Research Institute, Kisumu, Kenya; 2Center for Microbiology Research, Kenya Medical Research Institute, Nairobi, Kenya; 3Ob/Gyn & RS, University of California, San Francisco, San Francisco, CA, United States

1053 Long-Term Virologic Response in a Cohort of HIV-Infected Patients in South Africa
Kate Shearer1, Alana T. Brennan1, Mhrai Maskew1, Rebecca Berhanu1, Lawrence Long1, Matthew Fox2,3
1Health Economics and Epidemiology Research Office, Johannesburg, South Africa; 2Center for Global Health & Development, Boston, MA, United States; 3Right to Care, Johannesburg, South Africa

1054 CD4 Cell Decline and Time to Reaching ART Eligibility in HIV Patients From Rwanda
Chloe A. Teasdale1, Allison Zerbe1, Veronica Mugisha1, Ruben Sahabo1, Elaine J. Abrams1, Wafaa M. El-Sadr1,4, for Identifying Optimal Models of HIV Care in Africa Study
1ICAP, Columbia University, New York, NY, United States

1055 Predictors of Late Engagement To HIV Care in Western Kenya: A Cross-Sectional Study
Charles M. Kwebah1,2, Paula Brailstein1,4, Julius Kech1, Gilbert Simiyu1, Ann W. Mwaro1,2, Karia Woolis1,4, Kaloustani1,4, Abraham Silka3,4
1Medicine, Moi University Medical Research Centre, Eldoret, Kenya; 2Academic Model Providing Access to Healthcare, Eldoret, Kenya; 3Medicine, Moi University College of Health Sciences, School of Medicine, Eldoret, Kenya; 4University of Toronto, Dalla Lana School of Public Health, Toronto, ON, Canada; 5Behavioural Sciences, Moi University College of Health Sciences, School of Medicine, Eldoret, Kenya; 6Medicine, Indiana University School of Medicine, Indianapolis, IN, United States

1056 Cost Savings of Viral-Load Testing Before ART Second-Line Switch in a Resource-Limited Setting
Joanita Kigozi1, Christine Mugasha2, Alex Muganzi1, Alex Coutinho1, Yukari Manabe1
1Infectious Disease Institute, Kampala, Uganda; 2Jhpiego, Baltimore, MD, United States

1057 Peer Support and Engagement, HIV Care and Sexual Behaviors Among PLHIV Not On ART: A Randomized Trial
Larry W. Chang1,2, Gertrude Nakigozi1, Veena Billoux1, David Servadda1, Thomas Quinn1, Robert Bollinger1,2, Maria Waver1, Ronald Gray1, Steven Reynolds1
1Jhpiego, Baltimore, MD, United States; 2Jhpiego’s Health Care for Vulnerable Children Project, Kampala, Uganda; 3Laboratory of Immunoregulation, Division of Intramural Research, National Institute for Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States

Session P-X3 Poster Session
Wednesday March 5, 2014, 2:30 pm–4:00 pm Exhibit Hall D
The Treatment Cascade and Loss To Follow-Up

1058 Community-Based ART Programs in Resource-Limited Settings
Stephen Okoboli1, Ding Ervin1, Steven Persaud1, Jonathan Wangisi2, Darius Kato1, Chen Yalin1, Maureen Nyonyirono1, Celestin Bakanda1, Josephine Birungi1, David Moore2,3,4
1Research, The AIDS Support Organization, Kampala, Uganda; 2Research, British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada; 3Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada

1059 Gender Differences in Loss To Follow-up and Mortality in Older Adults On ART in Sub-Saharan Africa
Mansi Agarwal1,2, Matthew R. Lamb1, Veronica Mugisha1, Davies Kimanga1, Bonita Kilama1, Andrea A. Howard1, Elaine J. Abrams1, Wafaa M. El-Sadr1,4, Batya Elul1
1ICAP-Columbia University, New York, NY, United States; 2National AIDS and STI Control Programme, Nairobi, Kenya; 3National AIDS Control Programme, Dar es Salaam, Tanzania, United Republic of

1060 Comparative Effectiveness of HIV Care and Treatment Programs in East Africa
Elvin Geng1, Thomas Odeng2, Rita Lyamuya1, Alice Nakwogga-Muwangwa1, Mwesia Bwana1, Paula Brailstein2, Andrew Kambaghi1, Elizabeth Bukusi1, Geoffrey Sumi3, Lameck Diero1, Jeffrey Martin1,4,5,6
1Medicine, University of California San Francisco, San Francisco, CA, United States; 2KEMRI, Nairobi, Kenya; 3Medicine, NACP, Dar es Salaam, Tanzania, United Republic of; 4Kampala, Uganda; 5Medicine, MUST, Mbarara, Uganda; 6AMPATH, Eldoret, Kenya; 7Medicine, KEMRI, Nairobi, Kenya; NACP, Dar es Salaam, Tanzania, United Republic of; 8University of California San Francisco, San Francisco, CA, United States

1061 Loss To Follow-Up: Determining Outcomes for Adults Enrolled in HIV Services in Kenya
William Reidy1, Mansi Agarwal1, Matthew Lamb1, Mark Hawken1, Duncan Chege1, Batya Elul1, Elaine J. Abrams1, Elvin Geng1
1Mailman School of Public Health, ICAP-Columbia University, New York, NY, United States; 2School of Medicine, University of California at San Francisco, San Francisco, CA, United States

1062 Community ART Delivery for High Patient Retention - TASO Uganda Operational Research
Denis Mpima1,2,3, Birungi Josephine1, Luzze Ceaser1, Nanfuka1 Masitula1
1Medical, The AIDS Support Organisation, Kampala, Uganda; 2Medical, International Health Sciences University, Kampala, Uganda; 3Programmes and Strategic Information, The AIDS Support Organisation (TASO), Kampala, Uganda; 4Research, Canadian African Prevention Trials Network, Kampala, Uganda

1063 HIV Care Cascade Among Hard To Reach Populations in India: Need To Expand HIV Counseling and Testing
Shruti H. Mehta1, Gregory M. Lucas1, Suniti Solomon2, Aylur K. Srikrishnam1, Allison McFall1, F. Nandapogul1, Pachamuthu Balakrishnan1, Munirathnam S. Kumar1, David D. Celentano1, Suniti S. Solomon1
1Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States; 2School of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States; 3YR Gaitonde Centre for AIDS Research and Education, Chennai, India

1064 Unplanned Interruptions in HIV Care in Nigeria: Rates and Implications
Aima A. Ahonkhai1, Bolanle Banigbe1, Juliet Adeola1, Ifeyinwa Onwuatue1, Ingrid V. Bassett1, Elena Losina2, Kenneth A. Freedberg1, Propre Okonkwo1, Susan Regan1
1Massachusetts General Hospital, Boston, MA, United States; 2AIDS Prevention Initiative Nigeria, Abuja, Nigeria; 3Infectious Disease, Massachusetts General Hospital, Boston, MA, United States; 4Brigham and Women’s Hospital, Boston, MA, United States
Using the Side Door: Non-Linear Patterns Within the HIV Treatment Cascade in Zambia

Charles B. Holmes1, Angela Bengtson1, Izukanji Sikazwe1,2, Carolyn Bolton-Moore1,2, Lloyd B. Mulenga1, Patrick Musonda1,3, Benjamin H. Chi1,2
1Centre for Infectious Disease Research in Zambia, Lusaka, Zambia; 2University of North Carolina School of Medicine, Chapel Hill, NC, United States; 3University of East Anglia, East Anglia, United Kingdom

Effectiveness of Potential Improvements in the Cascade of HIV Treatment and Care in South Africa

Valentina Cambiano1, Silvia Bertagnolio1, Michael Jordan1, Jens Lundgren1, Alex Miners1, Deenan Pillay1, Paul Revill1, Francois Venter1, Andrew Phillips1
1UCL, London, United Kingdom; 2WHO, Geneva, Switzerland; 3University of Copenhagen, Copenhagen, Denmark; 4London School of Hygiene and Tropical Medicine, London, United Kingdom; 5University of York, York, United Kingdom; 6University of the Witwatersrand, Johannesburg, South Africa

Trends in Depression Among Patients Presenting for ART in Rural Uganda

Brian T. Chan1,2, Sheri D. Weiser3,4, Yap Bouni5, Jessica Haberer2,6, Annet Kembabazi7, Peter W. Hunt4, Jeffrey N. Martin8, David R. Bangsberg2,6, Alexander C. Tsai2,6
1Infectious Diseases, Massachusetts General Hospital, Boston, MA, United States; 2Harvard Medical School, Boston, MA, United States; 3Center for AIDS Prevention Studies, University of California San Francisco, San Francisco, CA, United States; 4Division of HIV/AIDS, University of California San Francisco, San Francisco General Hospital, San Francisco, CA, United States; 5Epicentre, Mbarara, Uganda; 6Center for Global Health, Massachusetts General Hospital, Boston, MA, United States; 7Mbarara University of Science and Technology, Mbarara, Uganda; 8Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, United States

Mental Health and Mortality in an HIV Treatment Cohort in Rural Uganda

Alexander C. Tsai1, 2, Brian T. Chan3, Yap Boum4, Jessica E. Haberer5, Annet Kembabazi2, Peter W. Hunt5, Jeffrey N. Martin2, David R. Bangsberg6
1Massachusetts General Hospital, Boston, MA, United States; 2Medicins San Frontieres, Mbarara, Uganda; 3Mbarara University of Science and Technology, Mbarara, Uganda; 4University of California San Francisco, San Francisco, CA, United States
## Conference Schedule Overview

<table>
<thead>
<tr>
<th>Time</th>
<th>Monday, March 3, 2014</th>
<th>Tuesday, March 4, 2014</th>
<th>Wednesday, March 5, 2014</th>
<th>Thursday, March 6, 2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30 AM</td>
<td>Plenary: HPV Vaccines: Progress to Date and Future Worldwide Directions <strong>Auditorium</strong></td>
<td>Plenary: B-Cell Responses to HIV Infection: Challenges and Opportunities <strong>Auditorium</strong></td>
<td>Plenary: HIV-1 Infection and Type-1 Interferon <strong>Auditorium</strong></td>
<td>Plenary: PEPFAR/Global Fund at 10 Years: Past, Present and Future <strong>Auditorium</strong></td>
</tr>
<tr>
<td>9:00 AM</td>
<td>Program Committee Workshop for New Investigators and Trainees <strong>Ballroom B/C</strong></td>
<td>Plenary: HIV in People Who Use Drugs <strong>Auditorium</strong></td>
<td>Plenary: NeuroHIV in 2014: Beyond Dementia <strong>Auditorium</strong></td>
<td>Plenary: PEPFAR/Global Fund at 10 Years: Past, Present and Future <strong>Auditorium</strong></td>
</tr>
<tr>
<td>9:30 AM</td>
<td><strong>ORAL ABSTRACT CONCURRENT SESSIONS</strong></td>
<td><strong>ORAL ABSTRACT CONCURRENT SESSIONS</strong></td>
<td><strong>ORAL ABSTRACT CONCURRENT SESSIONS</strong></td>
<td><strong>ORAL ABSTRACT CONCURRENT SESSIONS</strong></td>
</tr>
<tr>
<td>10:00 AM</td>
<td>Hepatitis <strong>Ballroom B/C</strong></td>
<td>NeuroHIV: Developments in Treatment and Pathogenesis <strong>RM 304</strong></td>
<td>Critical Issues in MTCT: Maternal Health and HIV Treatment in Children <strong>RM 304</strong></td>
<td>Interferon and Antibody at the Interface of Innate and Adaptive Immunity to HIV <strong>RM 312</strong></td>
</tr>
<tr>
<td></td>
<td>Prevention and Epidemiology: Evolving Trends <strong>Ballroom A</strong></td>
<td>Host Factors and HIV/SIV Replication <strong>RM 312</strong></td>
<td>HIV/SIV Pathogenesis <strong>RM 312</strong></td>
<td>CV and Other Complications <strong>Ballroom A</strong></td>
</tr>
<tr>
<td>12:15 PM</td>
<td>LUNCH</td>
<td>LUNCH</td>
<td>LUNCH</td>
<td>LUNCH</td>
</tr>
<tr>
<td>1:15 PM</td>
<td>Martin Delaney Panel: Hepatitis C Virus: From Trials and Tribulations to Triumph <strong>Ballroom B/C</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:30 PM</td>
<td><strong>THEMED DISCUSSION CONCURRENT SESSIONS</strong></td>
<td><strong>THEMED DISCUSSION CONCURRENT SESSIONS</strong></td>
<td><strong>THEMED DISCUSSION CONCURRENT SESSIONS</strong></td>
<td><strong>THEMED DISCUSSION CONCURRENT SESSIONS</strong></td>
</tr>
<tr>
<td>2:30 PM</td>
<td><strong>CONCURRENT WORKSHOPS</strong></td>
<td><strong>POSTER SESSIONS</strong></td>
<td><strong>CONCURRENT SYMPOSIA</strong></td>
<td><strong>POSTER SESSIONS</strong></td>
</tr>
<tr>
<td>3:00 PM</td>
<td>Clinical Trial Design and Analysis <strong>Ballroom B/C</strong></td>
<td></td>
<td>CONCURRENT SYMPOSIA</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Frontiers in Laboratory Science Workshop <strong>Ballroom A</strong></td>
<td></td>
<td>TB: Looking to the Future: Resistance, Persistence, Monitoring, and Control <strong>Ballroom B/C</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Workshop for Clinicians Who Are New to Hepatitis C Management: A Case-Based Interactive Session <strong>RM 304</strong></td>
<td></td>
<td>Visualizing the Virus <strong>Ballroom A</strong></td>
<td></td>
</tr>
<tr>
<td>4:00 PM</td>
<td></td>
<td>CONCURRENT SYMPOSIA</td>
<td>Know Your Epidemic: From Data to Action <strong>RM 304</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>CONCURRENT SYMPOSIA</td>
<td>ORAL ABSTRACT SESSION</td>
<td></td>
</tr>
<tr>
<td>4:30 PM</td>
<td><strong>OPENING SESSION</strong></td>
<td></td>
<td>Malignancies and Pharmacology <strong>RM 312</strong></td>
<td></td>
</tr>
<tr>
<td>5:00 PM</td>
<td>Bernard Fields Lecture: Making and Breaking Barriers to Cross-Species HIV-1 Transmission <strong>Auditorium</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>N’Galy-Mann Lecture: Application of Scientific Knowledge and Evidence to Limit the Progression of HIV/AIDS and Fight Other Endemic Diseases in West Africa <strong>Auditorium</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7:00 PM</td>
<td>Welcome Reception</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>